john
newsomdavi
jnd
major
intern
figur
field
neurolog
neuroimmunolog
combin
clinic
expertis
commit
scientif
understand
diseas
mechan
implic
treatment
influenc
gener
neurologist
neuroscientist
except
person
qualiti
intellig
toler
energi
modesti
greatli
miss
jnd
brought
clinic
observ
laboratori
vice
versa
experi
muscl
spindl
electrophysiolog
intens
care
medicin
start
collabor
ricardo
miledi
univers
colleg
london
work
myasthenia
gravi
mg
discoveri
antibodi
acetylcholin
receptor
serum
patient
jon
lindstrom
colleagu
demonstr
passiv
transfer
diseas
mice
inject
patient
igg
klau
toyka
dan
drachman
led
jnd
test
effect
plasma
exchang
treatment
remark
efficaci
therapywhich
last
sever
weeksshow
convincingli
myasthenia
inde
caus
humor
immun
discoveri
follow
jnd
other
laboratori
owe
much
implic
simpl
clinic
experi
next
year
team
london
oxford
systemat
investig
role
thymu
involv
cell
immun
mg
defin
exist
humor
immun
voltageg
calcium
channel
lambert
eaton
syndrom
show
similarli
case
acquir
neuromyotonia
associ
antibodi
voltageg
potassium
channel
vgkc
retir
jnd
step
asid
laboratori
continu
see
mg
patient
edit
brain
began
establish
major
intern
trial
thymectomi
mg
gil
wolf
gari
cutter
mani
other
eventu
fund
nih
meanwhil
team
continu
identifi
new
antibodyassoci
condit
form
mg
central
nervou
system
disord
ensur
legacyth
diagnosi
treatment
immunotherapyrespons
conditionswil
persist
talk
briefli
review
achiev
taken
forward
last
ten
year
josep
dalmau
md
phd
limbic
enceph
refer
inflammatori
process
involv
hippocampi
amygdala
less
frequent
frontobas
insular
region
disord
use
consid
extrem
rare
invari
associ
cancer
unrespons
treatment
howev
recent
studi
indic
limbic
enceph
frequent
previous
thought
substanti
number
patient
may
recov
increas
recognit
limbic
enceph
due
part
develop
clinic
diagnost
criteria
identif
antibodi
direct
two
broad
categori
antigen
intracellular
classic
paraneoplast
antigen
includ
hu
among
other
cell
surfac
antigen
includ
voltageg
potassium
channel
vgkc
nmethyldaspart
receptor
nmdar
other
express
neuropil
hippocampu
disord
relat
first
categori
antibodi
associ
cancer
lung
testi
promin
brain
infiltr
tcell
limit
respons
treatment
disord
relat
second
categori
antibodi
associ
less
frequent
tumor
appear
antibodymedi
respond
better
immunotherapi
studi
limbic
enceph
identifi
larg
group
alli
disord
limbic
system
often
involv
area
brain
also
affect
particular
interest
disord
associ
antibodi
extracellular
epitop
heterom
nmda
receptor
patient
syndrom
often
young
women
ovarian
teratoma
although
disord
also
affect
men
children
without
tumor
patient
present
sever
psychiatr
symptom
first
seen
psychiatrist
subsequ
patient
develop
seizur
dyskinesia
autonom
instabl
hypoventil
correl
antibodi
titer
outcom
antibodi
direct
subunit
nmda
receptor
differenti
diseas
number
disord
attribut
antibodi
subunit
vitro
studi
indic
patient
antibodi
modul
number
nmda
receptor
autoimmun
encephalitid
target
antigen
cell
surfac
neuron
neuron
process
hippocampu
phenotyp
patient
differ
antinmda
receptor
enceph
resembl
classic
limbic
enceph
frequent
relapsingremit
seizur
memori
deficit
work
progress
suggest
autoantigen
ion
channel
receptor
critic
involv
process
learn
memori
studi
disord
provid
link
immunolog
process
neuron
event
involv
memori
cognit
seizur
neuron
degener
interferon
ifn
induc
myxoviru
resist
protein
mxa
recent
use
indirect
marker
neutral
antibodi
ifn
patient
multipl
sclerosi
ms
mxa
also
inhibit
viral
replic
modifi
cellular
function
includ
apoptot
pathway
moreov
recent
studi
suggest
haplotyp
snp
mxa
promot
region
affect
respons
ifnbeta
treatment
ms
goal
investig
genet
patholog
role
mxa
patient
ms
examin
snp
mxa
promot
region
ms
patient
normal
control
ms
patient
fulfil
mcdonald
criteria
moreov
elucid
function
role
snp
conduct
luciferas
assay
vector
includ
patientderiv
artifici
mutat
mxa
promot
region
also
examin
mxa
protein
express
peripher
blood
monocyt
pbmc
quantit
rtpcr
found
significantli
higher
frequenc
haplotyp
ms
patient
correl
overexpress
mxa
report
associ
wors
respons
ifntreat
moreov
obtain
novel
find
show
play
lead
part
type
ifn
play
similar
role
independ
unrel
type
ifn
quantit
rtpcr
demonstr
higher
express
mxa
ms
patient
normal
control
snp
mxa
promot
region
may
play
import
role
pathophysiolog
ms
hyper
express
mxa
associ
ms
studi
mxa
may
lead
novel
therapeut
strategi
ms
plasmacytoid
cell
clue
pathogenesi
multipl
sclerosi
crawford
colin
l
imperi
colleg
medicin
chare
cross
hospit
london
uk
secondari
progress
multipl
sclerosi
spm
lymphoid
follicl
contain
b
plasma
cell
observ
howev
plasma
cell
stain
specif
marker
confin
perivascular
space
found
brain
parenchyma
multipl
sclerosi
ms
patient
cell
brain
parenchyma
consid
plasma
cell
contain
subplasmalemm
linear
densiti
spld
frequent
binucl
featur
present
plasma
cell
instead
cell
could
plasmacytoid
cell
precursor
epithelioid
cell
sarcoidosi
also
found
contain
spld
sarcoidosi
giant
cell
due
fusion
common
binucl
cell
ms
could
also
aris
cell
fusion
rather
divis
plasmacytoid
cell
identifi
type
dendrit
cell
cell
increas
tenfold
cerebrospin
fluid
patient
earli
ms
nonlepromat
leprosi
granulomat
disord
similar
sarcoidosi
order
produc
autoimmun
anim
model
nonlepromat
leprosi
dutch
bantam
rabbit
inject
suspens
human
sensori
peripher
nerv
sural
nerv
dorsal
root
plu
adjuv
rabbit
develop
state
granulomat
hypersensit
ie
epithelioid
cell
granuloma
produc
skin
test
site
use
dilut
suspens
peripher
nerv
antigen
variou
nonmyelin
fraction
use
site
cell
whose
cytoplasm
contain
abund
rough
endoplasm
reticulum
spld
observ
cell
observ
indistinguish
plasma
cell
contain
small
thicken
plasma
membran
plasmalik
cell
also
found
endoneurium
activ
fraction
produc
cell
spld
deoxycholateextract
membran
fraction
dose
produc
low
speed
nuclear
pellet
myelin
remov
fraction
also
induc
plasmalik
cell
axon
damag
endoneurium
plasmacytoid
dendrit
cell
could
identifi
ms
tissu
use
specif
marker
confirm
specif
nonmyelin
autoantigen
may
implic
pathogenesi
ms
furthermor
plasmacytoid
dendrit
cell
secret
larg
amount
interferon
alpha
cytokin
could
caus
axon
damag
ms
patient
implic
cell
pathogenesi
multipl
sclerosi
ms
anim
model
increasingli
apprais
cell
central
nervou
system
cn
ms
patient
shown
highli
activ
effector
memori
phenotyp
contribut
cn
factor
acquisit
phenotyp
cell
elucid
proinflammatori
cytokin
crucial
gener
mainten
memori
cell
produc
cell
tissu
microenviron
inflammatori
diseas
reveal
potent
activ
infiltr
cell
lead
enhanc
cytotox
toward
target
cell
goal
investig
whether
present
cn
context
ms
ii
determin
whether
situ
enhanc
deleteri
cell
respons
cn
target
cell
thu
contribut
observ
tissu
damag
primari
cultur
human
astrocyt
significantli
increas
express
upon
activ
proinflammatori
stimuli
ifngamma
tnfalpha
flow
cytometri
order
determin
cell
could
function
sourc
cultur
myelin
specif
human
cell
line
upon
cocultur
activ
astrocyt
cell
acquir
effector
memori
phenotyp
increas
perforin
granzym
b
level
flow
cytometri
moreov
cell
cytotox
toward
primari
cultur
human
adult
oligodendrocyt
releas
astrocytemedi
function
enhanc
cell
function
abrog
block
antibodi
immunohistochemistri
perform
activ
ms
lesion
show
increas
proport
astrocyt
express
demonstr
physiolog
relev
vitro
observ
result
underlin
contribut
cn
resid
cell
name
astrocyt
microenviron
favor
cytotox
cell
respons
via
suffici
amount
situ
alreadi
shown
promot
autoimmun
effector
cell
respons
autoimmun
diseas
rheumatoid
arthriti
celiac
diseas
bioavail
cn
may
implic
exacerb
tissu
damag
target
oligodendrocyt
ms
pathogenesi
diagnos
multipl
sclerosi
ms
alway
easi
ms
demyelin
diseas
neuromyel
optica
nmo
may
indistinguish
clinic
although
antiaquaporin
aqp
antibodi
differenti
nmo
ms
clinic
possibl
link
two
demyelin
diseas
remain
mysteri
recent
advanc
proteom
technolog
search
biomark
biomark
signatur
accur
identifi
clinic
syndrom
would
allow
improv
diagnosi
diseas
monitor
magnet
beadbas
purif
follow
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
employ
profil
human
cerebrospin
fluid
csf
protein
peptid
total
sampl
patient
definit
ms
remiss
relaps
nmo
remiss
relaps
primari
progress
multipl
sclerosi
ppm
studi
particip
gave
written
inform
consent
use
reagent
set
chemic
coat
magnet
bead
revers
phase
clinprottm
acid
matrix
solut
elut
sampl
drop
onto
maldi
sampl
plate
anchorchiptm
spectra
obtain
autoflex
ii
subsequ
tandem
ms
analysi
perform
ultraflex
bruker
dalton
criteria
peak
detect
signaltonois
ratio
peakwidth
filter
maximum
peak
number
pretreat
data
graph
spectra
evalu
statist
analysi
use
clinprotoolstm
softwar
bruker
dalton
reproduc
profil
obtain
clear
signal
approxim
fifti
peak
detect
csf
sampl
differenti
distribut
sampl
ms
nmo
remiss
notic
sampl
ppm
separ
effect
use
platform
one
key
variabl
contribut
separ
mz
defin
ctermin
fragment
neuroendocrin
peptid
tandem
ms
analysi
applic
magnet
beadbas
separ
combin
malditofm
techniqu
csf
sampl
hold
potenti
advanc
understand
biochem
basi
ms
nmo
studi
requir
valid
clinic
effect
diseas
specif
identifi
biomark
role
granzym
b
cellsinduc
neurotox
neuroprotect
strategi
use
new
serineproteas
inhibitor
osaka
univers
osaka
japan
boehringeringelheim
osaka
japan
toyonaka
municip
hospit
osaka
japan
signific
role
semaphorin
immun
system
report
recent
investig
mainli
axon
guidanc
molecul
develop
central
nervou
system
cn
class
semaphorin
express
antigen
present
cell
cell
suggest
activ
cell
via
cell
immunoglobulin
domain
mucin
domain
tim
critic
molecul
differenti
therefor
gener
monoclon
antibodi
immun
mice
establish
elisa
system
measur
serum
level
multipl
sclerosi
ms
patient
patient
spinocerebellar
degener
scd
patient
enceph
statist
analysi
perform
welch
ttest
serum
level
significantli
higher
ms
patient
patient
scd
enceph
p
b
p
b
respect
especi
onethird
patient
ms
exhibit
mark
high
level
express
suggest
involv
pathogenesi
ms
may
also
suggest
heterogen
ms
pathogenesi
next
investig
express
experiment
autoimmun
encephalomyel
eae
mice
immunohistochem
examin
reveal
infiltr
cell
spinal
cord
eae
mice
exhibit
mark
express
overal
result
suggest
may
potenti
biomark
ms
may
import
molecul
pathogenesi
ms
oligoclon
igg
band
cerebrospin
fluid
csf
found
patient
multipl
sclerosi
ms
chronic
inflammatori
demyelin
disord
affect
central
nervou
system
cn
import
issu
whether
ig
recogn
diseaserelev
structur
neural
target
eg
galcer
crossreact
infecti
agent
eg
mycoplasma
e
coli
whether
reflect
intrathec
activ
blineag
cell
secret
ig
direct
undetermin
specif
antigen
deriv
inflammatori
process
postul
lipid
mimicri
pathogenesi
induct
ms
autoimmun
examin
csf
igg
crossreact
myelin
microbi
lipid
focus
respect
upon
acetylcerebrosid
design
fmc
fast
migrat
cerebrosid
higher
tlc
rf
galcer
myelin
lipid
b
mfglii
glycoglycerocholinolipid
fermentan
c
lp
e
coli
uk
strain
bacteri
lipid
analysi
patient
includ
csf
sampl
ms
patient
classifi
relapsingremit
rrm
secondari
progress
spm
primari
progress
ppm
comparison
nine
neurolog
diseas
ond
control
divid
inflammatori
iond
noninflammatori
niond
elev
antibodi
significantli
higher
ppm
group
compar
spm
group
vs
p
rrm
remiss
group
compar
spm
group
vs
p
lesser
chang
found
antigalc
antisulfatid
antibodi
strike
consider
interest
highli
elev
antimicrobi
fermentan
e
coli
antibodi
found
mening
patient
one
patient
subacut
scleros
paneneceph
sspe
one
patient
meningoenceph
iond
group
compar
niond
control
p
b
noteworthi
antilipid
antigen
elev
occur
tandem
microbi
self
antigen
find
consist
crossreact
immunoglobulin
human
ms
csf
microbi
myelin
glycolipid
ms
patient
suggest
role
microbi
surfac
myelin
antigen
particularli
glycolipid
antigen
pathogenesi
ms
examin
larger
number
ms
control
istituto
tecnologi
biomedich
cnr
bari
itali
studi
six
monozygot
mz
twin
pair
femal
male
discord
multipl
sclerosi
ms
two
diseas
concord
mz
pair
femal
male
unrel
coupl
patienthealthi
control
subject
ageand
sexmatch
twin
pair
analyz
well
patient
free
immunomodulatori
treatment
mz
twin
unrel
subject
analys
independ
avoid
expect
high
biolog
variat
two
group
might
prevent
discoveri
differenti
express
gene
exon
array
data
mz
twin
load
normal
rma
onechannelgui
environ
subsequ
princip
compon
pca
analysi
confirm
strong
cluster
twin
pair
alreadi
observ
platformsunpublish
overcom
bia
observ
biolog
variabl
among
coupl
mz
twin
higher
variabl
observ
coupl
obscur
identif
differ
express
gene
import
array
data
partek
gs
softwar
ad
hoc
anova
model
could
implement
handl
effect
batch
remov
new
anova
model
built
partek
gs
order
take
account
remain
sourc
variat
patient
statu
gender
age
potenti
interact
anova
factor
use
select
list
gene
differ
express
signific
bhcorrect
pvalu
b
focus
also
detect
specif
altern
splice
event
mean
identif
differ
express
exon
analysi
perform
partek
gs
environ
use
anova
model
altern
splice
factor
set
statu
patient
paramet
identifi
differenti
express
gene
exon
diseas
discord
mz
twin
gene
exon
unrel
patient
healthi
control
gene
exon
healthi
cotwin
compar
unrel
healthi
control
exon
also
list
exon
differenti
express
unrel
patient
control
gradient
number
differenti
express
exon
among
twin
among
healthi
twin
unrel
healthi
subject
among
unrel
patient
control
support
hypothesi
ms
trait
healthi
cotwin
relev
altern
splice
data
verifi
mean
specif
rtpcr
approach
darlington
johnson
trina
baror
amit
antel
jack
neuron
suscept
cytotox
immunemedi
injuri
neuroinflammatori
disord
includ
multipl
sclerosi
acut
chronic
encephalitid
restrict
express
mhc
molecul
neuron
implic
injuri
mediat
mhcantigenindepend
immun
effector
mechan
previous
report
innat
immun
cell
nk
gammadeltat
cell
induc
loss
human
neuron
vitro
consequ
initi
destruct
support
astrocyt
darlington
et
al
j
neuropath
exp
neurol
press
shortterm
cell
kill
neuron
astrocyt
caus
caspasedepend
fragment
cytoskelet
protein
gfap
goal
character
mechan
astrocyt
injuri
determin
overal
consequ
neuron
surviv
shortterm
cell
induc
subleth
activ
lead
caspasedepend
fragment
gfap
primari
human
astrocyt
occur
contact
depend
manner
cytotox
experi
indic
effect
could
attribut
cell
rather
cell
incub
activ
cell
exogen
lectin
phytohemagglutinin
pha
promot
adhes
cell
surfac
glycosyl
receptor
result
actual
astrocyt
cytotox
lead
neuron
loss
lectindepend
effect
observ
short
term
activ
cell
howev
polyclon
expand
short
term
mbpreactiv
cell
induc
lectindepend
astrocyt
cytotox
polar
cell
less
cytotox
polar
counterpart
data
indic
extent
cellmedi
target
cell
injuri
determin
intrins
cytotox
potenti
cell
extent
cellcel
contact
interact
target
cell
cytotox
potenti
may
induc
subleth
injuri
astrocyt
cellcel
interact
limit
long
term
consequ
astrocyt
injuri
neuron
surviv
remain
defin
whether
suffici
upregul
cell
adhes
molecul
inflam
cn
support
cell
mediat
cytotox
andor
whether
endogen
lectin
capabl
support
immuneneur
interact
cn
also
remain
establish
convent
multipl
sclerosi
cm
similar
clinic
manifest
investig
feasibl
diffus
tensor
imag
dti
magnet
reson
spectroscopi
mr
assess
microscop
fiber
tract
injuri
corpu
callosum
cc
normalappear
white
matter
nawm
patient
nmo
multipl
sclerosi
ms
studi
propos
novel
approach
use
appar
diffus
coeffici
adc
fraction
anisotropi
fa
brain
deriv
dti
mr
classif
featur
discrimin
patient
rnmoosm
cm
japan
twenti
patient
rnmoosm
median
expand
disabl
statu
score
edss
cm
patient
median
edss
rang
studi
weight
imag
dti
mr
chemic
shift
imag
singl
voxel
brain
mr
allow
vivo
examin
axon
integr
quantifi
neuron
marker
nacetylaspart
naa
often
express
ratio
creatin
cr
test
directli
relationship
chang
dti
paramet
naa
concentr
ms
lesion
nawm
normal
appear
corpu
callosum
nacc
studi
indic
fa
ms
patient
significantli
decreas
nacc
nawm
possibl
due
reduct
smallcalib
axon
data
show
significantli
lower
fa
posterior
limb
intern
capsul
rnmoosm
patient
cm
patient
healthi
volunt
bonferroni
adjust
naacr
rnmo
osm
group
significantli
decreas
posterior
lobe
subdivis
wm
decreas
fa
cc
wm
decreas
naa
wm
correl
diseas
durat
edss
score
conclus
propos
method
basi
combin
featur
effect
classif
mere
use
featur
separ
may
help
differenti
rnmo
osm
cm
patient
control
ms
p
differ
group
concentr
observ
result
indic
appar
deviat
immun
regulatori
cell
phenotyp
seen
system
level
regard
transcript
deviat
vivo
cytokin
secretori
pattern
although
tbet
rorc
display
higher
rel
express
ms
repres
transcript
deviat
toward
phenotyp
evalu
togeth
find
ifng
decreas
plasma
ms
patient
subsequ
analysi
subgroup
ms
well
cytokin
level
transcript
factor
express
cerebrospin
fluid
ensu
persist
high
level
express
circul
cell
ci
patient
favour
earli
convers
clinic
defin
multipl
sclerosi
patient
clinic
isol
syndrom
ci
suggest
multipl
sclerosi
develop
clinic
defin
ms
cdm
studi
evalu
express
tbet
cell
monocyt
peripher
blood
ci
patient
month
first
clinic
event
furthermor
correl
express
transcript
factor
patient
clinic
outcom
ifng
product
pbmc
studi
includ
ci
patient
sex
age
match
control
detect
tbet
perform
intracellular
flow
cytometri
product
ifng
pbmc
measur
elisa
higher
level
observ
cell
monocyt
ci
patient
acut
phase
control
tbet
express
higher
monocyt
ci
patient
acut
phase
one
control
tbet
express
higher
cell
patient
acut
phase
patient
remiss
phase
ifngamma
level
significantli
higher
ci
patient
acut
phase
control
ifng
level
decreas
remiss
phase
level
remain
high
followup
period
patient
convert
cdm
acut
phase
group
patient
convert
cdm
show
higher
express
cell
higher
express
tbet
cell
control
nonconvert
patient
show
higher
express
cell
control
group
patient
show
higher
product
ifng
control
remiss
ci
patient
convert
cdm
show
higher
express
cell
control
addit
express
higher
cell
convert
nonconvert
patient
group
patient
show
higher
product
ifng
control
higher
patient
patient
convert
cdm
seem
play
pathogenet
role
ci
persist
high
level
circul
cell
ci
patient
first
clinic
event
may
favor
earli
convers
cdm
relaps
dynam
multipl
sclerosi
depend
control
properti
peripher
immun
toler
autoimmun
character
presenc
relapsingremit
dynam
multipl
sclerosi
goal
studi
demonstr
relapsingremit
dynam
gener
failur
feedback
control
two
compet
popul
regul
peripher
toler
effector
regulatori
cell
develop
comput
model
human
immun
system
use
system
dynam
framework
stochast
differenti
equat
base
biolog
knowledg
analysi
show
finetun
paramet
regul
neg
feedback
effector
regulatori
tcell
immun
system
abl
gener
relapsingremit
dynam
autoimmun
dynam
stabl
obtain
wide
rang
paramet
close
normal
function
immun
system
addit
found
stochast
stimul
immun
system
strongli
influenc
time
relaps
appear
prevent
predict
also
found
unexpect
predict
increas
activ
effector
tcell
circumst
gener
strong
control
respons
prevent
presenc
relaps
final
introduc
perturb
model
mimick
immunotherapi
aim
increas
activ
either
effector
regulatori
tcell
demonstr
effect
therapi
highli
depend
time
underli
dynam
immun
system
impli
immunotherapi
must
develop
person
manner
focus
obtain
healthier
dynam
control
modul
peripher
toler
keep
absolut
number
tcell
certain
rang
summari
studi
provid
view
autoimmun
dynam
process
provid
new
clue
develop
immunotherapi
helminth
infect
concurr
ms
significantli
reduc
diseas
sever
previous
shown
author
grow
evid
indic
b
cell
play
key
role
restrain
unwant
selfreact
cell
respons
differ
autoimmun
model
mice
helminth
infect
ms
patient
give
rise
b
cell
popul
produc
high
level
tolllik
receptor
tlr
function
sentinel
recogn
differ
microbi
molecul
elucid
role
tlr
helminth
infect
examin
express
b
cell
helminthinfect
uninfect
ms
patient
peripher
blood
b
cell
helminthinfect
ms
subject
uninfect
ms
patient
healthi
control
purifi
use
magnet
cell
sort
surfac
express
b
cell
significantli
higher
helminthinfect
ms
patient
compar
uninfect
ms
patient
healthi
control
differ
express
observ
group
moreov
helminthinfect
ms
patient
engag
induc
preferenti
expans
secret
b
cell
manner
examin
whether
differenti
activ
regulatori
b
cell
impact
cell
immun
respons
b
cell
previous
stimul
ligand
cocultur
allogen
cell
examin
flow
cytometri
express
ifngamma
product
stimul
b
cell
highli
effici
induc
express
alloreact
cell
convert
posit
wherea
engag
alter
express
likewis
follow
stimul
b
cell
induc
gener
produc
cell
moreov
percentag
cell
express
ifngamma
significantli
lower
cultur
contain
b
cell
stimul
agonist
compar
activ
via
experiment
set
suppress
ifngamma
abrog
express
silenc
sirna
data
indic
produc
b
cell
link
recognit
helminth
product
via
provid
novel
target
parasit
suppress
cellmedi
autoimmun
diseas
regulatori
cell
acut
stabl
relapsingremit
multipl
sclerosi
modul
therapi
regulatori
cell
treg
play
fundament
role
prevent
immun
reaction
self
antigen
recent
data
suggest
intracellular
express
program
death
receptor
identifi
subset
treg
enhanc
suppress
abil
antigen
stimul
result
surfac
express
role
treg
impair
ms
still
contradictori
analyz
activ
treg
peripher
blood
relapsingremit
multipl
sclerosi
rrm
patient
healthi
control
hc
csf
ms
patient
individu
noninflammatori
condit
also
examin
result
show
wherea
csf
treg
significantli
augment
ms
patient
cell
compar
peripher
blood
patient
control
clinic
sub
analys
nevertheless
demonstr
peripher
treg
significantli
increas
patient
stabl
sm
compar
relaps
am
diseas
patient
respond
glatim
acet
copaxon
copa
compar
am
copaunrespons
patient
contrast
activ
treg
similar
csf
peripher
blood
group
analyz
treg
increas
peripher
blood
interferon
b
ifnb
respons
patient
suppress
abil
treg
significantli
higher
sm
copaor
ifnbrespons
compar
am
copaunresponsiveindividu
data
herein
suggest
treg
play
pivot
role
pathogenesi
ms
offer
biolog
explan
diseas
relaps
mechan
associ
respons
copa
ifnb
clinic
isol
syndrom
ci
repres
first
neurolog
symptom
suggest
demyelin
lesion
central
nervou
system
cn
accord
magnet
reson
imag
mri
risk
multipl
sclerosi
ms
develop
far
suffici
immunolog
marker
predict
even
diseas
activ
effici
regist
ci
treatmentinterferon
beta
aim
studi
compar
immunolog
statu
month
interferon
beta
intramuscularli
weekli
ifnb
treatment
two
group
ci
patient
respond
r
nonrespond
nr
ifnb
therapi
accord
clinic
mri
diseas
activ
within
first
year
treatment
patient
method
peripher
blood
taken
treatment
month
ifnb
therapi
ci
patient
raverag
age
year
fm
nraverag
age
year
fm
ci
defin
first
demyelin
event
least
lesion
flair
mri
imag
posit
oligoclon
band
cerebrospin
fluid
nr
defin
occurr
least
one
relaps
one
new
lesion
mri
first
year
treatment
flow
cytomet
facscalibur
monoclon
antibodi
bd
bioscienc
use
mononuclear
cell
immunophenotyp
subpopul
student
test
pearson
correl
use
statist
analysi
intergroup
pair
comparison
perform
use
manova
statist
signific
correl
found
amount
cell
peripher
blood
treatment
relaps
frequenc
first
year
ifnb
treatment
p
r
five
nr
patient
statist
signific
correl
intergroup
differ
test
immunolog
marker
ifnb
treatment
respons
base
preliminari
result
number
cell
peripher
blood
may
one
immunolog
marker
ms
prognosi
determin
treatment
efficaci
multipl
sclerosi
ms
autoimmun
central
nervou
system
cn
diseas
character
inflammatori
infiltr
alongsid
demyelin
axon
axon
transect
degener
neuron
exact
patholog
process
though
still
unclear
explor
possibl
innat
immun
respons
involv
diseas
immunopathogenesi
particular
gammadelta
cell
concentr
ms
lesion
previous
report
gammadelta
cell
direct
cytotox
cytokin
releas
examin
possibl
injuri
also
mediat
via
antibodi
depend
cell
cytotox
adcc
autoantibodi
myelin
compon
found
ms
patient
activ
gammadelta
cell
upregul
express
fcg
receptor
rais
possibl
bind
antibodi
facilit
adcctyp
interact
vitro
experiment
system
establish
use
human
antibodi
rituximab
bridg
antibodi
b
lymphoma
target
cytotox
measur
inhous
develop
multipl
paramet
flow
cytometri
techniqu
result
show
e
ratio
adcc
cytotox
gammadelta
cell
target
cell
line
significantli
increas
presenc
rituximab
p
b
effect
could
abrog
remov
fc
portion
antibodi
p
b
vs
integr
rituximab
use
cell
p
b
vs
popul
suggest
antibodymedi
cytolyt
contribut
furthermor
use
intracytoplasm
flow
cytometri
found
antibodyco
target
cell
could
induc
product
th
cytokin
gammadelta
cell
interestingli
capabl
produc
subtyp
cytokin
exclus
resid
popul
p
b
find
tie
togeth
innat
adapt
immun
respons
interact
involv
stimul
antibodi
product
possibl
cn
molecul
myelin
via
express
gammadelta
cell
could
use
antibodi
enact
guid
attack
cn
target
via
mechan
adcc
studi
offer
novel
insight
possibl
role
gammadelta
cell
ms
involv
potenti
pathogen
immunoregulatori
function
natur
killer
nk
cell
major
effector
cell
innat
immun
respons
relev
sever
autoimmun
diseas
investig
valley
cytotox
implic
multipl
sclerosi
ms
relaps
cytotox
may
one
way
nk
cell
regul
natur
scale
autoimmun
respons
object
examin
nk
cytotox
newli
diagnos
treatment
naiv
ms
subject
relaps
compar
age
sex
match
healthi
control
control
anoth
static
neurolog
condit
stabl
chronic
spinal
cord
injuri
method
fourhour
chromium
releas
assay
use
target
cell
line
use
laboratori
technician
blind
clinic
statu
subject
three
differ
effector
target
e
cell
ratio
studi
analyz
pair
test
result
eighteen
ms
subject
immunotherapi
spinal
cord
injur
sci
subject
static
neurolog
deficit
well
individu
match
age
sex
healthi
laboratori
control
statist
signific
reduct
nk
percent
kill
ms
subject
compar
age
sex
match
control
mean
sem
vs
sem
mean
sem
vs
sem
mean
sem
vs
sem
differ
statist
signific
three
e
cell
ratio
df
p
df
p
df
p
sci
subject
statist
signific
reduct
nk
percent
kill
compar
age
sex
match
control
mean
sem
vs
sem
df
p
although
trend
two
e
ratio
reach
statist
signific
ms
subject
treatment
minim
neurolog
deficit
signific
reduct
nk
cytotox
abil
compar
health
control
compar
group
sever
static
neurolog
impair
without
autoimmun
diseas
support
concept
intrins
nk
cytotox
dysfunct
earli
ms
diseas
process
possibl
contribut
autoimmun
dysregul
sinc
evid
cytotox
abil
may
one
way
nk
cell
orchestr
neuroregul
data
would
implic
potenti
target
futur
therapi
vereyken
elli
dijkstra
christin
teunissen
charlott
wide
recogn
macrophag
play
import
role
pathogenesi
multipl
sclerosi
ms
benefici
detriment
effect
deplet
infiltr
macrophag
suppress
effect
clinic
sign
experiment
allerg
encephalomyel
convers
elimin
macrophag
lead
impair
remyelin
lysolecithin
induc
demyelin
differ
subtyp
macrophag
exist
differ
function
immun
respons
tissu
repair
two
extrem
classic
activ
ca
macrophag
cytotox
altern
activ
aa
macrophag
growth
promot
type
macrophag
found
ms
lesion
ca
locat
mostli
activ
border
aa
center
lesion
perivascular
due
differ
local
question
becam
whether
differ
activ
macrophag
migrat
differ
could
attract
differ
cell
type
central
nervou
system
cn
studi
migrat
differ
activ
macrophag
organotyp
cn
cultur
effect
either
demyelin
neuron
damag
migrat
final
intrins
migratori
capac
macrophag
studi
direct
migrat
filter
influenc
chemokin
higher
number
aa
macrophag
migrat
untreat
spheroid
compar
ca
macrophag
differ
migrat
also
seen
induct
demyelin
neuron
damag
compar
demyelin
neuron
damag
differ
number
migrat
macrophag
observ
ca
aa
macrophag
could
migrat
deep
spheroid
reach
neuron
cell
bodi
axon
howev
observ
frequent
aa
macrophag
studi
whether
differ
migrat
due
intrins
migratori
capac
macrophag
studi
migrat
across
filter
blind
well
chamber
higher
number
aa
macrophag
migrat
respons
compar
ca
macrophag
macrophag
migrat
well
toward
neuron
condit
medium
indic
presenc
solubl
chemokin
medium
intrins
migratori
capac
aa
macrophag
greater
compar
ca
macrophag
even
cn
environ
spheroid
aa
macrophag
migrat
deeper
possibl
due
neuron
attract
might
also
play
role
local
aa
ms
lesion
interferonbeta
signal
transduct
multipl
sclerosi
autoantibodi
antibodi
phenotyp
specif
cell
subset
cell
analyz
multicolor
fac
second
step
simplifi
method
antibodi
detect
use
cell
line
abl
evalu
signal
interferonbeta
autolog
sera
serum
free
media
treat
nontreat
rrm
use
cell
line
sera
rrm
patient
could
rapidli
detect
autoantibodi
interferon
beta
multi
colour
flow
cytometri
conjunct
phosphoantibodi
power
reproduc
tool
detect
immedi
effect
agent
molecul
autoantibodi
inhibitor
signal
pathway
primari
cell
defect
immun
regul
could
result
breakdown
immun
toler
lead
develop
multipl
sclerosi
ms
postul
molecular
mimicri
crossreact
yet
undefin
epitop
autoreact
cell
activ
peripher
toler
broken
diseas
initi
reactiv
immun
impair
ms
extrem
complex
pathway
shown
associ
product
immunoregulatori
cytokin
impair
molecul
could
associ
develop
ms
aim
studi
analys
possibl
role
costimulatori
pathway
onset
progress
ms
verifi
whether
immunotherapi
effect
express
molecul
enrol
studi
relapsingremit
multipl
sclerosi
rrm
patient
subdivid
two
group
acut
relaps
diseas
am
stabl
diseas
sm
express
costimulatori
molecul
well
product
myelin
basic
protein
mbp
stimul
peripher
blood
mononuclear
cell
analys
flowcytometri
effect
differ
immunotherapi
glatim
acet
copaxon
copa
interferon
beta
ifnb
also
evalu
result
show
percentag
cell
express
reduc
am
compar
sm
individu
p
associ
import
decreas
product
mbpstimul
cell
patient
p
copa
ifnbeta
treatment
influenc
costimulatori
molecul
conclus
data
suggest
impair
result
reduct
product
could
play
import
role
pathogenesi
multipl
sclerosi
monitorag
express
protein
could
novel
diagnost
tool
remit
multipl
sclerosi
ms
decad
mechan
action
remain
elus
although
recent
studi
suggest
multipl
cellular
andor
solubl
factor
might
involv
mediat
ga
effect
ms
experiment
autoimmun
encephalomyel
eae
nk
cell
potenti
regulatori
cell
ms
eae
fractalkin
receptor
express
glial
cell
cn
solubl
fractalkin
dictat
migrat
nk
cell
cn
patholog
circumst
consequ
nk
cell
home
cn
significantli
impair
defici
mice
investig
whether
impair
home
nk
cell
cn
influenc
therapeut
effect
ga
eae
eae
induc
mice
immun
peptid
adjuv
cfa
group
wild
type
mice
mice
treat
ga
pb
upon
eae
induct
clinic
paramet
monitor
compar
among
group
ga
confer
moder
protect
eae
wild
type
mice
mean
clinic
score
vs
p
b
maximum
clinic
score
vs
p
b
respect
contrast
ga
treatment
alter
clinic
cours
ea
e
mice
mean
clinic
score
vs
p
b
maximum
clinic
score
vs
p
n
respect
demonstr
therapeut
effect
ga
eae
complet
lost
mice
current
work
focu
dissect
nk
cell
might
contribut
therapeut
effect
ga
use
combin
cell
transfer
monoclon
antibodi
induct
substanc
p
human
pbmc
express
substanc
p
receptor
peripher
blood
ms
patient
substanc
p
sp
neuropeptid
store
termini
sensori
neuron
sp
induc
proinflammatori
cytokin
mediat
effect
bind
specif
neurokinin
nk
receptor
previou
studi
shown
receptor
antagonist
reduc
clinic
histolog
sign
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
member
cytokin
famili
drive
pathogen
cell
popul
involv
initi
eae
possibl
ms
express
function
sp
receptor
ms
clear
object
determin
effect
substanc
p
express
normal
pbmc
determin
express
receptor
peripher
blood
ms
method
normal
pbmc
treat
sp
sp
sp
receptor
antagonist
sp
pseudoantagonist
lp
control
h
quantit
real
time
pcr
qpcr
perform
primer
valu
normal
microglobulin
rna
extract
whole
blood
ms
sampl
control
qpcr
perform
primer
data
normalis
via
result
treatment
sp
increas
rel
quantiti
pbmc
rel
quantiti
receptor
rna
ms
patient
significantli
lower
natalizumab
therapi
reduc
number
cell
within
csf
tenfold
number
lymphocyt
addit
effect
cell
number
persist
least
month
cessat
treatment
extend
studi
prolong
differenti
effect
natalizumab
lymphocyt
number
csf
investig
number
phenotyp
leukocyt
express
major
histocompat
complex
mhc
ii
cerebr
perivascular
space
cpv
hypothes
natalizumab
reduc
number
antigen
present
cell
apc
cpv
inflammatori
cell
number
cpv
cerebr
tissu
assess
immunohistochem
stain
patient
ms
develop
progress
multifoc
leukoencephalopathi
pml
natalizumab
therapi
control
includ
locationmatch
cerebr
autopsi
materi
patient
without
cn
diseas
ms
patient
treat
natalizumab
patient
pml
associ
natalizumab
therapi
absolut
number
cpv
patient
ms
treat
natalizumab
significantli
lower
control
group
due
extens
destruct
tissu
architectur
express
mhc
class
ii
molecul
number
dendrit
cell
dc
significantli
decreas
cpv
patient
ms
treat
natalizumab
cell
detect
observ
may
explain
differenti
prolong
effect
natalizumab
therapi
leukocyt
number
csf
multipl
sclerosi
ms
inflammatori
diseas
central
nervou
system
axon
damag
degener
contribut
significantli
progress
irrevers
neurolog
disabl
similar
pathogen
myelin
autoimmun
autoimmun
respons
neuron
antigen
may
contribut
axon
damag
irrevers
disabl
ms
autoantibodi
axon
cytoskelet
protein
neurofila
light
nfl
associ
cerebr
atrophi
ms
recent
report
nfl
autoimmun
pathogen
mice
howev
tcell
respons
nfl
ms
patient
examin
identifi
character
tcell
prolif
respons
nfl
compar
myelin
oligodendrocyt
glycoprotein
mog
ms
patient
healthi
control
use
carboxyfluorescein
succinimidyl
ester
cfse
dilut
assay
show
respons
mog
domin
cell
respons
nfl
observ
tcell
popul
mog
nflreactiv
cell
express
indic
memori
phenotyp
moreov
contrast
mogstimul
predominantli
induc
interferongamma
tcell
respons
nfl
observ
indic
induct
interferongamma
tumor
necrosi
factoralpha
well
find
tcell
respons
nfl
ms
patient
may
reflect
transient
activ
pathogen
potenti
presenc
also
healthi
control
indic
cell
part
normal
immun
repertoir
school
biochemistri
immunolog
dublin
ireland
ms
patient
treat
ifn
beta
report
reduc
level
proinflammatori
cytokin
ifn
gamma
increas
level
antiinflammatori
cytokin
howev
precis
mechan
action
ifn
beta
unclear
antigen
present
cell
particularli
dendrit
cell
dc
play
crucial
role
direct
cell
respons
via
product
regulatori
cytokin
includ
famili
member
promot
induct
ifn
gammasecret
helper
th
cell
wherea
promot
develop
regulatori
cell
recent
famili
member
togeth
shown
promot
develop
cell
demonstr
play
pathogen
role
autoimmun
disord
protect
role
anoth
famili
member
demonstr
experiment
autoimmun
enceph
eae
model
antagonis
induct
cell
upregul
therefor
studi
investig
effect
ifn
beta
treatment
product
human
dc
dc
stimul
recombin
ifn
beta
h
cytokin
concentr
assay
elisa
cell
stain
express
analys
flow
cytometri
altern
dc
cultur
presenc
ifn
beta
activ
tlr
ligand
h
use
stimul
allogen
cell
day
supernat
assay
elisa
cytokin
demonstr
ifn
beta
enhanc
product
dc
furthermor
stimul
allogen
cell
dc
grown
presenc
ifn
beta
increas
cell
decreas
product
treatment
dc
ifn
beta
also
upregul
express
cell
surfac
inhibitori
molecul
marker
tolerogen
dc
data
suggest
ifn
beta
may
exert
protect
effect
modul
cytokin
profil
dc
cell
expand
activ
tolerogen
dc
cell
central
role
initi
autoimmun
respons
ms
cell
occupi
ecolog
nich
peripheri
regul
homeostat
mechan
investig
claim
cell
homeostat
abnorm
occur
ms
basi
abnorm
could
clearli
establish
object
test
hypothesi
rrm
patient
prematur
thymic
involut
lead
reduc
gener
recent
thymic
emigr
rte
follow
compensatori
homeostat
prolifer
cell
test
hypothesi
use
facsaria
cell
sorter
isol
subset
cell
patient
agematch
healthi
control
base
express
level
specif
isol
subset
rte
nonrt
use
realtim
pcr
quantifi
signal
joint
cell
receptor
excis
circl
sjtrec
beta
trec
dna
subset
marker
thymic
output
addit
homeostat
marker
analyz
flow
cytometri
within
differ
subset
result
control
true
rte
show
signific
declin
trec
level
increas
age
wherea
rrm
compar
cell
consist
low
trec
level
irrespect
age
second
rrm
rte
nonrt
show
significantli
increas
express
receptor
wherea
nonrt
increas
level
report
first
definit
evid
thymic
abnorm
rrm
lead
reduc
thymic
output
compensatori
homeostat
prolifer
affect
rte
nonrt
cell
chang
may
increas
autoreact
predispos
rrm
multipl
sclerosi
ms
immunemedi
diseas
central
nervou
system
cn
cytokin
chemokin
solubl
mediat
immun
system
involv
pathogenesi
ms
regul
transmigr
immun
cell
cn
mediat
subsequ
develop
tissu
damag
alter
cytokin
chemokin
profil
cerebrospin
fluid
blood
shown
aim
studi
examin
whether
molecul
could
use
marker
diseas
activ
marker
differ
subtyp
ms
method
studi
includ
subject
patient
differ
subtyp
ms
patient
clinic
isol
syndrom
ci
healthi
control
among
ms
patient
patient
treat
interferonbeta
sera
level
cytokin
includ
trail
fa
fasl
mif
tnfalpha
ifngamma
determin
use
elisa
bioplex
suspens
array
system
median
level
macrophag
migrat
inhibitori
factor
mif
sera
lower
untreat
patient
ms
healthi
control
vs
pgml
p
especi
relapsingremit
ms
rrm
patient
also
signific
differ
rrm
primari
progress
ms
patient
vs
pgm
p
level
mif
also
lower
ci
patient
compar
healthi
control
vs
pgml
p
also
level
tnfalpha
upregul
ms
patient
compar
healthi
control
differ
ms
subtyp
vs
pgml
ifntreat
patient
level
upregul
compar
untreat
patient
vs
pgml
p
result
show
mif
could
use
potenti
ms
subtyp
marker
observ
need
valid
substanti
patient
group
kondo
komori
mika
tomimoto
hidekazu
tanaka
masami
tanaka
keiko
takahashi
ryousuk
matsuo
hidenori
saida
takahiko
nagasaki
medic
center
neurolog
nagasaki
japan
multipl
sclerosi
ms
japan
classifi
two
group
convent
ms
cm
opticospin
ms
osm
report
former
associ
confer
suscept
latter
follow
find
posit
associ
neuromyel
optica
nmo
japanes
osm
antibodi
relationship
among
cm
seroposit
seroneg
osm
becom
main
focu
interest
longitudin
extens
myeliti
promin
featur
relat
antibodi
posit
group
patient
group
cm
seroposit
seroneg
long
spinal
ls
ms
contigu
spinal
cord
lesion
segment
length
studi
hla
class
ii
associ
within
group
patient
cm
seroposit
lsm
seroneg
lsm
enrol
studi
pcramplif
hladr
gene
dr
allel
determin
sequencespecif
oligonucleotid
probe
hladp
allel
amplifi
allelespecif
primer
determin
dp
allel
data
publish
nalajima
et
al
http
jshiuminacjphladatadatahtml
use
control
subject
compar
control
subject
allel
tend
increas
cm
patient
vs
p
determin
allel
remain
ambigu
allel
frequenc
carri
cm
higher
control
vs
p
lsm
vs
p
frequenc
seroposit
seroneg
lsm
also
differ
significantli
vs
p
frequenc
carri
cm
lower
lsm
vs
p
increas
lsm
compar
control
seroposit
lsm
seroneg
lsm
total
lsm
vs
control
p
cm
vs
p
allel
frequenc
cm
seroposit
seroneg
lsm
control
respect
signific
differ
observ
consid
linkag
disequilibrium
fail
find
differ
number
subject
studi
reveal
cm
lsm
differ
immunogenesi
howev
fail
show
particular
dp
allel
confer
suscept
three
group
contrast
previou
report
other
solubl
trail
baff
level
multipl
sclerosi
therapi
hacettep
univers
oncolog
institut
depart
basic
oncolog
ankara
turkey
primer
medic
imag
center
ankara
turkey
tumor
necrosi
factorrel
apoptosisinduc
ligand
trail
member
tumor
necrosi
factor
famili
immunomodulatori
capac
protect
role
autoimmun
trail
inhibit
cell
activ
cell
cycl
progress
ifngamma
product
may
import
modul
diseas
express
downregul
mechan
tcelldriven
respons
critic
b
cell
surviv
matur
baff
affect
humor
cellmedi
respons
increas
solubl
baff
sbaff
protein
level
report
sever
autoimmun
disord
studi
focus
express
trail
level
lymphocyt
multipl
sclerosi
ms
patient
healthi
individu
evalu
effect
therapi
solubl
trail
baff
level
ms
patient
age
gender
match
relaps
remit
ms
patient
healthi
control
includ
studi
patient
evalu
prognosi
age
diseas
onset
diseas
durat
expand
diseas
sever
score
edss
also
cranial
magnet
reson
detail
number
infra
supratentori
plaqu
number
contrast
enhanc
plaqu
corpu
callosum
atrophi
enhanc
brain
atrophi
analys
karni
urshanski
natali
mausner
karin
fahoum
fira
tel
aviv
souraski
medic
center
tel
aviv
univers
tel
aviv
israel
tel
aviv
souraski
medic
center
tel
aviv
israel
neurotrophin
implic
play
neuroprotect
role
ms
lesion
report
patient
rrm
pbmc
secret
low
level
bdnf
upregul
stimul
defect
studi
product
regul
neurotrophin
mrna
bdnf
ngf
immun
cell
patient
rrm
pbmc
patient
rrm
untreat
patient
patient
treat
match
healthi
control
hc
incub
h
monoclon
antibodi
mab
isotyp
control
ic
mrna
quantiti
bdnf
ngf
pbmc
studi
realtim
qrtpcr
reaction
instrument
gapdh
gene
run
parallel
intern
control
reaction
set
result
express
product
ratio
neurotrophin
mrna
vs
gapdh
mrna
basal
express
neurotrophin
mrna
bdnf
mrna
similar
patient
hc
p
ns
ngf
mrna
tend
lower
patient
vs
hc
p
mrna
lower
patient
vs
hc
p
stimul
pbmc
mab
upregul
mrna
express
bdnf
ngf
compar
effect
ic
hc
bdnf
mrna
vs
respect
p
ngf
mrna
vs
respect
p
b
mrna
vs
respect
p
b
comparison
upregulatori
capac
stimul
use
ratio
mrna
product
stimul
vs
ic
hc
patient
bdnf
mrna
ratio
vs
respect
p
b
ngf
mrna
ratio
vs
respect
p
mrna
ratio
vs
respect
p
signific
differ
neurotrophin
mrna
express
found
pbmc
untreat
treat
patient
patient
followedup
treatment
initi
month
blood
trail
express
lymphocyt
solubl
trail
baff
level
analys
flow
cytometri
elisa
respect
patient
analys
gender
age
diseas
onset
diseas
durat
initi
symptom
prognost
factor
edss
ms
patient
mean
basal
flowtrail
express
rate
control
group
detect
howev
ms
patient
basal
ftrail
level
valuesn
control
mean
basal
trail
wherea
other
signific
differ
aspect
gender
age
diseas
onset
diseas
durat
prognosi
edss
two
group
also
similar
detail
cranial
mri
featur
patient
group
high
ftrail
level
treatment
month
mean
ftrail
level
found
p
b
wherea
month
p
b
ms
patient
mean
solubl
basal
trail
level
control
group
statist
differ
p
n
mean
solubl
trail
level
valu
significantli
increas
sixth
month
therapi
mean
basal
baff
level
control
ms
patient
statist
signific
p
b
statist
signific
sbaff
level
found
treatment
month
studi
evalu
effect
therapi
serial
trail
baff
level
longitudin
pretreat
period
detect
signific
differ
serum
strail
level
compar
healthi
control
serum
level
strail
significantli
higher
month
pretreat
valu
ms
patient
mean
basal
flowtrail
express
rate
higher
control
group
howev
also
observ
two
subgroup
patient
express
differ
trail
rate
similar
higher
level
compar
control
trail
express
level
significantli
lower
month
pretreat
valu
detect
decreas
trail
level
therapi
may
depend
cleavag
membran
trail
specif
metalloproteas
solubl
trail
support
literatur
autoimmun
diseas
pretreat
period
baff
level
found
significantli
higher
ms
group
howev
interferon
treatment
signific
effect
longitudin
data
suggest
lead
modul
solubl
trail
level
lead
secondari
compensatori
mechan
downregul
inflammatori
respons
hail
pasichnyk
dion
giuliani
fabrizio
infiltr
cell
macrophag
character
lesion
inflammatori
diseas
central
nervou
system
multipl
sclerosi
ms
activ
cytotox
cell
releas
granzym
b
grb
serin
proteas
induc
neurotox
degrad
myelin
injur
neuron
howev
separ
effect
subset
cell
term
grb
express
neurotox
describ
object
studi
explor
compar
level
grb
express
lymphocyt
subset
well
evalu
separ
effect
human
neuron
injuri
human
lymphocyt
activ
day
anti
neg
select
use
magnet
separ
express
granzym
b
cell
subset
measur
realtim
pcr
human
cortic
foetal
neuron
hfn
wk
age
cultur
alon
cocultur
unactiv
activ
whole
cell
subset
polyornithin
coat
cultur
plate
h
neuron
viabil
assess
use
immunocytochemistri
microtubul
associ
neuron
count
manual
rtpcr
reveal
activ
cell
express
grb
fold
comparison
unactiv
cell
activ
cell
also
express
fold
grb
compar
cell
contrast
cell
activ
absenc
cell
level
grb
compar
cell
viabil
hfn
significantli
low
cocultur
activ
tcell
activ
cell
wherea
hfn
surviv
cocultur
activ
cell
find
demonstr
lymphocyt
trigger
high
express
grb
cell
grb
mrna
express
correl
neuron
kill
cell
major
effector
neuron
kill
howev
activ
cell
depend
cell
grb
express
studi
go
evalu
cytotox
effect
postselect
activ
cell
aranami
sato
wakiro
yamamura
takashi
depart
immunolog
nation
institut
neurosci
ncnp
kodaira
japan
multipl
sclerosi
ms
chronic
inflammatori
diseas
central
nervou
system
activ
autoreact
cell
target
myelin
antigen
differenti
effector
cell
presum
play
pathogen
role
report
cell
lack
costimulatori
molecul
express
cell
expand
ms
patient
cell
clone
deriv
cell
exhibit
high
abil
produc
ifng
howev
specif
antigen
pathogen
role
cell
ms
unclear
report
cell
ms
abnorm
differenti
cell
enrich
specif
alphabcrystallin
cryab
highli
express
oligodendrocyt
astrocyt
activ
ms
lesion
normal
brain
age
sexmatch
forti
untreat
ms
patient
remiss
state
nine
healthi
subject
hs
enrol
studi
examin
cytokin
product
cell
upon
polyclon
stimul
pma
ionomycin
found
predominantli
produc
ifng
analyz
express
tbet
essenti
transcript
factor
cell
intracellular
tbet
stain
found
cell
tbet
high
popul
among
cell
albeit
higher
express
tbet
cell
cell
cell
contain
fewer
cell
express
report
induc
cell
regul
ifng
product
analyz
frequenc
cell
respond
ovalbumin
ova
myelin
basic
protein
mbp
cryab
found
frequenc
cell
respond
cryab
ova
mbp
cell
ms
patient
significantli
higher
hs
cell
ms
hs
specif
respond
neither
antigen
result
suggest
cell
enrich
abnorm
differenti
cell
autoreact
cryab
might
contribut
autoimmun
inflamm
ms
multipl
sclerosi
ms
patholog
studi
vivo
evalu
kinet
lesion
volum
variat
time
use
frequent
mri
scan
purpos
patient
relaps
remit
ms
cours
n
follow
new
lesion
show
persist
blood
brain
barrier
bbb
damag
visual
contrast
enhanc
least
three
observ
select
lesion
analyz
use
six
consecut
observ
lesion
volum
calcul
use
semiautom
contour
method
flair
mainli
sensit
water
chang
sequenc
administr
two
differ
contrast
dose
gadolinium
gd
acut
phase
lesion
visual
flair
sequenc
consist
result
larger
gd
enhanc
volum
follow
time
similar
kinet
profil
howev
gd
enhanc
disappear
visual
flair
sequenc
persist
reach
stabl
volum
consist
smaller
maximum
volum
gd
enhanc
phase
interpol
volum
kinet
lesion
multiparametr
fit
suitabl
describ
diffus
expans
contract
phenomena
biolog
environ
gener
random
walk
type
profil
describ
detail
flair
volum
kinet
profil
result
two
differ
phenomena
follow
two
differ
kinet
first
one
mainli
associ
earliest
part
curv
probabl
depend
bbb
disrupt
inflamm
second
one
follow
first
partli
overlap
probabl
reflect
cellular
infiltr
caus
irrevers
tissu
abnorm
result
indic
tissu
damag
involv
part
ms
lesion
visual
acut
phase
unifi
hypothesi
underli
pathogen
mechan
gener
hypothesi
support
model
acut
ms
lesion
target
morpholog
organ
follow
center
mainli
inflammatori
infiltr
tissu
damag
inner
peripheri
bbb
damag
caus
solubl
inflammatori
factor
diffus
infiltr
extern
peripheri
edema
made
fluid
diffus
bbb
damag
area
addit
acut
phase
lesion
shrink
usual
leav
stabil
hyperintens
model
impli
stabl
abnorm
made
center
acut
lesion
tissu
damag
cell
infiltr
persist
behind
heal
bbb
renew
interest
role
b
cell
antigen
present
cell
apc
occur
follow
recent
result
demonstr
benefici
effect
b
cell
deplet
therapi
relaps
remit
multipl
sclerosi
ms
sinc
effect
fairli
immedi
like
peripher
b
cell
central
role
pathogenesi
diseas
demonstr
activ
peripher
b
cell
capabl
effici
present
myelin
antigen
autolog
peripher
cell
contrast
cpg
oligodeoxynucleotid
activ
peripher
b
cell
ms
patient
healthi
control
unabl
stimul
autolog
cell
prolifer
respons
antigen
test
small
popul
b
cell
ms
patient
healthi
control
b
cell
effici
bound
myelin
basic
protein
flow
cytometri
correl
apc
function
addit
begun
dissect
capac
ex
vivo
peripher
memori
b
cell
antigen
present
thu
far
observ
memori
b
cell
capabl
present
recal
antigen
autolog
cell
healthi
control
ms
patient
predict
memori
b
cell
b
cell
ms
patient
abl
present
myelin
oligodendrocyt
glycoprotein
autolog
cell
result
suggest
memoryactiv
b
cell
may
import
popul
apc
context
ms
methyltioadenosin
mta
immunomodulatori
activ
inhibit
activ
nfkb
prevent
methyl
tcell
activ
show
benefici
effect
anim
model
multipl
sclerosi
ms
goal
studi
compar
mta
therapi
ms
diseas
modifi
drug
dmd
assess
tissu
injuri
protect
mediat
mta
mta
therapi
evalu
mice
immun
peptid
develop
chronicprogress
experiment
autoimmun
encephalomyel
eae
murin
interferon
beta
ifnbeta
glatiram
acet
well
mta
administ
ip
everi
day
day
immun
clinic
histolog
score
record
blind
axon
protect
quantifi
confoc
microscopi
mta
therapi
demonstr
doserespons
effect
amelior
eae
mice
complet
suppress
diseas
higher
dose
mcmkg
intermedi
dosag
mta
show
better
efficaci
murin
ifnbeta
uday
ga
mgday
prevent
eae
inde
found
synergi
mta
glatiram
acet
sinc
suboptim
dosag
combin
drug
effici
suppress
diseas
tissu
damag
prevent
decreas
amount
axon
damag
quantifi
confoc
microscopi
label
axon
final
found
toxic
dose
test
mta
potent
immunomodulatori
effect
display
synergi
dmd
prevent
axon
damag
model
ms
effect
glatiram
acet
ga
combin
minocyclin
min
secondgener
tetracyclin
investig
cours
eae
mice
result
signific
reduct
diseas
sever
burden
attenu
inflamm
axon
loss
demyelin
investig
effect
combin
therapi
ga
min
induct
matur
phenotyp
blood
monocytederiv
dendrit
cell
dc
multipl
sclerosi
ms
patient
express
hladr
studi
flow
cytometr
analysi
immatur
idc
matur
dc
mdc
untreat
ga
treat
ms
patient
thirteen
relapsingremit
ms
patient
healthi
control
hc
includ
studi
ten
ms
patient
group
retest
month
period
ga
treatment
marker
express
dc
untreat
ms
hc
studi
vitro
absenc
presenc
ga
gamin
dc
ga
treat
ms
patient
without
vitro
addit
min
found
vitro
ga
alon
p
b
combin
min
p
b
downregul
dc
antigen
present
capabl
hladr
wherea
combin
treatment
affect
p
also
myeloid
dc
activ
ms
hc
prolong
ga
treatment
vivo
two
month
affect
p
antigen
present
capabl
dc
wherea
treat
vitro
min
cell
also
reduc
p
b
activ
marker
express
myeloid
phenotyp
acquisit
present
data
demonstr
possibl
combin
effect
ga
min
peripher
blood
monocyt
deriv
dc
ms
patient
cytokineneuroantigen
nag
fusion
protein
promis
new
class
antigenspecif
therapi
treatment
cn
autoimmun
diseas
primari
object
studi
assess
therapeut
efficaci
select
cytokineneuroantigen
fusion
protein
lewi
rat
model
eae
express
system
sever
cytokinenag
fusion
protein
deriv
cytokin
domain
compris
ifnbeta
antigen
domain
fusion
protein
compris
major
encephalitogen
determin
myelin
basic
protein
refer
neuroantigen
nag
predict
cytokin
domain
would
bind
respect
cytokin
receptor
antigen
present
cell
apc
simultan
promot
antiinflammatori
tolerogen
activ
apc
target
nag
domain
class
ii
mhc
antigen
process
pathway
enhanc
present
target
present
nag
cytokinecondit
apc
would
predict
inhibit
nagspecif
cell
interact
apc
fusion
protein
express
purifi
subcutan
administ
salin
test
inhibit
eae
three
differ
cytokinenag
fusion
protein
potent
inhibitor
eae
fusion
protein
incorpor
cytokin
ntermin
domain
fusion
protein
secret
cytokin
ctermin
domain
fusion
protein
ifnbeta
cytokin
ntermin
domain
ifnbetanag
fusion
protein
fusion
protein
administ
rat
per
week
total
three
inject
week
least
one
week
later
rat
challeng
nag
cfa
induc
eae
compar
nag
alon
fusion
protein
strongli
attenu
subsequ
activ
induct
eae
fusion
protein
also
inhibit
eae
administ
encephalitogen
challeng
onset
eae
pretreat
rat
mechan
toler
activ
shown
adopt
transfer
studi
conclus
cytokinenag
fusion
protein
incorpor
ifnbeta
cytokin
domain
may
compris
effect
tolerogen
therapi
cn
autoimmun
diseas
object
studi
elucid
statin
therapeut
potenti
suppress
chronic
autoimmun
respons
multipl
sclerosi
ms
specif
studi
statininduc
chang
dendrit
cell
dc
matur
antigen
present
capac
statininduc
chang
dc
cytokin
product
may
modifi
cell
differenti
develop
autoimmun
respons
ms
order
assess
statininduc
chang
dc
matur
measur
surfac
express
hla
class
class
ii
surfac
dc
matur
absenc
presenc
simvastatin
result
patient
relaps
remit
rr
ms
reveal
simvastatin
significantli
decreas
percentag
hla
class
p
p
p
express
cell
consist
inhibit
dc
matur
function
effect
simvastatininduc
inhibit
dc
antigen
present
capac
confirm
experi
myelin
basic
protein
mbp
tcell
clone
rtpcr
studi
measur
simvastatininduc
chang
dc
cytokin
product
detect
signific
upregul
p
p
inhibit
p
p
gene
express
measur
secret
cytokin
dc
cultur
reveal
upregul
p
downregul
p
p
p
protein
level
statintr
comparison
untreat
cultur
final
evalu
extent
statininduc
inhibit
dc
matur
chang
dc
cytokin
secret
inhibit
cell
differenti
identifi
simvastatintr
dc
cellto
cell
contact
supernat
simvastatintr
dc
inhibit
cell
differenti
result
reveal
simvastatin
suppress
dc
antigen
present
capac
chang
dc
cytokin
product
collect
inhibit
differenti
casereport
cladribin
alemtuzumab
haematolog
treatment
chronic
lymphat
leukemia
stabil
effect
secondaryprogress
multipl
sclerosi
multipl
sclerosi
ms
chronic
demyelin
disord
central
nervou
system
cn
sever
ms
form
known
relapsingremit
form
rrm
begin
ms
typic
autoimmun
inflammatori
activ
usual
proce
year
secondaryprogress
form
spm
prevail
neurodegener
variabl
residu
inflamm
current
ms
drug
direct
inflamm
signific
neuroregen
potenti
therefor
effect
greatest
rrm
decreas
spm
sever
new
drug
studi
ms
includ
cytostat
agent
cladribin
monoclon
antibodi
cell
surfac
marker
b
cellsalemtuzumab
alreadi
use
haematooncolog
ho
practic
object
report
stabil
effect
cladribin
alemtuzumab
ho
treatment
spm
casereport
caucasian
man
ms
histori
sinc
first
symptom
optic
neuriti
left
eye
secondari
progress
cours
sinc
treatment
histori
involv
corticosteroid
ms
relaps
combin
immunosuppress
lowdos
oral
corticosteroid
azathioprin
mg
daili
later
methotrex
mg
weekli
inflamm
central
process
pathophysiolog
multipl
sclerosi
ms
avail
treatment
ms
patient
target
inflammatori
process
accordingli
gene
express
studi
perform
three
main
clinic
form
ms
experiment
autoimmun
encephalomyel
eae
anim
model
ms
found
overal
modul
express
inflammatori
gene
particular
found
regul
chemokin
receptor
alreadi
describ
associ
patholog
inflamm
ms
eae
therefor
test
function
activ
vivo
sjl
mice
affect
relapsingremit
rr
eae
modul
activ
use
engin
monomer
variant
name
administ
prevent
therapeut
compar
efficaci
differ
dose
methylprednisolon
refer
compound
compar
subcutan
sc
intraperiton
ip
administr
prevent
treatment
significantli
delay
diseas
onset
dose
depend
way
display
effect
clinic
paramet
observ
signific
clinic
effect
treatment
start
diseas
onset
neuropatholog
analysi
hand
show
efficaci
therapeut
treatment
found
statist
signific
dosedepend
decreas
demyelin
axon
loss
number
infiltr
cell
mice
spinal
cord
cell
macrophag
mice
compar
control
immunolog
analysi
reveal
expect
act
agspecif
cell
prolifer
interfer
differenti
effector
cell
howev
observ
inhibit
releas
upon
antigen
stimul
taken
togeth
result
suggest
therapeut
mechan
may
reli
interfer
immun
cell
recruit
includ
mild
clinic
efficaci
prevent
set
neural
protect
tissu
damag
evalu
administr
start
first
clinic
attack
compris
ntermin
cytokin
domain
rat
gmcsf
mcsf
ctermin
antigen
domain
nag
encephalitogen
determin
myelin
basic
protein
biolog
activ
cytokinenag
fusion
protein
examin
vitro
assay
util
irradi
splenic
apc
myelin
basic
protein
mbp
specif
cell
clone
gmcsfnag
fusion
protein
approxim
fold
potent
nag
alon
stimul
antigen
prolifer
mbpspecif
cell
clone
mcsfnag
fusion
protein
fold
potent
nag
fusion
protein
slightli
potent
nag
abil
fusion
protein
potenti
antigen
prolifer
depend
coval
linkag
cytokin
nag
domain
addit
gmcsf
mcsf
plu
nag
separ
molecul
potenti
mbpspecif
cell
prolifer
addit
data
reinforc
concept
cytokinenag
fusion
protein
enhanc
antigen
prolifer
target
antigen
apc
instanc
nag
target
gmcsfnag
mcsfnag
specif
inhibit
pretreat
assay
respect
cytokin
gmcsf
mcsf
vice
versa
addit
cytokinenag
fusion
protein
specif
potenti
antigen
prolifer
presenc
particular
apc
subset
gmcsfnag
mcsfnag
fold
potent
nag
alon
presenc
dc
macrophag
fusion
protein
stimul
potenti
antigen
recognit
presenc
b
cell
cell
apc
conclus
gmcsf
mcsf
cytokin
domain
target
nag
domain
dc
macrophag
apc
subset
data
indic
cytokineantigen
fusion
protein
may
provid
import
tool
studi
apc
subset
promot
inflammatori
tolerogen
respons
experiment
autoimmun
encephalomyel
natalizumab
recombin
human
antibodi
direct
integrin
novel
agent
prevent
migrat
immun
cell
brain
reduc
number
relaps
relapsingremit
multipl
sclerosi
rrm
signific
increas
tumor
necrosi
factor
tnf
express
product
peripher
blood
mononuclear
cell
pbmc
well
trend
toward
worsen
fatigu
previous
report
patient
rrm
treat
natalizumab
period
month
report
rel
express
cytokin
cerebrospin
fluid
csf
pbmc
patient
rrm
month
natalizumab
treatment
longterm
effect
fatigu
sever
scale
fss
expand
disabl
statu
scale
edss
multipl
sclerosi
impact
scale
symbol
digit
modal
test
sdmt
rel
mrna
express
cytokin
measur
realtim
rtpcr
methodolog
administr
natalizumab
mg
iv
infus
everi
week
dramat
reduc
csf
mononuclear
cell
count
p
b
express
tnf
interferongamma
ifng
mrna
significantli
increas
pbmc
p
b
p
b
interleukin
il
transform
growth
factorbeta
remain
unchang
contrast
csf
cell
express
level
ifng
decreas
p
b
p
b
increas
p
b
although
edss
improv
significantli
p
b
fss
sdmt
remain
unchang
compar
baselin
score
entir
cohort
howev
score
improv
patient
sever
diseas
edss
n
n
attenu
immun
cell
traffick
brain
reduct
proinflammatori
cytokin
central
nervou
system
compart
correl
improv
neurolog
function
measur
edss
rel
differ
function
measur
fatigu
detect
group
sever
neurolog
disabl
specul
increas
product
proinflammatori
cytokin
peripheri
may
imped
improv
fatigu
natalizumab
treat
patient
rrm
azathioprin
aza
thiopurin
drug
wide
use
immunosuppress
antiinflammatori
agent
organ
transplant
chemotherapi
shown
sever
clinic
trial
aza
effect
modifi
cours
ms
administ
lymphocytesuppress
dose
well
toler
effect
reduc
ms
new
brain
inflammatori
lesion
studi
investig
action
human
dendrit
cell
dc
describ
first
time
impair
vitro
differenti
dc
inhibitori
effect
dc
activ
process
may
inhibit
fulli
activ
process
dc
induc
function
less
immunogen
phenotyp
reduc
dc
express
compar
control
find
add
novel
action
mechan
aza
immun
modul
dc
differenti
cultur
presenc
absenc
two
dose
immatur
dc
activ
h
lp
matur
state
evalu
surfac
marker
express
hladr
flow
cytometri
dendrit
cell
macropinocytosi
capabl
examin
dextranfitc
assay
dc
function
evalu
allostimulatori
abil
antigen
specif
stimul
ck
product
express
evalu
realtim
pcr
result
show
inhibit
dc
differenti
precursor
reduc
express
lp
activ
found
regul
result
less
potent
induct
allogen
cell
prolifer
reduc
antigen
specif
prolifer
thu
treat
dc
lp
activ
lead
decreas
stimul
memori
cell
moreov
find
dc
treat
retain
endocyt
activ
lp
stimul
indic
reduc
express
determin
less
effici
costimul
goe
togeth
less
matur
therefor
tolerogen
dc
phenotyp
matur
dc
incub
express
reduc
indic
downmodul
molecul
cell
surfac
data
suggest
immunomodulatori
effect
aza
involv
side
immun
synaps
dc
cell
reveal
specif
way
action
futur
interest
investig
ex
vivo
isol
dc
treat
patient
togeth
treg
subpopul
celecoxib
specif
nonsteroid
antiinflammatori
drug
nsaid
indic
treatment
arthriti
pain
recent
studi
shown
benefit
treatment
colorect
cancer
though
associ
risk
cardiovascular
event
may
imped
implement
recent
shown
trifluoromethyl
analogu
celecoxib
abbrevi
tfmcelecoxib
lack
activ
induc
cellular
retent
posttransl
mechan
involv
perturb
endoplasm
reticulum
chaperon
er
mol
pharmacol
also
demonstr
celecoxib
inhibit
eae
mechan
brain
brain
brain
mediat
downregul
cytokin
adhes
factor
chemokin
present
studi
analys
mode
action
tmfcelecoxib
detail
well
assess
effect
eae
model
use
recombin
cell
line
establish
lab
found
tmfcelecoxib
block
secret
heterodim
homodim
heterodim
potenc
wildtyp
celecoxib
comprehens
analysi
erresid
chaperonesfoldas
associ
cofactor
show
tmfcelecoxib
induc
signific
transcript
upregul
part
molecular
mass
protein
complex
involv
retrotransloc
misfold
protein
prior
degrad
experi
use
sirna
knockdown
well
immunoprecipit
select
er
chaperon
reveal
pictur
multipl
chaperon
interact
involv
er
retent
cytokin
tmfcelecoxib
also
first
time
assess
efficaci
tmfcelecoxib
eae
tmfcelecoxib
appear
decreas
clinic
score
effect
indistinguish
celecoxib
analysi
perform
assess
effect
ifngamma
secret
eae
model
tmfcelecoxib
may
constitut
first
drug
treatment
neuroinflammatori
disord
multipl
sclerosi
work
mechan
disrupt
cytokin
fold
er
total
lack
inhibitori
activ
benefici
sinc
inhibit
prostaglandin
synthesi
associ
deleteri
alter
endotheli
cell
potenti
contribut
develop
cardiac
event
multipl
sclerosi
common
demyelin
diseas
central
nervou
system
cn
though
etiolog
agent
ms
still
unknown
epidemiolog
data
suggest
environment
agent
viru
may
initi
diseas
theiler
murin
encephalomyel
viru
tmev
murin
picornaviru
induc
demyelin
diseas
suscept
strain
mice
inject
intracrani
theiler
virusinduc
demyelin
tvid
lesion
similar
seen
ms
patient
thu
tvid
valuabl
anim
model
studi
ms
current
interferonbeta
ifnb
major
treatment
option
ms
patient
unfortun
ifnb
treatment
success
ms
patient
often
produc
undesir
side
effect
thu
search
altern
therapi
area
intens
investig
within
field
ms
interferon
tau
ifnt
type
ifn
produc
rumin
pregnanc
less
cytotox
ifnb
equal
effect
immunomodul
crossspeci
reactiv
ifnt
key
use
treatment
human
immunemedi
diseas
ms
therapeut
potenti
oral
ifnt
treatment
ms
assess
stage
iii
clinic
trial
object
studi
test
abil
ifnt
amelior
tvid
elucid
mechan
immunomodul
tmevinfect
mice
inject
ip
encapsul
ifnt
everi
day
eight
week
treatment
began
week
postinfect
hypothes
ifnt
would
stabil
clinic
score
decreas
inflamm
demyelin
decreas
type
cytokin
initi
result
reveal
ifnttreat
mice
improv
clinic
score
start
week
posttreat
likewis
test
coordin
reveal
mice
treat
ifnt
regain
function
nontreat
mice
exhibit
increas
disabl
histopatholog
reveal
decreas
inflamm
demyelin
treat
mice
lastli
splenicderiv
cell
stimul
ex
vivo
tmev
increas
express
type
type
cytokin
ifng
tnfa
result
indic
possibl
remyelin
within
ifnttreat
mice
studi
use
electron
microscopi
underway
test
hypothesi
flow
cytometr
studi
elucid
phenotyp
cell
express
chemokinecytokin
receptor
ifnttreat
versu
nontreat
mice
poster
session
bloodbrain
barrier
chemokin
bloodbrain
barrier
breakdown
repair
follow
gliotox
drug
inject
brainstem
streptozotocindiabet
rat
bondan
lallo
maria
anet
univers
paulista
univers
cruzeiro
sul
paulo
brazil
ethidium
bromid
eb
caus
local
oligodendrogli
astrocyt
disappear
primari
demyelin
glia
limitan
disrupt
suppos
bloodbrain
barrier
bbb
breakdown
schwann
cell
invas
hyperglycemia
observ
diabet
mellitu
known
caus
chang
behaviour
glial
cell
aim
studi
investig
bbb
integr
inject
eb
brainstem
diabet
nondiabet
rat
adult
male
wistar
rat
use
receiv
singl
intraven
inject
streptozotocin
mgkg
submit
day
later
singl
inject
eb
group
salin
solut
ii
cisterna
ponti
ten
microlitr
eb
salin
solut
also
inject
nondiabet
rat
group
iii
iv
respect
rat
anaesthet
perfus
heart
h
day
eb
salin
inject
brainstem
section
collect
process
light
transmiss
electron
microscopi
studi
immunohistochem
stain
use
glial
fibrillari
acid
protein
gfap
astrocyt
marker
group
anim
receiv
colloid
carbon
ink
intraven
rout
min
submit
euthanasia
rat
group
ii
iv
sign
astrocyt
loss
leakag
ink
blood
vessel
inject
site
group
iii
astrocyt
disappear
began
h
area
still
devoid
astrocyt
process
day
leakag
carbon
particl
seen
h
day
group
h
day
group
iii
ebinduc
lesion
tight
junction
show
detect
ultrastructur
chang
due
lack
perivascular
astrocyt
group
inject
eb
diabet
rat
group
present
delay
macrophag
activ
lesser
remyelin
comparison
rat
group
iii
although
oligodendrocyt
major
remyelin
cell
brainstem
schwann
cell
invad
ebinduc
lesion
firstli
appear
day
nondiabet
rat
day
diabet
rat
result
indic
shortterm
streptozotocininduc
diabet
hinder
bbb
reconstruct
oligodendrocyt
schwann
cell
remyelin
comparison
nondiabet
rat
eb
inject
proinflammatori
cytokin
elev
concentr
autoimmun
diseas
involv
peripheri
eg
rheumatoid
arthriti
cn
eg
multipl
sclerosi
circul
affect
neuroinflamm
fulli
character
report
show
regulatori
chang
system
endotheli
cell
compos
bloodbrain
barrier
bbb
mous
model
lipopolysaccharid
lp
treatment
use
illustr
mechan
bbb
regul
four
aspect
studi
pharmacokinet
assay
bbb
permeabl
bloodborn
transcript
regul
receptor
subunit
bbb
level
posttransl
regul
endotheli
receptor
differ
greatli
respect
mrna
transcript
evid
cn
inflamm
induc
lp
remain
intact
least
min
intraven
inject
reach
cn
parenchyma
region
differ
brain
spinal
cord
invivo
insitu
brain
perfus
show
permeat
bbb
nonsatur
lp
induc
signific
increas
uptak
brain
spinal
cord
partli
relat
higher
gener
permeabl
bbb
strike
activ
system
cerebr
endothelia
cn
parenchym
cell
mediat
neuroinflamm
result
suggest
bbb
interfac
bloodborn
interact
cn
basal
state
inflamm
bloodbrain
barrier
characterist
multipl
sclerosi
kooij
gij
van
horssen
jack
van
der
pol
susann
dijkstra
christin
de
vri
bloodbrain
barrier
bbb
select
barrier
central
nervou
system
cn
system
circul
essenti
mainten
regul
neuroparenchym
environ
optim
neuron
function
act
physic
barrier
due
presenc
welldevelop
tight
junction
brain
endotheli
cell
imped
entranc
circul
molecul
immun
cell
cn
specif
transport
system
lumin
ablumin
membran
regul
transcellular
traffic
small
hydrophil
molecul
exclud
potenti
harm
compound
multidrug
resist
efflux
pump
previous
demonstr
loss
bbb
integr
appar
multipl
sclerosi
ms
anim
model
experiment
allerg
encephalomyel
magnet
reson
imag
use
newli
develop
contrast
agent
ultrasmal
particl
iron
oxid
uspio
specif
imag
inflammatori
event
bbb
leakag
anim
model
ms
patient
postmortem
analysi
wellcharacter
ms
patient
materi
also
reveal
alter
vascular
level
surround
perivascular
space
howev
remain
unknown
whether
molecular
function
bbb
affect
cours
ms
whether
contribut
diseas
immunohistochem
analysi
activ
inact
lesion
postmortem
ms
patient
materi
reveal
express
multipl
multidrug
resist
mdr
protein
decreas
predominantli
chronic
activ
lesion
level
brain
endothelium
contrast
alter
express
nutrient
transport
could
detect
vitro
model
bloodbrain
barrier
demonstr
gene
protein
express
glucos
transport
mdr
protein
decreas
inflammatori
agent
interestingli
efflux
capac
brain
endotheli
cell
pump
ligand
multidrug
resist
pump
diminish
inflammatori
condit
data
suggest
alter
bbb
function
physic
molecular
level
critic
determin
ms
lesion
format
bbb
dysfunct
contribut
tissu
damag
due
accumul
unwant
compound
cell
brain
parenchyma
improv
tumor
necrosi
factoralphainduc
disrupt
blood
brain
barrier
properti
mous
brain
capillari
endotheli
cell
sonob
takeuchi
hideyuki
kataoka
kunio
kawanokuchi
jun
mizuno
tetsuya
suzumura
akio
nagoya
univers
nagoya
japan
interleukin
il
member
famili
cytokin
includ
mrna
reportedli
express
activ
cell
lung
macrophag
lung
endotheli
cell
promot
helper
type
immun
respons
via
produc
addit
report
mice
highli
suscept
experiment
autoimmun
encephalomyel
eae
compar
wild
type
mice
suggest
regul
function
via
induc
cytokin
interestingli
mrna
also
reportedli
detect
brain
tissu
howev
cellular
sourc
function
brain
remain
unclear
thu
test
cell
express
function
brain
studi
use
mice
assess
express
mrna
extract
total
mrna
whole
brain
tissu
mix
glial
cell
cultur
primari
microglia
primari
astrocyt
primari
fibroblast
primari
neuron
mous
primari
endotheli
cell
bcec
perform
rtpcr
explor
protein
express
perform
immunohistochemistri
western
blot
evalu
permeabl
blood
brain
barrier
bbb
use
bcec
line
establish
bbb
model
perform
permeabl
assay
use
evan
blue
albumin
count
transmigr
cell
rtpcr
immunohistochem
analysi
show
brain
capillari
endotheli
cell
bcec
produc
microglia
astrocyt
neuron
fibroblast
oligodendrocyt
addit
increas
tj
protein
occludin
recov
express
level
downregul
tumor
necrosi
factor
tnf
alpha
bcec
permeabl
assay
cell
transmigr
assay
confirm
partial
suppress
tnfalphaincreas
permeabl
cell
migrat
across
bcec
collect
result
suggest
produc
brain
endotheli
cell
protect
tnfalphaassoci
collaps
bbb
control
inflammatori
cell
migrat
across
bbb
ms
eae
destruct
bloodbrain
barrier
bbb
integr
featur
neuroinflammatori
process
pathogenesi
experiment
autoimmun
encephalomyel
eae
studi
util
triptolid
trd
purifi
effect
ingredi
tripterygium
wilfordii
chines
herb
eae
rat
investig
kinet
chang
bbb
well
express
intercellular
adhes
eae
induc
wistar
rat
treat
trd
clinic
score
evalu
among
eae
trdtreat
complet
freund
adjuv
fca
group
accord
five
fork
method
albumin
serum
cerebrospin
fluid
csf
sampl
rat
examin
day
postinocul
pi
permeabl
bbb
evalu
calcul
csf
albumin
quotient
qa
time
brain
spinal
cord
remov
immunohistochemistri
stain
eae
model
studi
present
oneway
cours
diseas
diseas
appear
fca
group
clinic
symptom
occur
day
pi
eae
group
trdtreat
group
day
pi
clinic
symptom
reach
peak
display
hindlimb
paralysi
irrit
rapid
loss
bodi
weight
eae
group
mean
clinic
score
eae
group
higher
trdtreat
group
vs
p
b
day
pi
qa
reach
peak
eae
group
higher
fca
group
vs
p
b
qa
gradual
decreas
trdtreat
group
qa
increas
slightli
initi
stage
gradual
increas
reach
maximum
day
pi
later
eae
group
result
suggest
differ
qa
statist
signific
eae
group
trdtreat
group
vs
f
p
b
imag
analysi
show
mean
stain
photodens
trdtreat
group
lower
eae
group
vs
f
p
b
day
pi
earli
stage
eae
injuri
bbb
prior
appear
clinic
symptom
trd
downregul
also
repair
bbb
amelior
eae
semaphorin
famili
solubl
membraneassoci
protein
character
conserv
sema
domain
although
semaphorin
origin
identifi
axon
guidanc
molecul
emerg
sever
semaphorin
play
signific
role
immun
respons
exampl
express
cell
function
ligand
enhanc
humor
cellular
immun
respons
via
mice
resist
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
anoth
semaphorin
provid
costimulatori
signal
cell
nonredund
role
regul
respons
treatment
mice
antibodi
inhibit
develop
eae
thu
semaphorin
signific
role
peripher
immun
system
patholog
condit
eae
howev
unclear
whether
semaphorin
relat
immun
respons
system
bloodbrain
barrier
bbb
central
nervou
system
cn
investig
express
semaphorin
cn
eae
relev
bbb
eae
induc
mice
immun
peptid
spinal
cord
mice
subject
immunohistochem
analysi
semaphorin
express
infiltr
cell
around
mening
spinal
cord
eae
cell
express
semaphorin
lymphocyt
other
presum
macrophag
plexin
one
candid
receptor
semaphorin
express
lectinposit
cell
suppos
microglia
endotheli
cell
ec
express
pattern
consid
possibl
semaphorin
associ
immun
cell
traffick
bbb
analysi
vitro
semaphorin
enhanc
express
adhes
molecul
ec
result
indic
semaphorin
express
infiltr
cell
spinal
cord
eae
may
associ
traffick
immun
cell
cn
interferonbeta
regul
adenosin
express
bloodbrain
barrier
interferon
ifn
beta
treatment
reduc
relaps
rate
multipl
sclerosi
ms
mechan
action
remain
incomplet
understood
aim
clarifi
benefici
effect
ifnbeta
treatment
ms
ectoenzym
produc
adenosin
adenosin
monophosph
amp
amp
abundantli
present
site
inflamm
importantli
adenosin
product
activ
possess
antiinflammatori
neuroprotect
activ
current
studi
elect
assess
influenc
ifnbeta
treatment
express
surfac
primari
cultur
human
bloodbrain
barrier
endotheli
cell
bbbec
human
astrocyt
use
immunofluoresc
stain
flow
cytometri
ii
transmigr
lymphocyt
use
vitro
model
bbb
iii
activ
serum
ms
patient
use
radiochem
assay
final
iv
express
postmortem
ms
brain
sampl
skin
biopsi
ms
patient
use
immunohistochem
stain
result
show
ifnbeta
increas
express
bbbec
astrocyt
consequ
transmigr
lymphocyt
bbbec
significantli
reduc
strongli
express
microvasculatur
sampl
postmortem
ms
brain
moreov
major
ms
patient
clear
upregul
solubl
serum
activ
skin
microvascular
express
ifnbeta
treatment
upregul
subsequ
increas
adenosin
product
might
contribut
benefici
effect
ifnbeta
ms
via
enhanc
endotheli
barrier
function
disintegrin
metalloproteas
princip
convertas
tumour
necrosi
factor
tnf
major
immunomodulatori
cytokin
addit
also
cleav
number
membranebound
protein
includ
chemokin
adhes
molecul
fractalkin
implic
multipl
sclerosi
ms
pathogenesi
express
endotheli
cell
ms
white
matter
spinal
cord
rat
experiment
autoimmun
encephalomyel
eae
shown
laboratori
upregul
studi
vitro
express
inhibitor
fractalkin
human
brain
endotheli
cell
line
mrna
protein
level
proinflammatori
condit
fractalkin
upregul
mrna
level
tnf
treatment
howev
fractalkin
significantli
immunocytochem
analysi
reveal
increas
fractalkin
express
also
occur
protein
level
determin
shed
activ
perform
elisa
assay
cell
treat
tnf
ngml
releas
ng
fractalkinemg
protein
time
greater
amount
fractalkin
bound
cell
membran
condit
sought
determin
protein
express
follow
tnf
treatment
signific
increas
protein
express
could
determin
use
either
immunocytochemistri
western
blot
densitometri
thu
hypothes
increas
shed
fractalkin
due
increas
enzym
activ
increas
protein
express
proteas
activ
assay
proinflammatori
condit
use
innozymetm
activ
kit
ongo
test
hypothesi
also
investig
immunohistochem
colocalis
express
level
fractalkin
ms
control
brain
tissu
extent
associ
inflammatori
demyelin
neurodegen
process
within
tissu
assess
parallel
studi
highlight
shed
fractalkin
inflammatori
condit
critic
event
requir
investig
shed
fractalkin
endotheli
cell
could
mediat
leukocyt
recruit
extravas
via
modul
express
certain
adhes
molecul
could
act
prevent
fractalkin
receptor
mediat
migrat
leukocyt
mask
receptor
novel
access
determin
develop
sever
monocytedriven
enceph
aid
maclean
redmann
rachel
ivey
nathan
didier
peter
lackner
andrew
tulan
nation
primat
research
center
new
orlean
unit
state
despit
reduc
incid
hiv
dementia
patient
highli
activ
antiretrovir
therapi
haart
improv
surviv
result
increas
cumul
preval
nervou
system
complic
aid
fundament
gap
remain
knowledg
relat
mechan
pathway
involv
develop
hivassoci
neurolog
diseas
lesion
associ
enceph
includ
mark
astrocyt
microgli
activ
frequent
multinucl
giant
cell
high
viral
load
lesion
consist
multipl
dissemin
foci
inflammatori
cell
throughout
brain
pathogenesi
lesion
unknown
thought
associ
alter
bbb
heretofor
possibl
determin
individu
enceph
post
mortem
examin
order
determin
possibl
predict
enceph
macaqu
infect
siv
correl
level
protein
serumplasma
presenc
enceph
degre
enceph
particular
anim
determin
blind
histopatholog
evalu
studi
taken
quantifi
tight
junction
protein
found
diminish
anim
highest
degre
encephalitislevel
protein
although
disrupt
bbb
present
termin
aid
yet
known
begin
bbb
disrupt
demonstr
vivo
use
protein
serum
use
techniqu
would
possibl
determin
particular
anim
develop
enceph
thu
posit
schedul
necropsi
earliest
stage
determin
level
glial
protein
serum
show
possibl
determin
correl
post
mortem
also
predict
individu
enceph
death
could
profound
impact
elucid
pathogenesi
neuroaid
use
rhesu
macaqu
model
allow
one
euthan
anim
earliest
stage
neurolog
diseas
predict
hive
patient
infect
hiv
thu
tailor
treatment
administ
sonic
hedgehog
secret
human
astrocyt
promot
optim
bloodbrain
barrier
function
bloodbrain
barrier
bbb
compos
tightli
bound
endotheli
cell
ec
regul
entri
bloodborn
molecul
immun
cell
cn
perivascular
astrocyt
regul
bbb
permeabl
secret
essenti
factor
ident
remain
unclear
recent
studi
indic
hedgehog
hh
signal
pathway
adult
tissu
play
import
role
vascular
prolifer
differenti
tissu
repair
studi
show
human
astrocyt
express
secret
sonic
hh
convers
human
bbbec
bear
hh
receptor
signal
transduc
smoothen
smo
well
transcript
factor
gli
famili
furthermor
show
activ
hh
pathway
bbbec
restrict
passag
solubl
tracer
fitcbsa
decreas
surfac
express
intercellular
cell
adhes
molecul
decreas
bbbec
secret
proinflammatori
chemokin
monocyt
chemoattract
protein
modifi
boyden
chamber
assay
migrat
lymphocyt
across
human
bbbec
monolay
also
reduc
bbbec
treatment
sonic
hh
hh
pathway
agonist
vitro
treatment
bbbderiv
ec
inflammatori
cytokin
tnfalpha
ifngamma
downregul
mrna
express
smo
deregul
hh
signal
pathway
prevent
barrier
stabil
properti
sonic
hh
data
provid
strong
evid
antiinflammatori
bbbpromot
effect
astrocytesecret
sonic
hh
suggest
proinflammatori
environ
disrupt
bbb
impact
least
part
hh
signal
brain
ec
bloodbrain
barrier
bbb
regul
entri
cell
molecul
brain
entri
cell
macromolecul
brain
parenchyma
bbb
breakdown
correl
clinic
symptom
inflammatori
patholog
condit
multipl
sclerosi
reninangiotensin
system
ra
complex
hormon
system
multipl
function
primarili
regul
blood
vessel
tonu
permeabl
activ
compound
angiotensin
ii
act
two
receptor
object
studi
examin
role
ra
bbb
two
distinct
model
brain
inflamm
use
entorhin
cortex
lesion
model
allow
studi
inflammatori
respons
traumat
brain
injuri
site
stab
wound
direct
bleed
parenchyma
simultan
milder
inflammatori
respons
distal
dentat
gyru
synaps
degener
lead
glial
activ
second
model
transgen
mice
overexpress
chemokin
brain
show
perivascular
accumul
leukocyt
without
symptom
treatment
pertussi
toxin
ptx
result
cellular
infiltr
parenchyma
tofthansen
et
al
j
immunol
presenc
locat
ra
compon
investig
realtim
rtpcr
immunohistolog
two
anim
model
receptor
upregul
astrocyt
dentat
gyru
ipsilater
hippocampu
day
post
entorhin
cortex
lesion
horseradish
peroxidas
hrp
leakag
across
bbb
observ
site
ptxtreat
mice
bbb
breakdown
loss
glia
limitan
integr
shown
hrp
leakag
loss
betadystroglycan
bdg
stain
model
stain
observ
wherea
receptor
subtyp
detect
stain
close
associ
gfap
bdg
stain
consist
express
astrocyt
glia
limitan
also
seen
glia
limitan
site
stab
wound
entorhin
cortex
lesion
model
find
suggest
differenti
role
two
receptor
brain
inflamm
rais
interest
new
question
function
basivireddi
buttmann
mathia
rieckmann
peter
dept
neurolog
univers
wuerzburg
wuerzburg
germani
germani
dept
neurolog
univers
british
columbia
vancouv
canada
dept
neurolog
univers
wuerzburg
wuerzburg
germani
canada
junction
adhes
moleculea
jama
member
immunoglobulin
super
famili
major
constitu
endotheli
tight
junction
thought
regul
tight
junction
assembl
immun
cell
transmigr
jama
express
epitheli
tight
junction
shown
regul
paracellular
permeabl
solut
thrombocyt
monoclon
antibodi
potent
jama
agonist
induc
platelet
secret
aggreg
use
antibodi
investig
jamamedi
chang
cell
morpholog
paracellular
permeabl
well
underli
intracellular
signal
mechan
vitromodel
human
bloodbrain
barrier
bbb
immort
well
lowpassag
primari
human
cerebr
endotheli
cell
cultur
vitro
stimul
antibodi
cell
morpholog
determin
phase
contrast
microscopi
immunocytochemistri
paracellular
permeabl
solut
assess
use
fluorescentlabel
dextran
transwel
system
role
map
kinas
elucid
specif
chemic
inhibitor
phosphoryl
statu
map
kinas
determin
western
blot
activ
jama
induc
chang
cell
morpholog
typic
confluent
cobbleston
pattern
widen
intracellular
space
develop
lammellipodi
filopodi
cell
extens
actin
stain
show
reduct
stress
fibr
permeabl
assay
reveal
increas
permeabl
small
molecular
weight
dextran
kda
jama
activ
induc
delay
sustain
erk
phosphoryl
activ
jnk
jama
effect
larg
neutral
parallel
treatment
chemic
inhibitor
erk
phosphoryl
map
kinas
jamainduc
alter
cell
morpholog
increas
paracellular
permeabl
solut
could
abolish
erk
inhibitor
therefor
erk
signal
disrupt
interendotheli
jama
interact
antibodi
bind
mediat
observ
effect
vitro
model
human
bbb
jama
intracellular
signal
pathway
activ
jama
may
novel
therapeut
target
neurolog
diseas
breakdown
bbb
edema
format
play
pathogen
role
stroke
multipl
sclerosi
studi
also
show
possibl
circul
antibodi
caus
breakdown
blood
barrier
integr
adhes
molecul
bloodbrain
barrier
involv
monocyt
recruit
cn
multipl
sclerosi
ms
inflammatori
demyelin
lesion
associ
compromis
bloodbrain
barrier
bbb
perivascular
infiltr
immun
cell
central
nervou
system
cn
movement
leukocyt
blood
cn
orchestr
mani
factor
includ
cell
adhes
molecul
enabl
immun
cell
adher
cross
bbb
nerv
injuryinduc
protein
ninjurin
describ
adhes
molecul
promot
nerv
regener
homotyp
fashion
recent
identifi
proteom
screen
bbbassoci
protein
use
human
bbbderiv
endotheli
cell
ec
goal
studi
role
transbbb
migrat
immun
cell
express
regul
local
human
bbbec
determin
western
blot
wb
flow
cytometri
immunocytoand
immunohistofluoresc
function
role
assess
use
vitro
model
human
bbb
confirm
express
vitro
bbbec
wb
flow
cytometri
situ
confoc
microscopi
show
regul
upon
treatment
proinflammatori
cytokin
tnf
ifngamma
furthermor
immunoreact
detect
vitro
astrocyt
situ
ms
lesion
cn
materi
obtain
anim
model
experiment
autoimmun
encephalomyel
eae
demonstr
present
peripher
blood
immun
cell
preferenti
express
monocyt
compar
lymphocyt
final
use
modifi
boyden
chamber
assay
show
migrat
ex
vivo
monocyt
across
human
endothelium
significantli
reduc
follow
treatment
bbbec
compet
peptid
parwgwrhgpin
blockad
increas
bbb
permeabl
find
suggest
novel
adhes
molecul
cn
endothelium
act
regul
monocyt
migrat
brain
doxycyclin
treatment
decreas
morbid
mortal
murin
ncc
evid
reduct
apoptosi
oxid
stress
mmp
activ
alvarez
krishnamurthi
janani
teal
judi
murin
neurocysticercosi
ncc
character
differenti
disrupt
barrier
protect
central
nervou
system
cn
microenviron
among
host
factor
involv
respons
matrix
metalloproteinas
mmp
recent
describ
import
player
doxycyclin
commonli
prescrib
antimicrobi
drug
also
act
antiinflammatori
agent
broad
mmp
inhibitori
properti
studi
examin
effect
doxycyclin
treatment
murin
model
ncc
anim
treat
doxycyclin
exhibit
lower
number
parasit
reduc
morbid
mortal
cours
infect
although
similar
level
leukocyt
infiltr
observ
treatment
doxycyclin
seem
provid
appropri
condit
host
surviv
reduc
level
apoptosi
oxid
stress
detect
among
infiltr
well
cn
tissu
establish
mmp
blocker
doxycyclin
appear
reduc
degrad
junction
complex
protein
parenchym
vessel
also
lower
level
cytokin
known
increas
permeabl
cn
barrier
addit
doxycyclin
treatment
associ
overal
reduct
express
activ
mmp
particularli
area
leukocyt
infiltr
result
indic
partial
inhibit
broad
rang
mmp
establish
environ
within
cn
conduc
restrain
infect
promot
host
surviv
suggest
potenti
doxycyclin
therapeut
agent
control
exacerb
respons
often
found
cn
infect
pathogenesi
idiopath
intracrani
hypertens
iih
remain
unclear
iih
almost
alway
associ
obes
recognis
proinflammatori
state
increas
express
number
adipokin
cytokin
chemokin
includ
whether
mediat
play
role
pathogenesi
iih
remain
uninvestig
aim
studi
investig
signific
differ
express
leptin
iih
patient
compar
age
sex
match
control
group
mediat
select
preliminari
screen
forti
two
differ
cytokin
chemokin
immunoblot
show
appar
differ
iih
control
patient
leptin
level
measur
use
enzym
link
immunosorb
assay
elisa
cerebrospin
fluid
csf
serum
thirtyseven
patient
diagnosi
iih
fortytwo
control
subject
control
subdivid
three
group
patient
inflammatori
neurolog
diseas
n
patient
noninflammatori
neurolog
diseas
n
patient
present
headach
neurolog
symptom
whose
investig
normal
n
statist
analysi
utilis
kruskal
walli
test
analysi
covari
csf
serum
level
leptin
level
significantli
differ
iih
patient
three
control
group
serum
leptin
level
significantli
associ
bodi
mass
index
group
p
find
suggest
csf
serum
leptin
level
iih
patient
differ
compar
condit
suggest
specif
mediat
play
role
pathogenesi
iih
multipl
sclerosi
ms
chronic
inflammatori
demyelin
diseas
central
nervou
system
cell
inflam
lesion
express
chemokin
receptor
role
chemokin
bind
receptor
like
interferon
gammainduc
protein
interferoninduc
tcell
alphachemoattract
well
bind
pathogenesi
ms
unresolv
aim
studi
estim
level
serum
cerebrospin
fluid
csf
relapsingremit
ms
rrm
patient
relaps
stabl
stage
diseas
compar
result
control
group
also
decid
evalu
effect
methylprednisolon
mp
therapi
serum
level
ms
patient
relaps
studi
group
consist
rrm
patient
relaps
rrm
patient
stabl
stage
diseas
control
group
relaps
ms
patient
blood
sampl
obtain
steroid
therapi
five
day
treatment
mp
dose
g
iv
daili
level
chemokin
measur
elisa
method
level
significantli
higher
csf
rrm
patient
relaps
pgml
stabl
phase
diseas
pgml
comparison
control
group
pgml
p
b
csf
level
significantli
higher
patient
relaps
comparison
stabl
rrm
p
b
level
differ
significantli
control
valu
effect
mp
therapi
serum
level
result
suggest
involv
pathogenesi
ms
cleavag
mmp
reduc
cell
migrat
may
supplement
effect
immunomodulatori
therapi
multipl
sclerosi
chemokin
direct
migrat
peripher
blood
mononuclear
cell
pbmc
across
blood
brain
barrier
bbb
central
nervou
system
cn
process
thought
initi
tissu
damag
occur
multipl
sclerosi
ms
express
chemokin
demonstr
within
activ
lesion
ms
control
brain
low
percentag
cell
major
peripher
blood
cerebrospin
fluid
monocyt
express
receptor
thu
consid
play
key
role
recruit
pbmc
bbb
ms
matrix
metalloproteinas
mmp
particularli
mmp
involv
ms
pathogenesi
includ
bbb
disrupt
colocalis
cn
inflammatori
lesion
mmp
cleav
chemokin
therebi
alter
activ
investig
process
mmp
effect
chemotact
activ
effect
vivo
immunomodulatori
treatment
pbmc
migrat
respons
current
investig
demonstr
whether
drug
treatment
specif
effect
could
influenc
truncat
vitro
process
mmp
analys
use
matrixassist
laser
desorptionionis
quadrupol
timeofflight
mass
spectrometri
maldi
qtof
ms
cell
chemotaxi
cleav
intact
assess
use
migrat
assay
utilis
calcein
fluoresc
label
cell
prior
addit
insert
fluorescentblock
membran
pore
measur
fluoresc
undersid
membran
enabl
acquisit
real
time
migrat
data
assess
effect
vivo
drug
treatment
pbmc
migrat
preand
posttreat
month
patient
either
interferon
beta
beta
glatiram
acet
natalizumab
process
mmp
cleav
four
amino
acid
nterminu
within
h
result
twofold
reduct
migrat
cell
monocyt
cell
line
compar
intact
increas
fold
migrat
pbmc
untreat
ms
patient
occur
within
min
respons
vivo
migrat
like
reduc
moreov
express
mmp
cn
ms
like
result
truncat
may
augment
effect
immunomodulatori
therapi
reduc
migrat
monocyt
cell
across
bbb
skew
proinflammatori
innat
immun
immun
defici
mice
impair
cognit
function
inhibit
synaptogenesi
recent
evid
suggest
cell
influenc
neuron
plastic
support
learn
memori
exampl
sever
combin
immunedefici
scid
mice
shown
impair
cognit
perform
revers
follow
inject
exogen
tcell
genet
match
donor
mechan
underli
benefici
effect
cell
brain
well
understood
show
scid
mice
possess
fewer
hippocamp
synaps
along
reduc
hippocamp
express
synaptogen
protein
compar
wt
mice
moreov
myeloid
cell
occupi
subarachnoid
ventricular
space
exhibit
skew
proinflammatori
phenotyp
scid
mice
compar
wild
type
control
proinflammatori
cytokin
produc
mening
myeloid
cell
propos
diffus
brain
parenchyma
affect
astrogli
express
show
antiinflammatori
cytokin
interleukin
il
increas
express
astrocyt
proinflammatori
cytokin
suppress
tnfa
inhibit
express
supposedli
respons
reduc
synaps
cognit
impair
observ
scid
mice
result
shed
light
mechan
underli
cognit
dysfunct
associ
immun
declin
might
also
lead
develop
new
futur
therapi
cognit
mental
condit
target
immun
cell
benefit
central
nervou
system
use
imageguid
patholog
analysi
previous
demonstr
multipl
sclerosi
ms
lesion
abnorm
imag
wi
magnet
transfer
ratio
lesion
show
axon
swell
reduc
axon
nak
atpas
contrast
lesion
abnorm
lesion
compar
leukocyt
accumul
lesion
address
inflammatori
mechan
character
express
chemokin
receptorligand
pair
studi
compris
autopsi
brain
tissu
five
secondari
progress
ms
spm
five
nonneurolog
control
case
base
imag
characterist
thirti
region
interest
roi
excis
use
immunohistochemistri
evalu
myelin
statu
leukocyt
accumul
express
select
ms
control
roi
eight
ten
region
chronicact
chronicinact
demyelin
lesion
region
histopatholog
divers
rang
normal
partial
myelin
complet
demyelin
demyelin
region
correspond
chronic
activ
lesion
mononuclear
phagocyt
distribut
chronicact
lesion
resembl
chronicact
lesion
parenchym
tcell
significantli
increas
roi
compar
lesion
ms
nwm
express
associ
reactiv
microglia
macrophag
activ
chronic
activ
ms
lesion
express
increas
astrocyt
cell
vascular
element
inflammatori
cell
distribut
number
correl
stage
demyelin
versu
imag
characterist
therefor
imag
correl
axon
patholog
affect
differenti
inflammatori
leukocyt
distribut
robust
express
inflammatori
element
ms
lesion
highlight
role
chemokinereceptor
pair
cn
inflamm
poster
session
neuroimmun
pharmacolog
crosstalk
pilot
trial
low
dose
naltrexon
primari
progress
multipl
sclerosi
multipl
sclerosi
studi
center
hospit
gallar
gallar
va
itali
naltrexon
oral
semi
synthet
opiat
antagonist
licens
treatment
heroin
alcohol
addict
howev
opiat
antagonist
activ
complet
abrog
lower
dose
mg
trigger
prolong
regul
endogen
opioid
neuroprotect
immunomodulatori
function
symptomat
effect
spastic
pain
fatigu
low
dose
naltrexon
ldn
multipl
sclerosi
ms
report
anecdot
observ
avail
far
sixthmonth
phase
ii
multicentr
openlabel
therapeut
trial
ldn
mgdie
carri
patient
pt
diagnosi
primari
progress
pp
ms
femal
male
mean
age
median
edss
thirtyf
patient
complet
month
therapi
dropout
occur
two
major
advers
event
pt
grade
iii
sever
iv
lifethreaten
disabl
occur
trial
remain
advers
event
grade
interf
function
ii
interf
activ
daili
live
transitori
haematolog
abnorm
pt
urinari
tract
infect
pt
mild
irrit
pt
commonest
neurolog
disabl
progress
patient
end
studi
regard
efficaci
measur
signific
reduct
spastic
along
evid
posit
effect
fatigu
depress
found
regard
qualiti
life
gener
trend
improv
final
baselin
evalu
albeit
statist
signific
physic
function
role
physic
energi
social
function
benefit
item
pbmc
level
mor
start
increas
month
begin
therapi
still
increas
month
therapi
discontinu
p
b
associ
found
allel
variant
gene
respons
treatment
ldn
safe
well
toler
patient
ppm
also
abl
show
posit
influenc
spastic
fatigu
depress
pure
placebolik
effect
improb
tempor
profil
observ
chang
longer
time
drug
administr
longer
followup
could
definit
address
whether
ldn
consid
reliabl
therapeut
option
ms
patient
bipolar
disord
bpd
schizophrenia
scz
sever
disord
repres
enorm
social
familiar
individu
burden
scz
disabl
psychiatr
disord
character
psychosi
cognit
impair
well
known
scz
bpd
associ
abnorm
dopamin
signal
pathway
recent
data
literatur
demonstr
alter
express
level
protein
involv
modul
pathway
brain
peripher
tissu
shown
protein
mrna
level
dopamin
camp
regul
phosphoprotein
downregul
dorsolater
prefront
cortex
dlpfc
patient
scz
bpd
compar
control
due
difficulti
access
brain
tissu
absenc
object
laboratori
test
biomark
measur
express
blood
cell
subpopul
lymphocyt
nk
cell
b
lymphocyt
monocyt
take
advantag
close
relat
nervou
immun
system
use
flow
cytometri
analyt
method
result
shown
express
diminish
lymphocyt
b
lymphocyt
monocyt
bpd
patient
also
decreas
lymphocyt
nk
cell
scz
patient
result
show
express
immun
cell
agre
report
reduc
protein
dlpfc
bpd
scz
patient
data
suggest
express
lymphocyt
monocyt
could
use
sourc
biomark
help
diagnosi
andor
treatment
respons
neuropsychiatri
disord
mohan
fernando
samodha
c
mu
opioid
receptor
hmor
play
signific
role
opioid
toler
express
hmor
shown
differenti
regul
follow
cytokin
stimul
aim
determin
dose
timedepend
effect
morphin
hmor
express
sknsh
cell
use
quantit
realtimepcr
qrtpcr
immunocytochemistri
icc
timedepend
upregul
hmor
identifi
ngml
h
p
b
h
p
b
induc
hmor
upregul
measur
use
qrtpcr
n
pretreat
receptor
antagonist
reduc
ngml
induc
upregul
hmor
conclud
plausibl
depend
mechan
effect
morphin
hmor
express
show
timedepend
h
downregul
hmor
mrna
express
n
use
confoc
microscopi
icc
show
morphin
induc
chang
hmor
mrna
express
reflect
hmor
protein
express
chang
conclus
evid
interact
morphin
hmor
express
vitro
may
elucid
mechan
behind
opioidinduc
opioid
toler
next
aim
measur
chang
hmor
protein
express
use
immunoblot
analysi
futur
studi
includ
elucid
signal
transduct
pathway
result
chang
hmor
express
neuron
treat
morphin
concurr
use
signal
inhibitor
aim
determin
effect
hmor
express
sknsh
cell
depend
specif
intracellular
signal
protein
understand
neuroimmun
interact
hmor
express
may
identifi
potenti
molecular
target
prevent
opioid
receptor
express
downregul
perhap
opioid
toler
eae
induc
male
agematch
mice
myelin
oligodendrocyt
glycoprotein
mog
peptid
adjuv
monitor
diseas
sever
use
scale
limp
tail
ataxia
limp
tail
weak
hind
limb
complet
hind
limb
paralysi
death
inhibitor
administ
daili
mgkg
po
begin
day
postimmun
lymphocyt
activ
cytokin
product
measur
splenocyt
follow
ten
day
inhibitor
treatment
found
mice
treat
mif
inhibitor
less
sever
eae
within
seven
day
treatment
cumul
diseas
index
vs
inhibitortr
mice
also
larger
popul
regulatori
cell
vs
prolifer
product
cytokin
ifngamma
respons
antigen
unchang
follow
conclus
treatment
mice
remain
protect
compar
vehicletr
control
cumul
diseas
index
vs
find
demonstr
inhibitor
mif
protect
eae
potenti
expans
regulatori
cell
howev
inhibitor
treatment
dampen
peripher
immun
respons
antigen
product
inflammatori
cytokin
suggest
altern
role
mif
perhap
traffick
inflammatori
cell
cn
bioavail
mechan
protect
inhibitor
could
novel
therapeut
approach
treatment
ongo
ms
inflammatori
diseas
support
nih
grant
ai
nmss
grant
multipl
sclerosi
ms
idiopath
inflammatori
demyelin
neurodegen
diseas
cn
current
believ
environment
genet
factor
contribut
onset
progress
diseas
occur
earli
adulthood
interestingli
infecti
agent
psycholog
stress
suspect
play
role
acquisit
progress
diseas
sinc
earli
character
late
theiler
murin
encephalomyel
viru
tmev
picornaviru
upon
intracrani
inocul
suscept
mice
ie
sjl
caus
persist
infect
character
acut
polioenceph
follow
chronic
inflammatori
demyelin
diseas
resembl
human
ms
interest
effect
stress
pathogenesi
experiment
model
ms
current
studi
interest
effect
chronic
stress
virusspecif
adapt
immun
respons
tmev
sjl
mice
mechan
respons
modul
use
known
immunodomin
viral
peptid
specif
either
cell
found
stress
decreas
virusspecif
cell
respons
spleen
cn
intriguingli
stress
increas
virusspecif
circul
antibodi
respons
serum
stress
mice
compar
nonstress
mice
result
shift
type
toward
type
immun
indic
serum
cytokin
cell
stimul
assay
moreov
suppress
cell
respons
appear
fulli
attribut
alter
cell
percentag
indic
flow
cytometri
final
glucocorticoid
found
partial
respons
decreas
respons
cell
function
effect
stress
part
revers
concurr
administr
mimick
dexamethason
administr
cell
thought
mediat
viral
clearanc
model
data
indic
stress
induc
immunosuppress
may
provid
mean
enhanc
viral
persist
within
cn
activ
immun
amyloidbeta
significantli
impair
memori
perform
healthi
mice
activ
immun
amyloidbeta
abeta
shown
prevent
amyloid
plaqu
deposit
differ
mous
model
alzheim
diseas
ad
whether
induct
immun
respons
abeta
also
improv
memori
function
still
controversi
identifi
cognit
immunolog
phenotyp
healthi
mice
immun
abeta
complet
freund
adjuv
cfa
immun
significantli
alter
behavior
phenotyp
mice
compar
control
mice
receiv
abeta
cfa
myelin
oligodendrocyt
glycoprotein
induc
eae
mice
abeta
cfa
immun
mice
reveal
decreas
locomotor
activ
reduc
habitu
learn
highli
defici
spatiallearn
abil
object
recognit
task
quantit
rtpcr
data
demonstr
upregul
number
macrophag
cell
relat
gene
cn
abeta
mice
particular
ifng
furthermor
reactiv
gliosi
detect
abeta
mice
chronic
phase
diseas
shown
gfap
immunohistochemistri
quantit
rtpcr
gfap
periton
macrophag
immun
mice
csf
tnfa
gene
transcript
highli
upregul
summari
immun
healthi
mice
abeta
cfa
induc
inflammatori
cascad
significantli
impair
cognit
function
result
illustr
potenti
danger
activ
immun
neuron
antigen
demonstr
complex
immun
respons
abeta
pathogenesi
ad
abeta
immun
plaqu
patholog
free
anim
even
provid
suitabl
model
autoimmun
mediat
cognit
impair
lewitu
wilfyarkoni
adi
ziv
yaniv
shabatsimon
maytal
gersner
roman
zangen
abraham
schwartz
michal
depress
anim
model
often
associ
reduc
bdnf
level
impair
neurogenesi
hippocampu
previou
observ
cell
recogn
cnsspecif
antigen
regul
adult
brain
neurogenesi
express
bdnf
creat
basi
present
studi
boost
tcell
level
cope
depress
show
vaccin
weak
agonist
myelinderiv
peptid
amelior
depress
behavior
induc
chronic
mild
stress
rat
behavior
outcom
accompani
restor
hippocamp
bdnf
level
neurogenesi
result
present
studi
introduc
novel
approach
vaccin
cnsrelat
antigen
therapeut
mean
fight
depress
vaccin
antidepress
therapi
encompass
sever
molecular
cellular
mechan
known
regul
antidepress
drug
therefor
suggest
immunebas
therapi
consid
treatment
depress
myelin
oligodendrocyt
glycoprotein
mog
induc
experiment
autoimmun
encephalomyel
eae
preclin
model
ms
striatum
particularli
prone
degener
ms
rather
select
involv
eae
striatal
neuron
exhibit
mark
upregul
ampa
receptormedi
transmiss
sinc
presymptomat
phase
diseas
alter
striatal
glutam
transmiss
secondari
abnorm
express
phosphoryl
state
ampa
receptor
trigger
microglia
activ
tnfa
releas
modul
earli
gene
accordingli
applic
activ
microglia
tnfa
activ
lymphocyt
replic
normal
neuron
synapt
defect
observ
eae
data
reveal
import
role
synapt
dysfunct
solubl
factor
releas
activ
microglia
patholog
process
eae
macroautophagi
deliv
cytoplasm
constitu
lysosom
degrad
skelet
muscl
tissu
therebi
could
affect
adapt
immun
respons
via
deliveri
intracellular
antigen
mhc
class
ii
present
cell
investig
constitut
immunemedi
macroautophagi
regul
mhc
express
primari
human
myoblast
rhabdomyosarkoma
cell
line
ccl
immunocytochemistri
immunoblot
flow
cytometri
identifi
tnfalpha
complex
mixtur
inflammatori
cytokin
predomin
regulatori
factor
macroautophagi
skelet
muscl
loss
macroautophagi
predispos
muscl
cell
tnfreceptor
mediat
apoptosi
tnfalpha
enhanc
hladr
surfac
level
interferongamma
treat
myoblast
synergist
effect
tnfalpha
ifngamma
result
higher
intracellular
hladr
express
suggest
tnfalpha
facilit
antigen
process
via
macroautophagi
effici
mhc
class
ii
load
find
establish
mechan
tnfalpha
regul
macroautophagi
mhc
class
ii
express
skelet
myocyt
suggest
tnfalpha
key
mediat
potenti
therapeut
target
cellmedi
inflammatori
myopathi
macroautophagi
involv
endogen
opioid
well
exogen
opiat
affect
immun
respons
achiev
indirect
action
via
bind
opioid
receptor
express
cell
neuroendocrin
system
direct
action
via
bind
opioid
receptor
express
immunocyt
effect
direct
action
opioid
immunocyt
modul
prolifer
activ
death
express
opioid
receptor
kappa
class
kor
cell
monocytemacrophag
origin
report
howev
precis
role
kor
regul
fulli
understood
studi
examin
express
kor
cell
murin
macrophag
cell
line
done
transcript
protein
level
use
semiquantit
rtpcr
western
blot
respect
mous
rat
brain
cell
mous
tcell
line
select
express
kor
use
posit
control
data
obtain
shown
cell
express
kor
level
examin
abil
proinflammatori
cytokin
interferongamma
regul
kor
express
ifngamma
increas
kor
mrna
concentrationand
timedepend
manner
find
confirm
increas
level
kor
protein
ifngammatr
cell
collect
data
present
shown
cell
basal
express
kor
kor
could
upregul
ifngamma
observ
line
previou
find
korselect
ligand
dynorphina
modul
secret
prolifer
cell
cerebr
ischemia
accompani
acut
inflamm
involv
activ
microglia
infiltr
neutrophil
pmn
monocyt
brain
whether
microglia
protect
neuron
ischem
death
still
debat
use
model
applic
innat
immun
cell
onto
hippocamp
slice
ohc
investig
effect
neuron
death
ischemia
show
appli
pmn
exacerb
neuron
damag
wherea
microglia
protect
neuron
oxygen
glucos
depriv
ogd
two
way
appli
approach
transgen
ohc
mice
eyfp
express
neuron
fluoresc
label
microglia
observ
microglia
engag
close
physic
contact
neuron
ogd
blockag
microglia
migrat
neuron
ogd
abolish
microglia
mediat
protect
moreov
applic
microglia
pmn
simultan
indic
microglia
counteract
pmn
neurotox
timelaps
imag
reveal
phagocytosi
pmn
microglia
interfer
phagocytosi
use
rgd
nacetylglucosamin
abrog
microgli
abil
reduc
pmn
neurotox
taken
observ
togeth
microglia
might
protect
neuron
ischemia
two
way
directli
physic
interact
neuron
ii
indirectli
clearanc
inflam
tissu
toxic
pmn
thu
nonselect
antiinflammatori
treatment
ischemia
would
counterintuit
cerebr
ischemia
among
immunolog
event
characteris
earli
respons
microglia
cell
within
endang
region
microglia
surround
parenchyma
migrat
surround
microglia
site
injuri
key
event
exert
respons
respect
region
whether
microglia
cell
exhibit
benefici
detriment
effect
still
highli
debat
shown
serin
proteas
thrombin
inflammatori
mediat
act
via
proteaseactiv
receptor
modul
microglia
function
eg
cytokin
product
focus
role
microglia
ischemia
use
vitro
cocultur
primari
hippocamp
neuron
microglia
cell
line
show
microglia
migrat
activ
dramat
enhanc
ischemia
similar
migrat
enhanc
microglia
cocultur
seen
select
activ
activ
peptid
without
ischem
exposur
moreov
investig
depend
regul
express
show
lysosom
activ
phagocytot
cell
found
regul
express
select
activ
microglia
cell
characteris
cytokin
product
therebi
statu
microgliaactiv
analys
level
proinflammatori
tnfalpha
stimul
primari
microglia
cell
result
implic
microglia
activ
might
regul
microglia
function
cerebr
ischemia
recent
demonstr
cyclooxygenas
express
die
oligodendrocyt
onset
demyelin
theiler
murin
encephalomyel
viru
tmev
model
multipl
sclerosi
ms
find
consist
hypothesi
express
oligodendrocyt
might
render
cell
suscept
glutamatemedi
excitotox
much
manner
express
neuron
increas
neuron
cell
death
object
goal
determin
whether
inhibitor
decreas
demyelin
tmev
induc
demyelin
tmevidd
limit
excitotox
death
oligodendrocyt
vitro
mice
infect
intracerebr
da
strain
tmev
either
given
control
diet
chow
contain
inhibitor
deriv
celecoxib
spinal
cord
control
mice
harvest
day
infect
score
inflamm
demyelin
follow
luxol
fast
blue
stain
vitro
experi
organotyp
cultur
prepar
post
natal
day
spinal
cord
grown
permeabl
filter
co
cultur
expos
excitotoxin
kainic
acid
ka
presenc
absenc
inhibitor
cell
death
white
matter
gray
matter
assess
h
later
immunofluoresc
confoc
microscopi
use
cell
death
indic
activ
caspas
oligodendrocyt
marker
cyclic
nucleotid
phosphodiesteras
cnpase
tmevidd
model
ms
inhibitor
effect
score
inflamm
significantli
decreas
amount
demyelin
p
b
mannwhitney
nonparametr
ttest
vitro
inhibitor
decreas
amount
kainduc
cell
death
white
matter
gray
matter
p
b
anova
tukeykram
inhibitor
reduc
demyelin
tmevidd
model
vitro
result
indic
inhibitor
may
therapeut
effect
limit
glutamatemedi
excitotox
oligodendrocyt
death
voulgarikokota
delorm
bruno
taoufik
era
tseveleki
vivian
charbord
pierr
probert
lesley
anda
voulgarikokota
athen
greec
bone
marrow
mesenchym
stem
cell
msc
nonhematopoet
multipot
stem
cell
popul
differenti
osteoblast
adipocyt
chondrocyt
vivo
vitro
bone
marrow
msc
support
hemopoiesi
provid
proper
environ
hematopoiet
stem
cell
renew
prolifer
differenti
substitut
osteoblast
osteocyt
nonhematopoiet
cell
bone
marrow
stroma
accord
support
role
msc
secret
plethora
differ
cytokin
trophic
factor
antiapoptot
factor
shown
msc
recruit
site
neural
injuri
inflamm
prevent
neuron
death
secret
neurotroph
antiapoptot
factor
well
promot
local
neurogenesi
aim
studi
evalu
msc
neuroprotect
capac
investig
pathway
involv
bone
marrow
mesenchym
stem
cell
flush
mice
cultur
passag
fac
analysi
confirm
puriti
msc
cultur
n
cell
mous
embryon
cortic
neuron
isol
embryo
neuron
two
cell
popul
cultur
togeth
use
cocultur
insert
cell
expos
nmda
excitotox
neuron
death
assess
h
later
use
ldh
assay
altern
embryon
cortic
neuron
day
cultur
msc
condit
medium
h
nmda
ad
cultur
gene
express
array
perform
use
neuron
rna
sampl
show
msc
induc
express
mani
neuroprotect
neurotroph
factor
neural
cell
suppress
time
varieti
apoptot
molecul
result
show
presenc
msc
mscscondit
medium
significantli
protect
neuron
excitotox
environ
cytotox
effect
myasthenia
gravi
sera
cardiomyocyt
vitro
differ
antibodi
composit
vari
diseas
sever
cytotox
effect
assess
evalu
morpholog
measur
adenyl
kinas
ak
releas
cell
use
flow
cytometri
propidium
iodid
annexinv
stain
incub
mg
sera
induc
morpholog
chang
cell
compar
cell
treat
sera
healthi
human
donor
perinuclear
vesicl
inclus
bodi
present
minor
cell
treat
human
sera
regardless
whether
patient
control
serum
mean
normal
ak
releas
valu
cell
treat
mg
sera
concentr
control
standard
deviat
oneway
anova
analysi
reveal
signific
differ
patient
control
group
p
compar
patient
within
mg
group
signific
differ
detect
p
girardi
cell
treat
mgsera
concentr
h
prior
flow
cytometr
examin
show
cell
death
rate
compar
control
serum
standard
error
mean
two
group
respect
p
oneway
anova
test
less
annexinv
posit
cell
indic
apoptosi
could
detect
mg
patient
control
group
systemat
variat
accord
antibodi
profil
concentr
mg
sever
clinic
paramet
observ
dose
time
depend
conclud
mg
sera
cytotox
effect
heart
cell
cultur
system
causal
link
mg
heart
diseas
direct
affect
cardiomyocyt
like
mechan
ebv
latenc
phenotyp
characteris
line
use
line
screen
express
neurotrophin
ligand
receptor
select
high
affin
tropomyosin
receptor
kinas
trka
trkb
trkc
common
low
affin
tumour
necrosi
factor
receptor
member
fdclike
cell
line
also
analys
neurotrophin
compon
express
question
fdc
potenti
provid
paracrin
neurotrophin
signal
burkitt
lymphoma
b
cell
neurotrophin
neurotrophin
receptor
express
detect
flow
cytometri
revers
transcript
polymeras
chain
reaction
pcr
real
time
pcr
method
cell
line
full
complement
ebv
latenc
gene
express
posit
neurotrophin
brain
deriv
neurotroph
factor
bdnf
neurotrophin
receptor
question
burkitt
lymphoma
cell
express
limit
ebv
latenc
gene
reveal
restrict
express
neurotrophin
compon
fdclike
line
also
express
neurotrophin
neurotrophin
receptor
thu
paracrin
signal
burkitt
lymphoma
cell
fdc
may
occur
via
axi
perhap
enhanc
b
cell
surviv
multipl
sclerosi
ms
common
caus
sever
neurolog
disabl
result
interrupt
myelin
tract
central
nervou
system
famili
aggreg
case
differ
diseas
risk
among
ethnic
group
resid
geograph
region
well
document
support
role
genet
influenc
ms
pathogenesi
howev
modest
herit
reflect
complex
genet
effect
multifacet
geneenviron
interact
human
leukocyt
antigen
hla
gene
cluster
chromosom
repres
strongest
suscept
locu
ms
genomewid
primari
signal
aris
gene
class
ii
genom
segment
locu
complex
hierarch
ci
tran
allel
effect
detect
includ
protect
signal
class
region
near
hlac
gene
past
two
year
seen
substanti
progress
develop
laboratori
analyt
approach
perform
largescal
genomewid
associ
studi
ms
complex
disord
triobas
studi
use
snp
array
ms
famili
recent
complet
report
classic
hla
risk
locu
stood
remark
strong
statist
signific
p
b
studi
also
yield
sever
promis
nonhla
lead
pursu
independ
dataset
combin
analysi
sampl
identifi
number
gene
associ
diseas
suscept
includ
interleukin
receptor
alpha
chain
also
known
chromosom
also
implic
pathogenesi
type
diabet
grave
diseas
chromosom
chromosom
progress
highthroughput
genotyp
sequenc
technolog
better
understand
structur
organ
human
genom
togeth
power
brain
imag
techniqu
refin
phenotyp
suggest
tool
may
final
exist
identifi
full
set
gene
influenc
pathogenesi
ms
baylor
colleg
medicin
houston
texa
usa
wherea
watsoncrick
dna
base
pair
chang
long
recogn
mechan
mutat
rearrang
human
genom
includ
delet
duplic
invers
appreci
recent
signific
sourc
genet
variat
diseas
result
dna
rearrang
refer
genom
disord
rearrang
genom
respons
inherit
well
sporad
trait
rearrang
associ
genom
disord
recurr
breakpoint
cluster
result
common
size
deletiondupl
nonrecurr
differ
size
analys
breakpoint
proxim
short
arm
chromosom
reveal
nonallel
homolog
recombin
nahr
major
mechan
recurr
rearrang
wherea
nonhomolog
endjoin
nhej
respons
mani
nonrecurr
rearrang
genom
architectur
featur
consist
lowcopi
repeat
lcr
also
call
segment
duplic
stimul
mediat
nahr
posit
hotspot
crossov
within
lcr
recent
elucid
dna
replic
mechan
nonrecurr
rearrang
term
fost
fork
stall
templat
switch
rearrang
introduc
variat
genom
select
act
upon
serv
evolutionari
function
analog
base
pair
chang
genom
rearrang
may
caus
mendelian
diseas
complex
trait
behavior
psychiatr
trait
eg
autism
schizophrenia
repres
benign
polymorph
variat
latter
copi
number
variat
cnv
ubiquit
human
genom
fact
two
human
contain
basepair
differ
due
structur
variat
genom
result
singl
nucleotid
polymorph
snp
mechan
rearrang
convey
phenotyp
divers
includ
gene
dosag
posit
effect
unmask
code
region
mutat
csnp
function
snp
creat
gainoffunct
fusion
gene
loss
function
gene
mutat
breakpoint
perhap
effect
transvect
de
novo
genom
rearrang
shown
caus
chromosom
mendelian
diseas
well
sporad
trait
understand
extent
genom
rearrang
gene
cnv
andor
gene
dosag
alter
respons
common
complex
trait
remain
rudimentari
cellular
differenti
permiss
repress
epigenet
modif
must
negoti
creat
celltyp
specif
gene
express
pattern
cell
fate
decis
checkpoint
dynam
development
decis
made
establish
specif
epigenet
pattern
mechan
herit
state
creat
especi
loss
repress
methyl
mark
elus
tbox
transcript
factor
famili
critic
import
sever
development
system
rang
embryogenesi
differenti
adult
tissu
immun
system
tbox
factor
tbet
eom
respons
cellular
differenti
event
sever
cell
type
notabl
cell
differenti
explor
mechan
development
import
transcript
factor
contribut
establish
epigenet
pattern
util
tbet
model
comprehens
mutagenesi
studi
surprisingli
suggest
addit
dna
bind
highli
conserv
tbox
domain
respons
recruit
chromatinmodifi
activ
target
gene
promot
examin
point
mutat
known
respons
sever
differ
human
genet
diseas
found
within
tbox
factor
tpit
found
two
distinct
surfac
tbox
domain
recruit
chromatinmodifi
activ
promot
requir
function
activ
tbet
target
gene
data
suggest
tbet
requir
suffici
allevi
repress
methyl
mark
mediat
function
interact
demethylas
repress
modif
remov
permiss
chromatin
environ
creat
tbox
depend
recruit
methyltransferas
target
gene
collect
data
suggest
abil
tbox
dna
bind
domain
function
establish
epigenet
state
target
gene
requir
abil
initi
celltyp
specif
development
gene
express
pattern
character
encephalitogen
cell
critic
identifi
therapeut
target
multipl
sclerosi
ms
end
use
small
interf
rna
sirna
suppress
molecul
express
encephalitogen
cell
determin
molecul
essenti
immunemedi
demyelin
diseas
use
sirna
specif
tbet
transcript
factor
found
tbet
critic
differenti
effector
function
encephalitogen
cell
system
administr
tbet
specif
sirna
inhibit
onset
experiment
autoimmun
encephalomyel
eae
treatment
establish
eae
sirna
amelior
diseas
found
receptor
gene
directli
regul
tbet
addit
pathogen
capac
myelinspecif
cell
greatli
diminish
tbet
suppress
interestingli
adopt
transfer
myelinspecif
cell
result
gener
hostderiv
cell
found
cn
thu
appear
cn
conduc
environ
differenti
cell
howev
system
administr
tbet
sirna
follow
adopt
transfer
cell
prevent
gener
cell
cn
indic
tbet
play
role
differenti
cell
addit
myelinspecif
cell
mice
spontan
eae
fail
transfer
eae
tbet
suppress
confirm
critic
role
tbet
spontan
autoimmun
demyelin
diseas
effort
determin
role
myelinspecif
cell
pathogenesi
found
cell
differenti
vitro
transfer
eae
distinct
popul
pathogen
cell
gener
vivo
data
suggest
tbet
may
viabl
therapeut
target
ms
capabl
suppress
cell
la
jolla
institut
allergi
immunolog
la
jolla
ca
unit
state
intestin
mucosa
form
largest
bodi
surfac
expos
exogen
antigen
innocu
pathogen
nonself
antigen
consist
chronic
antigen
exposur
gut
mucosa
also
lodg
larg
collect
activ
lymphocyt
physiolog
condit
remain
immun
quiescent
state
socal
gut
physiolog
inflamm
control
distinct
regulatori
mechan
includ
differ
type
regulatori
dc
cell
import
molecul
context
abundantli
produc
gut
crucial
system
mucos
immuneregul
among
multipl
role
capac
block
differenti
convert
cell
induc
treg
cell
paradox
also
display
proinflammatori
role
presenc
proinflammatori
cytokin
tnf
promot
convers
cell
effector
cell
contrast
deviat
put
princip
control
immun
respons
underscor
central
role
cytokin
orchestr
proand
antiinflammatori
natur
adapt
immun
nowher
els
critic
regul
balanc
product
suppress
immun
signific
mucos
surfac
gut
effici
immun
protect
pathogen
coincid
mainten
mucos
barrier
integr
selftoler
well
toler
toward
vast
load
harmless
nonself
antigen
deriv
food
benefici
commens
bacteria
identifi
metabolit
nutrient
vitamin
retino
acid
key
regul
immun
respons
capabl
inhibit
induct
proinflammatori
cell
promot
peripher
differenti
antiinflammatori
induc
treg
intestin
induc
regulatori
mechan
allow
environment
factor
control
aberr
endogen
immun
respons
outsid
induc
immun
toler
irrevers
howev
presenc
innat
danger
signal
retino
acid
effect
condens
synerg
innat
respons
promot
enhanc
protect
immun
dendrit
cell
dc
antigen
present
cell
influenc
activ
type
lymphocyt
includ
b
nk
cell
two
main
pathway
dc
develop
recogn
myeloid
dc
mdc
two
uniqu
subset
langerhan
cell
interstiti
dc
plasmacytoid
dc
pdc
main
sourc
antivir
immunomodulatori
type
interferon
subset
dc
display
uniqu
combin
surfac
marker
lectin
endow
distinct
phenotyp
function
dc
also
unavoid
target
prevent
treatment
develop
diseas
set
infect
cancer
microb
tumor
exploit
dc
evad
immun
dc
also
gener
resist
capac
readili
enhanc
dctarget
vaccin
context
patient
care
dc
provid
new
approach
diseas
pathogenesi
therapi
particular
clear
dc
play
critic
role
process
vaccin
address
explor
new
vaccin
design
har
dc
cancer
dc
gener
ex
vivo
cultur
either
blood
monocyt
bone
marrow
progenitor
cell
cytokin
combin
dc
load
tumor
antigen
differ
form
inject
back
patient
result
induct
clear
tumorspecif
immun
respons
well
clinic
respons
expand
strategi
cancer
type
well
infecti
diseas
hiv
novel
strategi
propos
directli
target
antigen
dc
vivo
multipl
dc
surfac
molecul
consid
target
need
allow
intern
antigen
cargo
process
present
mhc
class
class
ii
molecul
character
dc
subset
may
effect
target
antidc
antibodi
antibodi
fuse
antigen
carri
directli
desir
dc
maximum
immun
respons
varieti
infecti
diseas
neuroimmunolog
divis
inst
experiment
immunolog
depart
patholog
univers
hospit
zurich
switzerland
format
immun
synaps
apc
tcell
cytokin
capac
orchestr
ensu
immun
respons
context
ms
anim
model
eae
precis
function
phenotyp
encephalitogen
diseasemedi
cell
remain
elus
year
cytokin
secret
profil
effector
th
cell
divid
cell
immun
deviat
pathogen
regulatori
cell
wide
held
attract
therapeut
strategi
treatment
ms
paradigm
dismantl
discov
rather
induc
sister
cytokin
essenti
develop
autoimmun
diseas
demonstr
drive
express
th
cell
term
cell
coin
clear
associ
newli
describ
h
phenotyp
autoimmun
pathogen
implic
h
cytokin
critic
mediat
chronic
autoimmun
diseas
howev
notion
reli
almost
exclus
correl
associ
caus
link
cytokin
pathogen
yet
made
order
studi
actual
function
cytokin
context
autoimmun
vivo
gener
number
transgen
genetarget
mice
discov
current
notion
pathogen
cell
far
simplist
erron
discuss
cytokin
clearli
associ
pathogen
margin
contribut
develop
autoimmun
cnsdiseas
master
cytokin
drive
pathogen
independ
polar
b
cell
contribut
ms
pathophysiolog
gener
consid
base
potenti
react
particular
cn
antigen
produc
cnsdirect
autoantibodi
presenc
abnorm
csf
immunoglobulin
ig
typic
oligoclon
band
ocb
pattern
patholog
featur
demyelin
lesion
molecular
analys
b
cell
lineagetogeth
implic
contribut
cnsspecif
antibodi
ms
eg
complementmedi
injuri
antibodydirect
cytotox
adcc
eleg
approach
confirm
least
portion
cn
ig
bind
myelin
target
remain
unclear
whether
cn
antibodi
directli
contribut
pathogenesi
gener
consequ
tissu
injuri
repres
epiphenomenon
activ
cn
inflamm
certain
cnsdirect
antibodi
may
actual
benefici
support
remyelin
help
remov
debri
includ
growth
inhibitori
molecul
nogo
therebi
provid
permiss
environ
axon
regener
b
cell
contribut
ms
also
consid
beyond
capac
becom
antibodyproduc
cell
distinct
b
cell
subset
identifi
function
effect
apc
cell
normal
human
b
cell
recogn
activ
contribut
regul
immun
respons
part
secret
distinct
effector
cytokin
profil
contextdepend
fashion
patient
ms
chronic
activ
b
cell
describ
structur
reminisc
germin
center
may
affect
cn
independ
cell
well
promot
ongo
cell
activ
propag
ms
diseas
activ
defici
abil
ms
patient
b
cell
produc
downregulatori
cytokin
report
implic
directli
dysregul
ms
immun
process
promis
result
earli
phase
ms
studi
b
cell
deplet
rituximab
antibodi
support
role
b
cell
diseas
pathogenesi
rapid
onset
action
strategi
without
obviou
effect
igg
level
suggest
antibodyindepend
function
b
cell
like
contribut
observ
therapeut
effect
depart
cell
biolog
neurosci
istituto
superior
di
rome
itali
epsteinbarr
viru
ebv
infect
implic
sever
major
autoimmun
diseas
includ
multipl
sclerosi
ms
ms
evid
support
pathogen
role
ebv
come
epidemiolog
immunolog
histopatholog
studi
presenc
abnorm
deposit
ebvinfect
b
cellsplasma
cell
postmortem
brain
tissu
case
acut
relapsingremit
progress
ms
cours
compat
abnorm
humor
immun
persist
bcell
clone
expand
produc
immunonoglobulin
intrathec
format
intramening
bcell
follicl
latent
ebv
infect
promot
bcell
activ
growth
increas
immun
reactiv
ebv
patient
blood
cerebrospin
fluid
latent
lytic
ebv
protein
potent
immunogen
elicit
strong
band
tcell
immun
respons
ebv
could
promot
chronic
brain
inflamm
mechan
involv
autoimmun
eg
molecular
mimicri
rescu
selfreact
b
cell
andor
virusinduc
immunopatholog
result
inabl
immun
system
control
viral
infect
cn
properli
talk
shall
present
find
expand
previou
evid
dysregul
ebv
infect
ms
brain
discuss
scenario
cytotox
immun
respons
target
intracerebr
ebv
deposit
may
play
major
role
maintain
chronic
inflammatori
condit
ms
brain
accumul
data
indic
b
lymphocyt
antibodi
involv
pathogenesi
multipl
sclerosi
ms
rituximab
monoclon
antibodi
deplet
circul
b
cell
human
report
result
investigatoriniti
trial
rituximab
relaps
ms
patient
relapsingremit
ms
rrm
patient
continu
clinic
magnet
reson
imag
mri
activ
despit
treatment
fdaapprov
immunomodulatori
drug
imd
enrol
subject
receiv
dose
mgm
rituximab
week
continu
take
imd
twentythre
subject
underw
two
spinal
tap
one
week
pretreat
week
treatment
immunoglobulin
ig
g
concentr
igg
index
igg
synthesi
rate
electrophoresi
oligoclon
band
perform
central
lab
concentr
b
lymphocyt
cerebrospin
fluid
csf
determin
flow
cytometri
elisa
use
quantit
chemokin
level
csf
rituximab
posttreat
csf
b
cell
cell
decreas
significantli
compar
pretreat
report
cross
et
al
j
neuroimmunol
address
cell
decreas
follow
treatment
monoclon
antibodi
target
b
cell
array
chemokin
compar
csf
treatment
subject
csf
level
decreas
treatment
subject
remain
unchang
posttreat
increas
csf
subject
postrituximab
treatment
proport
declin
csf
correl
proport
declin
cell
number
csf
signific
reduct
csf
igg
index
igg
concentr
number
oligoclon
band
observ
trend
toward
decreas
igg
synthesi
rate
posttreat
note
b
cell
cell
significantli
reduc
csf
six
month
rituximab
declin
cell
number
correl
alter
csf
chemokin
pattern
specif
declin
csf
level
nation
ms
societi
usa
nation
institut
health
genentech
inc
biogen
idec
lp
fellow
nmss
usa
although
presenc
leukocyt
within
ms
lesion
indisput
rout
adhes
molecul
cell
access
brain
still
fulli
understood
use
lipid
raftbas
proteom
approach
identifi
melanoma
cell
adhes
molecul
immunoglobulin
superfamili
member
potenti
involv
leukocyt
migrat
across
bloodbrain
barrier
bbb
use
vitro
model
human
bbb
anim
model
ms
experiment
autoimmun
encephalomyel
eae
character
role
function
mcam
immun
cell
migrat
brain
demonstr
mcam
express
bbb
endotheli
cell
vitro
situ
mcam
express
upregul
inflammatori
cytokin
vitro
sinc
mcam
ligand
mcam
analys
mcam
express
peripher
blood
leukocyt
human
healthi
donor
ms
patient
mcam
detect
subset
activ
memori
lymphocyt
proport
mcam
cell
appear
higher
ms
patient
compar
control
furthermor
vitro
microscopi
studi
suggest
mcam
play
role
lymphocyt
adhes
diapedesi
preliminari
data
provid
evid
mcam
express
bbb
immun
cell
suggest
mcam
potenti
involv
ms
lesion
format
aim
project
identifi
novel
target
autoimmun
respons
multipl
sclerosi
ms
patient
test
potenti
pathogen
relev
anim
model
end
myelin
glycoprotein
purifi
human
postmortem
brain
separ
twodimension
electrophoresi
bind
igg
ms
sera
screen
western
blot
mass
spectrometri
immunoreact
spot
identifi
novel
target
diseas
associ
autoantibodi
respons
rat
homolog
transientlyexpress
axon
glycoprotein
sequest
juxtaparanod
domain
myelin
axon
also
express
adult
cortic
neuron
show
immunohistochemistri
autoantibodi
detect
sera
cerebrospin
fluid
csf
ms
patient
shown
recogn
nativ
antigen
surfac
transfect
cell
flow
cytometri
autoantibodi
respons
accompani
tcell
respons
peripher
blood
demonstr
elispot
prolifer
assay
pathogen
signific
autoimmun
respons
explor
adopt
cell
mediat
experiment
autoimmun
enceph
eae
model
rat
adopt
transfer
specif
tcell
induc
enceph
character
extens
inflamm
white
gray
matter
tract
spinal
cord
cortex
cotransf
specif
cell
myelin
oligodendrocyt
glycoprotein
mog
specif
mab
gener
focal
perivascular
demyelin
lesion
cortex
similar
report
ms
studi
identifi
novel
autoantigen
target
cell
autoantibodi
ms
suggest
respons
may
contribut
develop
gray
matter
patholog
diseas
recent
increas
evid
cell
particip
multipl
sclerosi
ms
pathophysiolog
vitro
vivo
studi
suggest
cell
may
involv
loss
myelin
axon
damag
latter
regard
caus
perman
neurolog
impair
observ
ms
howev
directli
damag
interact
antigenspecif
cell
central
nervou
system
cn
yet
unambigu
document
therefor
establish
organotyp
cn
slice
cultur
system
deriv
transgen
mice
express
gfp
myelin
ex
vivo
approach
allow
us
directli
monitor
interact
deriv
cell
myelin
axon
confoc
microscop
live
imag
strikingli
observ
direct
myelin
damag
mediat
cell
slice
puls
siinfekl
peptid
cognat
antigen
cell
cell
activ
furthermor
detect
decreas
neurofila
site
repeat
cellmyelin
contact
instanc
could
even
document
transsect
myelin
axon
thu
shown
first
time
myelin
loss
result
direct
immunolog
attack
cell
importantli
damag
confin
antigenspecif
interact
could
observ
unspecif
setup
eg
wildtyp
cell
puls
slice
control
peptid
accordingli
suggest
observ
transsect
myelin
axon
compos
least
twostep
mechan
first
antigen
specif
process
caus
myelin
damag
cell
presum
releas
perforingranzym
second
axon
injuri
result
collater
damag
high
preval
autoimmun
diseas
industri
countri
may
part
due
reduc
earli
life
exposur
common
microbi
agent
hygien
environ
investig
concept
model
effect
neonat
exposur
common
pathogenassoci
molecular
pattern
lipopolysaccharid
lp
experiment
autoimmun
encephalomyel
eae
assess
lpsmediat
effect
neuroimmun
paramet
ensu
neurolog
outcom
singl
intraperiton
exposur
lp
neonat
delay
onset
reduc
sever
moginduc
eae
compar
litterm
pbsexpos
mice
p
b
lymphocyt
prolifer
respons
mogexpos
antigen
present
cell
apc
suppress
among
cell
deriv
lpsexpos
anim
although
select
expans
cell
mediat
apc
lpsexpos
group
p
b
splenic
dendrit
cell
lpsexpos
anim
exhibit
reduc
express
mhc
class
ii
togeth
induct
prior
eae
p
b
spinal
cord
transcript
level
anim
eae
reveal
lower
lpscompar
pbsexpos
anim
associ
increas
level
lpsexpos
group
p
b
neuropatholog
studi
disclos
reduc
axon
myelin
loss
spinal
cord
lpscompar
pbsexpos
anim
eae
associ
increas
immunoreact
inde
robust
invers
correl
eae
sever
number
cell
detect
spinal
cord
p
b
find
support
concept
earlylif
pathogen
exposur
bias
immun
system
toward
toler
state
improv
diseas
outcom
might
provid
new
insight
neuroprotect
immunotherapi
kawachi
arakawa
musashi
yanagawa
kaori
nishizawa
masatoyo
depart
neurolog
brain
research
institut
niigata
univers
niigata
japan
play
critic
role
autoimmun
allerg
condit
diseas
progress
experiment
allerg
enceph
sever
attenu
mice
lymphocyt
detect
cerebrospin
fluid
multipl
sclerosi
ms
patient
ident
properti
remain
elus
object
character
evalu
function
cell
ms
peripher
blood
obtain
patient
relapsingremit
ms
neuroinflammatori
diseas
onid
healthi
volunt
hs
analyz
express
sever
chemokin
receptor
cell
surfac
peripher
mononuclear
cell
pbmc
detect
intracellular
ifng
flow
cytometri
within
cell
popul
frequenc
ifngproduc
cell
cell
treg
cell
pbmc
differ
ms
onid
hs
howev
within
doubl
neg
dn
cell
popul
ifngproduc
cell
decreas
frequenc
pbmc
ms
compar
hs
strikingli
cell
frequent
dn
cell
ms
compar
onid
hs
furthermor
found
sort
dn
cell
popul
ms
higher
express
transcript
encod
rorgt
rorc
hs
realtim
quantit
rtpcr
result
suggest
distinct
pool
dn
cell
ms
might
larger
onid
hs
innat
cell
includ
gd
cell
cell
constitut
larg
percentag
dn
cell
mice
shown
innat
cell
gd
cell
abil
produc
airway
neutrophilia
disord
set
imposs
detect
gd
cell
cell
express
pbmc
ms
therefor
suspect
product
deriv
per
se
also
distinct
lineag
innat
cell
except
gd
cell
might
critic
element
contribut
autoimmun
disord
ms
identifi
distinct
popul
dn
cell
express
ms
futur
studi
perform
investig
identif
innat
cell
lineag
product
pathogenesi
axi
ms
multipl
sclerosi
ms
chronic
inflammatori
demyelin
diseas
cn
studi
experiment
autoimmun
encephalomyel
shown
patholog
function
cell
cell
recent
identifi
effector
cell
type
produc
proinflammatori
cytokin
express
transcript
factor
rorgammat
howev
role
ms
remain
elucid
examin
frequenc
cell
blood
cerebrospin
fluid
csf
ms
patient
differ
stage
diseas
remiss
exacerb
data
demonstr
frequenc
cell
peripher
blood
remain
constant
diseas
cours
number
cell
dramat
increas
csf
relaps
time
observ
signific
decreas
cell
csf
patient
relaps
cell
clone
gener
peripher
blood
csf
ms
patient
clone
phenotyp
analyz
flow
cytometri
gene
express
profil
obtain
microarray
analysi
rtpcr
altogeth
data
suggest
cell
high
pathogen
potenti
thu
like
contribut
patholog
ms
develop
cell
receptor
tcr
transgen
mice
rr
mice
carri
tcr
specif
myelin
oligodendrocyt
glycoprotein
mog
peptid
present
ia
rr
mice
sjlj
background
spontan
develop
relapsingremit
fewer
case
chronic
progress
experiment
autoimmun
encephalomyel
eae
develop
spontan
eae
involv
recruit
mog
autoreact
b
cell
endogen
repertoir
transgen
cell
autoantibodi
format
depend
presenc
mog
autoantigen
occur
tcr
transgen
substrain
prone
develop
eae
mog
reactiv
autoantibodi
secret
b
cell
within
cn
bone
marrow
direct
conform
mog
epitop
hypothes
mog
releas
subclin
lesion
autoantibodi
form
subsequ
either
local
lymph
node
directli
cn
lesion
cn
character
massiv
demyelin
deposit
immunoglobulin
vitro
anti
mog
antibodi
activ
complement
lead
lysi
mog
express
transfect
therefor
consid
format
mog
autoantibodi
propathogen
step
enhanc
sever
spontan
eae
rr
mice
repres
first
spontan
anim
model
common
form
multipl
sclerosi
ms
relaps
remittingm
especi
appropri
studi
spontan
autoimmun
tb
cell
cooper
musk
antibodi
posit
myasthenia
gravi
muskmg
promin
bulbar
facial
involv
achr
antibodi
posit
myasthenia
gravi
achrmg
musk
antibodi
appear
predominantli
noncompl
fix
although
antibodi
also
seen
lower
level
howev
remain
unclear
antibodi
impair
neurotransmiss
immunis
mice
recombin
human
musk
phosphat
buffer
solut
freund
adjuv
two
boost
given
mice
also
receiv
pertussi
toxin
day
mice
immunis
recombin
musk
antibodi
titr
equival
seen
human
diseas
musk
antibodi
predominantli
non
complement
fix
complement
fix
determin
use
immunoflouresc
cell
base
assay
elisa
moreov
antibodi
appear
abl
activ
complement
vitro
musk
immunis
mice
show
minim
limb
muscl
weak
invert
screenhorizont
bar
although
trend
toward
impair
swallow
abil
ex
vivo
found
modest
consist
signific
reduct
miniatur
endplat
potenti
mepp
endplat
potenti
epp
amplitud
preserv
quantal
content
qc
confirm
postsynapt
dysfunct
mean
mepp
mv
musk
immunis
group
compar
mv
control
group
p
b
unpair
ttest
furthermor
identifi
modest
signific
reduct
endplat
area
length
neuromuscular
junction
diaphragm
muscl
use
fluoresc
label
bungarotoxin
mean
area
squar
micrometr
musk
immunis
group
compar
squar
micrometr
control
group
p
b
mann
whitney
test
studi
demonstr
musk
antibodi
abl
activ
complement
vitro
impair
neurotransmiss
caus
morpholog
chang
neuromuscular
junction
vivo
provid
evid
potenti
pathogen
role
caus
mg
b
cell
deplet
immun
intervent
central
nervou
system
autoimmun
diseas
investig
immunolog
mechan
associ
mediat
b
cell
deplet
experiment
autoimmun
encephalomyel
eae
background
b
cell
myelinspecif
antibodi
ab
play
pathogen
role
cn
autoimmun
diseas
recent
studi
indic
b
cell
may
also
regulatori
function
mediat
b
cell
deplet
approv
treatment
b
cell
lymphoma
rheumatoid
arthriti
may
also
reduc
inflamm
multipl
sclerosi
ms
understand
immunomodulatori
properti
b
cell
deplet
test
eae
induc
either
recombin
mous
mog
rmog
activ
b
cell
direct
secret
ab
conform
mog
encephalitogen
cell
determin
mog
model
requir
b
cell
pathogenesi
eae
induc
human
mice
deplet
b
cell
eae
prevent
mice
receiv
weekli
inject
start
day
prior
immun
reversalexperi
mice
random
treatment
onset
paralysi
treatment
revers
paralysi
induc
rmog
associ
reduct
cn
inflamm
frequenc
cn
b
cell
myelinspecif
ab
frequenc
myelinspecif
cell
well
regulatori
cell
treg
reduc
remain
antigenpres
cell
apc
b
celldeplet
mice
promot
differenti
myelinspecif
cell
contrast
b
cell
deplet
exacerb
mog
peptideinduc
eae
treg
also
reduc
polar
alter
use
apc
b
cell
rmog
mog
peptideimmun
mice
stimul
naiv
mogspecif
cell
prolifer
rmog
bcell
deplet
differenti
effect
mog
peptideand
mogprotein
induc
eae
peptideinduc
eae
deplet
exclus
b
cell
appear
sole
associ
reduct
treg
proteininduc
eae
howev
deplet
myelinspecif
b
cell
result
reduc
frequenc
due
lack
cell
activ
residu
apc
import
contribut
b
cell
autoantibodi
demonstr
pathogenesi
multipl
sclerosi
ms
lead
interest
use
autoantibodi
diagnost
prognost
biomark
use
cdna
phage
display
librari
deriv
ms
brain
plaqu
appli
serolog
antigen
select
identifi
antigen
target
specif
interact
antibodi
present
cerebrospin
fluid
csf
ms
patient
panel
antigen
target
identifi
detail
serolog
analysi
larg
panel
individu
ms
patient
control
csf
show
specif
sensit
discrimin
ms
patient
control
object
studi
character
novel
antigen
target
associ
antibodi
biomark
ms
analysi
immunoreact
profil
reveal
autoantibodi
reactiv
demonstr
differ
ms
subtyp
found
earli
stage
subset
ms
patient
moreov
increas
reactiv
toward
antigen
target
clinic
disabl
demonstr
detail
bioinformat
analys
perform
csfreactiv
epitop
rang
size
amino
acid
reveal
novel
antigen
remain
antigen
constitut
novel
epitop
encod
transcript
variant
known
gene
sever
clone
repres
epitop
cerebr
protein
epitop
novel
cdna
sequenc
origin
brain
librari
note
antigen
target
repres
epitop
similar
viral
protein
ebv
present
success
express
recombin
protein
antigen
target
obtain
synthet
peptid
remain
candid
immunoreact
purifi
recombin
protein
synthet
peptid
confirm
current
extend
screen
purifi
protein
synthet
peptid
addit
use
synthet
peptid
express
protein
monoclon
antibodi
product
perform
immunohistochem
stain
experiment
autoimmun
encephalomyel
tissu
monoclon
antibodi
conclus
autoantibodi
profil
epitop
deriv
ms
brain
tissu
could
serv
diagnost
marker
form
basi
identif
subgroup
ms
patient
may
benefit
specif
therapi
multipl
sclerosi
ms
autoimmun
demyelin
diseas
central
nervou
system
cn
autoimmun
respons
direct
yet
unidentifi
white
matter
antigen
distinct
featur
ms
presenc
local
immun
respons
within
cn
give
rais
igg
oligoclon
band
ob
cerebrospin
fluid
csf
one
still
obscur
pathogen
aspect
ms
concern
identif
antigen
target
igg
ob
order
identifi
ms
autoantigen
recogn
ob
igg
present
csf
appli
proteom
approach
coupl
immunoblot
human
white
matter
protein
separ
bidimension
electrophoresi
transfer
nitrocellulos
membran
probe
csf
igg
ms
patient
show
csf
ob
case
separ
igg
ob
nonob
igg
agaros
gel
isoelectrofocus
reactiv
igg
fraction
analyz
parallel
whole
csf
igg
immunoblot
presenc
igg
obspecif
autoantigen
assess
compar
analysi
immunereact
spot
obtain
two
igg
fraction
preliminari
result
show
csf
ob
igg
case
recogn
restrict
number
neural
protein
isoform
among
specif
isoform
transketolas
tk
recogn
csf
ob
igg
ms
patient
detail
analysi
provid
complet
pictur
fine
reactiv
ob
igg
result
obtain
indic
tk
major
autoantigen
ms
sinc
specif
tk
isoform
target
autoimmun
respons
csf
ms
patient
show
molecul
specif
recogn
ob
igg
identif
addit
autoantigen
case
target
tk
instrument
defin
complet
scenario
molecular
target
autoimmun
respons
ms
test
whether
local
baff
product
link
local
ig
product
ms
lesion
local
ig
product
express
tnf
famili
member
quantifi
qpcr
activ
inact
ms
lesion
observ
elev
transcript
baff
rel
april
proliferationinduc
ligand
activ
inact
ms
lesion
local
igg
product
within
ms
lesion
correl
strongli
local
baff
lesser
extent
april
transcript
result
underscor
relev
baffapril
system
mainten
b
lineag
cell
chronic
inflammatori
process
cn
ms
patient
thu
baff
april
promis
therapeut
target
gray
matter
diseas
multipl
sclerosi
poorli
understood
part
due
lack
mous
model
examin
role
entri
cell
white
gray
matter
cn
experiment
autoimmun
encephalomyel
eae
without
secondari
injuri
cerebr
cortex
use
intravit
twophoton
laser
scan
microscopi
intravit
mice
imag
role
gray
white
matter
diseas
spinal
cord
brain
mice
suscept
eae
induc
mog
peptid
complet
freund
adjuv
peak
eae
gfp
cell
predominantli
exclus
present
spinal
cord
absent
brain
mice
spinal
cord
gfp
cell
mostli
restrict
white
matter
preferenti
locomot
along
rostralcaud
axi
genotyp
remiss
nday
eae
produc
cell
gfp
wherea
cell
gfp
differ
ratio
produc
cell
genotyp
recruit
gfp
cell
gray
matter
evalu
induc
small
laser
injuri
layer
barrel
cortex
day
post
eae
induct
laser
injuri
recruit
gfp
cell
cortic
gray
matter
mice
ligand
induc
spinal
cord
well
brain
activ
day
recov
nday
eae
mice
necessari
entri
cell
gray
matter
eae
mice
propos
two
hit
model
cell
infiltr
cerebr
cortex
requir
neuroinflamm
induc
express
local
tissu
injuri
therapeut
potenti
adult
neural
stem
cell
ansc
suggest
sever
model
central
nervou
system
cn
insult
ansc
inject
intraven
migrat
home
damag
area
cn
previous
analyz
express
integrin
chemokin
receptor
vitro
differenti
ansc
effort
elucid
potenti
contribut
adhes
migrat
home
damag
area
cn
show
elev
express
stromal
cell
deriv
factor
inflam
area
cn
mice
experiment
autoimmun
encephalomyel
eae
also
show
upregul
express
receptor
differenti
ansc
studi
focus
search
sourc
insult
cn
involv
molecul
potenti
involv
migrat
home
immunostain
analysi
shown
reactiv
astrocyt
found
larg
number
inflam
region
eae
mice
major
sourc
elev
level
inflam
spinal
cord
also
found
oligodendrocyt
progenitor
cell
immunoreact
anoth
potenti
sourc
increas
interestingli
transcript
nonclass
cytokin
receptor
activ
nfkb
ligand
rankl
found
inflam
cn
compar
cn
healthi
mice
analysi
reveal
express
osteoprotegerin
opg
rankl
decoy
receptor
significantli
induc
follow
differenti
ansc
activ
receptor
rank
express
undifferenti
differenti
ansc
studi
effect
pro
antiinflammatori
cytokin
differenti
express
opg
involv
opgrankl
migrat
ansc
toward
insult
area
cn
investig
aberr
signal
due
defici
impair
antivir
respons
herp
simplex
viru
type
carr
wuest
todd
univers
oklahoma
health
scienc
center
oklahoma
citi
unit
state
chemokin
chemotact
nk
cell
activ
cell
dendrit
cell
highli
express
viral
infect
hypothes
absenc
chemokin
would
increas
sensit
infect
test
hypothesi
neurotrop
pathogen
herp
simplex
viru
type
evalu
mice
defici
receptor
ligand
combin
present
studi
follow
ocular
herp
simplex
infect
viral
titer
elev
central
nervou
system
cn
defici
mice
moreov
defici
result
sever
phenotyp
comparison
mice
defici
delet
result
impair
recruit
nk
dendrit
antigenspecif
cell
nervou
system
although
nk
dendrit
cell
mobil
similar
defici
mice
mice
exhibit
modif
mobil
antigenspecif
cell
defect
traffick
cell
cn
mice
due
absenc
signal
chemokin
receptor
doubl
defici
mice
exhibit
signific
chang
recruit
specif
cell
compar
wild
type
control
mice
indic
defect
observ
mice
result
defect
signal
select
loss
resist
infect
mice
directli
relat
aberr
recruit
hsvspecif
cell
nervou
system
depend
express
tofthansen
morten
owen
trevor
leukocyt
accumul
spontan
perivascular
space
transgen
mice
express
chemokin
tg
central
nervou
system
cn
control
myelin
basic
protein
promot
associ
clinic
patholog
previous
shown
system
inject
pertussi
toxin
ptx
mice
induc
parenchym
infiltr
across
glia
limitan
correl
develop
encephalopathi
stuporlik
symptom
weight
loss
tofthansen
et
al
j
immunol
experiment
model
allow
us
dissoci
event
involv
leukocyt
migrat
across
endotheli
barrier
across
glia
limitan
two
separ
compon
neurovascular
unit
use
laser
microdissect
follow
realtim
rtpcr
amplifi
rna
determin
gene
express
cell
perivascular
area
transgen
mice
treat
ptx
sinc
ptx
caus
recruit
monocytesmacrophag
well
cell
cn
tg
mice
investig
express
class
ii
transactiv
ciita
molecul
relat
antigen
present
regul
found
lower
level
normal
gapdh
ciita
express
ptx
treat
tg
mice
compar
pb
treat
tg
control
mice
express
perivascular
cell
cytokin
tnfalpha
ifngamma
alter
ptx
wherea
went
detect
rel
low
level
control
tg
mice
detect
higher
level
ptx
treat
tg
mice
result
may
reflect
differenti
particip
ifngamma
express
cell
migrat
across
neurovascular
unit
analyz
involv
antigen
present
cell
receptor
specif
cross
tg
mice
tcr
tg
mice
whose
cell
specif
myelin
oligodendrocyt
glycoprotein
mog
doubletransgen
offspr
show
sign
spontan
clinic
diseas
suggest
transendotheli
migrat
mogspecif
cell
perivascular
space
suffici
induc
encephalopathi
prior
studi
indic
cn
express
chemokin
normal
occur
along
basolater
surfac
microvasculatur
therebi
control
leukocyt
access
parenchyma
patient
multipl
sclerosi
ms
mice
experiment
autoimmun
encephalomyel
eae
howev
reloc
lumen
surfac
cn
venul
allow
egress
autoreact
leukocyt
perivascular
space
reloc
highli
correl
extent
perivascular
infiltr
hypothes
leukocytederiv
inflammatori
mediat
reloc
via
alter
express
receptor
examin
reloc
intraven
administr
cytokin
mice
cytokin
receptordefici
mice
immun
myelin
oligodendrocyt
glycoprotein
mog
also
identifi
perivascular
leukocyt
subset
induct
eae
determin
whether
leukocytederiv
cytokin
affect
endotheli
cell
express
receptor
examin
cn
specimen
mogimmun
mice
preclin
timepoint
reveal
venular
reloc
occur
prior
onset
clinic
diseas
venul
contain
perivascular
cell
express
administr
tnfa
induc
reloc
vessel
mice
target
delet
reloc
microvasculatur
contrast
mogimmun
mice
exhibit
reloc
predomin
perivascular
cell
suggest
role
cell
reloc
bbb
addit
bone
marrow
chimer
experi
reveal
loss
cn
determin
sever
eae
final
vitro
treatment
brain
endotheli
cell
induc
express
mrna
result
suggest
cn
traffick
cell
autoimmun
lead
alter
express
bbb
via
increas
endotheli
cell
express
studi
five
patient
acut
axon
motor
neuropathi
aman
patient
acut
inflammatori
demyelin
polyneur
aidp
patient
anteced
campylobact
jejuni
infect
patient
serum
antibodi
andor
isol
monocyt
healthi
subject
gb
patient
immatur
dendrit
cell
express
molecul
cultur
autolog
cell
stimul
lp
obtain
two
cj
strain
isol
gb
patient
cell
respons
lp
gangliosid
determin
releas
proinflammatori
cytokin
ifng
tnfa
patient
tight
correl
exist
cell
reactiv
gangliosid
individu
antibodi
respons
gangliosid
conclus
find
provid
evid
molecular
mimicri
also
level
cell
respons
suggest
import
contribut
cellular
immun
pathogenesi
gb
syndrom
gb
immunemedi
polyneuropathi
typic
develop
infect
campylobact
jejuni
antibodi
produc
clear
infect
crossreact
gangliosid
present
peripher
nerv
caus
nerv
damag
neurolog
diseas
polyreact
charact
antibodi
well
lack
memori
respons
suggest
tcell
independ
mechan
bcell
activ
sinc
dendrit
cell
dc
play
import
role
present
bacteri
antigen
regul
bcell
activ
investig
whether
lipooligosaccharid
lo
antigen
isol
campylobact
jejuni
strain
activ
dc
subsequ
induc
bcell
prolifer
monocytederiv
dc
healthi
donor
stimul
control
escherichia
coli
lipopolysaccharid
lp
lo
six
differ
c
jejuni
strain
isol
gb
patient
observ
c
jejuni
lo
effect
control
e
coli
lp
upregul
costimulatori
molecul
hladr
indic
full
dc
activ
addit
c
jejuni
lo
induc
dosedepend
secret
cytokin
tnfalpha
lo
c
jejuni
enhanc
antiigm
induc
prolifer
mucos
bcell
howev
cultur
supernat
dc
stimul
c
jejuni
lo
ad
bcell
prolifer
significantli
increas
effect
c
jejuni
lo
partli
depend
presenc
sialic
acid
sinc
lo
cstii
mutant
strain
well
sialidasetr
lo
less
effect
induc
dc
activ
bcell
prolifer
result
indic
lo
gbsassoci
c
jejuni
activ
dc
produc
solubl
factor
subsequ
enhanc
bcell
prolifer
effect
partial
depend
sialyd
lo
unravel
cellular
mechan
behind
antibodi
respons
caus
gb
necessari
develop
novel
strategi
limit
diseas
progress
improv
clinic
outcom
anteced
infect
intraven
immunoglobulin
plasma
exchang
efficaci
treatment
recent
nerv
growth
factor
ngf
new
drug
commonli
use
mani
peripher
nerv
disord
includ
gb
china
aim
determin
whether
ngf
safe
syndrom
make
preliminari
observ
efficaci
report
studi
two
univers
hospit
locat
west
north
china
respect
studi
design
parallel
group
random
control
trial
gb
demyelin
group
patient
divid
treatment
group
patient
control
group
b
patient
gb
mix
group
patient
divid
treatment
group
c
patient
control
group
patient
gb
axon
degener
group
patient
divid
treatment
group
e
patient
control
group
f
patient
group
c
e
treat
intraven
immunoglobulin
intramuscular
ngf
purityn
specif
activityn
aumg
protein
daili
week
group
b
f
treat
intraven
immunoglobulin
patient
neurolog
function
electrophysiolog
test
evalu
begin
end
treatment
rate
extent
recoveri
motor
nerv
conduct
veloc
ncv
group
better
group
b
p
b
recoveri
rate
full
recoveri
rate
motor
ncv
motor
nerv
wave
rang
group
c
greatli
better
group
p
b
clinic
recoveri
rate
full
recoveri
rate
show
obviou
differ
group
e
f
p
n
motor
nerv
wave
rang
group
e
demonstr
obvious
higher
group
f
p
n
addit
seriou
advers
event
found
nerv
growth
factor
kind
safe
treatment
possess
signific
effect
recoveri
demyelin
axon
degener
gb
circul
nucleic
acid
cna
shown
diagnost
util
human
diseas
aim
studi
sequenc
organ
extens
catalog
cna
compar
normal
rang
cna
patient
acut
multipl
sclerosi
am
serum
dna
otherwis
healthi
human
am
patient
extract
amplifi
sequenc
use
pyrosequenc
categor
origin
human
versu
xenogen
function
repeat
code
noncod
gene
chromosom
local
genom
frequenc
normalsam
sequenc
deriv
total
nucleotid
attribut
known
databas
sequenc
approxim
known
sequenc
genom
xenogen
bacteri
viral
genom
sequenc
origin
repeat
annot
gene
within
expect
rang
interestingli
code
sequenc
significantli
underrepres
vs
p
b
am
patient
compris
overrepresent
sequenc
alu
sequenc
p
b
reach
odd
ratio
p
b
cindex
unexpectedli
one
normal
found
hbv
genotyp
f
sequenc
wherea
distribut
cna
mostli
compar
genom
underrepresent
cd
argu
strongli
sole
apoptot
origin
cna
result
alu
alreadi
found
associ
ms
could
open
diagnost
horizon
use
technolog
well
capabl
uncov
occult
infect
vosslamb
van
der
voort
laura
van
baarsen
lisa
heijman
roel
crusiu
bart
killestein
joep
polman
chri
verweij
cor
multipl
sclerosi
ms
heterogen
diseas
reflect
differenti
respons
therapi
particular
ifnb
previous
heterogen
pharmacolog
respons
ifnb
therapi
rrm
patient
describ
evid
provid
baselin
statu
ifn
type
activ
neg
correl
pharmacolog
effect
ifnb
treatment
hypothes
interindividu
differ
ifn
type
respons
program
baselin
concomit
variat
ifnb
respons
may
result
interindividu
variat
ifnb
biolog
studi
investig
role
genet
variat
ifn
signal
compon
relat
heterogen
pharmacolog
respons
ifnb
determin
biolog
respons
peripher
blood
collect
rrm
patient
ifnb
therapi
untreat
rrm
patient
peripher
blood
collect
two
time
point
three
twelv
month
time
period
analyz
stabil
baselin
valu
time
baselin
stabil
biolog
respons
rate
analyz
taqman
low
densiti
array
tlda
use
mean
gene
express
level
set
ifn
type
respons
gene
genet
variat
determin
sever
compon
ifn
signal
cascad
use
taqman
genotyp
assay
convent
genom
pcr
ratio
gene
express
level
therapi
compar
occurr
genet
variat
compon
ifn
signal
pathway
extent
biolog
respons
correl
neg
baselin
express
type
ifn
respons
gene
set
r
p
baselin
stabil
time
reflect
correl
effici
r
p
n
next
determin
associ
genet
variat
ifn
signal
compon
ifn
type
respons
gene
activ
baselin
pharmacolog
intervent
ifnb
analysi
reveal
signific
associ
genet
variat
one
ifn
signal
compon
baselin
ifn
type
respons
gene
express
p
accordingli
signific
reduc
biolog
respons
observ
patient
contain
genet
variant
p
variat
ifn
signal
may
determin
part
heterogen
pharmacolog
clinic
respons
ifnb
rrm
multipl
sclerosi
ms
mous
model
eae
autoimmun
ai
diseas
depend
genet
environment
factor
share
immunopatholog
gene
eg
tyrosin
may
also
share
ai
diseas
gene
mice
singl
g
missens
mutat
make
ai
arthriti
resist
gondii
suscept
unlik
wildtyp
substrain
induc
eae
mice
use
doubl
inject
protocol
mogcfa
mice
resist
eae
reciproc
hybrid
suscept
p
b
antigen
specif
product
rant
ifngamma
specif
increas
mice
thu
share
ai
suscept
gene
eae
complement
genet
one
wildtyp
allel
next
test
whether
eae
mice
could
complement
environment
factor
use
pertussi
toxin
ptx
mogcfa
ptx
mice
immun
mogcfa
ptx
significantli
suscept
eae
mogcfa
immun
mice
vs
p
b
larg
number
cytokin
chemokin
increas
ptx
includ
ancillari
adjuv
contrast
ifngamma
rant
chang
significantli
genet
ptx
complement
summari
share
immunopatholog
ai
diseas
suscept
allel
complement
genet
environment
snp
consider
signific
given
potenti
role
genebyenviron
interact
ms
suscept
lamberteaton
myasthen
syndrom
lem
autoimmun
disord
peripher
nervou
system
characteris
proxim
muscl
weak
autonom
dysfunct
approxim
patient
associ
small
cell
lung
carcinoma
sclc
whilst
approxim
patient
autoantibodi
voltageg
calcium
channel
vgcc
transmembran
protein
locat
presynapt
nerv
termin
cerebellum
surfac
sclc
postul
antibodi
rais
determin
tumour
may
cross
react
vgcc
nerv
termin
result
neurolog
dysfunct
antibodi
may
convey
surviv
advantag
patient
one
hundr
consecut
unselect
patient
biopsyproven
sclc
recruit
time
tumour
diagnosi
hospit
within
trent
region
uk
assay
autoantibodi
vgcc
onconeuroantigen
surviv
rate
patient
paraneoplast
neurolog
syndrom
posit
onconeur
antibodi
sclc
patient
sclc
alon
compar
overal
patient
posit
vgcc
antibodi
eight
patient
pqtype
vgcc
antibodi
rang
pm
one
low
level
ntype
vgcc
pm
whilst
one
pqtype
ntype
vgcc
antibodi
pm
respect
ten
patient
four
typic
clinic
electrophysiolog
featur
lem
patient
onconeur
antibodi
hu
antibodi
patient
hu
ri
ri
amphiphysin
four
other
median
surviv
four
antibodi
posit
lem
patient
month
p
unpair
twoway
ttest
consider
greater
antibodi
neg
month
antibodi
posit
patient
month
although
preliminari
result
indic
presenc
function
activ
autoantibodi
confer
increas
surviv
advantag
compar
antibodi
neg
patient
addit
vgcc
antibodyposit
lem
surviv
longer
patient
similar
vgcc
autoantibodi
without
neurolog
symptom
patient
lamberteaton
myasthen
syndrom
lem
small
cell
lung
carcinoma
sclc
found
report
antibodi
specif
rather
sensit
paraneoplast
lem
phage
display
screen
studi
report
preliminari
result
amen
assay
system
clone
gene
use
recombin
protein
elisa
titrat
serum
sampl
test
healthi
control
patient
sclc
patient
lem
without
sclc
patient
sclc
lem
sampl
consid
posit
od
valu
least
three
sd
averag
od
healthi
control
sclclem
patient
test
posit
twentynin
sampl
test
assay
twentythre
test
posit
elisa
seventeen
phage
display
elisa
posit
valu
found
lem
without
sclc
sclc
median
averag
od
valu
sclclem
lem
without
sclc
hc
respect
high
titer
od
found
sclclem
group
none
test
strongli
posit
two
group
p
b
rule
fals
posit
immunoblot
use
confirm
low
od
titer
five
patient
vgcctiter
avail
treatment
titer
strongli
posit
treatment
diminish
treatment
vgcc
becam
neg
two
high
titer
antibodi
highli
specif
lem
patient
sclc
elisa
use
recombin
protein
sensit
specif
elabor
phage
display
assay
biollaz
gregoir
bernasconi
luca
cretton
christin
ursula
frei
karl
fontana
adriano
suter
glioma
among
fatal
tumor
attribut
immunosuppress
featur
tumor
cn
howev
rel
contribut
either
glioma
local
investig
report
syngen
glioma
trigger
protect
immun
respons
grow
subcutan
despit
fact
also
intracerebr
grown
glioma
infiltr
dc
cell
failur
control
intracerebr
glioma
correl
increas
immunosuppress
condit
intracerebr
tumor
tumor
infiltr
dendrit
cell
intracerebr
glioma
abl
stimul
cell
prolifer
vitro
brainloc
glioma
character
significantli
higher
number
regulatori
cell
higher
express
mrna
compar
glioma
skin
moreov
show
dc
intracrani
tumor
induc
vitro
higher
number
regulatori
cell
subcutan
tumor
dc
data
show
tumor
locat
dictat
effici
antitumor
immun
respons
mesenchym
stem
cell
msc
promis
therapeut
tool
autoimmun
diseas
coupl
immunesuppress
properti
multidifferenti
potenti
multipl
sclerosi
anim
model
experiment
autoimmun
encephalomyel
eae
autoimmun
diseas
character
widespread
demyelin
axon
loss
aim
studi
assess
clinic
efficaci
molecular
mechan
adiposederiv
msc
amsc
chronic
eae
administ
amsc
treat
induc
eae
mice
two
distinct
experiment
protocol
intraven
administr
amsc
diseas
onset
prevent
protocol
significantli
amelior
clinic
cours
decreas
spinal
cord
inflamm
demyelin
effect
mostli
due
peripher
impair
cell
function
gfp
amsc
migrat
persist
lymphoid
organ
inhibit
cell
prolifer
product
proinflammatori
mediat
addit
signific
number
amsc
also
found
within
inflam
spinal
cord
small
proport
underw
glial
differenti
addit
prevent
effect
amsc
significantli
reduc
eae
clinic
patholog
score
administ
diseas
stabil
day
postimmun
therapeut
protocol
signific
reduct
demyelin
axon
loss
experiment
condit
migrat
amsc
lymph
node
well
ex
vivo
inhibit
cell
significantli
reduc
amsc
administ
therapeut
protocol
effici
migrat
inflam
cn
within
demyelin
area
amsc
infiltr
accompani
increas
number
oligodendrocyt
progenitor
donor
origin
signific
subset
amsc
express
integrin
antibodi
inhibit
penetr
inflam
cn
mice
establish
diseas
taken
togeth
data
suggest
amsc
produc
benefici
effect
chronic
eae
bimod
mechan
similarli
neural
precursor
cell
depend
inflammatori
background
cell
may
inhibit
autoimmun
respons
lymphoid
organ
earli
diseas
stage
andor
promot
local
neuroregener
administ
chronic
phase
diseas
previous
demonstr
system
infus
mesenchym
stem
cell
msc
induc
peripher
toler
encephalitogen
myelin
antigen
howev
still
unknown
whether
system
deliveri
msc
could
affect
immun
respons
insid
central
nervou
system
cn
local
deliveri
intracystern
ic
may
result
signific
clinic
advantag
thu
compar
effect
msc
inject
system
ic
myelin
oligodendrocyt
glycoprotein
mog
immun
experiment
autoimmun
encephalomyel
eae
affect
mice
observ
rout
administr
led
similar
improv
clinic
histolog
score
signific
evid
transdifferenti
observ
group
system
infus
msc
induc
increas
regulatori
cell
decreas
effector
cell
isol
cn
treat
mice
compar
control
thu
immunomodulatori
activ
system
infus
msc
occur
induct
peripher
toler
also
inhibit
migrat
effector
cell
expans
regulatori
cell
target
organ
evalu
mscmediat
effect
moginduc
experiment
autoimmun
encephalomyel
histolog
molecular
analysi
central
nervou
system
specimen
show
decreas
axon
suffer
inhibit
astrogliosi
microglia
activ
upregul
gene
involv
bmp
notch
pathway
final
demonstr
msc
express
arginas
enzym
play
import
role
sever
biolog
process
includ
nitric
oxid
product
limit
pool
arginin
avail
synthas
consequ
microgli
cell
cultur
presenc
msc
decreas
product
find
suggest
msc
therapeut
effect
may
result
impair
arginin
metabol
thu
irrespect
lack
neural
differenti
msc
exert
remark
neuroprotect
effect
eae
univers
texa
health
scienc
center
houston
houston
texa
usa
magnet
reson
imag
mri
first
use
imag
live
subject
multipl
sclerosi
ms
year
ago
despit
limit
earli
rel
low
field
scanner
crude
imag
sequenc
immedi
evid
mri
provid
import
portal
patholog
diseas
patholog
previous
could
adequ
sampl
patient
lifetim
earli
studi
base
complet
constraint
place
relax
properti
water
molecul
impos
structur
characterist
microenviron
provid
earli
look
well
establish
ms
lesion
plaqu
introduct
paramagnet
contrast
agent
use
longitudin
serial
scan
patient
unveil
dynam
natur
lesion
format
evolut
time
mri
secur
import
place
diagnosi
diseas
monitor
evolut
diseas
process
investig
potenti
benefit
new
treatment
disord
mri
also
provid
import
inform
categor
diseas
activ
may
crucial
understand
result
investig
aberr
immun
respons
ms
patient
phenomena
appear
fundament
current
understand
approach
manag
potenti
devast
disord
least
earli
clinic
phase
ms
mri
aid
secur
diagnosi
diseas
also
enabl
shortterm
prognosi
diseas
cours
specif
mri
find
patholog
chang
present
affect
tissu
place
limit
correl
quantit
mri
find
clinic
disabl
current
constrain
use
mri
true
surrog
undermin
abil
serial
mri
measur
biolog
efficaci
new
therapeut
agent
central
issu
activ
address
includ
whether
composit
measur
convent
mri
paramet
provid
better
concomit
predict
correl
clinic
diseas
statu
short
long
term
better
puls
acquisit
higher
field
imag
better
delin
cortic
patholog
evolut
global
chang
brain
patholog
seen
advanc
mri
approach
reflect
distribut
chang
neuron
pathway
consequ
classic
focal
lesion
bespeak
independ
neurodegen
process
subtl
chang
cell
effector
function
clinic
critic
eg
autoimmun
diseas
allergi
insuffici
immun
respons
cancer
foundat
design
molecular
therapeut
thu
import
understand
modest
chang
receptor
engag
cell
surfac
process
vari
physiolog
circumst
complex
cell
signal
network
regul
cell
effector
function
abil
signal
intermedi
interact
network
encod
extens
studi
biochem
properti
addit
much
less
well
understood
concentr
signal
intermedi
insid
live
cell
vari
time
space
refer
variat
spatiotempor
pattern
critic
effici
signal
regul
live
cell
enrich
two
protein
locat
time
increas
interact
probabl
spatiotempor
pattern
need
studi
system
approach
spatiotempor
pattern
individu
signal
intermedi
becom
interest
compar
pattern
multipl
compon
network
first
therefor
determin
spatiotempor
pattern
element
cell
activ
activ
primari
cell
antigen
present
cell
strike
find
everi
signal
intermedi
uniqu
spatiotempor
pattern
divers
spatiotempor
pattern
critic
signific
sinc
spatiotempor
pattern
differ
dramat
signal
intermedi
likelihood
signal
intermedi
interact
vari
substanti
time
space
cell
activ
spatiotempor
pattern
signific
regul
cell
activ
second
provid
causal
support
hypothesi
address
particular
signal
intermedi
central
regul
cell
polar
shown
subcellular
local
overal
cellular
activ
critic
function
togeth
data
establish
regul
spatiotempor
patter
cell
activ
critic
element
control
effici
cell
activ
molecular
therapeut
target
regul
may
great
util
modul
cell
activ
autoimmun
diseas
allergi
insuffici
immun
respons
cancer
mrbase
technolog
chang
view
pathophysiolog
multipl
sclerosi
neuroimag
research
unit
depart
neurolog
scientif
institut
univers
ospedal
san
raffael
milan
itali
dramat
paradigm
shift
take
place
understand
pathophysiolog
multipl
sclerosi
ms
import
contribut
shift
made
possibl
advanc
magnet
reson
imag
mri
technolog
allow
accur
quantit
estim
structur
central
nervou
system
cn
damag
obtain
patient
ms
follow
evolut
cours
diseas
high
sensit
past
year
use
modern
quantit
mr
techniqu
inde
reshap
pictur
ms
lead
formul
call
axon
hypothesi
ie
chang
metabol
morpholog
densiti
axon
import
determin
function
impair
ms
context
metric
deriv
magnet
transfer
diffusionweight
mri
enabl
us
quantifi
extent
structur
chang
occur
within
lesion
normalappear
tissu
includ
gray
matter
increas
patholog
specif
irrevers
tissu
damag
convent
mri
proton
mr
spectroscopi
add
valuabl
piec
inform
biochem
natur
chang
final
function
mri
provid
new
insight
role
cortic
adapt
chang
limit
clinic
consequ
msrelat
irrevers
tissu
damag
consequ
extens
applic
mr
techniqu
current
understand
pathophysiolog
ms
diseas
white
matter
character
focal
inflammatorydemyelin
lesion
also
associ
subtl
diffus
damag
throughout
white
gray
matter
entir
cn
inflammatori
neurodegen
compon
diseas
process
present
earliest
clinic
phase
diseas
appear
least
partial
dissoci
addit
recoveri
repair
play
import
role
genesi
clinic
manifest
diseas
involv
structur
chang
eg
clearanc
inflamm
remyelin
plastic
reorgan
cortex
new
pictur
ms
import
implic
context
treatment
option
sinc
suggest
agent
protect
neurodegener
promot
tissu
repair
may
import
role
play
alongsid
agent
act
classic
inflammatori
compon
diseas
gangliosid
antibodi
found
acut
phase
sera
miller
fisher
syndrom
mf
patient
antibodi
believ
pathogen
factor
lead
neuromuscular
paralysi
previous
shown
vitro
mous
model
use
diaphragm
musclenerv
prepar
antibodi
bind
presynapt
neuromuscular
junction
activ
complement
system
culmin
format
membran
attack
complex
mac
function
electrophysiolog
analys
show
block
synapt
transmiss
neuromuscular
junction
initi
period
dramat
high
asynchron
releas
acetylcholin
associ
paralysi
muscl
morpholog
show
mac
deposit
neuromuscular
junction
neurofila
degrad
sinc
complement
involv
format
mac
import
factor
membran
injuri
gener
form
attract
pharmacotherapeut
target
test
two
experiment
drug
abl
inhibit
complement
cascad
level
without
affect
immunoprotect
role
upstream
complement
compon
eculizumab
alexion
pharmaceut
human
mous
monoclon
igg
specif
bind
human
block
cleavag
latter
first
compon
mac
recombin
form
soft
tick
saliva
protein
also
effect
inhibit
cleavag
human
use
mous
model
mf
assess
efficaci
drug
antibodymedi
neuropathi
result
demonstr
drug
effect
blocker
mac
format
vitro
mous
model
thu
complet
prevent
develop
neuron
damag
associ
paralysi
eculizumab
also
test
vivo
mous
mf
model
gener
intraperiton
inject
antibodi
follow
normal
human
serum
sourc
complement
untreat
mice
develop
respiratori
paralysi
due
transmiss
block
diaphragm
neuromuscular
junction
show
function
morpholog
hallmark
termin
motor
neuropathi
intraven
inject
eculizumab
found
protect
mice
complementmedi
damag
murin
mf
narcolepsi
lifelong
debilit
diseas
caus
defici
orexinhypocretin
signal
pathway
brain
orexinexpress
neuron
locat
later
hypothalamu
play
import
role
sleep
regul
feed
orexin
absent
csf
patient
narcolepsycataplexi
postmortem
studi
demonstr
neuron
absent
narcolept
diseas
highli
associ
mhc
class
ii
allel
suggest
condit
immunemedi
hypothesi
destruct
orexin
neuron
caus
autoimmun
specif
tcell
cross
blood
brainbarri
target
orexin
express
cell
aim
gener
anim
model
narcolepsi
immun
mice
express
human
mhc
class
ii
molecul
peptid
deriv
preproorexin
orx
peptid
previous
shown
bind
mice
femal
week
old
immunis
subcutan
peptid
pb
complet
freund
adjuv
cfa
ng
pertussi
toxin
ptx
inject
intraperiton
day
h
postimmunis
anim
day
immunis
lymph
node
deriv
tcell
test
prolifer
assay
orx
peptid
potent
activ
cell
vitro
orx
sensit
cell
restrict
group
immunis
control
anim
test
sleepi
motiv
statu
week
immunis
signific
differ
observ
experiment
control
group
final
brain
variou
stage
immunis
day
day
week
analys
number
orexin
neuron
hypothalamu
tcell
infiltr
marker
immun
neuron
activ
neuron
loss
activ
observ
practic
tcell
enter
brain
observ
strong
peripher
tcell
activ
restrict
howev
immun
activ
effect
behaviour
anim
gener
brain
patholog
lack
symptom
may
explain
fact
tcell
peripheri
cross
bloodbrain
barrier
bbb
despit
use
ptx
adjuv
immunis
protocol
progress
pathogenesi
inflammatori
autoimmun
diseas
peripher
nervou
system
lead
demyelin
andor
axon
damag
still
incomplet
resolv
particular
controversi
extent
autoimmunemedi
destruct
peripher
nerv
result
secondari
damag
central
nervou
system
ii
cell
contribut
diseas
address
question
appli
murin
model
induc
experiment
autoimmun
neuriti
ean
immun
mice
result
sever
axon
damag
mild
demyelin
importantli
mice
develop
die
back
axonopathi
apoptosi
larg
fraction
neuron
anterior
horn
lumbar
thorac
spinal
cord
progress
neurogen
muscular
atrophi
cell
deplet
experi
identifi
cell
decis
mediat
ean
cell
major
cellular
sourc
antigenspecif
product
regul
number
tumor
necrosi
factor
induc
nitric
oxid
synthas
macrophag
diseas
sciatic
nerv
mediat
axon
damag
subsequ
neuron
apoptosi
neurogen
muscular
atrophi
contrast
demyelin
peripher
nerv
slightli
amelior
celldeplet
mice
conclus
ean
cellmedi
autoimmun
diseas
affect
peripher
central
nervou
system
observ
implic
pathogenesi
autoimmun
cellmedi
diseas
peripher
nerv
clinic
relev
develop
specif
therapeut
strategi
aim
inhibit
autoimmun
attack
peripher
nerv
prevent
die
back
axonopathi
particular
confer
axon
protect
upmost
import
final
clinic
outcom
kiyozuka
fujioka
toshiki
kudeken
tsukasa
toho
univers
tokyo
japan
investig
effect
statin
experiment
autoimmun
neuriti
ean
atorvastatin
given
oral
ean
rat
daili
ean
induc
femal
lewi
rat
inject
synthet
peptid
bovin
myelin
protein
cfa
ean
rat
fed
vehicl
use
control
clinic
sign
assess
daili
use
gradescor
system
cauda
equina
ce
remov
day
postimmun
dpi
mrna
express
ifngamma
ce
studi
use
semiquantit
rtpcr
group
develop
ean
dpi
simultan
although
atorvastatintr
rat
show
milder
sign
earlier
recoveri
mononuclear
cell
infiltr
seen
ce
atorvastatintr
rat
also
milder
control
rat
rtpcr
reveal
ifngamma
mrna
express
dpi
mrna
express
dpi
atorvastatintr
rat
decreas
compar
control
rat
convers
mrna
express
dpi
thereaft
atorvastatintr
rat
increas
compar
control
rat
ean
atorvastatin
suppress
neurolog
deficit
cytokin
although
reciproc
upregul
cytokin
seen
moreov
suppress
observ
atorvastatintr
rat
upregul
mrna
data
suggest
ean
atorvastatin
suppress
activ
irrelev
cytokin
upregul
suppress
previou
studi
shown
antigangliosid
antibodi
caus
neuromuscular
presynapt
block
mous
phrenic
nervediaphragm
prepar
aim
studi
determin
whether
sera
affect
neuromuscular
transmiss
human
limb
muscl
axonalstimul
singl
fiber
electromyographi
perform
extensor
digitorum
communi
muscl
four
patient
acut
motor
axon
neuropathi
aman
antibodi
four
acut
inflammatori
demyelin
polyneuropathi
aidp
antigangliosid
antibodi
measur
elisa
antibodi
posit
four
aman
patient
none
aidp
patient
aman
patient
show
normal
jitter
block
acut
phase
diseas
within
week
onset
aidp
patient
jitter
normal
three
slightli
increas
remain
one
neuromuscular
transmiss
appear
impair
aman
patient
antibodi
suggest
antibodi
affect
neuromuscular
transmiss
human
limb
muscl
result
fail
support
find
experiment
studi
mous
phrenic
nerv
antigangliosid
antibodi
would
involv
node
ranvier
distal
motor
axon
near
motor
nerv
termin
neuromuscular
junction
earli
studi
evidenc
presenc
inflammatori
infiltr
muscl
facioscapulohumer
muscular
dystrophi
fshd
patient
order
evalu
contribut
inflamm
fshd
pathogenesi
progress
studi
evalu
peripher
blood
mononuclear
cell
pbmc
fshd
patient
control
percentag
tbet
cell
moreov
correl
percentag
tbet
express
cell
pbmc
product
ifng
tnfa
tgfb
diseas
sever
evalu
magnet
reson
imag
mri
clinic
examin
studi
includ
fshd
patient
sex
age
match
control
detect
tbet
perform
intracellular
flow
cytometri
product
ifng
tnfa
tgfb
pbmc
measur
elisa
differ
found
percentag
circul
cell
cell
cell
cell
cell
fshd
patient
control
higher
percentag
cell
observ
fshd
patient
control
found
higher
ifng
tnfa
level
fshd
patient
control
differ
observ
tgfa
level
divid
fshd
patient
two
differ
group
accord
mri
paramet
higher
percentag
cell
cell
cell
cell
found
peripher
blood
fshd
patient
inflammatori
pattern
patient
without
inflammatori
pattern
control
addit
number
cell
correl
score
fshd
patient
mri
inflammatori
pattern
show
signific
higher
ifng
tnfa
level
fshd
patient
without
inflammatori
pattern
healthi
subject
product
higher
fshd
patient
inflammatori
pattern
fshd
patient
without
inflammatori
pattern
group
patient
show
higher
level
control
data
suggest
inflamm
mainli
mediat
cell
may
play
import
role
fshd
promot
muscl
patholog
favour
disabl
progress
thymu
implic
possibl
site
origin
trigger
autoimmun
myasthenia
gravi
mg
sever
group
previous
report
analysi
regulatori
cell
treg
mg
thymu
howev
certain
pattern
chang
cell
subset
reveal
examin
pathogenesi
mg
analyz
pattern
treg
produc
cell
observ
thymu
specimen
mg
mg
nonmg
mg
human
thymic
tissu
consist
mggroup
child
thymu
immunolog
diseas
n
adult
thymu
immunolog
diseas
n
adult
thymu
thymoma
n
mg
group
adult
thymu
neoplasma
n
adult
thymu
hyperplasia
n
adult
thymu
thymoma
n
child
adult
thymi
without
immunolog
diseas
obtain
cardiac
surgeri
sampl
thymoma
nonneoplast
thymic
tissu
adjac
thymoma
analyz
perform
immunohistochem
analysi
thymic
section
visual
treg
produc
cell
antibodi
specif
use
combin
antibodi
data
obtain
leica
confoc
microscopi
quantif
posit
cell
signal
measur
use
imagej
softwar
studi
approv
ethic
committe
univers
tokushima
number
posit
cell
pixel
signal
thymic
medulla
higher
cortex
number
posit
cell
child
thymi
higher
adult
thymi
howev
signific
differ
number
posit
cell
among
adult
thymi
without
mg
signal
mg
thymi
seem
promin
mgthymi
produc
cell
rather
treg
may
alter
thymu
mg
patient
investig
occurr
japanes
patient
mg
detect
employ
immunofluoresc
use
hek
cell
transfect
human
sera
patient
mg
follow
depart
collect
obtain
written
inform
consent
two
patient
mg
symptom
relat
cn
disturb
mri
investig
brain
spinal
cord
reveal
long
spinal
cord
lesion
one
patient
recurr
optic
neuriti
paraplegia
consist
nmo
demyelin
midbrain
tegmentum
cerebr
white
matter
patient
posit
develop
mg
subsequ
thymectomi
preced
develop
multipl
sclerosi
case
patient
mg
frequent
exhibit
occurr
antibodi
strongli
relat
develop
cn
demyelin
disord
patient
myasthenia
gravi
mg
autoimmun
disord
affect
neuromuscular
junction
muscl
specif
kinas
musk
antibodi
found
variabl
proport
patient
generalis
diseas
acetylcholin
receptor
achr
antibodi
neg
typic
patient
promin
ocular
facial
bulbar
neck
respiratori
weak
often
requir
long
term
immunosuppress
therapi
document
clinic
cours
two
patient
long
term
follow
centr
correl
musk
antibodi
titr
use
standard
radioimmunoprecipit
assay
examin
igg
subclass
abil
activ
complement
attack
complex
vitro
sever
time
point
diseas
use
cell
base
assay
final
analys
function
effect
igg
antibodi
cultur
muscl
cell
musk
antibodi
patient
mainli
subclass
although
antibodi
also
seen
later
diseas
cours
found
musk
antibodi
abil
activ
complement
vitro
although
role
complement
vivo
remain
unclear
also
demonstr
musk
antibodi
patient
variabl
abil
caus
dispers
acetylcholin
receptor
cluster
fulli
differenti
muscl
cell
studi
show
musk
antibodi
caus
instabl
preform
achr
cluster
potenti
disrupt
neuromuscular
transmiss
vivo
furthermor
igg
subclass
switch
increas
abil
activ
complement
vitro
may
respons
fluctuat
diseas
cours
longterm
corticosteroid
cs
therapi
effect
treat
myasthenia
gravi
mg
problem
cumul
side
effect
toxic
still
need
resolv
studi
show
therapeut
efficaci
cyclosporin
cya
potent
immunosuppress
agent
mg
cya
expect
reduc
cs
dosag
howev
cya
side
effect
includ
dosedepend
nephrotox
hypertens
new
oral
microemuls
form
cya
mecya
develop
mecya
equal
biolog
activ
much
lower
dosag
old
formul
present
studi
evalu
csdosag
reduct
effect
safeti
mecya
therapi
gener
mg
twenti
three
patient
gener
mg
women
men
age
median
yo
rang
yo
enrol
studi
diagnosi
mg
base
typic
clinic
featur
posit
respons
edrophonium
neostigmin
decrement
respons
lowfrequ
repetit
nerv
stimul
posit
antiacetylcholin
receptor
antibodi
assay
patient
underw
thymectomi
receiv
cs
daili
prior
mecya
therapi
initi
mecya
dosag
mgkg
divid
two
dose
per
day
gradual
reduc
treatment
minim
efficaci
dosag
monitor
mecya
blood
level
adjust
maintain
trough
level
less
ngml
renal
function
serum
creatinin
bun
basi
clinic
respons
mgadl
score
mecya
therapi
daili
cs
dosag
significantli
reduc
mg
mg
mgadl
score
significantli
improv
point
point
point
also
signific
decreas
level
follow
therapi
side
effect
mecya
encount
increas
serum
creatinin
trichosi
hypertens
mild
toler
mecya
therapi
effect
safe
reduc
cs
dosag
patient
gener
mg
patient
earlyonset
myasthenia
gravi
eomg
onset
b
age
autoantibodi
acetylcholin
receptor
achr
also
lymph
nodelik
infiltr
thymic
medulla
includ
cell
area
germin
center
implic
mg
pathogenesi
musclespecif
kinas
musk
antibodi
normal
thymi
wherea
remain
patient
low
affin
antibodi
achr
thymi
similar
eomg
though
either
subgroup
atroph
investig
potenti
lymphocyt
traffick
compar
thymic
lymphat
vessel
lv
high
endotheli
venul
hev
mg
patient
infant
agedmatch
nonmyasthen
control
stain
paraffin
section
thymi
mg
patient
control
lymphat
vessel
mab
hev
mab
blood
vessel
antivon
willebrand
factor
pab
frequenc
disposit
cellular
content
hev
lv
analyz
entir
section
use
semiquantit
score
system
also
doublestain
immunofluoresc
lymphocyt
found
lv
similar
overal
frequenc
adult
sampl
fatsepta
around
residu
thymic
tissu
appear
emptycollaps
howev
control
infant
even
adult
mg
sampl
infiltr
eomg
low
affin
achr
ab
also
found
lv
within
thymic
tissu
corticomedullari
junction
near
infiltr
notabl
intern
lv
usual
dilatedpack
mani
cell
consist
emigr
statu
neither
lymphat
endotheli
cell
lymphocyt
show
sign
cell
divis
neg
expect
hev
restrict
infiltr
mg
thymi
appear
empti
final
small
proport
atroph
mg
sampl
show
lv
contain
lymphocyt
hev
remain
parenchym
area
adult
control
may
relic
burntout
infiltr
overal
result
suggest
increas
access
mg
thymi
incom
lymphocyt
via
hev
increas
export
via
lymphat
gener
circul
agre
involv
thymu
pathogenesi
eomg
notabl
also
mg
patient
low
affin
antibodi
achr
tbet
tissuespecif
transcript
factor
control
differenti
ifngamma
product
affect
igg
class
switch
pathogen
autoantibodi
product
new
evid
suggest
tbet
also
regul
cell
studi
examin
influenc
tbet
defici
develop
experiment
autoimmun
myasthenia
gravi
eamg
anim
model
human
myasthenia
gravi
mg
mg
eamg
celldriven
antibodymedi
autoimmun
disord
neuromuscular
junction
eamg
induc
mice
immun
acetylocholin
receptor
achr
combin
adjuv
onset
incid
sever
eamg
compar
tbet
defici
mice
control
mice
respons
helper
cell
b
cell
well
phenotyp
function
regulatori
cell
investig
show
tbet
mice
less
suscept
eamg
associ
defect
cell
b
cell
dendrit
cell
dc
respons
correl
expans
regulatori
treg
cell
well
enhanc
respons
cell
result
suggest
tbet
might
provid
potenti
therapeut
target
myasthenia
gravi
sever
symptom
show
intraindividu
correl
titer
igg
autoantibodi
myasthenia
gravi
mg
antibodi
acetylcholinereceptor
achr
muscl
specif
kinas
musk
lambert
eaton
myasthen
syndrom
lem
howev
interindividu
correl
titer
symptom
weak
evid
exist
inflammatori
properti
igg
depend
type
glycosyl
fc
moieti
affect
interact
fcgamma
receptor
high
degre
galactosyl
igg
antibodi
associ
clinic
remiss
rheumatoid
arthriti
differ
glycosyl
might
also
play
role
autoimmun
myasthen
syndrom
autoantibodi
mainli
achr
mg
lem
musk
mg
achr
mg
lem
occur
paraneoplast
syndrom
idiopath
autoimmun
diseas
associ
hla
haplotyp
contrast
musk
mg
known
paraneoplast
disord
differ
hla
associ
explor
immunopathogenesi
detail
studi
glycosyl
profil
igg
three
myasthen
syndrom
fcpart
tryptic
glycopeptid
analyz
mass
spectrometri
statist
analysi
perform
plsda
partial
least
squar
discrimin
analysi
sharpen
separ
group
observ
obtain
maximum
separ
class
control
patient
lem
character
low
degre
galactosyl
compar
agematch
control
next
biantennari
corefucosyl
agalacto
nglycan
structur
also
bisect
counterpart
carri
addit
nacetylglucosamin
elev
likewis
achr
mg
patient
musk
mg
patient
show
reduc
galactosyl
igg
fc
moieti
sever
igg
glycoform
lem
patient
show
correl
occurr
sclc
bisect
glycoform
decor
sialic
acid
residu
elev
wherea
non
corefucosyl
glycoform
reduc
reduc
degre
galactosyl
found
patient
lem
achr
mg
musk
mg
patient
igg
glycosyl
also
differ
lem
patient
without
sclc
current
studi
aim
corrobor
find
larger
patient
cohort
associ
igg
glycosyl
clinic
diseas
sever
b
cell
regul
activ
patient
myasthenia
gravi
myasthenia
gravi
mg
character
presenc
auto
antibodi
ab
acetylcholin
receptor
achr
patient
among
antiachr
neg
patient
subgroup
also
defin
antibodi
musclespecif
kinas
musk
overlap
antibodi
respons
regul
differenti
ab
product
b
cell
activ
relat
induc
cell
activ
diseas
subgroup
evalu
studi
peripher
blood
mononuclear
cell
stain
b
cell
b
cell
activ
factor
tnf
famili
baff
receptor
baffr
cell
marker
analyz
flowcytometri
baff
level
measur
sera
mg
patient
healthi
control
hc
elisa
mg
group
consist
gener
patient
without
thymoma
antimusk
ab
patient
antiachr
ab
patient
patient
none
ab
compar
agematch
hc
peripher
blood
patient
b
cell
without
differ
hc
b
cell
strongli
posit
baffr
group
well
baff
level
lower
mg
group
vs
pgml
p
compar
hc
howev
subtyp
defin
coexpress
significantli
increas
mg
group
compar
hc
vs
p
report
increas
baff
level
antibodi
mediat
autoimmun
diseas
support
mg
present
studi
howev
increas
b
cell
regul
cell
subset
mg
implic
differenti
effect
mg
subgroup
product
ab
present
work
support
research
fund
istanbul
univers
myasthenia
gravi
mg
autoimmun
diseas
defin
muscl
weak
due
autoantibodi
mediat
deplet
acetylcholin
receptor
achr
neuromuscular
junction
nmj
recent
shown
mice
immun
lp
achr
develop
mglike
diseas
cellindepend
lpsachr
induc
eamg
mice
abl
produc
signific
quantiti
high
affin
isotyp
switch
antiachr
igg
particularli
complement
recent
studi
patient
mg
indic
innat
immun
signal
baff
upregul
evalu
role
signal
develop
eamg
util
lpsachr
eamg
model
lp
ligand
wt
mice
immun
lp
achr
evalu
gener
muscl
weak
sera
antiachr
antibodi
patholog
igg
deposit
nmj
wt
mice
develop
mglike
muscl
weak
sera
antiachr
antibodi
igg
mac
deposit
nmj
howev
mice
develop
less
sever
diseas
reduc
incid
compar
wt
mice
associ
significantli
reduc
titer
avid
achr
mice
also
reduc
muscl
deposit
vs
wt
mice
reduc
muscl
mac
deposit
vs
wt
mice
follow
boost
immun
achr
lp
lymph
node
cell
stimul
vitro
achr
achr
plu
lp
analyz
prolifer
cytokin
product
cell
prolifer
respons
achr
stimul
fail
prolifer
lp
alon
stimul
cell
achr
lp
synerg
produc
significantli
higher
amount
ifng
wt
mice
mice
wt
cell
stimul
achr
alon
induc
product
howev
addit
lp
without
achr
induc
signific
product
wt
lymph
node
cell
cell
data
indic
promot
eamg
increas
antiachr
avid
enhanc
lymph
node
product
ifng
elucid
prognost
pathogen
signific
nmo
anoth
inflammatori
disord
transvers
myeliti
csf
level
nmo
relaps
remit
multipl
sclerosi
rrm
optic
neuriti
patient
neurolog
normal
control
measur
elisa
indirect
immunofluoresc
studi
show
vascular
stain
pattern
typic
nmoigg
sera
nmo
patient
nmo
patient
significantli
p
b
elev
csf
level
pgml
pgml
compar
rrm
patient
pgml
pgml
optic
neuriti
patient
pgml
pgml
control
pgml
pg
ml
particularli
nmo
igg
posit
patient
display
higher
csf
level
pgml
pgml
nmo
igg
neg
nmo
patient
pgml
pgml
result
suggest
involv
nmo
pathogenesi
nmo
igg
product
immunoblot
found
csf
igg
patient
specif
recogn
spot
identifi
dimethylargininasei
ddahi
aldehyd
reductasei
akriai
ddahi
present
two
isoform
recogn
respect
five
four
patient
immunohistochemistri
antiddahi
antiserum
depict
endotheli
cell
normal
human
cn
akriai
recogn
three
csf
enzym
wide
distribut
neuron
endothelia
immunohistochemistri
igg
csf
immunostain
neuron
endotheli
cell
mous
cn
presenc
autoantibodi
select
csf
patient
may
import
diagnost
pathogenet
implic
sinc
autoimmun
respons
ddahi
akriai
enzym
may
lead
vascular
andor
neuron
damag
two
major
mechan
involv
pathogenesi
broad
spectrum
neuropsychiatr
symptom
includ
chorea
hyperact
tic
emot
labil
obsessivecompuls
symptom
describ
associ
group
beta
hemolyt
streptococc
gabh
infect
patient
suffer
symptom
diagnos
sydenham
chorea
panda
suggest
antibodi
produc
gabh
may
cross
blood
brain
barrier
react
neural
cell
process
involv
molecular
mimicri
might
lead
emerg
neuropsychiatr
symptom
two
disord
date
anim
model
either
sydenham
chorea
panda
recent
found
lewi
rat
immun
mutanolysin
gabh
extract
show
increas
compuls
well
motor
disturb
sera
taken
immun
rat
demonstr
strong
immunoreact
gabh
antigen
neural
tissu
compar
sera
control
rat
addit
sera
rat
demonstr
movement
behavior
disturb
induc
high
level
calciumcalmodulindepend
protein
cam
kinas
activ
human
neuroblastoma
cell
shown
previous
acut
sydenham
chorea
panda
autoantibodi
immun
rat
target
striatum
thalamu
two
brain
region
implic
pathophysiolog
sydenham
chorea
panda
current
work
identifi
brain
epitop
involv
antibodi
bind
preliminari
result
support
hypothesi
immun
respons
gabh
may
part
underli
behavior
movement
abnorm
report
panda
sydenham
chorea
provid
import
step
toward
identif
specif
mechan
autoantibodi
glur
epsilon
adult
patient
nonparaneoplast
acut
limbic
enceph
takahashi
kubota
yuko
yamasaki
etsuko
nishimura
shigeko
tsunoga
hisano
fujiwara
tateki
nation
epilepsi
center
shizuoka
japan
incid
acut
enceph
millionyear
japanes
adult
patient
evid
viral
invas
cn
develop
method
detect
autoantibodi
nmdatyp
glutam
receptor
glur
epsilon
glur
delta
use
whole
molecul
synthes
pex
system
found
autoantibodi
glur
epsilon
patient
rasmussen
syndrom
two
patient
acut
enceph
takahashi
neurolog
thereaft
found
igmautoantibodi
glur
epsilon
csf
sampl
acut
stage
local
enceph
sampl
acut
stage
widespread
enceph
takahashi
futur
neurolog
recent
paraneoplast
antinmdar
enceph
associ
ovarian
teratoma
report
dalmau
ann
neurol
examin
autoantibodi
glur
epsilon
adult
patient
nonparaneoplast
acut
limbic
enceph
npale
examin
autoantibodi
glur
epsilon
sera
csf
adult
patient
npale
use
fulllength
glur
epsilon
molecul
immunoblot
ntermin
epitop
autoantibodi
immunoblot
use
bacteri
fusion
protein
contain
ntermin
peptid
glur
epsilon
amino
acid
residu
autoantibodi
glur
epsilon
found
mainli
npale
patient
around
year
old
autoantibodi
glur
epsilon
sera
detect
approxim
npale
patient
acut
chronic
stage
autoantibodi
csf
detect
acut
stage
recoveri
stage
chronic
stage
patient
csf
igmautoantibodi
glur
epsilon
detect
within
five
day
onset
npale
four
csf
autoantibodi
glur
epsilon
includ
epitop
ntermin
glur
epsilon
data
suggest
autoantibodi
glur
epsilon
produc
sera
infect
infiltr
cn
damag
bbb
acut
stage
affect
ntermin
glur
epsilon
chronic
stage
recoveri
function
bbb
reduc
level
autoantibodi
csf
bbb
hippocampi
amygdala
vulner
autoantibodi
glur
epsilon
includ
epitop
ntermin
may
bring
limbic
symptom
around
onset
patient
myasthenia
gravi
mg
antibodi
nicotin
acetylcholin
receptor
achr
muscl
specif
kinas
musk
remain
patient
term
seroneg
myasthenia
snmg
shown
recent
antibodi
bind
achr
dens
cluster
surfac
transfect
cell
neuromuscular
junction
musk
antibodi
thought
predominantli
subclass
antibodi
membran
water
channel
express
astrocyt
choroid
plexu
epitheli
cell
found
high
proport
patient
neuromyel
optica
nmo
clinic
characteris
optic
neuriti
myeliti
also
pathogen
mechan
alway
clear
establish
techniqu
measur
igg
subclass
complement
activ
vitro
hek
cell
transfect
either
achr
cluster
use
rapsyn
musk
incub
patient
sera
igg
subclass
activ
complement
compon
membran
attack
complex
mac
visualis
use
fluoresc
label
secondari
antibodi
flow
cytometri
use
quantifi
result
antibodi
cluster
achr
snmg
predominantli
subtyp
similar
seroposit
mg
deposit
activ
complement
compon
mac
demonstr
invitro
proport
patient
snmg
antibodi
musk
predominantli
also
signific
amount
antibodi
could
activ
complement
invitro
nmo
sera
mainli
antibodi
activ
complement
system
strongli
degre
complement
activ
correl
significantli
presenc
antibodi
group
patient
show
immunocytofluoresc
techniqu
use
identifi
presenc
antibodi
also
demonstr
function
properti
studi
provid
invitro
evid
complement
activ
autoimmun
neurolog
disord
give
insight
pathogenes
make
potenti
suitabl
target
therapi
use
complement
inhibitor
recent
studi
report
contrast
result
respect
presenc
antimyelin
protein
antibodi
multipl
sclerosi
ms
relat
diseas
activ
may
due
heterogen
specif
autoantibodi
ms
inabl
method
detect
pathogen
relev
antibodi
myelin
particl
use
detect
antimyelin
antibodi
cerebrospin
fluid
csf
ms
patient
subsequ
relat
mri
paramet
evalu
antimyelin
igg
antibodi
reactiv
determin
csf
ms
patient
n
clinic
isol
syndrom
ci
patient
n
use
novel
flow
cytometrybas
assay
addit
csf
patient
neurolog
diseas
ond
n
inflammatori
neurolog
diseas
ind
n
healthi
control
hc
n
test
compar
hc
increas
antimyelin
igg
antibodi
reactiv
frequent
found
csf
ci
patient
p
relapsingremit
rr
ms
patient
p
b
secondari
progress
sp
ms
patient
p
b
togeth
constitut
posit
csf
sampl
contrast
elev
antimyelin
igg
antibodi
respons
present
minor
primari
progress
pp
ms
patient
ind
patient
margin
present
healthi
control
absent
ond
patient
strikingli
antimyelin
igg
antibodi
reactiv
relat
number
lesion
brain
mri
ci
relapseonset
ms
patient
r
p
csf
antimyelin
igg
antibodi
promis
specif
biomark
ci
relapseonset
ms
correl
mr
measur
diseas
spectrum
neurolog
disord
associ
serum
voltageg
potassium
channel
vgkc
antibodi
includ
neuromyotonia
nmt
affect
peripher
nervou
system
limbic
enceph
le
affect
central
nervou
system
morvan
syndrom
mo
combin
featur
nmt
le
often
addit
autonom
dysfunct
eg
hyperhidrosi
bladder
difficulti
weight
loss
diseas
consid
autoimmun
basi
often
respond
well
steroid
plasma
exchang
wide
phenotyp
spectrum
vgkc
antibodyassoci
disord
howev
suggest
may
differ
antibodi
specif
condit
hypothes
antibodi
specif
vgkc
subtyp
associ
protein
might
distinguish
condit
use
varieti
biochem
immunolog
approach
investig
specif
antibodi
sera
patient
mo
mo
sera
immunoprecipit
subpopul
vgkc
solubilis
rabbit
brain
radioactivelylabel
bind
surprisingli
howev
mo
sera
bind
directli
cell
line
transfect
cdna
encod
subunit
moreov
addit
sd
deterg
vgkc
extract
tri
disengag
associ
protein
reduc
bind
therefor
test
known
associ
protein
found
mo
igg
bound
cell
express
protein
known
interact
potassium
channel
confirm
direct
immunoprecipit
egfptag
associ
protein
mo
rare
treatabl
neurolog
diseas
clinic
spectrum
broad
condit
easili
misdiagnos
observ
mo
antibodi
bind
protein
rather
directli
help
explain
vari
clinic
spectrum
mo
provid
definit
diagnost
test
previou
studi
detect
complex
antibodi
profil
retin
antigen
patient
glaucoma
heat
shock
protein
play
import
role
cell
surviv
normal
stress
condit
antibodi
heat
shock
protein
identifi
studi
sera
glaucoma
patient
aim
studi
analyz
immun
caus
retin
ganglion
cell
loss
rat
similar
loss
found
glaucoma
patient
lewi
rat
immun
mg
plu
freund
adjuv
pertussi
toxin
divid
three
group
group
euthan
week
n
group
week
n
group
week
n
control
anim
receiv
immun
euthan
week
n
group
intraocular
pressur
measur
cours
studi
blood
collect
sever
time
point
serum
use
detect
igg
antibodi
pattern
retina
via
western
blot
protein
g
bead
techniqu
antibodi
pattern
analyz
multivari
statist
techniqu
eye
harvest
day
anim
euthan
fix
flatmount
stain
detect
retin
ganglion
cell
rgc
nuclei
use
comput
assist
quantit
rgc
densiti
signific
chang
intraocular
pressur
observ
cours
studi
anim
immun
show
lower
number
rgc
comparison
control
p
b
anim
show
complex
antibodi
profil
detect
method
multivari
statist
method
could
show
signific
differ
group
p
b
group
show
signific
differ
control
group
week
immun
p
b
immun
anim
develop
complex
antibodi
profil
retin
antigen
previou
studi
could
demonstr
specif
antibodi
profil
retin
antigen
glaucoma
patient
thu
anim
model
might
benefici
approach
studi
develop
action
antiretin
antibodi
possibl
involv
neurodegen
process
optic
nerv
e
g
glaucoma
support
boehring
ingelheim
foundat
gangliosid
complex
gsc
target
antigen
syndrom
gb
thought
locat
axolemma
motor
nerv
antigen
associ
pure
motor
gb
may
exist
vicin
coloc
axolemma
patient
pure
motor
gb
may
antibodi
gsc
antigen
associ
purpos
studi
investig
gb
sera
antibodi
mixtur
analyz
clinic
electrophysiolog
find
patient
antibodi
gsc
sera
patient
gb
survey
antibodi
gsc
consist
two
nine
gangliosid
elisa
analyz
clinic
electrophysiolog
featur
patient
igg
antibodi
ten
gb
patient
igg
antibodi
six
patient
antigangliosid
antibodi
antibodi
clinic
find
patient
featur
preserv
sensori
system
infrequ
cranial
nerv
deficit
accord
characterist
pure
motor
gb
accord
criteria
hadden
et
al
ann
neurol
electrodiagnost
find
classifi
demyelin
pattern
four
patient
acut
motor
axon
neuropathi
two
abnorm
found
sensori
nerv
earli
motor
conduct
block
intermedi
nerv
segment
motor
nerv
without
lower
motor
conduct
veloc
found
five
patient
may
form
complex
axolemma
node
ranvier
paranod
motor
nerv
may
target
antigen
pure
motor
gb
especi
form
acut
motor
conduct
block
neuropathi
neuromyel
optica
nmo
devic
diseas
rare
welldescrib
demyelin
neurolog
syndrom
distinct
clinic
featur
manag
approach
differenti
nmo
common
caus
transvers
myeliti
particular
secondari
system
infect
import
prognost
therapeut
reason
presenc
serum
nmoigg
antibodi
support
diagnosi
nmo
detect
nmoigg
indirect
immunofluoresc
iif
rodent
brain
renal
method
current
avail
routin
use
diagnost
laboratori
group
recent
observ
presenc
atyp
nmoigglik
iif
stain
patient
transvers
myeliti
secondari
system
melioidosi
atyp
stain
could
mistaken
nmoigg
evalu
presenc
atyp
nmoigglik
iif
stain
pattern
system
infect
sera
patient
serolog
evid
acut
infect
caus
common
bacteri
viral
pathogen
inf
n
control
ctrl
n
test
use
fresh
frozen
section
rodent
brain
renal
papilla
antihuman
igg
conjug
none
patient
fulfil
clinic
radiolog
criteria
nmo
iif
stain
interpret
accord
origin
descript
nmoigg
varieti
differ
nmoigglik
iif
pattern
detect
inf
sera
ctrl
sera
although
differ
combin
stain
central
nervou
system
cn
microvessel
pia
subpia
virchowrobin
space
tubul
renal
papilla
detect
overal
pattern
atyp
compar
defin
lennon
et
al
studi
demonstr
import
experi
interpret
nmoigg
assay
strict
adher
origin
descript
nmoigg
essenti
correct
interpret
nmoigg
iif
pattern
particularli
patient
system
infect
may
complic
transvers
myeliti
given
clinic
implic
diagnosi
nmo
urgent
need
standardis
report
nmoigg
iif
pattern
develop
robust
confirmatori
assay
reduc
risk
report
atyp
nmoigglik
pattern
nmoigg
antibodi
water
channel
particularli
express
perivascular
astrocyt
podocyt
propos
marker
diagnosi
neuromyel
optica
nmo
howev
consensu
seropreval
optim
detect
method
yet
reach
setup
five
differ
assay
two
capabl
detect
perivascular
igg
reactiv
brain
tissu
immunofluoresc
nmoigg
three
assay
set
specif
detect
antibodi
immunofluoresc
flow
cytometri
cell
radioimmunoprecipit
assay
assess
sensit
specif
differ
assay
interrog
sera
nmo
patient
patient
high
risk
develop
nmo
hrnmo
patient
affect
acut
partial
transvers
myeliti
aptm
patient
multipl
sclerosi
ms
age
sex
match
healthi
control
expect
found
presenc
serum
nmoigg
reactiv
almost
exclus
restrict
patient
nmo
hrnmo
seropreval
sensit
rang
depend
assay
specif
rang
compar
result
obtain
five
assay
notic
lack
concord
sampl
howev
sensit
increas
assay
use
combin
detect
nmoigg
antibodi
may
repres
near
futur
valuabl
tool
assist
neurologist
differenti
diagnosi
patient
nmo
hrnmo
aptm
ms
current
lack
gold
standard
detect
antibodi
impli
necess
standard
detect
antibodi
ms
patient
use
sa
analysi
oligoclon
antibodi
band
ocb
csf
serum
uniqu
ocb
csf
indic
intrathec
antibodi
product
bodi
fluid
use
parallel
affin
select
ms
cdna
phage
display
librari
enrich
antigen
recogn
ms
immunoglobulin
select
round
phage
screen
enrich
coloni
pcr
dna
fingerprint
phage
elisa
test
use
confirm
specif
enrich
csf
serum
identifi
enrich
clone
exclus
enrich
serum
select
sole
identifi
select
round
perform
csf
moreov
identifi
common
cdna
clone
enrich
serum
csf
select
procedur
phage
elisa
perform
confirm
immunoreact
select
phage
clone
csf
serum
six
clone
show
immunoreact
compart
clone
show
exclus
reactiv
csf
immunoreact
csf
remark
higher
compar
serum
reactiv
consist
intrathec
antibodi
product
one
cdna
clone
extens
enrich
display
immunoreact
csf
serum
identifi
member
mitogen
activ
protein
kinas
mapk
famili
yet
describ
relat
ms
express
cdna
clone
demonstr
spinal
cord
healthi
experiment
autoimmun
encephalomyel
mice
western
blot
immunohistochemistri
use
sa
studi
autoantibodi
profil
ms
csf
serum
parallel
provid
clue
regard
intrathec
system
autoantibodi
product
diseas
antibodi
produc
immort
b
cell
csf
peripher
blood
ms
patient
control
patient
noninflammatori
inflammatori
neurolog
diseas
nind
oind
peripher
blood
mononuclear
cell
pbmc
csf
cell
cultur
presenc
epsteinbarr
viru
ebv
polyclon
growth
factor
combin
cell
inhibitori
b
cell
stimul
factor
irradi
allogen
pbmc
week
cultur
supernat
screen
presenc
immunoglobulin
g
igg
posit
cultur
clone
result
monoclon
antibodi
repres
enrich
b
cell
popul
vivo
compar
csf
blood
b
cell
immort
procedur
optim
present
obtain
iggposit
b
cell
line
ms
patient
origin
csf
patient
pbmc
anoth
ms
patient
nind
patient
immort
b
cell
line
isol
deriv
csf
cell
one
patient
pbmc
second
patient
pbmc
two
patient
investig
monoclon
b
cell
spectratyp
analysi
perform
obtain
b
cell
line
iggposit
b
cell
line
appear
monoclon
b
cell
immort
prove
use
method
product
monoclon
antibodi
optim
necessari
increas
effici
procedur
conclus
obtain
panel
iggposit
b
cell
line
ms
patient
control
futur
experi
cultur
supernat
monoclon
b
cell
use
screen
antibodi
bind
human
oligodendrogli
cell
line
hog
healthi
experiment
autoimmun
encephalomyel
eae
brain
tissu
rat
rhesu
monkey
virus
cytomegaloviru
cmv
ebv
devic
neuromyel
optica
prognost
implic
nmo
igg
statu
turkish
patient
devic
neuromyel
optica
nmo
inflammatorydemyelin
disord
predominantli
affect
optic
nerv
spinal
cord
debat
classif
name
disord
recent
find
show
underli
humor
abnorm
nmo
character
presenc
highli
specif
serum
antibodi
abund
water
channel
cn
call
nmoigg
studi
aim
evalu
statu
among
turkish
patient
nmo
find
clinic
signific
serum
sampl
patient
nmo
diagnos
accord
criteria
followedup
multipl
sclerosi
myelin
disord
unit
evalu
nmoigg
use
indirect
immunofluoresc
confirm
carri
immunoprecipit
employ
recombin
human
mean
age
onset
year
mean
diseas
durat
year
sex
ratio
f
diseas
follow
monophas
cours
five
patient
multiphas
cours
first
clinic
episod
optic
neuriti
transvers
myeliti
two
five
case
sera
taken
acut
attack
four
taken
remiss
posit
patient
among
nmoigg
seroposit
case
nine
edss
six
wherea
two
patient
seroneg
group
sever
disabl
p
b
nmoigg
posit
case
mean
edss
score
compar
nmoigg
neg
case
p
b
seroposit
case
femal
wherea
seroneg
case
male
p
b
diseas
durat
age
onset
monophas
multiphas
differ
significantli
group
three
seroposit
case
one
seroneg
case
sampl
remiss
differ
signific
one
seroneg
case
eight
seroposit
case
immunosuppress
treatment
time
sampl
p
b
nmo
rel
uncommon
among
demyelin
disord
find
rel
larg
singlecent
cohort
suggest
presenc
might
prognost
signific
assess
larger
seri
increas
number
diseas
specif
antibodi
membran
protein
identifi
new
antibodi
discov
associ
diseas
usual
respond
well
immunotherapi
need
establish
simpl
quantit
nonradioact
immunoassay
antibodi
test
novel
antibodi
patient
unexplain
neurolog
diseas
use
new
fluoresc
immunoprecipit
fipa
method
antibodi
membran
protein
use
express
fluoresc
protein
fp
luciferasetag
protein
human
embryon
kidney
cell
extract
deterg
solut
incub
patient
control
sera
immunoprecipit
either
protein
bead
antihuman
igg
precipit
measur
fluoresc
plate
reader
addit
substrat
luciferin
light
luminomet
acetylcholin
receptor
achr
antibodi
measur
immunoprecipit
enhanc
green
fpacetylcholin
receptor
musk
antibodi
immunoprecipit
mcherryfpmusk
result
correl
well
obtain
standard
radioimmunoprecipit
assay
patient
neuromyel
optica
serum
antibodi
use
either
enhanc
green
water
et
al
press
final
test
possibl
patient
sever
form
encephalopathi
rigid
myoclonu
excess
startl
novel
antibodi
glycin
receptor
use
egfpglycin
receptor
found
high
level
specif
antibodi
onset
level
fell
substanti
follow
treatment
correspond
clinic
remiss
hutchinson
et
al
press
result
show
potenti
either
fluoresc
protein
luciferas
construct
provid
novel
clinic
assay
rang
antibodi
exist
novel
target
approach
prove
use
identifi
new
antibodi
see
irani
abstract
sever
myelin
protein
central
nervou
system
cn
investig
potenti
target
humor
immun
respons
involv
format
multipl
sclerosi
ms
lesion
studi
investig
employ
recombin
antigen
andor
relev
peptid
preselect
target
spite
effort
precis
ident
ms
antigen
clearli
defin
yet
present
studi
overcom
tradit
approach
use
larg
panel
nativ
protein
antigen
deriv
white
matter
homogen
human
healthi
cn
resolv
bidimension
electrophoresi
techniqu
compar
igg
repertoir
sera
cerebrospin
fluid
csf
control
subject
ms
patient
primari
progress
secondari
progress
relaps
remit
immunoblot
resolut
white
matter
homogen
nine
spot
specif
recogn
csf
ms
patient
statist
relev
p
b
correspond
isoform
cytoskelet
protein
cnpase
radixin
collapsin
respons
mediat
protein
tubulin
naddepend
deacetylas
actin
interact
protein
particular
interest
one
isoform
transketolas
tk
specif
recogn
ms
csf
interestingli
tk
mostli
local
doubl
immunohistochemistri
matur
oligodendrocyt
ol
less
promin
posit
ol
precursor
neuron
healthi
human
cn
ms
section
tk
immunoreact
markedli
decreas
core
demyelin
lesion
still
present
subpopul
posit
ol
precursor
lesion
border
reactiv
astrocyt
macrophag
addit
tk
autoreact
csf
igg
secondari
progress
ms
patient
show
signific
reactiv
cytoskelet
protein
eight
spot
specif
recogn
seric
igg
p
b
correspond
specif
isoform
protein
involv
regul
cytoskeleton
alphacentractin
collapsin
respons
mediat
protein
syntaxin
bind
protein
cnpase
energi
product
tk
pyruv
kinas
among
protein
frequent
recogn
serum
ms
igg
one
isoform
cnpase
immunom
approach
shed
new
light
autoimmun
repertoir
present
ms
patient
reveal
novel
oligodendrogli
andor
neuron
molecul
potenti
import
pathogen
diagnost
prognost
implic
neuromyel
optica
nmo
idiopath
chronic
demyelin
inflammatori
diseas
characteris
predomin
involv
optic
nerv
spinal
cord
recent
antibodi
respons
water
channel
protein
establish
diagnost
biomark
nmo
current
assay
methodolog
consist
indirect
immunofluoresc
radioimmunoprecipit
assay
respect
introduc
cell
base
flow
cytometri
assay
measur
antibodi
human
glioblastoma
cell
line
stabli
transfect
use
lentivir
vector
overexpress
human
express
confirm
immnocytochemistri
western
blot
cell
lysat
test
antibodi
reactiv
serum
sampl
healthi
control
hc
ond
nmo
flow
cytometri
dilut
result
express
median
fluoresc
intens
mfi
correct
background
bind
control
cell
line
transfect
empti
vector
sampl
deem
posit
mfi
cutoff
mfi
hc
nmo
sampl
posit
median
mfi
rang
ms
hc
sampl
respect
p
b
anova
multipl
mfi
comparison
median
endpoint
titr
antibodi
confin
isotop
highli
depend
nativ
conform
protein
establish
novel
assay
allow
fast
reliabl
quantif
autoantibodi
assay
improv
autoantibodi
test
may
provid
new
insight
pathogen
role
antibodi
nmo
mascaroblanco
alvarez
k
sydenham
chorea
neurolog
disord
result
group
streptococc
infect
acut
rheumat
fever
disord
character
rapid
involuntari
movement
bodi
extrem
face
neuropsychiatr
disturb
pediatr
autoimmun
neuropsychiatr
disord
associ
streptococc
infect
panda
classif
appli
subgroup
children
tic
disord
obsessivecompuls
disord
develop
follow
streptococc
infect
believ
streptococc
infect
induc
crossreact
humor
respons
direct
neuron
determin
basal
ganglia
goal
studi
compar
autoantibodi
reactiv
acut
convalesc
sera
sydenham
chorea
panda
tic
patient
lysogangliosid
human
monoclon
antibodi
mab
lysogangliosid
deriv
sydenham
chorea
shown
high
avid
result
neuron
cell
signal
elev
level
cam
kinas
use
elisa
studi
patient
sera
collect
longitudin
pattern
dose
respons
curv
concentr
antibodi
versu
optic
densiti
od
result
show
antilysogangliosid
autoantibodi
elev
sera
taken
acut
phase
flare
diseas
correl
activ
cam
kinas
neuron
cell
serum
antibodi
elev
autoantibodi
lysogangliosid
correl
diseas
exacerb
behavior
movement
symptom
data
suggest
assay
level
antilysogangliosid
antibodi
may
use
along
clinic
find
diagnosi
sydenham
chorea
tic
panda
data
also
suggest
antilysogangliosid
antibodi
associ
diseas
activ
antibodymedi
neuron
cell
signal
high
avid
may
contribut
diseas
pathogenesi
acut
dissemin
encephalomyel
adem
rare
monophas
cn
demyelin
diseas
affect
grey
white
matter
brain
spinal
cord
even
though
adem
multipl
sclerosi
ms
share
patholog
characterist
clinic
cours
adem
differ
ms
therefor
differenti
adem
ms
import
effect
treatment
role
autoantibodi
cn
demyelin
diseas
unknown
howev
detect
myelinoligodendrocyt
glycoprotein
mog
reactiv
antibodi
report
ms
adem
role
antibodi
diagnosi
prognosi
remain
controversi
introduc
cell
base
flow
cytometri
assay
base
surfac
express
mog
human
glioblastoma
cell
line
transfect
lentivir
vector
contain
mog
sequenc
express
nativ
mog
transfect
cell
line
confirm
flow
cytometri
immunohistochemistri
western
blot
test
nativ
mog
reactiv
healthi
donor
patient
relaps
remit
rrm
secondari
progress
spm
primari
progress
ms
ppm
adem
result
express
median
fluoresc
intens
mfi
correct
background
bind
cell
line
transfect
empti
vector
sampl
deem
posit
mfi
cutoff
mfi
hc
sd
observ
antibodi
nativ
mog
significantli
elev
ms
patient
compar
control
high
titer
primarili
observ
adem
patient
find
confirm
previou
report
group
respect
antibodi
nativ
mog
ms
adem
studi
warrant
determin
whether
antimog
antibodi
use
discrimin
adem
earli
ms
studi
achr
vgkc
antibodi
serial
sampl
woman
year
histori
ocular
mg
treat
cholinesteras
inhibitor
develop
rapidli
progress
le
high
level
vgkc
antibodi
treat
intraven
immunoglobulin
steroid
plasma
exchang
vgkc
antibodi
fell
rapidli
made
good
recoveri
short
period
transvers
myeliti
respond
treatment
six
month
later
relaps
quadraparesi
longitudinallyextens
spinal
cord
lesion
measur
antibodi
achr
vgkc
avail
sampl
correl
result
clinic
find
vgkc
antibodi
high
onset
vgkcle
pm
fell
substanti
follow
treatment
normalis
year
achr
antibodi
present
nm
throughout
period
studi
fell
appreci
patient
treat
vgkcle
antibodi
present
onset
myeliti
rose
markedli
time
major
relaps
fallen
therapi
clinic
featur
time
point
reflect
well
rel
antibodi
titr
case
illustr
well
three
differ
antibodyassoci
diseas
singl
patient
correl
antibodi
diseas
statu
serial
studi
howev
antibodi
present
absenc
overt
myeliti
sydenham
chorea
sc
central
nervou
system
cn
disord
sequela
group
streptococcusinduc
acut
rheumat
fever
arf
deposit
antibodi
brain
may
result
movement
neuropsychiatr
abnorm
pediatr
autoimmun
neuropsychiatr
disord
associ
streptococc
infect
panda
repres
subgroup
obsess
compuls
disord
ocd
tic
disord
may
share
common
set
symptom
well
similar
propos
etiolog
sc
goal
studi
character
sc
panda
antibodi
respons
streptococc
neuron
antigen
studi
investig
streptococc
neuron
antigen
specif
well
cytotox
capabl
sc
panda
antibodi
use
enzym
link
immunosorb
assay
elisa
releas
assay
streptococc
type
protein
nacetylbetadglucosamin
glcnac
immunodomin
epitop
group
carbohydr
suggest
crossreact
antigen
arf
acut
sc
sera
cerebrospin
fluid
csf
show
significantli
greater
igg
reactiv
protein
glcnac
match
convalesc
sera
control
csf
although
match
panda
sera
show
similar
pattern
igg
reactiv
intact
streptococc
antigen
panda
acut
sera
show
significantli
elev
igg
level
protein
ntermin
peptid
comparison
nonpanda
control
sc
acut
sera
csf
igg
subclass
distribut
analysi
show
elev
level
protein
contrast
panda
acut
sera
demonstr
increas
acut
sc
panda
sera
show
elev
concentr
glcnacbsa
interest
increas
respons
glcnac
sc
acut
sera
sc
csf
igg
recogn
lysogangliosid
cn
gangliosid
associ
signal
transduct
brain
strongli
panda
csf
sc
panda
sera
csf
test
complementmedi
cytotox
releas
assay
sera
csf
sampl
induc
cytotox
sknsh
human
neuroblastoma
cell
analysi
igg
subclass
distribut
cell
surfacebound
antibodi
demonstr
sc
csf
predomin
subclass
label
sknsh
neuron
cell
new
data
support
hypothesi
antigroup
carbohydr
antibodi
noncompl
activ
subclass
may
play
import
role
pathogenesi
sc
panda
report
patient
suffer
chronic
sensori
atax
neuropathi
associ
oculomotor
paresi
immunolog
studi
reveal
igm
lambda
paraprotein
cold
agglutinin
igm
autoantibodi
react
suggest
presenc
antibodi
react
disialosyl
epitop
sural
nerv
biopsi
reveal
demyelin
neuropathi
without
igm
deposit
featur
suggest
canomad
partial
respons
intraven
immunoglobulin
plasmapheresi
report
case
rituximab
gain
widespread
accept
manag
bcell
malign
recent
use
treat
number
autoantibodymedi
diseas
includ
neuropathi
encourag
result
evalu
effect
rituximab
use
protocol
recommend
rheumatoid
arthriti
ie
mg
observ
disappear
disialosyl
antibodi
follow
increas
number
blood
observ
reduct
ataxi
handicap
score
onl
escal
correl
evolut
autoantibodi
level
result
case
report
encourag
studi
rituximab
therapi
neuropathi
associ
disialosyl
igm
autoantibodi
warrant
sydenham
chorea
central
nervou
system
cn
disord
character
involuntari
movement
affect
limb
face
lead
loss
coordin
chorea
patient
may
exhibit
psychiatr
psycholog
abnorm
includ
obsessivecompuls
disord
mechan
pathogenesi
sydenham
chorea
associ
anteced
group
streptococc
infect
induc
crossreact
humor
respons
direct
neuron
determin
antibodi
ab
group
streptococc
carbohydr
nacetylbetadglucosamin
glcnac
elev
sera
chorea
patient
choreaderiv
human
antistreptococc
monoclon
antibodi
mab
crossreact
glcnac
tubulin
lysogangliosid
induc
increas
cacalmodulin
depend
protein
kinas
cam
kinas
ii
activ
human
neuron
cell
line
object
creat
transgen
tg
mice
express
mab
heavi
light
chain
variabl
region
vh
vl
gene
v
geneexpress
tg
mice
studi
antibodi
deposit
brain
gain
insight
mechan
cn
disord
involv
antibrain
antibodi
tg
mice
creat
pronuclear
microinject
mab
vh
vl
construct
embryo
doubl
vh
vl
singl
vhonli
tg
mice
produc
geneintegr
verifi
tail
dna
pcr
use
vgenespecif
primer
elisa
determin
express
chimer
human
v
genemous
constant
region
antibodi
antigen
specif
tg
mous
sera
experi
perform
see
chimer
ab
would
deposit
brain
tg
mice
bloodbrain
barrier
breech
administr
lipopolysaccharid
lp
brain
organ
sacrif
tg
nontg
mice
collect
fac
analysi
character
splenic
lymph
node
bone
marrow
b
cell
confirm
chimer
ab
express
rtpcr
splenic
rna
verifi
v
gene
express
ab
deposit
brain
determin
immunohistochemistri
allotypespecif
antibodi
tg
mice
develop
crossreact
ab
specif
glcnac
lysogangliosid
tubulin
serum
chimer
chorea
ab
express
tg
mice
penetr
bound
antigen
brain
vivo
deposit
observ
brain
doubl
tg
singl
vh
tg
nontg
mice
antibrain
autoantibodi
lysogangliosid
tubulin
may
contribut
cn
disturb
sydenham
chorea
brain
disord
clarifi
patholog
implic
alzheim
diseas
ad
investig
possibl
relationship
amyloidbeta
abeta
deposit
astrocyt
express
motor
cortex
hippocampu
ad
patient
agematch
neurolog
diseas
case
case
express
exclus
subpopul
multipolar
fibrillari
astrocyt
great
major
astrocyt
locat
top
abeta
plaqu
ad
brain
nonad
case
wherea
independ
abeta
deposit
found
predominantli
nonad
brain
western
blot
cultur
human
astrocyt
constitut
express
level
protein
express
affect
exposur
peptid
elev
hyperton
sodium
chlorid
immunoprecipit
ctermin
fragmentbeta
ctfbeta
amyloid
precursor
protein
app
interact
ntermin
half
span
transmembran
helic
uniqu
subset
astrocyt
direct
contact
abeta
ad
brain
suggest
possibl
abeta
deposit
caus
abnorm
brain
water
homeostasi
interf
astrocyt
water
channel
function
alzheim
diseas
ad
major
caus
dementia
human
main
hallmark
disord
product
aggreg
betaamyloid
abeta
peptid
format
neurofibrillari
tangl
hyperphosphoryl
tau
protein
appear
cognit
declin
link
overproduct
short
peptid
abeta
solubl
aggreg
form
brain
parenchyma
microglia
known
surround
abeta
deposit
intern
peptid
circumst
target
degrad
thu
stimul
microgliosi
benefici
prevent
develop
diseas
show
inject
macrophag
colonystimul
factor
mcsf
transgen
mice
well
document
model
ad
weekli
basi
prior
appear
learn
memori
deficit
prevent
cognit
loss
mcsfinject
group
test
twater
maze
task
show
differ
compar
wildtyp
wt
anim
howev
number
trial
need
achiev
task
nearli
doubl
salineinject
transgen
mice
mcsf
also
increas
number
microglia
parenchyma
fold
fold
increas
cortex
hippocampu
respect
decreas
number
abeta
deposit
senil
plaqu
smaller
less
dens
brain
mcsftreat
mice
compar
litterm
control
treat
vehicl
solut
interestingli
higher
ratio
microglia
intern
abeta
brain
mcsftreat
anim
phagocytos
peptid
locat
late
endosom
lysosom
shown
coloc
marker
less
monom
also
detect
extracellular
protein
enrich
fraction
mcsftreat
transgen
mice
compar
vehicl
control
togeth
result
provid
compel
evid
system
mcsf
administr
power
treatment
stimul
microglia
prolifer
brain
degrad
abeta
prevent
cognit
declin
associ
abeta
burden
mous
model
ad
microglia
immun
cell
brain
activ
brain
alzheim
diseas
ad
patient
mous
model
ad
express
innat
immun
receptor
tolllik
receptor
present
studi
investig
role
receptor
progress
adlik
patholog
show
amyloid
beta
stimul
express
small
proport
microglia
gener
tripl
transgen
mice
defici
mice
harbor
mutant
human
presenelin
chimer
mousehuman
amyloid
precursor
protein
app
gene
defici
acceler
spatial
contextu
memori
impair
correl
increas
level
transform
growth
factor
beta
brain
express
level
also
lower
dentat
gyru
mice
gene
therapi
cell
bone
marrow
use
lentiviru
construct
express
rescu
cognit
impair
mice
inde
treatment
benefici
effect
restor
memori
consolid
process
disrupt
app
mice
data
suggest
act
endogen
receptor
clearanc
toxic
bone
marrowderiv
immun
cell
cognit
declin
markedli
acceler
context
defici
upregul
innat
immun
receptor
may
consid
potenti
new
power
therapeut
approach
ad
ronharel
segev
yifat
cardon
michal
schwartz
michal
hippocampu
one
brain
region
promin
affect
function
declin
even
consid
normal
age
agerel
decreas
found
hippocampusdepend
spatial
episod
memori
abil
previou
studi
shown
immun
cell
involv
maintain
variou
aspect
hippocamp
plastic
adulthood
neurogenesi
bdnf
product
perform
learningmemori
task
mwm
impair
immunedefici
mice
current
studi
abl
dissect
spatial
learn
abil
longterm
memori
perform
show
peripher
immun
cell
specif
support
hippocampusdepend
spatial
memori
moreov
sudden
imposit
immun
compromis
young
healthi
mice
caus
spatial
memori
impair
wherea
immun
reconstitut
revers
memori
impair
immun
defici
mice
hippocamp
mrna
analysi
suggest
immunedepend
spatial
memori
mainten
least
partial
mediat
regul
presynapt
protein
involv
fast
neurotransmitt
releas
reduc
express
level
gene
encod
presynapt
protein
found
immunedefici
mice
return
normal
level
follow
immun
reconstitut
final
relev
find
age
demonstr
increas
peripher
immun
activ
age
mice
improv
spatial
memori
perform
result
suggest
agerel
memori
loss
may
revers
least
extent
remot
controlvia
rejuven
senesc
immun
system
cognit
impair
includ
spatial
work
memori
deficit
occur
even
earli
stage
parkinson
diseas
pd
motor
symptom
bare
observ
premotor
phase
cognit
deficit
concern
howev
develop
pd
motor
function
disturb
central
dopamin
content
deepli
diminish
possibl
dopamin
level
deplet
may
influenc
also
cognit
function
pd
present
studi
mptp
administr
influenc
content
dopamin
deplet
memori
impair
studi
one
year
old
male
mice
receiv
mptp
mgkg
control
group
receiv
nacl
evalu
learn
memori
abil
morri
water
maze
behavior
test
provid
nt
notic
statist
signific
differ
latenc
reach
hidden
platform
swim
distanc
reach
hidden
platform
swim
speed
percentag
time
spent
correct
quadrant
annulu
cross
probe
trial
mptp
control
anim
result
swim
speed
latenc
swim
distanc
visibl
platform
test
similar
group
differ
significantli
mptp
intox
alter
locomotor
activ
memori
test
complet
behavior
experi
brain
concentr
monoamin
dopamin
da
noradrenalin
na
estim
use
highperform
liquid
chromatographi
hplc
correl
result
behavior
test
probe
trial
water
maze
level
monoamin
striatum
calcul
accuraci
spatial
memori
reliabl
correl
monoamin
level
striatum
dopamin
content
striatum
decreas
control
p
b
result
suggest
place
navig
learn
critic
depend
dopaminerg
system
probabl
distant
brain
structur
degener
besid
nigrostriat
pathway
might
involv
spatial
learn
memori
process
investig
longterm
observ
necessari
check
neurodegen
chang
distant
structur
brain
induc
nigrostriat
degener
might
caus
memori
deficit
anim
injur
dopaminerg
system
inject
sn
male
mice
week
posttreat
microgli
activ
examin
use
immunohistochem
stain
quantit
pcr
proinflammatori
cytokin
addit
particip
compon
adapt
immun
respons
includ
blymphocyt
tlymphocyt
mous
immunoglobulin
igg
studi
immunohistochem
use
marker
goat
antimous
igg
respect
differ
b
tlymphocyt
infiltr
sn
two
group
quantifi
count
cell
present
use
unbias
stereolog
differ
igg
immunoreact
group
evalu
observ
blind
treatment
group
enhanc
immunoreact
mous
igg
detect
earli
anim
week
persist
week
week
igg
stain
associ
microglia
neuron
neuropil
week
increas
stain
microglia
present
anim
mark
increas
b
cell
week
stain
declin
b
cell
infiltr
persist
proinflammatori
cytokin
level
elev
week
group
compar
group
observ
suggest
overabund
human
asyn
result
adapt
immun
respons
microgli
activ
tempor
cours
earli
appear
igg
stain
suggest
humor
immun
microgli
respons
may
close
link
inflammatori
process
may
contribut
dopamin
neuron
injuri
modul
respons
may
use
target
slow
progress
human
pd
vascular
endotheli
growth
factor
vegf
well
known
one
major
regul
angiogenesi
recent
report
implic
vegf
import
trophic
factor
nervou
system
exampl
low
level
vegf
mice
result
adultonset
amyotroph
later
sclerosi
like
syndrom
want
examin
role
vegf
context
cerebellar
degenerationin
particular
autosom
domin
degen
diseas
spinocerebellar
ataxia
type
belong
famili
polyglutamin
neurodegen
disord
caus
increas
number
cag
repeat
code
region
respect
protein
protein
mutat
ubiquit
express
recent
data
suggest
play
role
transcript
regul
wellstudi
mous
model
diseas
knockin
mous
discov
vegf
protein
level
perturb
rel
earli
pathogenesi
begin
understand
mechan
reduct
occur
perform
laser
captur
microdissect
purkinj
cell
cell
type
predominantli
affect
follow
rna
purif
quantit
rtpcr
found
signific
reduct
vegf
mrna
level
purkinj
cell
deriv
mice
employ
vegf
promot
luciferas
report
abl
show
mutant
inhibit
transcript
vegf
promot
furthermor
could
also
demonstr
chromatin
immunoprecipit
occupi
vegf
promot
suggest
induc
repress
via
direct
effect
vegf
promot
studi
rais
excit
possibl
decreas
vegf
level
could
starv
purkinj
neuron
key
trophic
factor
angiogen
support
convers
increas
vegf
might
abl
amelior
phenotyp
test
idea
taken
genet
approach
mate
mice
transgen
overexpress
vegf
neuron
knockin
model
found
overexpress
vegf
inde
improv
atax
phenotyp
find
implic
novel
regul
vegf
transcript
suggest
therapeut
role
vegf
expand
role
import
player
neurodegener
synapt
injuri
associ
memori
loss
alzheim
diseas
ad
shank
protein
abund
postsynapt
densiti
psd
central
excitatori
synaps
increas
evid
suggest
shank
promot
matur
enlarg
dendrit
spine
suggest
import
role
shank
protein
normal
cognit
develop
gept
combin
herbal
extract
also
call
geto
consist
four
activ
compon
panaxosid
flavonoid
tenuifolin
curcumin
previou
studi
show
gept
extract
work
improv
memori
declin
postpon
mci
old
patient
studi
investig
effect
gept
extract
express
subfield
within
hippocampu
transgen
mice
earli
stage
dementia
transgen
mice
randomli
divid
gept
group
intragastr
administr
gkgd
donepezil
group
intragastr
administr
mgkgd
transgen
model
group
normal
group
intragastr
administr
distil
water
fourmonth
treatment
regimen
gept
extract
administ
transgen
mice
spatial
memori
abil
measur
morri
water
maze
total
area
cover
integr
optic
densiti
subfield
within
hippocampu
determin
use
immunohistochem
stain
imagepro
plu
analysi
gept
treatment
regimen
mean
escap
latenc
period
significantli
shorten
vs
p
b
target
quadrant
search
time
significantli
increas
vs
p
b
compar
transgen
model
mice
signific
higher
level
express
detect
hippocamp
area
transgen
mice
treat
gept
level
transgen
model
mice
alon
total
area
posit
cell
cover
integr
optic
densiti
hippocamp
area
transgen
mice
treat
gept
significantli
increas
transgen
model
mice
vs
p
b
vs
p
b
gept
extract
obvious
improv
spatial
memori
abil
transgen
mice
earli
stage
dementia
probabl
mechan
may
associ
enhanc
express
multipl
sclerosi
ms
common
inflammatori
demyelin
disord
central
nervou
system
lesion
dissemin
time
space
diagnosi
ms
support
evid
intrathec
antibodi
synthesi
howev
autoimmun
neurolog
disord
may
show
similar
laboratori
pattern
present
case
paraneoplast
disord
immun
profil
distinct
ms
report
old
right
hand
woman
episod
posttraumat
acut
loss
left
central
vision
magnet
reson
imag
mri
brain
show
sever
small
nonenhanc
hyperintens
subcort
periventricular
white
matter
five
year
later
develop
vertigo
ataxia
repeat
mri
unchang
cerebrospin
fluid
analysi
show
numer
oligoclon
band
elev
igg
index
synthesi
rate
lymphocyt
pleocytosi
base
clinic
present
csf
find
diagnosi
ms
made
treatment
commenc
interferon
later
glatiram
acet
continu
worsen
develop
spasticatax
dysarthria
axial
appendicular
ataxia
render
bedbound
workup
includ
comprehens
paraneoplast
antibodi
evalu
neg
except
low
posit
pqtype
calcium
channel
antibodi
pmoll
normal
b
addit
csf
studi
show
oligoclon
band
evid
intrathec
igg
synthesi
flow
cytometri
csf
lymphocyt
predominantli
b
cell
cell
predominantli
ratio
biopsi
enlarg
inguin
lymph
node
show
high
grade
neuroendocrin
carcinoma
consist
primari
small
cell
cancer
ms
complex
disord
helper
tcell
play
import
role
least
form
central
paraneoplast
disord
mediat
action
cytotox
cell
disord
associ
inappropri
product
autoantibodi
ms
major
cell
csf
cell
predomin
b
cell
cell
csf
seen
patient
may
uniqu
diagnosticallyus
characterist
paraneoplast
neurolog
syndrom
paraneoplast
antinmethyldaspart
receptor
nmdar
enceph
sever
treatment
respons
enceph
predominantli
affect
young
women
ovarian
teratoma
patient
usual
develop
prodrom
fever
headach
follow
promin
psychiatr
symptom
shortterm
memori
loss
seizur
progress
catatonialik
stage
dyskinesia
autonom
instabl
hypoventil
report
immunopatholog
analysi
brain
ovarian
teratoma
specimen
two
patient
die
antinmdarassoci
enceph
tumor
patient
recov
promin
microgliosi
deposit
igg
rare
b
lymphocyt
infiltr
observ
hippocampu
forebrain
basal
ganglia
spinal
cord
detect
cell
express
marker
cytotox
tia
granzym
b
perforin
fasfa
ligand
extrem
uncommon
moder
amount
plasma
cell
detect
brain
section
suggest
intrathec
antibodi
product
complement
deposit
identifi
tumor
sampl
show
nmdarexpress
neuron
extens
infiltr
lymphocyt
macrophagesmonocyt
b
lymphocyt
plasma
cell
ovarian
teratoma
sampl
patient
without
nmdar
associ
enceph
show
similar
infiltr
cell
macrophag
monocyt
absent
b
lymphocyt
plasma
cell
patient
predomin
antinmdar
igg
subclass
antibodi
immunerespons
relev
cytotox
tcell
mechan
pathogenesi
antinmdarassoci
enceph
uptak
cytotox
specif
antiyo
antibodi
cerebellar
purkinj
cell
purkinj
cell
organotyp
cultur
kill
antiyo
igg
igg
neurolog
normal
ovarian
cancer
anticerebellar
antibodi
greenle
john
hill
kenneth
e
purkinj
cell
destruct
paraneoplast
cerebellar
degener
pcd
patient
gynecolog
cancer
accompani
high
serum
csf
titer
antiyo
antibodi
react
intern
antigen
purkinj
cell
role
antiyo
antibodi
caus
purkinj
cell
death
known
recent
found
purkinj
cell
organotyp
cultur
incorpor
igg
uptak
antiyo
igg
igg
normal
individu
result
cell
death
other
also
found
occasion
neurolog
normal
ovarian
cancer
patient
exhibit
anticerebellar
antibodi
recogn
yo
antigen
import
question
pcd
thu
whether
cytotox
effect
purkinj
cell
antiyo
antibodi
specif
whether
share
anticerebellar
antibodi
ovarian
cancer
patient
remain
neurolog
normal
studi
sera
three
neurolog
normal
patient
ovarian
cancer
adenocarcinoma
one
sarcoma
high
titer
anticerebellar
antibodi
reactiv
purkinj
cell
remain
neurolog
normal
mani
month
cancerassoci
death
none
sera
react
yo
antigen
western
blot
rat
cerebellar
organotyp
cultur
incub
sera
patient
sera
pcd
patient
exhibit
antiyo
antibodi
respons
concentr
antibodi
adjust
approxim
found
patient
csf
cultur
harvest
interv
hour
stain
antibodi
uptak
use
conjug
antihuman
igg
follow
confoc
microscopi
purkinj
cell
death
determin
use
dead
cell
stain
sytox
green
cultur
incub
antiyo
antibodi
show
widespread
igg
uptak
purkinj
cell
death
purkinj
cell
contain
igg
began
h
extens
h
although
purkinj
cell
uptak
igg
also
seen
cultur
incub
sera
three
neurolog
normal
patient
purkinj
cell
death
observ
cytotox
effect
antiyo
antibodi
cerebellar
purkinj
cell
specif
share
anticerebellar
antibodi
ovarian
cancer
patient
remain
neurolog
normal
character
pathogenesi
pn
report
new
antibodi
coexpress
yo
antibodi
serum
sampl
three
differ
patient
known
paraneoplast
cerebellar
degener
yo
antibodi
pool
use
screen
rat
cerebellum
cdna
librari
one
antibodi
found
react
uncharacteris
protein
known
coiledcoil
domaincontain
protein
protein
also
found
speci
conserv
immunoblot
protein
extract
show
protein
wide
express
central
nervou
system
except
frontal
cortex
spinal
cord
protein
also
present
organ
especi
spleen
test
sera
patient
variou
cancer
onconeur
antibodi
hu
yo
ri
amphiphysin
well
sera
healthi
blood
donor
without
onconeur
antibodi
screen
sensit
immunoprecipit
techniqu
four
patient
yo
antibodi
ovarian
cancer
one
lymphoma
one
prostat
cancer
also
antibodi
wherea
antibodi
detect
sera
potenti
new
onconeur
antibodi
associ
antiyo
function
larg
unknown
myasthenia
gravi
mg
prototyp
autoimmun
disord
nervou
system
patient
paraneoplast
mg
associ
thymic
neoplasm
thymoma
mg
may
associ
autoimmun
neurolog
disord
includ
paraneoplast
enceph
report
describ
second
case
multifoc
cortic
enceph
associ
thymoma
establish
associ
thymomarel
paraneoplast
syndrom
voltageg
potassium
channel
vgkc
antibodi
old
right
hand
woman
histori
seroposit
mg
invas
thymoma
treat
success
surgeri
radiat
chemotherapi
mg
pharmacolog
remiss
mycophenol
four
year
thymectomi
present
acut
onset
confus
seizur
progress
complet
mutism
examin
awak
alert
global
aphas
abl
imit
normal
strength
reflex
magnet
reson
imag
brain
show
innumer
nonenhanc
corticallybas
signal
abnorm
well
extens
left
mesial
tempor
lobe
abnorm
minim
enhanc
cerebrospin
fluid
analysi
show
lymphocyt
pleocytosi
cell
elev
protein
electroencephalogram
show
left
tempor
period
later
epileptiform
discharg
chest
comput
tomographi
abnorm
pleural
thicken
left
lung
prove
recurr
metastat
thymoma
serolog
evalu
posit
achr
striation
voltageg
potassium
channel
antibodi
partial
improv
respons
immunotherapi
one
cycl
chemotherapi
ultim
die
two
month
later
exampl
paraneoplast
enceph
involv
limbic
system
relat
structur
second
case
uniqu
pattern
multifoc
cortic
involv
associ
thymoma
potassium
channel
antibodi
found
case
antibodi
found
previous
report
case
paraneoplast
enceph
associ
thymoma
consid
differenti
diagnosi
mg
patient
develop
new
cognit
symptom
induct
tlr
express
peripher
nerv
upon
neurodegener
van
avondt
k
goethal
jacob
timmerman
v
janssen
peripher
neuropathi
group
molecular
genet
depart
vib
univers
antwerp
antwerpen
belgium
recent
year
field
innat
immun
chang
dramat
due
discoveri
famili
socal
tolllik
receptor
tlr
nodlik
receptor
nlr
induc
differ
signal
cascad
culmin
activ
mapk
interferon
respons
factor
irf
product
interestingli
origin
receptor
thought
involv
exclus
detect
pathogen
data
accumul
also
import
recognit
endogen
ligand
like
hsp
protein
degrad
extracellular
matrix
breakdown
product
indic
kind
stress
therefor
receptor
categor
danger
receptor
known
pivot
elicit
proper
stress
respons
also
peripher
nervou
system
contain
defens
mechan
alert
immun
system
case
danger
defens
respons
schwann
cell
play
major
role
upon
neurodegener
adopt
macrophag
like
phenotyp
start
secret
factor
import
recruit
inflammatori
cell
type
schwann
cell
becom
activ
neurodegener
clear
yet
would
like
test
hypothesi
certain
releas
compon
die
axon
trigger
toll
like
receptor
express
surfac
schwann
cell
though
recent
data
report
express
variou
tlr
glial
cell
central
nervou
system
situat
peripher
nervou
system
less
studi
remain
limit
studi
select
tlr
therefor
first
analys
basal
express
level
tlr
primari
schwann
cell
schwann
cell
appear
express
mainli
hardli
detect
unstimul
cell
use
signal
readout
could
show
tlr
function
especi
show
strong
respons
next
focus
comprehens
qpcr
analysi
innat
immun
receptor
compon
unstimul
versu
activ
peripher
nerv
induc
neurodegener
axotomi
sciatic
nerv
mice
control
axotomis
nerv
isol
sever
time
point
upon
injuri
process
rna
isol
qpcr
analysi
unstimul
nerv
mostli
express
compar
situat
primari
schwann
cell
detect
major
induct
upon
nerv
injuri
point
possibl
role
receptor
context
neurodegener
reach
peak
express
level
h
upon
injuri
alreadi
induc
earlier
time
point
conclus
data
show
major
shift
tlr
express
pattern
upon
neurodegener
like
illustr
special
function
tlr
basal
versu
activ
condit
peripher
nerv
use
wild
type
versu
knockout
mice
would
like
find
receptor
main
import
trigger
innat
immun
respons
schwann
cell
versu
sciatic
nerv
upon
neurodegener
genet
factor
believ
import
outcom
traumat
brain
injuri
tbi
howev
far
mainli
allel
variat
apolipoprotein
studi
human
tbi
strategi
identif
gene
regul
complex
trait
perform
linkag
analysi
larg
intercross
suscept
resist
strain
previous
identifi
sever
gene
region
regul
differ
aspect
inflamm
neurodegener
induc
spinal
ventral
root
avuls
vra
inbr
da
pvg
rat
quantit
trait
qtl
includ
regul
axotomyinduc
nerv
cell
loss
regul
express
mhc
class
ii
microglia
howev
known
qtl
regul
gener
aspect
neuroinflamm
cell
death
traumat
cn
injuri
order
studi
role
genet
factor
experiment
tbi
examin
parent
da
pvg
strain
well
congen
strain
da
background
standard
weight
drop
injuri
use
inflict
pariet
cortic
contus
let
weight
fall
onto
rod
flat
end
diamet
mm
height
cm
expos
dura
rod
allow
compress
tissu
maximum
mm
rat
receiv
craniotomi
serv
control
pericontusion
area
dissect
day
tbi
real
time
pcr
use
evalu
differ
apoptot
inflammatori
mrna
express
signific
upregul
inflammatori
molecul
complement
factor
class
ii
invari
chain
apoptot
factor
transform
relat
protein
tbi
compar
control
level
sever
transcript
higher
da
compar
pvg
increas
attenu
congen
rat
consist
promin
regulatori
effect
allel
differ
gene
locat
congen
fragment
congen
display
signific
differ
level
indic
differ
regul
apoptosi
result
provid
evid
genet
compon
tbi
also
support
notion
qtl
regul
vra
also
implic
regul
inflamm
apoptosi
tbi
strain
constitut
import
tool
studi
genet
influenc
tbi
children
autist
regress
fulfil
diagnost
criteria
accord
dsmiv
includ
questionnair
assess
cognitivebehavior
regress
detail
neurolog
psychiatr
evalu
childhood
autism
rate
scale
car
perform
studi
dna
isol
accomplish
use
standard
method
tnfalpha
ifngamma
genotyp
use
pcr
sequencespecif
primer
pcrssp
method
sera
patient
diagnos
autism
healthi
individu
includ
allel
frequenc
group
determin
hla
type
b
dr
allel
perform
pcrsso
method
patient
group
control
group
compar
regard
frequenc
hla
antigen
signific
differ
found
hla
higher
patient
group
though
signific
statist
one
odd
ratio
includ
frequent
patient
frequent
control
control
exist
patient
group
one
patient
none
control
tgfbeta
gene
region
ct
codon
cg
codon
polymorph
examin
ttgg
genotyp
frequenc
found
high
control
tcgg
genotyp
frequenc
high
patient
group
studi
show
variou
immunolog
abnorm
autist
children
might
marker
special
condit
autist
regress
seen
autism
spectrum
disord
chemokin
chemokin
receptor
ccr
detect
normal
human
central
nervou
system
cn
recent
evid
suggest
chemokin
ccr
involv
pathogenesi
immunemedi
inflamm
chronic
neurodegen
disord
alzheim
ad
parkinson
diseas
pd
instanc
increas
express
report
cn
patient
ad
pd
associ
patholog
chang
character
neurodegen
diseas
order
establish
import
polymorph
neurodegen
disord
venezuelan
patient
diagnos
sporad
ad
accord
nincdsadrda
criteria
mean
age
year
patient
pd
accord
pd
societi
brain
bank
criteria
healthi
individu
mean
age
year
without
kind
dementia
base
miniment
state
examin
studi
ag
polymorph
analyz
pcrrflp
genotyp
frequenc
determin
direct
count
statist
signific
genotyp
frequenc
estim
fisher
exact
test
p
valu
correct
accord
bonferroni
odd
ratio
confid
interv
calcul
measur
strength
associ
statist
signific
differ
found
ad
pd
patient
compar
control
group
frequenc
aa
genotyp
observ
decreas
group
patient
compar
healthi
individu
b
p
b
contrast
frequenc
ag
genotyp
observ
increas
neurodegen
disord
compar
healthi
individu
n
p
b
result
suggest
possibl
involv
gene
develop
lateonset
alzheim
diseas
parkinson
diseas
variou
report
identifi
confirm
first
time
nonhla
suscept
gene
multipl
sclerosi
ms
snp
receptor
gene
found
constitut
herit
risk
factor
multipl
sclerosi
odd
ratio
around
though
numer
earlier
studi
report
associ
lack
thereof
cytokin
receptor
gene
multipl
sclerosi
systemat
screen
cover
genet
divers
multipl
cytokin
loci
never
perform
use
haplotypetag
approach
base
select
snp
ceuhapmap
analys
associ
ms
around
snp
major
differ
function
class
cytokin
receptor
associ
cytokin
signal
transduct
factor
gammacdepend
cytokin
group
cytokin
cytokin
member
famili
soc
famili
member
total
gene
chromosom
gene
cluster
includ
discret
cytokin
cytokinerel
gene
major
includ
gene
never
analys
relat
ms
wherev
possibl
haptagsnp
select
coincid
complement
nonsynonym
snp
addit
screen
includ
glutam
receptor
gene
gria
grik
eaat
subfamili
latter
select
motiv
grow
bodi
evid
signific
role
glutam
signal
glial
cell
death
genotyp
perform
use
golden
gate
technolog
illumina
around
ms
patient
control
use
design
basurto
hospit
bilbao
exhaust
singleand
multiplemark
data
analysi
perform
haploview
plink
helixtre
mdr
softwar
follow
first
stage
identifi
associ
snp
one
suppressor
cytokin
one
oncostatin
receptor
osmr
signific
valu
withstand
permut
correct
found
modest
evid
cytokin
gene
interact
ms
suggest
trend
associ
nonsynonym
polymorph
glutam
receptor
observ
second
stage
studi
complet
present
result
combin
two
stage
occas
confer
data
contribut
further
understand
cytokin
genet
ms
clear
confirmatori
studi
addit
cohort
need
substanti
find
aris
screen
neurodegener
import
featur
mani
neurolog
disord
far
degre
genet
regul
axotomyinduc
nerv
cell
loss
unknown
previou
studi
describ
substanti
differ
degre
loss
motoneuron
spinal
ventral
root
avuls
vra
across
differ
inbr
rat
strain
use
unbias
experiment
approach
use
genet
dissect
elucid
relev
mechan
first
step
whole
genom
scan
da
x
pvg
intercross
show
evid
linkag
nerv
cell
loss
vra
quantit
trait
loci
qtl
chromosom
advanc
intercross
line
ail
creat
reciproc
breed
da
rat
subsequ
cross
offspr
breed
pair
carri
eight
ten
gener
studi
male
rat
subject
vra
day
postop
surviv
popul
respect
linkag
reproduc
reduc
confid
interv
linkag
peak
mb
respect
pure
addit
effect
two
loci
seen
significantli
contribut
addit
lod
individu
rat
ail
homozygot
da
pvg
allel
display
neuron
surviv
similar
correspond
parent
strain
suggest
strain
differ
mainli
regul
two
qtl
overlap
congen
strain
allel
da
background
demonstr
mb
fragment
significantli
attenu
loss
motoneuron
vra
congen
strain
use
dissect
mechan
preliminari
evid
suggest
increas
microglia
activ
earli
injuri
correl
increas
nerv
cell
loss
later
result
demonstr
natur
occur
allel
variabl
affect
suscept
axotomyinduc
nerv
cell
death
repres
first
qtl
character
fine
map
use
ail
overlap
congen
strain
exact
posit
gene
qtl
import
understand
genet
suscept
neurodegener
regul
diseas
progress
form
ms
mani
human
autoimmun
diseas
includ
multipl
sclerosi
ms
regul
mhc
complex
suscept
experiment
autoimmun
encephalomyel
eae
map
mhc
class
ii
region
support
notion
qualit
differ
class
ii
mediat
antigen
present
pivot
import
condit
previous
describ
larg
differ
mhc
ii
express
microglia
standard
mechan
nerv
injuri
ventral
root
avuls
vra
panel
inbr
rat
strain
use
daxpvg
intercross
advanc
intercross
line
ail
differ
mhc
ii
express
posit
genet
variat
encod
class
ii
transactiv
recent
demonstr
congen
strain
carri
allel
variat
display
variabl
suscept
eae
suggest
quantit
aspect
mhc
ii
express
may
also
import
regul
autoimmun
neuroinflamm
bn
rat
display
higher
constitut
mhc
ii
express
compar
da
although
bn
allel
studi
perform
genomewid
linkag
analysi
intercross
n
order
map
addit
genet
influenc
express
mhc
ii
vra
mrna
level
invari
chain
costimulatori
molecul
determin
use
quantit
rtpcr
addit
immunostain
record
identifi
qtl
subsequ
studi
ail
sever
region
found
regul
mhc
ii
two
strongest
qtl
locat
chromosom
chr
qtl
reproduc
ail
addit
evid
epistat
gender
effect
two
region
found
regul
sever
phenotyp
receptor
chr
receptor
chr
result
demonstr
high
degre
genet
heterogen
express
mhc
ii
microglia
nerv
injuri
differ
mhc
ii
across
strain
regul
mainli
one
domin
qtl
contain
addit
effect
sever
gene
region
identif
gene
underli
addit
qtl
import
understand
genet
background
autoimmun
diseas
ms
present
two
separ
studi
focu
role
gene
chromosom
suscept
multipl
sclerosi
ms
transcript
factor
involv
type
interferon
tolllik
receptor
signal
pathway
previous
found
associ
system
lupu
erythematosu
rheumatoid
arthriti
inflammatori
bowel
diseas
investig
whether
polymorph
gene
would
associ
yet
anoth
diseas
featur
autoimmun
ms
previou
studi
suggest
role
allel
variat
chromosom
multipl
sclerosi
ms
suscept
three
subregion
test
associ
ms
first
studi
genotyp
nine
singl
nucleotid
polymorph
snp
one
insertiondelet
polymorph
gene
collect
patient
ms
control
three
popul
two
casecontrol
cohort
spain
sweden
set
ms
trio
famili
finland
two
snp
bp
insertiondelet
polymorph
locat
promot
first
intron
gene
show
associ
signal
pvalu
b
data
cohort
combin
predispos
allel
present
common
haplotyp
popul
use
electrophoret
mobil
shift
assay
observ
allelespecif
differ
protein
bind
snp
bp
indel
proxim
ligat
assay
demonstr
increas
bind
transcript
factor
risk
allel
bp
indel
second
studi
test
marker
snp
microsatellit
across
three
subregion
finnish
ms
trio
famili
marker
show
nomin
signific
associ
ms
p
anoth
associ
found
apo
haplotyp
p
associ
replic
anoth
independ
dataset
famili
previou
suggest
defici
associ
replic
studi
find
add
short
list
gene
shown
associ
ms
one
popul
studi
add
evid
might
gene
pathway
common
multipl
autoimmun
diseas
type
interferon
system
like
involv
develop
diseas
format
antibodi
interferon
beta
proteinbas
diseasemodifi
agent
multipl
sclerosi
ms
crucial
problem
clinic
practic
antibodi
may
neutral
biolog
effect
protein
drug
potenti
decreas
therapeut
effect
goal
find
hla
allel
associ
develop
antibodi
interferonbeta
therapi
multipl
sclerosi
hla
genotyp
hlaa
b
c
perform
hybrid
sequencespecif
oligonucleotid
probe
immobil
microspher
amplifi
genom
dna
sampl
follow
flow
fluoresc
intens
analysi
accord
instruct
manufactur
one
lambda
canoga
park
ca
usa
high
resolut
hla
class
ii
type
identifi
two
hla
class
ii
allel
associ
develop
antibodi
two
independ
continu
binari
trait
associ
studi
odd
ratio
hla
alleleswer
strongli
associ
develop
bind
neutral
antibodi
associ
allel
differ
associ
allel
glycin
valin
substitut
posit
epitopebind
alphahelix
hla
class
ii
molecul
peptid
bind
motif
might
promot
bind
present
immunogen
peptid
may
eventu
break
cell
toler
facilit
antibodi
develop
first
studi
identifi
genet
factor
determin
immunogen
proteinbas
diseasemodifi
agent
tolllik
receptor
tlr
play
essenti
role
host
defens
respons
follow
recognit
pathogenassoci
molecul
self
molecul
tlr
gener
trigger
proinflammatori
factor
enhanc
antigenpres
cell
function
previou
studi
demonstr
presenc
variou
tlr
human
astrocyt
microglia
oligodendrocyt
mark
differ
howev
separ
tlr
either
type
glial
cell
microglia
rather
divers
set
tlr
express
least
found
insid
endosom
vesicl
astrocyt
oligodendrocyt
hand
express
limit
set
tlr
cell
surfac
upon
activ
astrocyt
select
strong
induct
observ
gene
profil
function
data
indic
activ
astrocyt
act
repair
mediat
aim
studi
investig
express
regul
function
tlr
adult
human
microglia
rat
oligodendrocyt
progenitor
cell
opc
use
real
time
pcr
antibodi
array
case
oligodendrocyt
morpholog
evalu
viabil
assay
well
immunofluoresc
stain
differenti
marker
adult
human
microglia
cultur
express
tlr
rel
high
mrna
level
tlr
express
also
control
tlr
ligat
treatment
differ
cytokin
remark
strongest
induc
tlr
especi
poli
c
addit
vivo
express
tlr
examin
use
mrna
extract
control
multipl
sclerosi
brain
reveal
enhanc
express
case
opc
hand
express
limit
set
tlr
high
level
lesser
extent
profil
cytokin
chemokin
respons
indic
tlr
agonist
elicit
broad
similar
cytokinechemokin
respons
human
adult
microglia
highli
purifi
oligodendrocyt
precursor
poli
c
potent
induc
oligodendrocyt
death
demyelin
lp
zymosan
contrast
promot
surviv
myelin
sheet
format
togeth
data
indic
tlr
cn
play
import
role
regul
innat
immun
respons
oligodendrocyt
develop
especi
act
domin
regul
cn
alzheim
diseas
ad
neurodegen
diseas
characteris
deposit
amyloidbeta
abeta
contain
plaqu
also
neuroinflammatori
chang
typifi
increas
proinflammatori
cytokin
express
brain
activ
microglia
consid
major
sourc
proinflammatori
cytokin
ad
recent
studi
highlight
import
adapt
immun
respons
particular
cell
patholog
diseas
clinic
trial
involv
activ
immunis
abeta
adjuv
result
develop
meningoenceph
subset
patient
associ
increas
infiltr
cell
brain
moreov
abetaspecif
cell
identifi
ad
patient
howev
interact
abetaspecif
cell
microglia
poorli
understood
studi
examin
role
cell
regulatori
cell
treg
abetainduc
microgli
activ
develop
method
gener
abetaspecif
cell
subtyp
ex
vivo
assess
effect
differ
cell
subtyp
secret
cytokin
microgli
activ
microgli
activ
determin
measur
product
proinflammatori
cytokin
tnfalpha
elisa
quantifi
cellsurfac
express
mhc
class
ii
flow
cytometri
data
show
cell
enhanc
abetainduc
product
tnfalpha
glial
cell
also
increas
surfac
express
mhc
class
ii
microglia
treg
cell
induc
significantli
smaller
increas
tnfalpha
product
microgli
express
compar
cell
recombin
ifngamma
stimul
activ
microglia
manner
similar
cell
respect
albeit
lesser
extent
suppress
abetainduc
product
tnfalpha
express
find
demonstr
cell
promot
microgli
activ
product
ifngamma
respect
inflammatori
respons
suppress
regulatori
cytokin
schwann
cell
disturb
follow
segment
demyelin
peripher
nervou
system
occur
diabet
patient
ethidium
bromid
eb
demyelin
model
schwann
cell
known
invad
contribut
myelin
repair
spinal
cord
schwann
cell
remyelin
central
nervou
system
well
known
event
gliotox
model
aim
investig
observ
behaviour
cell
local
eb
inject
spinal
cord
streptozotocin
diabet
rat
fortynin
adult
wistar
rat
use
receiv
singl
intraven
inject
streptozotocin
mgkg
submit
day
local
inject
eb
group
n
salin
solut
ii
n
spinal
cord
laminectomi
perform
first
lumbar
vertebra
allow
eb
solut
salin
solut
inject
dorsal
column
mean
hamilton
syring
one
microlitr
eb
also
inject
nondiabet
rat
iii
n
rat
group
anaesthet
perfus
heart
day
eb
salin
inject
spinal
cord
section
collect
process
light
transmiss
electron
microscopi
studi
comparison
final
balanc
myelin
repair
group
iii
day
assess
use
semiquantit
method
document
extent
natur
remyelin
semithin
section
ebinduc
lesion
diabet
rat
present
delay
macrophag
activ
greater
amount
myelinderiv
membran
center
ebinduc
lesion
lesser
remyelin
peripher
area
comparison
nondiabet
rat
although
oligodendrocyt
contribut
myelin
reconstruct
invad
schwann
cell
major
sourc
remyelin
firstli
appear
day
nondiabet
rat
day
diabet
rat
astrocyt
behaviour
seem
affect
diabet
evid
glial
loss
primari
demyelin
note
rat
group
ii
result
indic
shortterm
streptozotocininduc
diabet
hinder
schwann
cell
oligodendrocyt
remyelin
mean
remyelin
score
schwann
cell
oligodendrocyt
comparison
nondiabet
rat
respect
microglia
resid
immun
cell
central
nervou
system
cn
microglia
usual
isol
primari
cultur
studi
function
procedur
time
consum
ineffici
due
low
cell
number
microgliaderiv
oncogen
transform
cell
line
success
appli
certain
experi
cell
limit
sever
microgli
function
therefor
establish
sever
microgli
cell
line
mous
embryon
stem
me
cell
suitabl
studi
microglia
function
two
me
cell
line
mpiii
deriv
mice
differenti
microglia
cell
line
total
independ
cell
line
gener
exhibit
stabl
microgli
phenotyp
es
cell
deriv
microglia
esdm
cell
line
character
flow
cytometri
immunocytochemistri
function
assay
esdm
immunoreact
mhc
class
ii
furthermor
stimul
ifn
gamma
lp
show
upregul
proinflammatori
cytokin
ie
ino
tnfalpha
downregul
antiinflammatori
cytokin
ie
tgfbeta
compar
level
primari
microglia
esdm
express
show
concentr
depend
migrat
toward
fractalkin
capac
migrat
phagocytos
abeta
microspher
bead
esdm
compar
primari
microglia
superior
cell
vivo
character
esdm
lentivir
transduc
green
fluoresc
protein
gfp
transplant
cn
neonat
mice
analysi
engraft
cell
week
show
typic
ramifi
microgliallik
structur
esdm
coloc
marker
protein
function
esdm
vivo
shown
transplant
entorhin
cortex
age
transgen
app
mice
site
transplant
show
decreas
plaqu
size
less
amyloidbeta
peptid
load
compar
nontranspl
contralater
site
summari
esdm
mani
characterist
primari
microglia
make
suitabl
tool
studi
microgli
function
vitro
vivo
insult
central
nervou
system
cn
lead
initi
glial
respons
innat
cn
glial
respons
includ
induct
inflammatori
cytokin
chemokin
promot
recruit
leukocyt
cn
transcript
factor
signal
transduc
activ
transcript
stat
nuclear
factorkb
nfkb
interferon
regulatori
factor
irf
associ
cytokin
respons
signal
cellular
growth
prolifer
differenti
apoptosi
antivir
function
studi
involv
transcript
factor
glial
respons
hippocampu
follow
transect
entorhin
affer
axon
lesion
induc
upregul
gene
express
hippocampu
upregul
local
precis
zone
synapt
degener
dentat
gyru
wherea
coloc
microglia
astrocyt
stain
restrict
astrocyt
within
denerv
hippocampu
notabl
induct
lesionreact
hippocampu
depend
type
interferon
receptor
astrogli
upregul
nfkbdepend
addit
lesioninduc
mrna
express
leukocyt
infiltr
hippocampu
significantli
reduc
mice
inactiv
nfkb
signal
astrocyt
find
indic
involv
transcript
factor
lesioninduc
glial
respons
cn
neuroinflammatori
chang
acknowledg
characterist
featur
neurodegen
diseas
like
alzheim
diseas
chang
typifi
activ
microglia
increas
product
proinflammatori
cytokin
like
releas
activ
microglia
experiment
model
chang
coupl
deficit
cognit
function
recogn
interact
microglia
cell
contribut
mainten
microglia
quiescent
state
shown
interact
glycoprotein
express
neuron
receptor
express
microglia
import
modul
microgli
activ
evid
indic
antiinflammatori
cytokin
increas
neuron
express
express
decreas
neuron
prepar
knockout
mice
lyon
et
al
report
addit
neuron
prepar
wildtyp
mice
attenu
lpsinduc
releas
proinflammatori
cytokin
glia
neuron
prepar
knockout
ko
mice
fail
propos
due
decreas
express
consequ
decreas
interact
neuron
glia
howev
addit
attenu
lpsinduc
increas
similar
extent
mix
glia
prepar
wildtyp
ko
mice
consist
find
express
similar
wildtyp
ko
mice
treatment
young
age
wt
ko
mice
lp
result
exagger
increas
express
hippocamp
tissu
prepar
age
compar
young
mice
exacerb
ko
mice
chang
coupl
reduct
express
data
suggest
play
central
role
modul
neuron
express
propos
decreas
express
tissu
prepar
ko
mice
contribut
accentu
lpsinduc
neuroinflamm
observ
anim
mimic
axon
transect
earli
lesion
ms
tcell
reactiv
myelin
basic
protein
mbp
transfer
femal
sjln
mice
subsequ
subject
perfor
pathway
pp
lesion
entorhin
cortex
result
dens
anterograd
axon
termin
degener
dentat
gyru
brain
mice
tcell
transfer
pplesion
day
surviv
post
lesion
tcell
transfer
alon
pplesion
alon
unmanipul
control
mice
process
immunohistochem
tcell
microgliamacrophag
mbp
evalu
clearanc
myelin
debri
axon
lesion
result
massiv
infiltr
smaller
extent
cell
deaffer
dentat
gyru
pplesion
tcell
recipi
mice
compar
pplesion
mice
tcell
recipi
mice
control
mice
pplesion
tcell
recipi
mice
also
show
enhanc
activ
microglia
sign
enhanc
macrophag
recruit
observ
reduc
amount
mbp
particl
pplesion
tcell
recipi
mice
compar
pplesion
mice
indic
presenc
tcell
deaffer
dentat
gyru
enhanc
microglialmacrophag
clearanc
myelin
debri
confirm
increas
number
microgliamacrophag
contain
intracellular
mbp
materi
sign
phagocytosi
pplesion
tcell
recipi
mice
compar
pplesion
mice
axon
termin
degener
distal
site
axon
transect
may
precipit
develop
new
inflammatori
lesion
along
anterograd
degener
axon
enhanc
microglialmacrophag
phagocytot
capac
cell
infiltr
could
prove
benefici
regen
process
follow
ms
attack
possibl
role
inflamm
onset
progress
neurodegen
diseas
suggest
use
mous
prion
model
previous
show
system
inflamm
caus
prime
microglia
switch
proinflammatori
phenotyp
studi
aim
investig
molecular
mechan
associ
phenotyp
switch
mice
infect
prion
agent
system
challeng
lipopolysaccharid
salin
late
stage
diseas
week
compar
control
mice
hippocamp
tissu
collect
subject
microarray
analysi
quantitativertpcr
immunohistochemistri
select
receptor
mice
larg
number
molecul
role
immun
respons
signal
pathway
show
increas
express
includ
four
fc
receptor
fcr
signal
either
activ
itam
inhibitori
itim
motif
system
inflamm
induc
increas
activ
fcriii
fcriv
fcri
chang
inhibitori
fcrii
downregul
chang
fcr
express
accompani
entri
igg
parenchyma
preliminari
data
show
presenc
auto
antibodi
sera
infect
mice
capac
bind
neuron
system
inflamm
chronic
neurodegener
chang
ratio
activ
inhibitori
fcr
express
microglia
lower
signal
threshold
cell
activ
hypothes
crosslink
activ
fcr
result
excess
microglia
activ
product
cytotox
molecul
detriment
degener
neuron
within
dement
brain
situat
may
compound
entri
circul
igg
auto
antibodi
parenchyma
bind
neuron
studi
support
wellcom
trust
microglia
resid
cell
central
nervou
system
cn
belong
myeloid
lineag
experiment
model
neuroinflamm
microglia
demonstr
limit
capac
function
profession
antigen
present
cell
apc
compar
dendrit
cell
dc
human
peripher
blood
monocyt
differenti
immatur
dc
expos
granulocytemacrophag
colonystimul
factor
gmcsf
interleukin
il
matur
dc
subsequ
stimul
lipopolysaccharid
lp
therebi
becom
highli
effici
apc
address
potenti
human
adult
microglia
acquir
phenotyp
function
properti
dc
primari
cultur
human
adult
microglia
treat
gmcsf
without
subsequ
lp
activ
compar
human
monocyt
treat
similar
condit
dc
phenotyp
function
characterist
analog
monocyt
human
microglia
modifi
surfac
phenotyp
upon
gmcsf
treatment
downregul
monocyt
marker
acquir
adhes
receptor
dc
unlik
monocyt
howev
treat
microglia
decreas
major
histocompat
complex
mhc
class
ii
express
acquir
lipid
present
molecul
upon
lp
stimul
microglia
lack
matur
dc
marker
slightli
increas
costimulatori
molecul
lpsactiv
monocytederiv
dc
effici
promot
cell
prolifer
allogen
mix
leukocyt
reaction
wherea
similarli
treat
adult
microglia
decreas
abil
stimul
cell
prolifer
compar
untreat
counterpart
monocytederiv
dc
produc
high
level
tumor
necrosi
factor
tnf
wherea
microglia
produc
rel
low
amount
tnf
detect
monocyt
differenti
dc
downregul
mafb
mrna
transcript
factor
associ
macrophag
differenti
wherea
similarli
treat
microglia
maintain
high
level
mafb
howev
microglia
remain
low
phagocyt
activ
suggest
acquir
complet
macrophag
dc
phenotyp
data
show
condit
induc
effici
profession
apc
monocyt
gener
microglia
modest
apc
function
lesser
inflammatori
properti
suggest
potenti
microgli
role
dampen
local
inflamm
within
cn
autoimmun
respons
direct
schwann
cell
compon
whether
schwann
cell
promot
respons
present
autoantigen
tcell
remain
controversi
show
immunohistochemistri
human
schwann
cell
express
intracellular
machineri
requir
process
present
antigen
autoreact
cell
vitro
vivo
addit
interferongamma
result
increas
express
antigen
process
present
molecul
cultur
human
schwann
cell
furthermor
schwann
cell
sural
nerv
biopsi
gb
patient
show
increas
express
antigen
associ
transport
protein
antigen
present
mhc
class
ii
complex
compar
control
cocultur
experi
rodent
schwann
cell
express
ovalbumin
model
antigen
activ
prolifer
ovalbumin
specif
cell
pretreat
proinflammatori
cytokin
data
suggest
glia
cell
peripher
nervou
system
abil
process
present
antigen
activ
autoreact
cell
schwann
cell
may
therefor
promot
local
autoimmun
respons
inflammatori
neuropathi
specif
target
patholog
function
schwann
cell
may
futur
extend
therapeut
option
gb
astrocyt
microgli
respons
tlr
ligand
address
vivo
vitro
astrocyt
purifi
flow
cytometr
cellsort
transgen
mice
express
egfp
control
gfap
promotor
microglia
sort
cell
quantit
realtim
pcr
use
measur
gene
express
astrocyt
microglia
isol
naiv
mice
mice
receiv
ligand
polyi
c
lp
intrathec
inject
expect
naiv
microglia
express
wide
rang
tlr
receptor
coreceptor
eg
tlr
naiv
astrocyt
predominantli
express
messag
h
follow
inject
lp
polyi
c
astrocyt
microglia
show
signific
upregul
messag
consist
publish
report
astrocyt
express
rel
low
level
mrna
howev
dosag
use
lp
effect
polyi
c
induct
express
astrocyt
examin
role
microglia
astrocyt
respons
measur
lp
respons
astrocyt
primari
cultur
contain
variabl
proport
cell
type
astrocyt
cultur
contain
microglia
respond
lp
upregul
wherea
cultur
microglia
induc
astrocyt
although
case
express
strongli
upregul
microglia
astrocyt
shown
respond
poli
c
stimul
induct
cultur
contain
microglia
induct
cultur
microglia
suggest
astrocyt
upregul
respons
direct
stimul
factor
releas
tlrsignal
microglia
absenc
tlr
signal
steril
injuri
model
could
explain
lack
astrocyt
current
investig
factor
signal
pathway
involv
microglia
resid
immun
cell
central
nervou
system
normal
quiescent
becom
activ
infect
injuri
properti
chang
promot
repair
damag
process
extent
microgli
activ
regul
part
activationinduc
cell
death
aicd
although
mani
apoptot
aspect
microgli
aicd
mechan
elucid
littl
known
connect
activ
step
death
process
employ
dna
microarray
approach
identifi
ectoenzym
potenti
mediat
microgli
activ
aicd
use
mous
primari
microgli
cultur
show
via
calciummobil
metabolit
cyclicadpribos
cadpr
help
promot
microgli
activ
aicd
induc
lp
plu
ifngamma
lpsifng
suggest
link
two
process
accordingli
express
activ
well
intracellular
calcium
concentr
primari
microglia
increas
lpsifng
treatment
moreov
defici
treatment
cadpr
antagonist
confer
partial
resist
lpsifnginduc
aicd
also
reduc
microgli
activ
indic
induc
express
mrna
product
secret
mrna
express
express
mrna
attenu
defici
cadprantagonist
treatment
observ
effect
microgli
activ
probabl
mediat
via
cadprdepend
increas
effect
aicd
regul
product
result
thu
suggest
significantli
affect
regul
amount
function
activ
microglia
import
consequ
injuri
repair
process
brain
adult
mammalian
brain
multipot
selfrenew
neural
progenitor
cell
npc
may
gener
new
neuron
astrocyt
oligodendrocyt
npc
may
thu
serv
regen
tool
brain
damag
could
compens
howev
repair
process
respons
inflammatori
form
brain
injuri
character
failur
neuron
regener
predomin
occurr
astrocyt
known
astrogliosi
moreov
inflamm
gener
oxid
milieu
recent
report
directli
inhibit
neurogenesi
within
brain
therefor
intend
clarifi
possibl
molecular
pathway
underli
inflammationmedi
inhibit
neurogenesi
enhanc
astrogenesi
chronic
autoimmun
neuroinflamm
systemat
investig
effect
redox
modul
neural
stem
cell
vitro
vivo
well
anim
model
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
found
subtl
nontox
oxid
suppress
prolifer
npc
direct
differenti
toward
astrogli
lineag
expens
neuron
vice
versa
find
indic
oxid
play
instruct
role
direct
uncommit
npc
differenti
toward
astrogli
lineag
alter
default
develop
program
accord
data
class
iii
naddepend
histon
deacetylas
involv
variou
cellular
process
compris
energi
metabol
transcript
silenc
dna
repair
mediat
observ
redox
effect
mild
oxid
npc
lead
increas
deacetylas
activ
promot
proneuron
transcript
factor
furthermor
ongo
analysi
regul
cours
eae
present
result
provid
evid
yet
unknown
metabol
master
switch
impact
fate
neural
progenitor
inflammatori
condit
role
astrocyt
glutam
clearanc
impair
astrocyt
numer
abund
celltyp
central
nervou
system
cn
one
essenti
function
astrocyt
regul
level
extracellular
glutam
major
excitatori
neurotransmitt
mammalian
cn
astrocyt
express
glutam
transport
promin
excitatori
amino
acid
transport
perform
vast
major
synapt
glutam
clearanc
prevent
excitotox
overactiv
glutam
receptor
cell
surfac
neuron
howev
neuroinflammatori
condit
cytokin
shown
inhibit
astrocyt
glutam
uptak
kd
ectoenzym
involv
synthesi
potent
calcium
mobil
agent
cyclic
adenosin
diphosphoribos
cadpr
nicotin
acid
adenin
dinucleotid
phosphat
naadp
previou
studi
demonstr
astrocyt
express
upregul
upon
immun
viral
stimul
play
import
role
astrocyt
inflammatori
respons
upon
cytokin
stimul
perform
studi
focus
effect
proinflammatori
cytokin
express
astrocyt
result
astrocyt
glutam
uptak
abil
potenti
role
effect
also
test
primari
human
astrocyt
cultur
treat
glutam
uptak
abil
astrocyt
determin
perform
amplex
red
glutam
acidglutam
oxidas
assay
astrocyt
product
examin
elisa
express
astrocyt
test
realtim
pcr
immunocytochem
analys
result
show
induc
astrocyt
activ
indic
signific
increas
product
cytokinechemokin
furthermor
detect
timedepend
reduc
glutam
uptak
abil
astrocyt
complet
revers
coincub
specif
cadprantagonist
also
found
decreas
astrocyt
express
induc
revers
coincub
result
indic
glutam
clearanc
capabl
astrocyt
impair
cytokin
activ
decreas
express
astrocyt
contribut
impair
addit
provid
new
evid
upregul
immuneactiv
astrocyt
contribut
function
dysregul
neuroinflammatori
condit
patient
posthaart
era
new
syndrom
immun
reconstitut
inflammatori
syndrom
iri
emerg
patient
may
rapidli
progress
toward
develop
sever
enceph
ultim
death
even
absenc
opportunist
infect
cnsiri
larg
mediat
via
activatedt
cell
differenti
enceph
accompani
macrophag
infiltr
pauciti
cell
paradox
infiltr
brain
cell
patient
immun
suppress
low
peripher
cell
count
due
infect
repres
diagnost
challeng
treatment
dilemma
determin
mechan
cell
activ
iri
lymphocyt
normal
donor
seed
plate
cellswel
treat
nm
tat
transactiv
transcript
presenc
absenc
tpck
nfkb
blocker
nm
panpkc
inhibitor
chloroquin
pyramethamin
antibodi
map
epitop
tat
activ
cell
lymphocyt
expos
tat
peptid
deriv
clade
b
bru
strain
overlap
amino
acid
indic
cell
activ
granzym
b
level
measur
cultur
supernat
elisa
mean
sem
determin
donor
analyz
anova
dunnet
correct
data
indic
tat
activ
cell
doserespons
manner
activ
requir
nfkb
pathway
p
independ
pkc
activ
endocytot
pathway
import
tatmedi
activ
cell
treatment
chloroquin
decreas
cell
activ
tat
p
effect
seen
pyramethamin
cystein
rich
region
tat
critic
activ
cell
p
p
respect
tat
activ
cell
secret
effector
molecul
exemplifi
granzym
b
releas
mechan
tatinduc
activ
depend
endocytosi
tat
nfkb
signal
may
repres
novel
therapeut
target
treat
iri
cystein
rich
region
tat
critic
mediat
effect
neurolog
symptom
associ
dengu
fever
mani
recogn
centuri
symptom
rang
drowsi
irrit
short
term
memori
depress
mononeur
palsi
enceph
seizur
death
optic
spinal
syndrom
follow
monophas
neuromyel
optica
nmo
observ
dengu
viru
infect
suggest
influenc
genet
background
suscept
postnmo
despit
high
preval
tropicalsubtrop
countri
vaccinemedicin
avail
diseas
heat
shock
protein
hsp
highli
conserv
molecul
express
cell
type
variou
stress
condit
object
present
studi
determin
effect
dengu
viru
infect
rel
express
hsp
role
progress
infect
macrophag
primari
host
dengu
human
promonocyt
myeloblastoma
monocyt
cell
blood
deriv
macrophag
infect
dengu
viru
type
evalu
hsp
express
signific
express
observ
viral
infect
cell
predominantli
express
blood
deriv
macrophag
cell
order
determin
correl
express
viral
multipl
infect
cell
express
regul
rna
interfer
accumul
activ
macrophag
microglia
hallmark
viral
enceph
howev
mechan
recruit
function
infect
brain
poorli
defin
leukocyt
infiltr
critic
viru
erad
cell
caus
irrepar
damag
neuron
contribut
increas
morbid
mortal
host
west
nile
viru
wnv
enceph
signific
immunopatholog
compon
howev
poorli
understood
studi
investig
role
inflammatori
monocyt
wnv
infect
intranas
inocul
wnv
result
increas
increas
brain
post
infect
pi
flow
cytometri
bromodeoxyuridin
puls
show
microglia
undergon
prolifer
situ
deplet
peripher
inflammatori
monocyt
infect
abrog
increas
microglia
macrophag
suggest
share
circul
precursor
pi
chimera
reconstitut
cfmsegfp
bone
marrow
show
larg
number
gfp
peripherallyderiv
microglia
macrophag
express
phenotyp
brain
suggest
cell
common
inflammatori
monocyt
precursor
furthermor
adopt
transfer
inflammatori
monocyt
migrat
brain
express
microgli
macrophag
phenotyp
wnv
infect
confirm
inflammatori
monocytederiv
macrophag
microglia
utilis
differ
adhes
molecul
enter
infect
brain
blockad
late
reduc
macrophag
immigr
result
long
term
surviv
lethal
model
lymphocyt
functionassoci
blockad
reduc
macrophag
immigr
improv
surviv
importantli
blockad
impact
number
immigr
microglia
major
macrophag
infiltr
brain
produc
nitric
oxid
treatment
aminoguanidin
pi
result
reduct
number
noproduc
macrophag
increas
mous
surviv
day
togeth
data
indic
role
nomedi
immunopatholog
infiltr
macrophag
wnv
enceph
herp
simplex
enceph
hse
commonli
identifi
caus
acut
sporad
nonepidem
enceph
characteris
sever
swell
brain
tissu
purpos
inflamm
restor
homeostasi
elimin
invad
pathogen
promot
recoveri
tissu
damag
cytokin
immun
mediat
play
essenti
role
cn
inflamm
activ
chemokin
adhes
molecul
recruit
immun
cell
parenchyma
stimul
endogen
glial
cell
inflammatori
respons
howev
regul
adequ
lead
chronic
tissu
damag
caus
infiltr
peripher
lymphocyt
cn
collagen
deposit
aim
studi
provid
control
vitro
system
measur
cytokin
respons
upon
hsv
infect
mean
cytometrybas
assay
allow
multiplex
analysi
final
investig
effect
antiinflammatori
agent
cytokin
level
cell
model
compris
pure
murin
microglia
astrocyt
neuron
cocultur
cell
line
establish
explor
cytokin
respons
upon
infect
moder
neurovirul
strain
highli
neurovirul
strain
cell
cultur
supernat
taken
indic
time
point
subsequ
probe
total
cytokin
utilis
commerci
avail
bioplex
assay
compar
cell
infect
gener
vigor
cytokin
respons
compar
cell
infect
microglia
produc
far
highest
cytokin
level
contrari
previou
studi
experi
clearli
indic
neuron
astrocyt
sens
infect
howev
synthesi
restrict
certain
type
cytokin
low
concentr
addit
compar
pure
microglia
cocultur
reveal
shift
cytokin
express
mark
decreas
kc
function
level
suggest
crosstalk
individu
cell
type
cytokin
cascad
repres
vast
interdepend
network
studi
multipl
cytokin
provid
improv
insight
role
pathophysiolog
hsv
cn
infect
human
immunodefici
viru
type
invad
central
nervou
system
cn
earli
stage
infect
trigger
profound
humor
immun
respons
distinguish
plasmablast
infiltr
intrathec
igg
synthesi
aim
studi
character
memori
b
cell
receptor
usag
cerebrospin
fluid
csf
singlecel
rtpcr
use
sampl
csf
memori
b
cell
repertoir
includ
plasmablast
treat
untreat
hiv
patient
sequenc
amplifi
variabl
region
heavi
vh
lightchain
vl
product
identifi
rearrang
variabl
region
j
segment
determin
degre
homolog
germlin
sequenc
expand
memori
b
cell
clone
detect
csf
subject
repertoir
demonstr
similar
distribut
vh
vl
famili
germlin
usag
famili
heavi
chain
famili
light
chain
domin
respect
repertoir
treat
untreat
repertoir
howev
show
signific
differ
amount
b
cell
clonal
expans
vs
p
degre
vh
germlin
homolog
vs
p
increas
memori
b
cell
clonal
expans
somat
hypermut
observ
untreat
subject
associ
presenc
intrathec
viru
increas
number
csf
plasmablast
infect
elicit
promin
cn
memori
b
cell
respons
clonal
expans
somat
hypermut
enhanc
presenc
intrathec
viru
consist
target
antibodi
respons
rearrang
vh
vl
sequenc
clonal
expand
b
cell
may
use
gener
recombin
antibodi
recreat
epitop
specif
humor
immun
respons
treat
untreat
diseas
neurotrop
jhm
strain
mous
hepat
viru
jhmv
result
extens
opc
migrat
remyelin
opc
transplant
environ
persist
viru
present
possibl
cell
may
suscept
infect
therefor
experiment
goal
studi
determin
opc
abl
support
jhmv
replic
cytokin
treatment
affect
viral
growth
present
studi
demonstr
jhmv
abl
infect
replic
within
primari
cultur
opc
deriv
neural
progenitor
cell
addit
treatment
infect
opc
recombin
mous
ifngamma
inhibit
viral
replic
dosedepend
manner
although
product
mrna
protein
mute
jhmvinfect
opc
produc
ifngammatreat
jhmvinfect
cell
recombin
inhibit
viral
replic
final
ifngamma
unabl
control
jhmv
replic
opc
deriv
type
receptor
knockout
mice
data
indic
jhmv
capabl
infect
opc
gener
neural
progenitor
cell
control
viral
replic
depend
secret
identifi
cellular
receptor
strain
mv
inhibit
cell
prolifer
engag
mv
propos
import
mechan
mvinduc
immunosuppress
addit
cell
exhibit
immunosuppress
activ
may
involv
mechan
respons
mvinduc
sspe
well
studi
mvinduc
immunosuppress
evalu
character
peripher
blood
cell
pbc
sspe
patient
compar
control
pbc
total
sspe
patient
boy
mean
age
year
children
girl
boy
mean
age
year
noninflammatori
inflammatori
diseas
stain
phenotyp
cell
subset
result
implic
may
also
use
cell
entri
receptor
strain
mv
caus
sspe
lower
presenc
inhibitori
nk
receptor
cell
sspe
may
caus
alter
regul
cell
well
present
work
support
research
fund
istanbul
univers
project
maingat
ferdinand
viappiani
serena
zhu
yu
afkhamigoli
amir
power
infect
human
immunodefici
viru
hiv
result
neurodegener
caus
aberr
activ
glial
cell
although
impact
concurr
system
infect
neurolog
diseas
remain
uncertain
studi
role
recurr
immun
activ
neurolog
function
viral
replic
brain
use
hiv
aid
model
felin
immunodefici
viru
fiv
infect
administ
lipopolysaccharid
lp
compon
membran
gramneg
bacteria
cat
infect
fiv
week
postinfect
follow
serial
neurobehavior
assess
protein
mrna
extract
cerebr
cortex
basal
ganglion
immunoblot
neuron
marker
rtpcr
analys
inflammatori
gene
fivinfect
uninfect
anim
differ
significantli
multipl
neurobehavior
task
gait
memori
time
associ
reduc
weight
gain
immunosuppress
fivinfect
group
fivinfect
car
treat
lp
develop
less
sever
neurobehavior
deficit
mean
deficit
score
fivlp
group
versu
fiv
group
cell
level
blood
suppress
fiv
infect
group
compar
uninfect
anim
howev
cell
level
blood
also
lower
blood
accompani
reduc
transcript
abund
brain
among
lpstreat
fivinfect
anim
rel
untreat
fivinfect
anim
presynapt
protein
synaptophysin
vesicular
acetylcholin
transport
reduc
fivinfect
anim
togeth
upregul
mrna
chemokin
neuron
basal
ganglia
cortex
fivinfect
anim
effect
also
revers
lp
treatment
repeat
lp
exposur
improv
neurolog
function
rescu
synapt
architectur
fivinfect
anim
mechan
involv
reduc
viral
replic
concomit
cell
infiltr
brain
find
underscor
benefici
aspect
select
activ
innat
immun
neurolog
diseas
depart
patholog
microbiolog
univers
nebraska
medic
center
omaha
ne
unit
state
microglia
astrocyt
import
effector
cell
cn
innat
immun
respons
parenchym
infect
tolllik
receptor
tlr
famili
pattern
recognit
receptor
prr
facilit
recognit
conserv
antigen
motif
variou
pathogen
lead
downstream
product
inflammatori
mediat
pivot
glial
recognit
aureu
preval
cn
pathogen
elicit
proinflammatori
mediat
releas
recent
studi
laboratori
reveal
correl
loss
signal
aberr
infiltr
aureu
brain
abscess
model
may
provid
insight
interfac
adapt
immun
cn
parenchym
infect
sinc
exert
mani
proinflammatori
activ
propos
exagger
releas
mice
compensatori
mechan
mount
effect
antibacteri
immun
respons
face
loss
import
prr
studi
signal
via
adaptor
essenti
induct
cn
innat
immun
experiment
brain
abscess
model
specif
absenc
signal
significantli
impair
product
wide
rang
proinflammatori
molecul
attenu
neutrophil
macrophag
influx
cn
result
exagger
necrosi
infect
tissu
collect
studi
reveal
import
role
famili
molecul
regul
innat
adapt
immun
respons
gramposit
infect
cn
parenchyma
sydenham
chorea
major
neurolog
sequela
group
streptococcalinduc
acut
rheumat
fever
arf
like
due
autoimmun
molecular
mimicri
host
pathogen
first
clue
pathogenesi
diseas
identif
human
monoclon
antibodi
mab
deriv
sydenham
chorea
demonstr
crossreact
specif
group
streptococc
antigen
react
striatal
tissu
brain
antigen
lysogangliosid
tubulin
mab
acut
sydenham
chorea
sera
csf
target
surfac
human
neuron
cell
caus
induct
calciumcalmodulin
depend
protein
cam
kinas
ii
activ
dopamin
releas
sera
streptococc
diseas
sequela
convalesc
sydenham
chorea
sera
demonstr
increas
antibodi
reactiv
brain
antibodi
mediat
signal
cam
kinas
ii
primari
neuron
cell
striatal
tissu
demonstr
increas
cam
kinas
ii
activ
react
acut
sydenham
chorea
sera
csf
new
preliminari
data
suggest
dopamin
receptor
target
crossreact
antibrain
mab
sera
serum
antibodi
relat
disord
pediatr
autoimmun
neurolog
disord
associ
streptococci
obsess
compuls
behavior
vocal
tic
ticlik
movement
demonstr
level
cam
kinas
ii
activ
increas
intermedi
level
reactiv
lysogangliosid
evid
although
present
patient
howev
comparison
match
acut
convalesc
panda
sera
taken
exacerb
demonstr
elev
cam
kinas
ii
activ
associ
diseas
studi
anim
model
sydenham
chorea
reveal
immun
group
streptococc
antigen
led
behavior
chang
correl
antibodi
deposit
striatum
well
reactiv
serum
igg
dopamin
receptor
induct
cam
kinas
ii
activ
data
consist
current
hypothesi
disinhibit
basal
gangliathalamocort
pathway
may
involv
sydenham
chorea
treatment
haloperidol
receptor
antagonist
depart
neurolog
john
hopkin
univers
baltimor
md
unit
state
patient
hiv
infect
aggress
treat
antiretrovir
drug
develop
paradox
subacut
enceph
develop
syndrom
coincid
drop
viral
load
recoveri
cell
count
blood
left
untreat
may
result
death
week
neuropatholog
evalu
show
massiv
infiltr
cell
predomin
cytotox
cell
associ
glial
cell
activ
neuron
injuri
rel
spare
myelin
studi
pathophysiolog
syndrom
first
determin
mechan
activ
cell
hiv
protein
tat
impact
antiretrovir
drug
tatmedi
activ
cell
occur
independ
cell
receptor
nfkb
depend
use
human
neuron
cultur
found
supernat
activ
cell
neurotox
granzym
b
major
neurotox
substanc
releas
activ
cell
granzym
b
caus
neuron
injuri
independ
perforin
mechan
neuron
injuri
granzym
b
sequenti
involv
activ
giprotein
coupl
receptor
notchsign
pathway
express
potassium
channel
follow
neurit
trim
neuron
cell
death
apoptosi
pharmacolog
molecular
blockad
result
protect
cell
mediat
neuron
injuri
previou
studi
suggest
role
activ
cell
thu
repres
novel
therapeut
target
syndrom
bone
marrow
stern
cell
rescu
brain
diseas
microglia
immun
cell
central
nervou
system
patrol
brain
environ
ramif
respond
quickli
presenc
pathogen
brain
damag
bone
marrow
deriv
cell
bmdc
abil
popul
cn
differenti
function
parenchym
microglia
well
perivascular
microglia
even
though
bmdc
enter
brain
parenchyma
throughout
cn
normal
mice
seem
preferenti
attract
region
afflict
neurodegener
neurolog
insult
great
interest
fact
bloodderiv
microgli
cell
associ
amyloid
plaqu
cell
abl
prevent
format
elimin
presenc
amyloid
deposit
mice
develop
major
hallmark
alzheim
diseas
ad
cell
also
recruit
brain
mous
model
brain
diseas
acut
injuri
exact
mechan
involv
event
yet
fulli
character
like
stress
damag
neuron
send
signal
resid
microglia
produc
specif
chemokin
caus
recruit
bmderiv
microglia
number
protein
act
endogen
ligand
tolllik
receptor
tlr
express
surfac
microglia
trigger
nfkb
signal
gene
transcript
would
necessarili
lead
subtl
inflammatori
respons
consequ
prolifer
chemoattract
myeloid
cell
interest
fact
need
massiv
neurodegener
bbb
breakdown
therefor
propos
neuron
especi
danger
abil
interact
microglia
stimul
prolifer
recruit
although
physiolog
relev
phenomenon
still
larg
unknown
specul
natur
process
take
place
provid
surviv
signal
help
stress
injur
infect
neuron
time
control
innat
immun
respons
may
also
limit
cn
toxic
elimin
foreign
materi
debri
thu
contribut
creat
environ
permiss
regener
recoveri
sinc
toxic
secret
protein
frequent
caus
mani
brain
diseas
cellular
therapi
may
prove
quit
effect
prevent
remov
main
trigger
neurodegener
hematopoiet
stem
cell
repres
therefor
fantast
new
vehicl
deliv
key
molecul
improv
recoveri
repair
elimin
toxic
protein
canadian
institut
health
research
cihr
support
research
transform
growth
factorbeta
tgfbeta
pleiotrop
effect
benefici
harm
central
nervou
system
cn
transgen
mice
overproduc
cytokin
astrocyt
higher
number
cell
brain
without
show
overt
sign
inflamm
howev
immun
endogen
ectop
express
cn
antigen
cell
infiltr
inflamm
aggrav
consist
observ
synthesi
glial
cell
tgfbeta
signal
cn
activ
sever
day
onset
paralysi
mice
autoimmun
encephalomyel
sequenti
glial
cell
modul
signal
induc
infiltr
cell
inflammatori
lesion
pharmacolog
inhibit
signal
amelior
paralyt
diseas
reduc
accumul
pathogen
cell
express
cn
prime
peripher
cell
alter
pathway
indic
effect
direct
within
brain
yet
affect
immun
system
earli
product
cn
creat
permiss
danger
environ
initi
autoimmun
inflamm
inhibit
signal
may
benefit
treatment
acut
phase
autoimmun
cn
inflamm
late
pregnanc
benefici
ms
third
trimest
associ
approxim
reduct
relaps
rate
estriol
estrogen
uniqu
pregnanc
reach
highest
level
third
trimest
estriol
treatment
previous
shown
amelior
experiment
autoimmun
encephalomyel
eae
use
dose
equival
occur
natur
late
murin
pregnanc
numer
mechan
involv
estriol
mediat
protect
diseas
includ
antiinflammatori
well
neuroprotect
mechan
antiinflammatori
mechan
previous
includ
induct
favor
chang
cytokin
chemokin
regulatori
cell
present
recent
observ
effect
estriol
treatment
matrix
neuroprotect
effect
includ
spare
axon
densiti
myelin
white
matter
well
neuron
stain
gray
matter
estrogen
receptor
er
alpha
erbeta
differenti
mediat
antiinflammatori
neuroprotect
effect
togeth
observ
eae
provid
rational
clinic
trial
treatment
estriol
pregnanc
dose
relaps
remit
multipl
sclerosi
rrm
trial
includ
antiinflammatori
well
neuroprotect
outcom
measur
distinct
femal
predomin
exist
varieti
human
autoimmun
disord
includ
multipl
sclerosi
ms
differenti
gender
suscept
also
observ
mani
experiment
anim
model
autoimmun
diseas
includ
experiment
autoimmun
encephalomyel
eae
increas
level
sex
hormon
produc
pregnanc
report
reduc
clinic
symptom
ms
interestingli
clinic
symptom
ms
worsen
postpartum
mark
reduc
sex
hormon
level
work
laboratori
illustr
larg
number
complex
process
affect
estrogen
might
contribut
strike
abil
estradiol
deriv
inhibit
clinic
histolog
sign
eae
mice
effect
requir
sustain
exposur
rel
low
dose
exogen
hormon
offer
better
protect
initi
prior
induct
eae
although
oral
ethinyl
estradiol
ee
could
partial
revers
clinic
eae
given
onset
diseas
main
area
discuss
includ
inhibit
encephalitogen
cell
role
regul
newli
describ
membran
receptor
mer
agonist
inhibit
inflammatori
cell
migrat
central
nervou
system
tissu
neuroprotect
effect
promot
axon
myelin
surviv
final
new
data
show
synergist
treatment
effect
combin
cell
receptor
peptid
therapi
ms
patient
effect
eae
mediat
alpha
receptor
beta
receptor
result
dramat
downregul
recent
demonstr
major
pathogen
cytokin
eae
chimera
studi
demonstr
directli
inhibit
pathogen
cell
rather
mediat
suppress
effect
cell
type
includ
macrophag
dendrit
cell
mechanist
import
immunosuppress
prevent
eae
also
involv
upregul
contribut
activ
regulatori
cell
treg
new
find
indic
agonist
bind
select
mer
mediat
full
protect
eae
upregul
pathway
treg
cell
well
antiinflammatori
cytokin
protect
effect
agonist
eae
suggest
potenti
use
therapi
ms
fred
hutchinson
cancer
research
center
univers
washington
seattl
wa
usa
microchimer
mc
refer
harbor
small
number
cell
dna
origin
anoth
genet
distinct
individu
cell
traffic
mother
fetu
pregnanc
found
persist
mani
year
later
respect
host
hematopoiet
cell
transplant
iatrogen
chimer
often
complic
chronic
graftvshost
diseas
condit
resembl
autoimmun
diseas
strongli
determin
donorrecipi
hlarelationship
consid
observ
togeth
led
hypothesi
natur
acquir
mc
pregnanc
childmoth
hla
relationship
impact
risk
subsequ
autoimmun
diseas
mc
also
acquir
twin
blood
transfus
possibl
older
sibl
transfer
via
matern
circul
later
pregnanc
antibodi
brain
lesson
lupu
betti
diamond
b
diamond
p
huerta
c
kowal
j
lee
b
volp
subset
antidna
antibodi
present
lupu
patient
crossreact
nmda
receptor
nmdar
modul
nmdar
function
mediat
excitotox
death
neuron
vitro
vivo
antibodi
preset
serum
lupu
patient
also
found
cerebrospin
fluid
brain
tissu
demonstr
antibodi
present
circul
caus
brain
injuri
compromis
integr
bloodbrain
barrier
may
caus
memori
deficit
behavior
disturb
depend
whether
penetr
hippocampu
amygdala
respect
histopatholog
analysi
display
noninflammatori
loss
neuron
antibodi
via
transplacent
transmiss
caus
abnorm
fetal
brain
develop
lead
thin
cortic
plate
delay
acquisit
normal
reflex
impair
adulthood
isol
task
depend
intact
cortex
overal
studi
demonstr
capac
antibodi
caus
acquir
chang
cognit
behavior
caus
congenit
nongenet
alter
fetal
brain
develop
specul
brainreact
antibodi
may
often
present
therefor
frequent
threat
optim
brain
function
develop
myasthenia
gravi
mg
tcell
depend
antibodi
respons
direct
acetylcholin
receptor
achr
neuromuscular
junction
studi
immun
toler
autoantigen
gener
transgen
mous
achr
alpha
chain
express
normal
physiolog
pattern
muscl
n
brain
thymu
use
model
assess
mechan
regul
toler
achr
sinc
achr
express
thymu
expect
central
toler
would
domin
sever
line
evid
suggest
peripher
mechan
may
play
signific
role
first
cell
toler
maintain
age
spite
thymic
involut
respons
self
determin
foreign
antigen
still
seen
old
mice
month
age
second
cell
toler
remain
function
air
knockout
anim
carri
transgen
third
cross
mice
carri
transgen
tcr
specif
ligand
toler
easili
broken
fourth
adopt
transfer
tcr
transgen
cell
label
cfse
reveal
slight
decreas
number
cell
divis
seen
transgen
host
oppos
nontransgen
host
fifth
use
thymu
transplant
approach
demonstr
tcell
toler
depend
transgen
express
muscl
thymu
lastli
toler
state
could
overcom
treat
mice
consist
mechan
toler
regul
peripher
regulatori
reg
cell
explor
second
transgen
founder
line
gener
transgen
express
slightli
higher
level
fold
muscl
thymu
preliminari
thymu
transplant
adopt
transfer
experi
new
founder
line
suggest
central
toler
may
also
involv
ongo
studi
second
transgen
line
design
assess
whether
air
andor
reg
cell
play
role
whether
level
express
andor
distribut
ligand
among
thymic
epitheli
subset
critic
work
support
part
apc
subcontract
pilot
grant
san
antonio
area
foundat
myasthenia
gravi
foundat
america
uthscsa
erc
grant
nih
classic
complement
pathway
autoimmun
myasthenia
gravi
pathogenesi
p
christadoss
mice
defici
complement
factor
resist
celldepend
antibodi
mediat
autoimmun
myasthenia
gravi
eamg
induc
cfaacetylcholin
receptor
achr
immun
achr
immun
defici
mice
lymph
node
cell
lnc
produc
less
eamg
resist
defici
mice
less
serum
moreov
increas
serum
immun
complex
cic
level
correl
eamg
diseas
sever
riiisj
mice
cic
promot
eamg
sever
stimul
product
via
fc
gamma
receptor
interact
howev
mbl
receptor
defici
mice
equal
suscept
eamg
wildtyp
mice
implic
mbl
pathway
involv
eamg
develop
complement
accumul
upregul
also
observ
recent
discov
eamg
mice
induc
lpsachr
immun
antibodi
administr
follow
achr
immun
suppress
eamg
reduc
lnc
product
neuromuscular
junction
deposit
igg
complex
treatment
antibodi
twice
week
four
week
mice
ongo
clinic
eamg
reduc
clinic
sever
diseas
lnc
product
antibodi
administr
suppress
eamg
reduc
antiachr
antibodi
bind
complement
therefor
agent
block
ccp
factor
andor
could
use
target
therapi
mg
research
team
molecular
biomark
tokyo
metropolitan
institut
gerontolog
tokyo
japan
musk
antibodi
found
seroneg
mg
patient
experiment
autoimmun
mg
model
requir
show
pathogen
musk
antibodi
mg
provid
evid
activ
immun
musk
protein
reproduc
myasthenia
gravi
rabbit
next
focu
musk
antibodi
caus
mg
pathogen
role
musk
antibodi
mg
question
number
achr
reduc
complement
deposit
nmj
bicep
brachii
muscl
muskposit
patient
mg
mechan
mg
caus
achr
antibodi
well
delin
reveal
mechan
abl
simpli
appli
mg
musk
antibodi
musk
antibodi
identifi
predominantli
subclass
activ
complement
found
agrininduc
cluster
achr
strongli
block
presenc
musk
antibodi
wherea
absorpt
antibodi
purifi
musk
product
prevent
block
effect
result
show
musk
antibodi
effect
inhibit
format
agrininduc
achr
cluster
intriguingli
monoval
fab
fragment
musk
antibodi
rabbit
eamg
also
inhibit
achr
cluster
agrin
cell
indic
complementmedi
mechan
necessarili
requir
inhibit
examin
reduc
express
achr
nmj
soleu
muscl
paret
normal
rabbit
fluoresc
microscopi
addit
structur
nmj
paret
rabbit
well
size
branch
motor
termin
significantli
reduc
electron
microscop
observ
nmj
rabbit
eamg
induc
inject
musk
protein
demonstr
signific
loss
complex
convolut
synapt
fold
destruct
eamg
model
cite
resembl
phenotyp
human
mg
musk
antibodi
result
show
musk
antibodi
inhibit
anterograd
retrograd
signal
requir
maintain
synapt
structur
matur
nmj
eamg
model
musk
antibodi
facilit
understand
pathogen
mechan
mg
musk
antibodi
function
role
musk
molecul
matur
neuromuscular
junction
cell
constitut
express
immunotolerogen
human
histocompat
leukocyt
antigen
g
hlag
recent
describ
new
type
human
natur
thymusderiv
regulatori
cell
hlagpo
treg
treg
suppress
immun
respons
foreign
selfantigen
play
key
role
mechan
autoimmun
challeng
role
hlagpo
treg
respect
function
role
multipl
sclerosi
hlag
posit
hlagpo
cell
found
cerebrospin
fluid
csf
tissu
specimen
ms
patient
contrast
noninflammatori
neurolog
diseas
ond
hlagpo
cell
enrich
csf
ms
patient
substanti
popul
cell
coexpress
hlag
local
inflammatori
lesion
ms
patient
suggest
hlagpo
cell
accumul
site
cn
inflamm
csfderiv
hlagpo
cell
reveal
clear
predomin
central
memori
cell
phenotyp
show
marker
activ
ico
significantli
higher
express
inflammatori
chemokin
receptor
use
vitro
model
human
blood
brain
barrier
show
hlagpo
cell
propens
migrat
vigor
driven
inflammatori
chemokin
rant
ligand
ligand
contrast
treg
purifi
peripher
blood
hlagpo
treg
cell
nt
differ
suppress
capac
healthi
control
importantli
hlagpo
cell
directli
isol
csf
ms
patient
potent
suppress
prolifer
autolog
respond
cell
work
character
pathophysiolog
role
hlagpo
treg
novel
popul
human
treg
respect
ms
data
show
hlagpo
natur
treg
chemokinedepend
propens
transmigr
bloodbrain
barrier
accumul
csf
cn
lesion
ms
patient
importantli
patientderiv
hlagpo
treg
function
activ
suppress
autolog
cell
activ
site
inflamm
therefor
assum
natur
regulatori
cell
specif
recruit
cn
order
counterbal
autoimmun
inflammatori
activ
work
contribut
understand
hlagpo
natur
treg
provid
import
pathophysiolog
exampl
benefici
cell
inflamm
ms
implic
pathophysiologicaltherapeut
point
view
bloodbrain
barrier
bbb
play
crucial
role
protect
central
nervou
system
cn
restrict
entri
cell
molecul
brain
cn
disord
multipl
sclerosi
ms
breakdown
bbb
allow
activ
leukocyt
infiltr
brain
parenchyma
lead
format
characterist
demyelin
lesion
interleukin
il
lymphocyt
appear
essenti
pathogenesi
numer
inflammatori
diseas
includ
ms
spite
intensifi
focu
lymphocyt
contribut
disrupt
bbb
leukocyt
infiltr
cn
import
earli
event
develop
ms
remain
unclear
develop
optim
method
success
gener
human
line
vitro
peripher
blood
memori
lymphocyt
healthi
donor
demonstr
respons
human
memori
lymphocyt
naiv
lymphocyt
produc
subset
cell
coexpress
ifngamma
show
disrupt
bbb
tight
junction
vitro
vivo
receptor
cytokin
upregul
human
endothelium
inflamm
moreov
human
cell
transmigr
effici
across
brain
endotheli
cell
via
adhes
molecul
alcam
promot
lymphocyt
recruit
across
bbb
concert
action
interestingli
also
note
increas
percentag
lymphocyt
well
subpopul
cell
coproduc
ifngamma
cell
line
expand
peripher
blood
women
activ
ms
gener
healthi
men
women
control
studi
refin
phenotyp
human
lymphocyt
emphas
import
lymphocyt
infiltr
cn
consequ
involv
lesion
format
ms
studi
examin
role
mogspecif
cell
microgli
activ
also
assess
abil
neuron
modul
microgli
activ
investig
possibl
role
ligandreceptor
interact
microgli
activ
assess
measur
cell
surfac
express
mhc
class
ii
flow
cytometri
product
proinflammatori
cytokin
tnfalpha
result
demonstr
cell
potent
activ
microgli
cell
upregul
cell
surfac
express
mhc
class
ii
induc
product
tnfalpha
b
b
neuron
attenu
cellinduc
product
tnfalpha
b
microglia
effect
mhc
class
ii
express
inhibitori
effect
neuron
cellinduc
proinflammatori
cytokin
product
microglia
revers
coincub
anti
receptor
antibodi
b
find
show
cell
potent
activ
microglia
activ
attenu
ligandreceptor
interact
neuron
microglia
experiment
autoimmun
encephalomyel
eae
well
known
anim
model
multipl
sclerosi
upon
activ
myelin
reactiv
cell
invad
central
nervou
system
cn
initi
diseas
remain
unknown
whether
myelin
reactiv
cell
may
also
infiltr
cn
diseas
recoveri
investig
whether
cn
still
suscept
infiltr
activ
prolifer
rest
myelin
reactiv
cell
recoveri
phase
eae
rest
myelin
reactiv
cell
obtain
isol
drain
lymph
node
immun
anim
follow
vitro
restimul
mbp
subsequ
cell
incub
h
rest
depriv
medium
h
flow
cytometr
analys
perform
character
rest
cell
time
transfer
cell
label
spio
cfse
intraven
inject
differ
stage
eae
h
h
post
transfer
either
mri
perform
cn
immun
organ
isol
analyz
express
cfse
flow
cytometr
analysi
show
rest
myelin
reactiv
tcell
gener
vitro
use
transfer
neg
low
transfer
recoveri
cell
could
detect
cn
soon
h
transfer
use
vivo
mri
remain
present
cn
least
day
flow
cytometr
analysi
show
transfer
cell
prolifer
cn
h
transfer
prolifer
cell
less
abund
peripheri
low
number
cell
cn
apoptot
necrot
amount
cell
death
much
higher
peripheri
compar
cn
final
transfer
rest
myelin
reactiv
cell
recoveri
phase
also
led
clinic
diseas
relaps
contrast
normal
monophas
diseas
cours
anim
result
show
clinic
recoveri
cn
eae
still
suscept
infiltr
inflammatori
activ
myelin
reactiv
cell
could
indic
immunoregul
myelin
reactiv
cell
recoveri
primarili
mediat
peripher
immun
organ
intraven
inject
cell
possibl
escap
control
direct
extravas
blood
exert
pathogen
function
cn
flow
cytometr
analysi
infiltr
immun
cell
inflamm
injuri
central
nervou
system
cn
offer
valuabl
insight
mechan
diseas
regener
due
limit
number
cell
isol
individu
anim
diseas
model
necessari
limit
character
small
number
marker
andor
pool
sever
sampl
establish
flow
cytometr
approach
allow
us
identifi
infiltr
immun
cell
type
differentiationmaturationstatu
four
stain
combin
marker
cell
nk
nk
cell
b
cell
macrophag
microglia
dendrit
cell
one
stain
give
us
opportun
dissect
subset
immun
cell
precis
way
addit
fluoresc
label
bead
use
quantifi
absolut
number
cell
popul
cn
experiment
autoimmun
encephalomyel
eae
could
show
even
onset
diseas
certain
cell
type
alreadi
infiltr
consider
amount
amplifi
onset
symptom
peak
maximum
diseas
score
relaps
immun
respons
constrict
composit
immun
cell
type
alter
substanti
compar
onset
diseas
use
marker
specif
cell
subset
naiveeffector
memori
cell
regulatori
cell
combin
intracellular
cytokin
stain
follow
transit
stage
cell
differenti
inflammatori
lesion
final
presenc
antigenpres
cell
apc
like
macrophag
dendrit
cell
subset
chang
matur
monitor
cours
diseas
protocol
also
success
appli
studi
braininfiltr
cell
mous
model
stroke
combin
flow
cytometri
data
histolog
analysi
context
diseas
cours
allow
well
defin
represent
mechan
involv
diseas
patholog
report
paradox
develop
spontan
experiment
autoimmun
encephalomyel
eae
myelin
oligodendrocyt
glycoprotein
mog
specif
cell
receptor
tcr
transgen
mice
absenc
target
autoantigen
show
anim
cell
crossreact
altern
selfmimick
autoantigen
neurofilamentm
nfm
transgen
strain
cell
express
transgen
tcr
recogn
mog
context
iab
mice
spontan
develop
eae
involv
optic
nerv
spinal
cord
report
proport
mice
come
spontan
eae
absenc
cognat
target
autoantigen
ie
mog
eae
mogsuffici
mog
mogdefici
mice
indistinguish
clinic
express
number
locat
lesion
cellular
composit
isol
protein
cn
materi
found
fraction
contain
predominantli
nfm
protein
induc
strong
prolif
activ
cell
salient
epitop
sequenc
share
mog
essenti
tcr
contact
residu
respons
cell
recombin
nfm
protein
synthet
peptid
heteroclit
regard
mog
result
higher
prolifer
activ
cytokin
product
appear
crossreact
mog
nfm
privat
respons
pattern
limit
tcr
also
note
oligoclon
mog
reactiv
cell
freshli
isol
prime
mice
first
report
immunolog
selfmimicri
involv
two
distinct
autoantigen
within
target
organ
neurodegener
import
featur
multipl
sclerosi
ms
underli
mechan
axon
loss
poorli
understood
investig
whether
twoporedomain
potassium
channel
contribut
neurodegener
experiment
autoimmun
encephalomyel
eae
use
knockout
mice
pharmacolog
approach
use
elisa
prolifer
assay
fac
analysi
electrophysiolog
measur
character
lymphocyt
knockout
mice
eae
induc
mog
peptid
wildtyp
mice
knockout
mice
neurodegener
measur
immunohistochem
stain
spinal
cord
section
magnet
reson
imag
mri
mous
brain
knockout
mice
show
dramat
amelior
eae
diseas
cours
shown
immunohistochem
stain
subsequ
count
axon
predefin
area
spinal
cord
knockout
mice
also
less
suscept
neurodegener
compar
wildtyp
mice
less
axon
loss
immun
system
knockout
mice
show
normal
phenotyp
endogen
cannabinoid
anandamid
known
block
fail
reduc
infgamma
product
prolifer
rate
isol
lymphocyt
knockout
mice
anandamid
also
show
effect
potassium
outward
current
lymphocyt
demonstr
electrophysiolog
measur
daili
applic
anandamid
wildtyp
mice
undergo
eae
reduc
diseas
sever
brain
atrophi
assess
repeat
mri
scan
individu
mice
less
atrophi
channel
member
twopor
domain
potassium
channel
famili
wide
express
within
brain
contribut
maintain
regul
rest
membran
potenti
variou
neuron
cell
type
efflux
k
ion
play
major
role
apoptot
cell
death
neuron
suggest
role
channel
neurodegener
occur
ms
modul
channel
may
provid
neuroprotect
potenti
therefor
studi
leak
potassium
channel
neuroinflammatori
disord
urgent
await
multipl
sclerosi
ms
diseas
suscept
tie
major
histocompat
complex
mhc
haplotyp
contain
allel
exhibit
almost
complet
linkag
disequilibrium
recent
studi
suggest
differenti
role
gene
pair
drive
modifi
autoimmun
character
specif
contribut
diseas
pathogenesi
human
transgen
tg
mice
carri
allel
creat
subsequ
cross
tg
mice
carri
ms
patientderiv
myelin
basic
protein
mbp
specif
cell
receptor
tcr
two
line
express
differ
level
show
differenti
skew
gener
versu
popul
rag
well
anim
mbpautoreact
cell
escap
delet
drive
spontan
autoimmun
low
rate
rag
anim
depend
level
express
inflammatori
infiltr
demyelin
associ
neuron
damag
present
throughout
spinal
cord
consist
classic
mbp
eae
diseas
addit
minor
involv
brainstem
peripher
nerv
root
spontan
well
activ
induc
diseas
posit
scan
combinatori
librari
pscl
demonstr
degeneraci
tcr
recognit
epitop
within
sever
bacteri
viral
human
protein
serv
molecular
mimic
vivo
studi
ongo
tcrhla
hla
transgen
mice
determin
patholog
relev
crossreact
relationship
antigen
spread
vivo
studi
emphas
patholog
contribut
allel
develop
autoreact
cell
express
sole
mhc
class
ii
molecul
defin
patholog
role
cn
autoimmun
multipl
sclerosi
ms
complex
diseas
one
common
chronic
inflammatori
disord
central
nervou
system
cn
model
commonli
use
dissect
gene
neuroinflamm
myelin
oligodendrocyt
glycoproteininduc
experiment
autoimmun
encephalomyel
mogea
mimic
human
diseas
larg
extent
chronic
pattern
histopatholog
lesion
genomewid
linkag
analysi
previous
perform
cross
eaesuscept
mhc
ident
eaeresist
rat
strain
identifi
quantit
trait
locu
qtl
rat
chromosom
regul
lpsinduc
product
proinflammatori
cytokin
name
tnf
use
congen
line
two
rat
strain
confirm
role
locu
regul
proinflammatori
cytokin
also
regul
mogea
finemap
region
perform
advanc
intercross
line
ail
influenc
eae
dissect
gener
ail
influenc
lpsinduc
tnf
product
pristaneinduc
arthriti
pia
dissect
initi
eae
qtl
resolv
two
loci
first
locu
regul
clinic
phenotyp
eae
overlap
two
qtl
regul
antimog
product
locu
mb
harbor
approxim
gene
includ
rgma
gene
play
role
spinal
cord
injuri
mice
second
locu
regul
eae
overlap
qtl
regul
pia
antimog
tnf
product
among
interest
gene
qtl
nfat
lat
particular
interest
due
involv
immun
regul
autoimmun
diseas
activ
tcell
function
studi
show
differenti
express
spleen
congen
parent
pvg
rat
thu
abl
defin
two
import
qtl
rat
affect
outcom
experiment
encephalomyel
arthriti
associ
regul
cytokin
product
associ
studi
perform
larg
materi
ms
patient
control
addit
function
studi
congen
rat
aim
defin
gene
pathogen
mechan
eae
ms
multipl
sclerosi
ms
sexual
dimorph
chronic
demyelin
autoimmun
diseas
central
nervou
system
result
disabl
paralysi
murin
model
ms
experiment
allerg
encephalomyel
eae
young
male
sjlj
mice
report
resist
eae
older
male
age
femal
suscept
compar
wide
age
rang
mice
immun
plp
cfa
found
femal
diseas
sever
remain
constant
age
contrast
eae
diseas
sever
increas
increas
age
immun
male
young
male
significantli
less
sever
eae
older
male
significantli
diseas
equival
age
femal
cumul
diseas
score
peak
sever
day
affect
sever
index
increas
age
immun
male
femal
incid
affect
age
sex
season
effect
sinc
castrat
young
sjlj
mice
restor
relaps
remit
eae
suscept
compar
test
gene
express
hormon
level
young
suscept
resist
sjlj
male
mice
serum
progesteron
level
remain
constant
sjlj
male
level
male
fluctuat
time
specif
serum
progesteron
significantli
lower
sjlj
mice
wk
converg
level
wk
time
frame
correl
previous
publish
chang
suscept
eae
delayedtyp
hypersensit
respons
microarray
analysi
wk
old
test
found
dehydrogenas
enzym
convert
pregnelon
progesteron
significantli
lower
sjlj
mice
compar
suggest
lower
serum
level
progesteron
due
reduc
progesteron
synthesi
test
verifi
progesteron
level
relat
eae
suscept
plan
implant
progesteron
pellet
induc
eae
placebo
pellet
implant
eae
induc
previou
sexual
dimorph
elimin
implant
sham
pellet
increas
eae
sever
equal
femal
eae
sever
nonimpl
male
significantli
less
sever
eae
suggest
stress
implant
abrog
sexual
dimorph
studi
show
age
season
stress
alter
eae
sexual
dimorph
sjlj
mice
illustr
import
genebyenviron
interact
eae
diseas
sever
suscept
male
wistar
rat
randomli
divid
group
normal
group
rat
eae
group
first
detect
function
morpholog
chang
brain
stem
auditori
evok
potenti
baep
somatosensori
evok
potenti
sep
routin
neuropatholog
method
immunohistochem
examin
second
analyz
mirna
express
use
mirna
express
microarray
third
oligonucleotid
microarray
carri
data
correl
publish
data
protein
gene
express
result
show
clinic
onset
eae
group
sudden
time
onset
averag
day
incid
rate
clinic
score
patholog
manifest
includ
signific
inflammatori
cell
infiltr
cerebrospin
tissu
format
vessel
glove
appar
amyelin
zone
myelin
stain
immunohistochem
examin
found
larg
number
activ
cell
brain
spinal
cord
compar
normal
group
piec
mirna
upregul
twice
piec
downregul
twice
addit
result
correl
relev
dna
microarray
data
mirna
control
express
gene
matrix
known
import
progress
ms
identifi
mirna
particip
posttranscript
gene
regul
pathophysiolog
eae
mirna
might
molecular
featur
becom
biomark
ms
relat
patholog
previous
shown
cell
autoreact
direct
epitop
second
extracellular
loop
myelin
proteolipid
protein
plp
correl
strongli
develop
brainstem
cerebellar
lesion
multipl
sclerosi
ms
patient
anim
model
ms
plp
present
throughout
compact
myelin
extern
face
myelin
membran
second
extracellular
loop
would
therefor
potenti
access
antibodi
current
studi
investig
put
function
properti
autoantibodi
direct
region
plp
role
play
lesion
local
elisa
patient
ms
n
found
increas
serum
level
antibodi
specif
myelin
proteolipid
protein
plp
compar
healthi
control
n
patient
disord
cn
cnd
patient
n
whole
human
plp
hplp
multipl
plp
peptid
test
consist
reactiv
direct
peptid
second
extracellular
loop
plp
antiplp
antibodi
ms
patient
usual
mixtur
igm
isotyp
occasion
wherea
major
control
sera
igm
isotyp
plpspecif
antibodi
also
test
abil
opson
myelin
phagocytosi
macrophag
sera
contain
high
titr
plp
peptidespecif
antibodi
preadsorb
plp
peptid
control
peptid
use
opson
assay
plp
peptid
could
specif
absorb
opson
activ
degre
sampl
test
posit
correl
abil
sera
opson
myelin
edss
score
ms
patient
antiplp
antibodi
test
abil
affect
lesion
develop
degre
demyelin
anim
model
plpspecif
cell
alon
inject
hej
mice
lesion
develop
brainstem
cerebellum
antibodi
inject
togeth
cell
result
lesion
brainstem
cerebellum
result
strongli
suggest
plpspecif
antibodi
could
function
relev
pathogenesi
ms
determin
frequenc
function
natur
killer
nk
cell
untreat
patient
multipl
sclerosi
background
nk
cell
multicompet
lymphocyt
innat
immun
system
whose
central
role
host
defens
immun
regul
autoimmun
increasingli
recogn
last
year
notabl
expans
nk
cell
correl
treatment
respons
daclizumab
treat
ms
patient
frequenc
phenotyp
expans
bloodderiv
nk
cell
cell
subset
investig
flow
cytometri
ex
vivo
follow
activ
classic
nk
cell
mitogen
interleukin
il
limit
concentr
monokin
untreat
patient
clinic
isol
syndrom
ci
relaps
remit
ms
compar
healthi
blood
donor
addit
determin
cytolyt
activ
rest
cytokineactiv
nk
cell
cytolyt
cell
toward
cell
line
cem
allogen
mitogenstimul
cell
blast
flow
cytometrybas
cytotoxoc
degranul
assay
ex
vivo
frequenc
nk
cell
cell
similar
patient
control
contrast
ms
patient
show
impair
expans
bright
nk
cell
cell
follow
stimul
express
level
activ
marker
hladr
consist
higher
nk
cell
subset
similar
cell
ms
patient
compar
healthi
control
rest
nk
cell
ms
patient
show
increas
cytolyt
activ
toward
cem
cell
primari
allogen
cell
blast
increas
upon
cytokin
activ
phenotyp
function
cell
alter
ms
increas
activ
cytolyt
potenti
toward
cell
impair
expans
suggest
nk
cell
involv
regul
antigendriven
autoimmun
ms
natalizumab
human
recombin
monoclon
antibodi
late
activ
approv
treatment
patient
multipl
sclerosi
ms
phase
ii
studi
fail
demonstr
differ
natalizumab
treatment
group
placebo
group
regard
gadolinium
enhanc
lesion
magnet
reson
imag
mri
three
month
discontinu
therapi
object
studi
assess
clinic
ms
diseas
activ
surrog
diseas
marker
mri
immunolog
paramet
peripher
blood
csf
well
safeti
ms
patient
discontinu
natalizumab
therapi
studi
longitudin
serial
crosssect
assess
patient
treat
natalizumab
context
two
phase
iii
clinic
trial
origin
enrol
subgroup
patient
follow
month
annual
relaps
rate
neurolog
diseas
progress
assess
expand
disabl
statu
scale
diseas
surrog
marker
magnet
reson
imag
mri
cellular
humor
immun
marker
peripher
blood
csf
advers
event
drug
monitor
regard
clinic
diseas
activ
neuroimag
immun
respons
major
patient
cohort
stabl
decreas
lymphocyt
cell
number
alter
cell
ratio
return
normal
month
cessat
natalizumab
infecti
complic
observ
first
longterm
followup
patient
discontinu
natalizumab
observ
clinic
radiograph
immunolog
rebound
phenomenon
discontinu
natalizumab
therapi
stoop
marcel
verbraak
jafari
naghmeh
van
meur
marjan
wierenga
annet
luider
laman
jon
hintzen
rogier
multipl
sclerosi
ms
complex
diseas
underli
mechan
remain
poorli
understood
systemat
comparison
differenti
occur
peptid
cerebrospin
fluid
csf
ms
patient
versu
refer
group
allow
identif
diseas
relat
secret
molecul
tissu
debri
therefor
perform
state
art
malditof
mass
spectrometri
larg
seri
csf
sampl
csf
closest
sourc
brain
secretori
product
tissu
debri
allow
identif
differenti
occur
peptid
ms
patient
select
control
group
one
peptid
sequenc
differenti
detect
clusterin
apolipoprotein
j
normal
adult
brain
one
major
clusterin
express
site
chronic
inflamm
injuri
brain
clusterin
express
increas
sever
function
ascrib
clusterin
ie
phagocyt
recruit
signal
cell
aggreg
complement
inhibit
lipid
transport
studi
aim
unravel
whether
clusterin
sequenc
found
csf
express
mrna
protein
level
within
ms
brain
tissu
quantit
pcr
use
analysi
clusterin
mrna
express
within
ms
brain
normal
appear
white
matter
nondement
control
brain
clusterin
mrna
express
significantli
increas
ms
brain
tissu
compar
brain
tissu
nondement
control
moreov
situ
analysi
show
elev
clusterin
protein
express
activ
preactiv
lesion
compar
nondement
control
preliminari
data
suggest
main
cell
express
clusterin
astrocyt
addit
cell
within
perivascular
infiltr
also
occasion
express
clusterin
collect
data
show
clusterin
activ
express
mrna
protein
level
ms
brain
result
support
hypothesi
clusterin
activ
involv
inflamm
ms
myelin
cell
reactiv
may
play
pathogen
role
ms
other
shown
regulatori
cell
treg
function
disturb
relapsingremit
rr
ms
patient
secondari
progress
sp
ms
patient
goal
current
studi
clarifi
differ
treg
activ
earli
chronic
diseas
stage
ms
studi
treg
function
homeostasi
ms
analyz
function
capac
homeostat
paramet
precursor
naiv
treg
ntreg
memori
treg
mtreg
also
measur
mbp
mog
prolif
respons
cell
includ
treg
naiv
memori
cell
treg
includ
rrand
spm
patient
hc
mean
cfse
dilut
assay
measur
cytokin
product
myelin
reactiv
cell
suppress
capac
facssort
ntreg
impair
earli
chronic
ms
patient
wherea
latter
group
show
restor
mtreg
function
chronic
ms
patient
increas
number
mtreg
compar
agematch
earli
ms
patient
wherea
ntreg
frequenc
differ
cell
receptor
excis
circl
trec
number
reduc
ntreg
earli
ms
patient
indic
diminish
ntreg
thymic
output
mbp
mog
prolif
respons
cell
tregdeplet
naiv
memori
cell
significantli
higher
rrm
patient
compar
hc
spm
patient
significantli
higher
proport
myelin
reactiv
memori
cell
ms
patient
compar
hc
produc
data
provid
evid
disturb
thymic
ntreg
develop
function
earli
ms
diseas
stage
may
play
role
peripher
activ
myelin
antigen
reactiv
cell
lead
cn
patholog
futur
therapeut
immun
intervent
ms
may
focu
earli
restor
treg
function
suppress
pathogen
myelin
reactiv
cell
inflam
bloodbrain
barrier
promot
recruit
effector
memori
lymphocyt
howev
phenotyp
migrat
lymphocyt
mechan
cell
cross
bbb
remain
larg
unknown
object
evalu
phenotyp
mechan
lymphocyt
access
cn
use
csf
obtain
ms
patient
spinal
cord
materi
mog
induc
eae
demonstr
lymphocyt
mostli
effector
memori
em
phenotyp
granzymebhi
show
purifi
human
tem
lymphocyt
transmigr
readili
across
human
bbb
endotheli
cell
ex
vivo
unfraction
lymphocyt
bbb
endothelium
promot
select
recruit
tem
lymphocyt
furthermor
provid
evid
activ
select
recruit
ifngand
lymphocyt
human
mous
bbb
endothelium
vitro
vivo
final
show
migrat
lymphocyt
across
bbbec
depend
independ
alcam
pselectin
studi
thu
provid
evid
activ
role
bbb
recruit
potenti
autoaggress
tem
lymphocyt
cn
small
kd
heat
shock
protein
induc
varieti
cell
follow
stress
inflamm
promot
cell
surviv
inhibit
inflamm
littl
known
local
phosphoryl
form
central
nervou
system
tissu
autoimmun
irradi
injuri
studi
examin
express
phosphoryl
form
spinal
cord
experiment
autoimmun
encephalomyel
eae
gamma
ray
irradi
western
blot
analysi
show
weakli
express
normal
spinal
cord
significantli
increas
spinal
cord
eae
p
b
immunohistochemistri
show
constitut
express
neuron
fibrou
astrocyt
spinal
cord
normal
rat
immunoreact
increas
primarili
fibrou
astrocyt
white
matter
eaeaffect
spinal
cord
similar
find
also
recogn
spinal
cord
irradi
howev
inflammatori
cell
eae
immunoposit
collect
postul
increas
phosphoryl
constitut
present
neuron
glial
cell
rescu
host
cell
includ
neuron
glial
cell
autoimmun
attack
radiat
induc
injuri
central
nervou
system
work
support
program
basic
atom
energi
research
institut
baeri
part
nuclear
r
program
fund
kosef
south
korea
import
neuropatholog
featur
multipl
sclerosi
ms
also
lesion
within
brain
format
astrogli
scar
firm
interact
astrocyt
extracellular
matrix
protein
like
involv
astrogliosi
inde
increas
appear
variou
extracellular
matrix
protein
fibronectin
lesion
site
ms
describ
sobel
mitchel
van
horssen
et
al
astrogliosi
repres
major
mechan
impedi
remyelin
axon
regener
ms
tissu
transglutaminas
multifunct
enzym
well
known
protein
crosslink
activ
cellular
level
implic
adhes
migrat
fibroblast
monocyt
cell
onto
extracellular
matrix
protein
includ
fibronectin
akimov
belkin
balklava
et
al
data
suggest
pivot
role
cellmatrix
interact
observ
present
astrocyt
activ
ms
lesion
question
whether
play
role
astrocytefibronectin
interact
vitro
end
intracellular
surfac
express
primari
cultur
rat
astrocyt
detect
addit
observ
inflammatori
mediat
present
cn
ms
patient
regul
product
astrocyt
inde
combin
enhanc
product
mrna
protein
primari
cultur
rat
glial
cell
particularli
astrocyt
contrast
surfac
express
downregul
particularli
tnfa
furthermor
adhes
astrocyt
onto
fibronectin
least
partli
mediat
determin
sirna
studi
pharmacolog
inhibit
activ
conclud
present
astrocyt
differenti
regul
inflammatori
mediat
suggest
cellular
pool
molecul
exist
probabl
separ
function
clearli
involv
interact
astrocyt
extracellular
matrix
protein
fibronectin
thu
contribut
astrogliosi
therebi
possibl
impair
regener
astrocyt
play
number
import
physiolog
role
central
nervou
system
cn
homeostasi
inflamm
stimul
astrocyt
secret
cytokin
chemokin
guid
macrophagesmicroglia
tcell
site
injuryinflamm
herein
describ
process
control
suppressor
cytokin
signal
soc
protein
famili
protein
neg
regul
adapt
innat
immun
respons
object
studi
determin
soc
express
regul
primari
astrocyt
function
implic
express
studi
describ
immunomodulatori
cytokin
induc
express
primari
astrocyt
transcript
level
transcript
activ
induc
ga
element
within
promot
studi
defici
astrocyt
indic
requir
express
sirna
studi
demonstr
express
reli
activ
specif
sirna
inhibit
astrocyt
enhanc
proinflammatori
respons
stimul
heighten
express
chemokin
rant
promot
chemotaxi
macrophag
tcell
result
indic
induc
primari
astrocyt
order
attenu
chemokinerel
inflamm
cn
soc
protein
may
serv
therapeut
target
attenu
unwant
inflammatori
respons
within
cn
microglia
infiltr
macrophag
consid
major
produc
tumor
necrosi
factor
tnf
play
key
role
ischem
tissu
injuri
brain
inflamm
report
tnf
produc
microglia
macrophag
neuroprotect
experiment
stroke
mice
found
cortic
infarct
significantli
exacerb
tnfknock
mice
compar
wildtyp
mice
bone
marrowchimer
tnfknock
mice
graft
wildtyp
bone
marrow
cell
develop
larger
infarct
bone
marrow
chimer
wildtyp
mice
graft
tnfknock
bone
marrow
cell
identifi
neuroprotect
role
microglialbut
macrophagederiv
tnf
increas
infarct
receptor
r
knock
mice
compar
wildtyp
mice
suggest
microglialderiv
tnf
exert
neuroprotect
effect
absenc
tnf
associ
reduc
microgli
popul
size
express
tolllik
receptor
unmanipul
brain
enhanc
proinflammatori
gene
express
unmanipul
ischem
brain
find
identifi
neuroprotect
role
microglialderiv
tnf
acut
phase
focal
cerebr
ischemia
suggest
microglia
determin
extent
endang
cortic
neuron
surviv
ischem
stroke
pathogenesi
neurogen
disord
includ
human
immunodefici
viru
hiv
associ
dementia
exacerb
imbal
metalloproteinas
mmp
inhibitor
tissu
inhibitor
metalloproteinas
timp
timp
exhibit
divers
nonclass
effect
includ
antiapoptot
effect
induct
neuroinflamm
like
serv
multipl
function
addit
modul
mmp
activ
publish
studi
demonstr
differenti
express
acut
versu
chronic
activ
astrocyt
brain
tissu
specif
laboratori
system
use
studi
mechan
regul
neuroprotect
effect
primari
human
neural
cell
neurotoxin
virusvir
protein
molecular
manipul
promoterluciferas
report
construct
use
result
indic
acut
interleukin
il
activ
upregul
multipl
mechan
chronic
downregul
primarili
transcript
control
show
novel
ccaat
displac
protein
cdp
repressor
element
involv
astrocyt
regul
use
staurosporin
macrophagetrop
viru
glutam
induc
cell
death
cultur
human
neuron
assay
equival
neuroprotect
effect
brainderiv
neurotroph
factor
bdnf
classic
neurotrophin
neuroprotect
effect
also
seen
mutant
mmp
bind
indic
neuroprotect
independ
mmp
neurotroph
signal
emerg
possibl
pathway
recent
studi
adenovir
inject
scid
mous
hive
model
led
astrocyt
express
suggest
potenti
therapeut
approach
taken
togeth
result
demonstr
regul
complex
may
play
critic
role
neuroprotect
function
astrocyt
data
import
unravel
mechan
underli
astrocyt
respons
chronic
neuroinflamm
broader
implic
inflammatori
diseas
involv
mmptimp
imbal
past
decad
mani
studi
focus
neuroinflamm
harm
featur
ad
implic
antiinflammatori
therapi
may
benefici
recent
immun
amyloid
betapeptid
abeta
propos
treatment
ad
experiment
model
shown
abeta
accumul
brain
key
featur
diseas
revers
immunotherapi
mediat
least
part
phagocytosi
microglia
coordin
collabor
clinic
neuropatholog
followup
patient
first
trial
activ
abeta
immun
full
length
peptid
elan
pharmaceut
date
neuropatholog
immun
ad
patient
iad
die
month
first
immun
dose
case
explor
express
microgli
protein
relat
plaqu
remov
compar
unimmun
ad
control
immunostain
observ
cerebr
cortex
iad
case
ad
control
indic
phagocyt
activ
group
howev
iad
case
show
abeta
within
lysosom
activ
microglia
indic
abeta
phagocytos
wherea
phagocyt
activ
ad
control
associ
abeta
within
microglia
suggest
microglia
qualit
differ
immun
observ
highlight
point
rather
simpli
demonstr
microglia
activ
specif
way
microglia
activ
import
determin
role
ad
patholog
extent
chang
activ
microglia
reflect
chang
cognit
function
remain
determin
howev
clinic
data
far
suggest
despit
clearanc
plaqu
activ
abeta
immun
benefit
cognit
function
stress
life
event
known
increas
risk
multipl
sclerosi
ms
exacerb
phenomenon
thought
caus
inadequ
level
antiinflammatori
hormon
cortisol
stress
cortisol
end
product
hypothalamuspituitaryadren
hpa
axi
also
known
stressaxi
routin
use
synthet
form
prednison
treat
relaps
ms
postmortem
vivo
studi
clearli
show
stressaxi
chronic
activ
ms
howev
postmortem
studi
ms
brain
donor
recent
found
highli
signific
invers
relationship
respons
stressaxi
sever
ms
huitinga
et
al
ann
neurol
therefor
perform
followup
studi
femal
ms
brain
donor
specif
determin
consequ
stressaxi
activ
sever
ms
clinic
endocrin
neuropatholog
data
includ
ms
brain
donor
analyz
use
statist
softwar
clearli
confirm
earlier
data
moreov
level
tau
glutam
cerebrospin
fluid
csf
correl
amount
corticotropin
releas
hormon
crh
drive
stressaxi
furthermor
analysi
neuropatholog
report
reveal
increas
demyelin
decreas
remyelin
present
donor
low
cortisol
sever
ms
result
emphas
import
high
cortisol
level
overcom
ms
inflamm
phenomenon
observ
pioneer
anim
studi
earli
nineti
tonelli
et
al
immunol
rev
observ
correl
tau
glutam
csf
level
crh
suggest
neurodegener
contribut
chronic
activ
stressaxi
ms
base
data
postul
low
stressaxi
respons
possibl
consequ
genet
predisposit
lead
sever
ms
current
perform
studi
ms
lesion
obtain
netherland
brain
bank
identifi
glucocorticoid
driven
mechan
affect
pathogenesi
ms
lesion
use
immunohistochemistri
laser
dissect
microscopi
combin
qpcr
analysi
kone
et
al
ann
neurol
number
immunolog
function
depend
circadian
rhythm
regular
sleep
impact
type
magnitud
immun
respons
follow
antigen
challeng
exampl
vaccin
littl
known
underli
mechan
one
possibl
could
circadian
sleepdepend
modul
immun
respons
natur
regulatori
cell
ntreg
cell
shown
varieti
studi
neg
regul
adapt
immun
respons
could
show
normal
sleep
suppress
activ
ntreg
highest
night
almost
suppress
activ
present
morn
depriv
sleep
abrog
rhythm
studi
whether
ntreg
suppress
helper
cytokin
extent
suppress
modifi
sleep
circadian
rhythm
withinsubject
crossov
design
six
healthi
young
men
examin
defin
condit
two
occas
ie
sleep
sleep
depriv
venou
blood
drawn
period
everi
h
ntreg
function
explor
vitro
ntreg
suppress
helper
cytokin
product
almost
suppress
helper
cytokin
product
sleep
wake
condit
wake
condit
suppress
helper
cytokin
product
decreas
afternoon
respons
ntreg
function
rhythm
might
sleep
depend
hormon
prolactin
preliminari
vitro
experi
could
show
prolactin
increas
ntreg
suppress
function
studi
show
ntreg
suppress
helper
cytokin
product
suppress
disturb
sleep
depriv
henc
ntreg
contribut
sleepdepend
modul
immun
respons
although
classic
regard
disord
white
matter
alter
neuron
compart
central
nervou
system
cn
precoci
larg
independ
demyelin
multipl
sclerosi
ms
glutam
excitotox
propos
major
determin
neurodegener
ms
experiment
ms
howev
physiolog
studi
address
synapt
transmiss
immunomedi
aggress
central
myelin
still
lack
mean
neurophysiolog
record
singl
neuron
slice
investig
neuron
synapt
function
major
oligodendrocyt
glycoprotein
mog
induc
experiment
autoimmun
encephalomyel
eae
preclin
model
ms
striatal
neuron
particularli
prone
degener
ms
exhibit
complex
dynam
alter
glutamateand
gabamedi
transmiss
start
presymptomat
phase
diseas
evolv
independ
inflammatori
infiltr
demyelin
axon
injuri
chang
activ
nmda
nonnmda
glutam
receptor
naca
exchang
voltagedepend
na
channel
contribut
upregul
excitatori
input
striatal
neuron
gabamedi
transmiss
persist
downregul
data
reveal
import
role
synapt
dysfunct
patholog
process
eae
provid
rational
use
neuroprotect
strategi
sinc
earli
stage
ms
found
experiment
autoimmun
encephalomyel
eae
mg
cell
specif
accumul
dorsal
svz
nich
start
preclin
stage
blood
deriv
mgmacrophag
resid
mg
cell
infiltr
dorsal
svz
initi
secret
ifngamma
tnfalpha
moreov
overexpress
either
ifngamma
tnfalpha
ependym
cell
suffici
direct
mobil
mg
cell
toward
svz
find
prompt
us
defin
crosstalk
inflammatori
cue
resid
anpc
thu
use
laser
captur
microdissect
lcm
found
overexpress
subset
chemokin
within
eae
svz
moreov
ifngamma
tnfalpha
vitro
stimul
induc
anpc
overexpress
abovement
chemokin
thu
suggest
anpc
capabl
chemoattract
blood
deriv
cell
inflamm
constitut
chemokin
express
anpc
make
neurogen
nich
preferenti
site
inflammatori
cell
extravas
thu
impair
physiolog
function
might
explain
preferenti
affect
periventricular
area
neuroinflamm
crucial
role
cytokin
shape
cell
respons
document
numer
autoimmun
diseas
recent
describ
cytokin
shown
exhibit
proand
antiinflammatori
properti
favor
cell
differenti
cell
detriment
differenti
absenc
receptor
mice
enhanc
suscept
experiment
autoimmun
encephalomyel
eae
due
absenc
inhibitori
signal
develop
convers
demonstr
promot
ctl
function
mous
cell
inform
human
cell
exist
moreov
human
cn
sourc
identifi
goal
investig
impact
human
cell
function
determin
potenti
human
cn
sourc
cell
healthi
donor
shortli
stimul
vitro
analyz
use
flow
cytometrybas
assay
addit
activ
cell
led
signific
dosedepend
increas
prolifer
ifngamma
granzym
b
product
less
impact
human
cell
significantli
boost
prolifer
express
subunit
assess
realtim
pcr
rest
human
adult
microglia
express
lowundetect
basal
level
mrna
stimul
ligand
significantli
induc
moder
boost
mrna
level
suggest
local
antigen
present
cell
could
produc
within
cn
upon
environment
stimuli
result
underscor
proinflammatori
impact
human
cell
show
cytokin
could
local
provid
cn
human
microglia
current
investig
cell
ms
patient
react
stimul
burden
affect
peopl
worldwid
sever
evid
indic
abnorm
dopamin
system
scz
bpd
neuron
calcium
sensor
protein
mani
function
dopamin
receptor
desensit
inhibit
involv
mani
aspect
neurotransmiss
regul
ionic
channel
neurotransmitt
releas
enhanc
exocytos
also
protein
mrna
express
level
found
increas
prefront
cortex
pfc
scz
bpd
patient
well
document
express
neural
neuroendocrin
cell
recent
shown
also
express
mast
cell
neutrophil
import
function
mast
cell
stimul
fc
epsilon
ritrigg
exocytos
releas
arachidon
acid
metabolit
sought
investig
whether
could
express
peripher
blood
mononuclear
cell
pbmc
correspond
express
cell
level
pfc
scz
bpd
subject
use
flow
cytometri
result
shown
express
diminish
lymphocyt
b
lymphocyt
monocyt
bpd
patient
also
decreas
lymphocyt
nk
cell
scz
patient
result
show
correl
express
pfc
pbmc
scz
bpd
patient
howev
result
show
might
put
biomark
psychiatr
disord
work
necessari
investig
function
lymphocyt
monocyt
financi
support
cnpq
fapemig
thymectomi
first
report
treatment
nonthymomat
myasthenia
gravi
mg
howev
indic
use
thymectomi
popul
base
random
trial
data
lack
last
year
corticosteroid
pharmacolog
immunotherapi
use
increasingli
mg
either
alon
thymectomi
time
period
outcom
mg
improv
dramat
whether
thymectomi
contribut
posit
develop
remain
point
content
recent
data
reviewedth
mgtx
studi
group
receiv
fund
nind
singleblind
twoarm
trial
approxim
center
particip
worldwid
intent
enrol
gener
mg
subject
primari
studi
aim
answer
three
question
extend
transstern
thymectomi
ettx
combin
strictli
defin
prednison
protocol
compar
prednison
protocol
alon
result
greater
improv
myasthen
weak
result
lower
total
dose
prednison
thu
decreas
likelihood
concurr
longterm
toxic
effect
enhanc
qualiti
life
reduc
advers
event
symptom
associ
therapi
inclus
criteria
mg
foundat
america
class
acetylcholin
receptor
antibodi
posit
age
least
year
year
diseas
durat
year
patient
prednison
recruit
studi
commenc
late
divers
regulatori
obstacl
encount
due
intern
natur
trial
averag
time
site
satisfi
local
us
feder
regul
month
juli
center
readi
enrol
screen
mg
patient
encount
total
mg
patient
screen
vast
major
inelig
fiftyon
patient
enrol
pace
recruit
increas
addit
site
variou
stage
regulatori
approv
entri
criteria
modifi
slightli
favor
inclusionincreas
upper
age
limit
year
diseas
durat
year
result
favor
thymectomi
would
establish
benefit
unequivoc
failur
show
differ
would
suggest
thymectomi
unnecessari
procedur
nonthymomat
popul
lead
cost
save
thu
result
impact
clinic
practic
transcript
correl
presenc
number
altern
aamph
ino
transcript
protein
express
pronounc
wt
mice
absent
mice
data
provid
first
evid
develop
aamph
cn
infecti
diseas
model
highlight
essenti
role
immunopatholog
c
neoforman
meningoenceph
agraw
yong
wee
univers
calgari
calgari
canada
mmp
member
implic
detriment
role
neuroinflammatori
diseas
multipl
sclerosi
ms
howev
fact
mmp
famili
member
interact
compens
may
even
inhibit
made
biolog
mmp
ms
difficult
one
examin
sever
mmp
member
simultan
elev
ms
eae
anim
model
ms
thought
result
activ
mani
cell
type
condit
anoth
possibl
gener
induc
sever
mmp
engag
diseas
process
novel
approach
affect
mmp
ms
could
alter
activ
induc
extracellular
matrix
metalloproteinas
induc
emmprin
also
known
basigin
found
surfac
variou
cell
type
inact
state
emmprin
induc
fibroblast
tumor
cell
produc
activ
variou
mmp
whether
emmprin
play
similar
role
immun
system
unclear
specif
object
determin
role
extracellular
matrix
metalloproteinas
emmprin
mmp
regul
mous
eae
util
mous
model
eae
wherein
anim
develop
clinic
diseas
infiltr
leukocyt
cn
result
demyelin
variou
tissu
mice
dissect
util
flow
cytometri
fac
histolog
stain
western
blot
gelatin
zymographi
report
activ
specif
tcell
cultur
lead
secret
high
level
glycosyl
emmprin
vivo
find
increas
number
emmprin
posit
cell
cn
mice
onset
eae
sign
compar
control
continu
rise
diseas
progress
emmprin
immunoreact
detect
cn
infiltr
resid
cellular
popul
final
emmprin
null
mice
although
suscept
eae
show
slightli
delay
onset
reduc
sever
eae
diseas
versu
wildtyp
control
taken
togeth
result
indic
earli
rise
emmprin
consist
subsequ
evolv
patholog
eae
may
attribut
role
mmp
induc
diseas
target
emmprin
could
help
influenc
mark
elev
mmp
diseas
process
ms
cytotox
lymphocyt
ctl
consid
import
effector
cell
contribut
cn
damag
neuroinflammatori
disord
challeng
mechan
cell
injur
neuron
major
histocompat
complex
mhc
class
restrict
cellcontactdepend
interact
ctl
neuron
cell
determin
specif
emphasi
place
interdepend
perforin
granzym
b
immuneneuron
interact
use
hippocamp
neuron
cell
combin
tcell
receptor
tcr
transgen
cell
oti
paradigm
mhc
class
restrict
immuneneuron
interact
cocultur
analyz
timelaps
videomicroscopi
twophoton
microscopi
conjunct
immunohistochemistri
electrophysiolog
record
molecularbiolog
assay
timelaps
videomicroscopi
show
ctl
kill
neuron
fast
depend
cellcel
contact
well
antigen
appr
h
realtim
electrophysiolog
record
basal
neuron
paramet
upon
direct
contact
effector
cell
reveal
immedi
chang
membran
capacit
resist
appr
decreas
min
similar
kinet
mhc
restrict
neuron
show
rapid
influx
upon
ctl
interact
assum
observ
effect
like
reflect
consequ
tcrdepend
poreform
via
granzymeperforin
pathway
next
studi
effect
oti
cell
defici
granzym
b
perforin
interestingli
quantif
neuron
kill
reveal
ctl
defici
granzym
b
perforin
maintain
neurotox
albeit
migratori
veloc
significantli
slow
absenc
granzym
b
singlecel
record
howev
show
perforin
defici
cell
lost
capabl
induc
neuron
membran
chang
influx
immedi
effect
maintain
absenc
granzym
b
ctlmediat
injuri
mhc
class
induc
neuron
cell
fast
antigen
cellcel
contact
depend
process
effector
cell
immedi
affect
basal
cellular
paramet
induc
influx
mhc
restrict
way
acut
electrophysiolog
consequ
immuneneuron
interact
requir
perforin
perforin
granzym
b
redund
longterm
neurotox
fleisherberkovich
benshmuel
sarit
bengurion
univers
beersheva
israel
increas
evid
suggest
inflamm
play
crucial
role
deterior
neurodegen
diseas
inflammatori
respons
sustain
chronic
microgli
activ
includ
overproduct
toxic
factor
microgli
cell
proinflammatori
cytokin
prostaglandin
nitric
oxid
although
mani
physiolog
role
turn
harm
produc
high
level
inflammatori
condit
lead
apoptosi
brain
inflamm
regul
neuropeptid
bradykinin
bk
member
kinin
famili
group
shortliv
peptid
form
respons
pathophysiolog
event
like
inflamm
bk
exert
effect
via
two
kinin
receptor
receptor
gprotein
coupl
receptor
receptor
constitut
express
variou
cell
receptor
induc
cell
activ
proinflammatori
factor
although
bk
proinflammatori
function
peripheri
broadli
studi
role
brain
yet
clear
recent
novel
neuroprotect
role
bk
suggest
via
inhibit
lipopolysaccharid
lp
induc
releas
proinflammatori
cytokin
microgli
cell
goal
present
studi
examin
long
term
effect
bk
receptor
agonist
basal
lpsinduc
releas
microgli
cell
nitrit
stabl
endproduct
oxid
level
measur
use
griess
assay
h
exposur
bk
nm
reduc
basal
releas
nm
respect
bk
decreas
product
control
level
receptor
agonist
bk
nm
lead
reduct
synthesi
receptor
agonist
nm
reduc
basal
releas
also
bk
nm
attenu
lpsinduc
product
dosedepend
manner
maximum
decreas
concentr
nm
compar
lp
treatment
alon
similarli
receptor
agonist
dosedepend
attenu
lpsinduc
product
maximum
respect
result
impli
possibl
neuroprotect
role
bk
via
attenu
releas
microgli
cell
basal
inflammatori
condit
lindblom
piehl
fredrik
diez
margarita
karolinska
institutet
stockholm
sweden
complement
system
implic
sever
neurodegen
disord
inflammatori
compon
eg
multipl
sclerosi
ms
alzheim
huntington
amyotroph
later
sclerosi
al
experiment
system
neuron
proven
extrem
sensit
lysi
activ
complement
far
degre
genet
heterogen
regul
complement
system
unknown
character
express
complement
compon
differ
rat
strain
mechan
nerv
injuri
injuri
model
use
lumbar
ventral
root
avuls
vra
well
character
model
nerv
injuryinduc
inflamm
neurodegener
kinet
studi
perform
inbr
da
pvg
rat
use
sever
postop
surviv
time
day
linkag
studi
perform
bn
lew
intercross
anim
studi
day
vra
quantit
rtpcr
immunohistochemistri
use
determin
level
express
well
complement
inhibitor
clusterin
kinet
studi
demonstr
increas
express
earli
vra
significantli
higher
level
da
compar
pvg
clusterin
mrna
also
increas
injuri
induct
slower
highest
express
day
injuri
strain
contrast
express
reduc
vra
wherea
level
normal
pvg
day
level
da
rat
remain
lower
studi
time
point
whole
genom
scan
express
perform
bn
lew
intercross
show
linkag
sever
gene
region
one
quantit
trait
locu
qtl
regul
chr
reach
threshold
genomewid
signific
da
strain
suscept
nerv
cell
loss
pvg
display
higher
level
lower
level
support
notion
dysregul
local
inflammatori
respons
involv
complement
activ
contribut
nerv
cell
loss
gene
map
cross
demonstr
polygen
influenc
sever
suggest
qtl
larg
da
pvg
intercross
current
studi
laboratori
exact
posit
respons
gene
contribut
knowledg
role
complement
system
condit
neuroinflamm
neurodegener
microglialdriven
inflamm
featur
age
brain
neurodegen
condit
inflammatori
chang
typifi
cytokin
releas
tumour
necrosi
factor
alpha
tnfalpha
upregul
correspond
signal
pathway
previou
evid
laboratori
shown
rosiglitazon
peroxisom
prolifer
activ
receptor
gamma
pparg
agonist
abil
attenu
proinflammatori
cytokin
releas
restor
age
relat
deficit
ltp
present
find
suggest
pretreat
rosiglitazon
affect
pparg
activ
sinc
mrna
express
downstream
indic
activ
unchang
rosiglitazon
also
exert
effect
pparg
protein
express
find
concur
previou
evid
suggest
antiinflammatori
action
rosiglitazon
independ
pparg
previou
evid
laboratori
shown
antiinflammatori
action
rosiglitazon
mediat
abil
increas
express
studi
effect
rosiglitazon
mix
glia
astrocyt
microglia
mimick
pretreat
studi
also
show
rosiglitazon
treatment
induc
increas
astrocyt
p
b
microglia
evid
suggest
rosiglitazon
attenu
lpsinduc
increas
via
releas
astrocyt
mani
neurodegen
disord
character
microglia
activ
respons
must
tightli
regul
unrestrain
activ
gener
chronic
inflammatori
milieu
might
lead
autoimmun
extracellular
adenosin
modul
cellular
activ
gprotein
coupl
adenosin
receptor
adora
mediat
signal
cellular
respons
extracellular
adenosin
orchestr
express
pattern
four
differ
adora
subtyp
character
capac
enhanc
inhibit
camp
level
studi
effect
adenosin
neuroinflamm
character
adora
express
profil
rest
tolllik
receptor
tlr
primari
rhesu
microglia
rest
microglia
express
mrna
upon
activ
microglia
strongli
upregul
downregul
express
level
sinc
signal
result
opposit
effect
signal
predict
rel
contribut
adenosinemedi
signal
would
enhanc
fold
tlractiv
microglia
consequ
adenosinemedi
inhibit
tlrinduc
tnfa
much
potent
inhibit
activ
rest
microglia
could
demonstr
sensit
adenosinemedi
inhibit
well
overal
inhibitori
potenti
enhanc
activ
microglia
microglia
acquir
enhanc
inhibitori
phenotyp
h
upon
tlrmediat
activ
enhanc
inhibitori
potenti
sustain
h
use
specif
antagonist
determin
simultan
increas
mediat
signal
decreas
signal
respons
describ
effect
addit
demonstr
induc
adora
profil
activ
microglia
abl
crossinhibit
cytokin
product
induc
varieti
tlr
data
reveal
import
novel
mechanist
aspect
endogen
brake
inflamm
would
suggest
explor
partial
agonist
antagonist
therapeut
possibl
dampen
microgli
activ
ongo
inflamm
microrna
form
famili
sever
hundr
short
noncod
rna
molecul
predict
regul
express
proteincod
gene
mirnamedi
gene
regul
therefor
expect
influenc
pathogenesi
mani
diseas
order
studi
form
gene
regul
multipl
sclerosi
lesion
follow
twostep
strategi
first
step
isol
ms
lesion
differ
type
along
control
white
matter
macrodissect
fix
frozen
brain
section
total
rna
extract
sampl
amplifi
realtim
pcr
among
examin
microrna
could
detect
form
lesion
specif
express
profil
second
step
combin
laser
captur
microdissect
individu
cell
analysi
purifi
cultur
immun
cell
subset
astrocyt
assign
microrna
regul
ms
lesion
specif
cell
lineag
data
indic
microrna
upregul
ms
lesion
induc
vitro
activ
cell
monocytesmacrophag
astrocyt
work
provid
first
insight
mirna
mediat
gene
regul
multipl
sclerosi
lesion
studi
two
main
part
first
number
treg
cell
identifi
cell
determin
use
flow
cytometri
examin
csf
blood
sampl
obtain
patient
acut
viral
mening
enceph
n
experienc
acut
relaps
ms
n
well
patient
noninflammatori
neurolog
diseas
use
control
n
treg
cell
significantli
increas
blood
ms
patient
compar
cn
infect
control
csf
also
significantli
increas
patient
cn
infect
compar
control
increas
trend
seen
csf
activ
ms
patient
next
number
treg
cell
identifi
cell
recent
activ
helper
cell
surfac
phenotyp
determin
csf
blood
sampl
obtain
anoth
seri
ms
patient
acut
relaps
well
control
recent
activ
helper
cell
shown
significantli
increas
blood
ms
patient
addit
followup
studi
patient
tubercul
mening
show
treg
cell
blood
increas
improv
infect
csf
increas
earli
peak
stage
diseas
treg
cell
cn
system
circul
patient
cn
infect
seem
regulatori
role
thu
measur
use
monitor
diseas
statu
contrast
number
may
relev
monitor
ms
diseas
activ
well
establish
neurodegen
disord
associ
evid
microglialdriven
inflamm
inflammatori
chang
includ
enhanc
activ
microgli
cell
proinflammatori
cytokin
releas
recent
data
show
activ
orphan
receptor
singl
ig
molecul
sigirr
inhibit
proinflammatori
cytokin
signal
ligand
sigirr
downstream
signal
event
trigger
receptor
activ
unknown
studi
set
investig
effect
lipopolysaccharid
lp
microgli
activ
cytokin
secret
hippocamp
tissu
prepar
sigirr
knockout
mice
also
assess
whether
recentlycharacteris
member
ligand
superfamili
antiinflammatori
properti
might
modul
lpsinduc
chang
microgli
activ
assess
measur
cell
surfac
express
intracellular
adhes
molecul
icam
polymeras
chain
reaction
pcr
proinflammatori
cytokin
tnfalpha
pcr
elisa
interact
sigirr
assess
immunofluoresc
confoc
microscopi
result
demonstr
lpsinduc
increas
express
p
b
icam
p
b
p
b
p
b
tnfalpha
p
b
mrna
enhanc
mice
compar
wildtyp
mice
attenu
lpsinduc
increas
p
b
wildtyp
mice
antagonist
effect
observ
mice
find
show
sigirr
antiinflammatori
action
cn
sinc
mice
show
enhanc
respons
lp
treatment
furthermor
possibl
ligand
sigirr
sinc
antagonist
effect
lpsinduc
signal
observ
mice
colocalis
sigirr
taken
togeth
data
suggest
interact
sigirr
signific
immunomodulatori
system
cn
despit
advanc
antibiot
manag
acut
bacteri
mening
remain
life
threaten
neurolog
diseas
manag
rapidli
estim
incid
per
peopl
per
year
develop
countri
ten
time
develop
region
cellular
immun
respons
cn
play
major
role
control
infect
studi
cytokin
protect
harm
role
may
play
cn
poorli
understood
glial
cell
main
immun
cell
cn
known
releas
cytokin
immun
mediat
form
network
stimulatori
inhibitori
effect
time
dose
depend
releas
cytokin
microglia
astrocyt
neuron
mix
cultur
test
cell
type
follow
pneumococc
infect
cell
cultur
infect
clinic
isol
streptococcu
pneumonia
first
isol
csf
second
oropharynx
cytokin
releas
cultur
supernat
measur
variou
time
point
use
commerci
avail
bioplex
assay
mix
cultur
show
control
releas
cytokin
comparison
pure
microgli
cultur
contrast
find
previou
studi
infect
pure
microgli
astrocyt
neuron
cultur
found
activ
produc
cytokin
infect
cultur
show
signific
increas
cytokin
releas
compar
uninfect
cultur
neurolog
isol
induc
backward
dose
effect
lower
cytokin
level
produc
higher
concentr
organ
effect
seen
orophanyng
isol
could
revers
heat
inactiv
infect
inoculum
find
demonstr
time
dose
depend
profil
cytokin
product
cn
respons
pneumococc
infect
may
import
understand
neurolog
pathogenesi
pneumococc
infect
differenti
primari
adult
microglia
alter
respons
activ
capac
apc
show
although
cell
morpholog
express
level
activ
marker
markedli
differ
differenti
either
factor
yield
microglia
phenotyp
function
resembl
macrophag
mcsf
gmcsfdifferenti
microglia
respons
activ
activ
intriguingli
mcsfdifferenti
microglia
express
higher
level
mrna
protein
produc
larger
amount
proinflammatori
cytokin
respons
activ
compar
gmcsfdifferenti
microglia
differenti
adult
microglia
growth
factor
produc
endogen
central
nervou
system
thu
unlik
chang
apc
function
alter
innat
respons
infecti
stimuli
ssrna
virus
resid
primat
microglia
may
therebi
help
shape
rather
initi
adapt
immun
respons
immunoregulatori
role
perforin
anim
model
cellmedi
demyelin
diseas
accumul
evid
indic
cell
may
contribut
significantli
diseas
pathogenesi
multipl
sclerosi
autoimmun
diseas
nervou
tissu
gain
insight
potenti
mechan
cell
subset
may
induc
nervou
tissu
injuri
studi
anim
model
herein
refer
mice
spontan
develop
cellmedi
demyelin
diseas
associ
axon
damag
primarili
due
transgen
express
cell
costimulatori
ligand
microglia
previous
report
cell
accumul
central
nervou
system
cn
mice
potent
ifngamma
produc
respons
cytokin
prerequisit
diseas
develop
sinc
ifngamma
power
induc
mhci
express
common
mechan
cell
mediat
destruct
mhc
iexpress
cell
perforin
pathway
hypothes
ifngamma
product
cn
cell
promot
upregul
mhci
express
neuron
andor
oligodendrocyt
could
becom
target
mhcirestrict
perforindepend
cellmedi
cytotox
attack
mhci
express
detect
oligodendrocyt
neuron
preclin
anim
cell
observ
close
contact
mhc
iexpress
oligodendrocyt
mice
defici
perforin
express
exhibit
clinic
patholog
featur
perforin
compet
anim
acceler
onset
hasten
expansionaccumul
cell
cn
could
nt
attribut
dispar
peripher
cell
popul
result
indic
oligodendrocyt
potenti
interact
cn
cell
mhcidepend
fashion
clinic
manifest
diseas
demyelin
occur
perforindepend
mechan
perforin
appear
rather
regul
expans
cell
within
cn
diabet
ketoacidosi
mice
elicit
uniqu
cytokin
respons
serum
brain
diabet
keotacidosi
dka
complic
type
diabet
requir
immedi
recognit
treatment
despit
care
treatment
children
high
risk
intracrani
complic
dka
therapi
brain
swell
stroke
bleed
caus
complic
unknown
howev
dka
elicit
system
inflammatori
respons
associ
elev
cytokin
therefor
system
local
product
cytokin
cn
might
contribut
neuroinflamm
varieti
mechan
sought
determin
level
cytokin
serum
brain
tissu
dka
use
juvenil
mous
model
dka
develop
dka
h
inject
streptozocin
alloxan
serum
cortex
sampl
obtain
control
dka
mice
quantit
analys
cytokin
interleukin
il
keratinocytederiv
chemokin
kc
mous
ortholog
human
interferon
ifn
g
tumor
necrosi
factor
tnf
use
multiplex
immunoassay
transform
growth
factor
tgf
level
analys
elisa
mice
confirm
dka
significantli
higher
serum
glucos
betaohbutyr
level
weight
loss
compar
control
p
b
n
analysi
serum
reveal
dka
mice
significantli
elev
level
proinflammatori
cytokin
kc
p
b
n
antiinflammatori
cytokin
p
b
n
p
b
n
versu
control
contrast
antiinflammatori
cytokin
significantli
alter
brain
decreas
p
b
n
dka
mice
increas
p
b
n
signific
differ
level
proinflammatori
cytokin
p
n
kc
p
n
dka
mice
versu
control
also
found
kc
level
serum
correl
weight
lost
dka
mice
p
b
n
blood
glucos
level
p
b
n
result
novel
sinc
inflammatori
respons
occur
brain
uniqu
system
respons
differenti
chang
inflamm
serum
brain
might
contribut
factor
intracrani
complic
dka
also
indic
mayb
relationship
level
proinflammatori
cytokin
sever
dka
panatec
tuebingen
germani
autoimmun
central
nervou
system
cn
inflamm
found
multipl
sclerosi
ms
experiment
autoimmun
encephalomyel
eae
requir
activ
myelin
reactiv
cell
peripheri
insid
target
organ
antigen
present
cell
apc
microglia
cn
resid
apc
shown
present
cryptic
epitop
myelin
basic
protein
mbp
insid
cn
lesion
ms
patient
order
better
understand
event
lead
gener
display
epitop
investig
antigen
process
machineri
mbp
process
acut
eae
differ
apc
popul
isol
suscept
da
resist
aci
rat
immun
onset
diseas
da
rat
cathepsin
activ
determin
use
activ
site
direct
probe
addit
human
recombin
mbp
digest
lysosom
content
microglia
splenic
b
cell
splenic
dc
fragment
analys
found
mbp
process
microglia
rat
strain
domin
cathepsin
destroy
main
immunogen
epitop
process
strain
similar
peripheri
cn
mbp
effici
destroy
cell
type
investig
obviou
differ
two
strain
suggest
differ
process
account
differ
suscept
mous
microglia
cultur
catg
proteas
domin
mbp
process
rat
primari
microglia
catd
limit
present
epitop
acut
eae
highlight
need
caution
translat
knowledg
antigen
process
one
speci
anoth
orian
natalia
popa
lucil
gioda
jose
boucraut
studi
model
olfactori
axotomi
recruit
nk
cell
express
mhcia
b
ligand
includ
main
olfactori
bulb
mob
first
relay
olfactori
sensori
pathway
mob
receiv
affer
olfactori
mucosa
target
neural
progenitor
cell
gener
subventricular
zone
svz
migrat
along
rostral
migratori
stream
rm
sensori
deafferent
mob
axotomi
olfactori
receptor
neuron
induc
retrograd
neuron
cell
death
mucosa
increas
apoptot
cell
death
svz
along
rostrocaud
extent
rm
parallel
increas
cell
prolifer
svz
extens
rm
locat
mob
preced
full
neuron
repair
appear
use
qpcr
observ
express
olfactori
bulb
nk
specif
receptor
level
express
similar
observ
hepat
tissu
recruit
immun
cell
axotomi
confirm
techniqu
flow
cytometri
immunolabel
polyclon
antisera
experi
detect
recruit
immun
cell
svz
weak
express
detect
qpcr
sole
part
normal
brain
express
strongli
induc
mob
axotomi
show
first
time
recruit
immun
cell
includ
nk
cell
model
olfactori
axotomi
deciph
role
vivo
nk
cell
neuron
death
neuron
repair
main
object
mice
shown
blockad
lead
earlier
onset
increas
sever
diseas
although
ligand
observ
infiltr
immun
cn
cell
eae
cell
type
express
molecul
complet
resolv
data
avail
human
cn
goal
assess
express
pdl
human
cn
cell
establish
whether
molecul
could
local
contribut
modul
immun
respons
human
primari
cn
cultur
either
kept
basal
condit
stimul
proinflammatori
cytokin
respect
mimick
healthi
vs
ms
cn
environ
express
analyz
realtim
pcr
flow
cytometri
human
primari
cultur
astrocyt
oligodendrocyt
brain
endotheli
cell
express
bare
detect
level
mrna
protein
level
follow
proinflammatori
cytokin
ifngamma
tnfalpha
treatment
observ
increas
express
cell
especi
astrocyt
oligodendrocyt
brain
endotheli
cell
upregul
preferenti
combin
cytokin
potent
enhanc
express
cell
type
test
either
cytokin
alon
result
underlin
enhanc
effect
proinflammatori
environ
basal
express
human
brain
cell
current
evalu
whether
pdl
express
human
cn
cell
immunomodul
human
cell
research
fund
grant
multipl
sclerosi
societi
canada
neurocysticercosi
ncc
common
parasit
diseas
central
nervou
system
cn
caus
helminth
taenia
solium
diseas
associ
hyper
inflammatori
respons
thought
detriment
host
primari
goal
understand
mechan
involv
induct
inflammatori
respons
ncc
tolllik
receptor
play
import
role
induct
host
inflammatori
respons
propos
studi
role
tlr
cn
immunopathogenesi
murin
ncc
murin
ncc
express
toll
like
receptor
analyz
real
time
pcr
microscopi
tlr
except
express
regul
differenti
among
differ
cell
type
among
first
upregul
parasit
infect
abundantli
express
particularli
astrocyt
foot
process
termin
blood
vessel
present
periventricular
mening
area
next
role
analyz
vivo
mice
highli
suscept
ncc
compar
wild
type
counterpart
histopatholog
analysi
reveal
sever
patholog
character
lack
perivascular
lymphocyt
cuf
increas
microgliosi
tissu
damag
compar
wild
type
anim
mice
observ
elicit
weaker
immun
respons
determin
reduc
reactiv
sera
solubl
parasit
antigen
total
number
infiltr
immun
cell
individu
cell
type
myeloid
cell
alphabetat
cell
gammadeltat
cell
b
cell
significantli
reduc
earli
wk
late
wk
infect
accordingli
level
sever
proinflammatori
cytokin
chemokin
tnfalpha
ifngamma
rant
reduc
cn
mice
ncc
mice
express
inflammatori
cytokin
reduc
astrocyt
present
leptomening
periventricular
area
thought
import
earli
cn
infect
mice
exhibit
reduc
immun
respons
murin
ncc
death
mice
experiment
ncc
along
increas
patholog
parasit
burden
suggest
import
role
immunopathogenesi
murin
ncc
report
isol
subpopul
murin
cnsdc
basi
differ
surfac
marker
dc
subset
differ
capac
stimul
cell
prolifer
fact
one
dc
popul
inhibit
prolifer
cell
dc
type
also
differ
popul
dynam
cours
eae
may
indic
play
differ
role
evolut
diseas
order
investig
eaecn
deriv
dc
exert
differ
effector
mechan
compar
regulatori
stimulatori
dc
perform
gene
express
array
pathway
analysi
show
cellular
growth
movement
main
biolog
process
distinguish
three
dc
subset
gene
involv
growth
cellular
prolifer
investig
particularli
express
gene
involv
recognit
captur
present
antigen
valid
sever
gene
involv
chemotaxi
home
differenti
express
dc
subset
suggest
dc
subset
may
attract
differ
type
cell
cn
differ
observ
three
dc
subset
may
indic
distinct
role
eae
pathogenesi
identif
specif
marker
well
phenotyp
character
dc
subset
may
help
specif
manipul
dc
subset
order
attenu
cn
autoimmun
inflamm
associ
reduc
diseas
sever
decreas
inflammatori
respons
brain
murin
neurocysticercosi
symptomat
phase
neurocysticercosi
ncc
associ
type
inflammatori
cytokin
respons
central
nervou
system
cn
thought
respons
sever
neuropatholog
mortal
associ
diseas
brain
infect
mesocestoid
corti
murin
model
neurocysticercosi
induc
massiv
influx
immun
cell
type
cytokin
express
understand
mechan
involv
develop
inflammatori
respons
role
toll
like
receptor
tlr
analyz
murin
ncc
tlr
tlr
except
upregul
differenti
express
among
variou
nervou
tissu
infiltr
immun
cell
mice
lack
central
regul
tlr
induc
respons
display
enhanc
abil
surviv
infect
compar
wildtyp
mice
although
number
parasit
brain
remain
similar
cn
mice
quiescent
absenc
perivascular
lymphocyt
cuf
decreas
microgliosi
tissu
damag
number
myeloid
cell
cell
gdt
cell
b
cell
present
brain
real
time
pcr
elisa
analysi
show
decreas
level
sever
inflammatori
cytokin
chemokin
tnfa
ifng
cours
infect
microscopi
analysi
reveal
mice
express
inflammatori
cytokin
reduc
leptomening
periventricular
area
brain
known
influenc
leukocyt
infiltr
ncc
signal
also
appear
influenc
humor
immun
infect
mice
associ
lower
parasit
solubl
antigenspecif
ab
titer
patient
infect
taenia
solium
destruct
larva
therapeut
treatment
parasit
life
cycl
associ
strong
inflammatori
respons
diseas
manifest
better
contain
diseas
along
absenc
inflammatori
respons
lack
neuropatholog
mice
may
help
formul
therapeut
immun
intervent
strategi
neurocysticercosi
matsumoto
kohyama
kuniko
hiraki
keiko
tokyo
metropolitan
institut
neurosci
tokyo
japan
accumul
evid
strongli
suggest
cell
autoantibodi
reactiv
myelin
oligodendrocyt
glycoprotein
mog
play
critic
role
pathogenesi
multipl
sclerosi
ms
present
studi
tri
elucid
pathomechan
lesion
format
progress
ms
analyz
role
b
cell
moginduc
experiment
autoimmun
encephalomyel
eae
exhibit
variou
clinic
subtyp
mimick
ms
special
attent
paid
examin
presenc
absenc
autoantibodi
conform
epitop
mog
molecul
relaps
remit
rr
secondari
progress
sp
eae
induc
rat
immun
recombin
rat
mog
synthet
peptid
cover
entir
extracellular
domain
mog
respons
cell
immun
rat
mog
mog
peptid
determin
cell
prolifer
assay
autoantibodi
linear
conform
epitop
assay
convent
elisa
flow
cytometri
use
nativ
mogexpress
cell
respect
immun
synthet
peptid
reveal
encephalitogen
epitop
resid
peptid
residu
residu
induc
rr
sp
eae
howev
diseas
sever
mog
peptideea
gener
milder
mogea
cell
taken
mogimmun
rat
respond
mog
sera
mogimmun
rat
react
mog
throughout
observ
period
interestingli
sera
rat
rreae
react
mog
protein
peptid
observ
period
epitop
spread
cell
antibodi
level
analysi
conform
epitop
cme
sera
mogimmun
rat
reveal
titer
anticm
antibodi
parallel
diseas
statu
find
demonstr
develop
relaps
mog
peptideea
occur
without
autoantibodi
involv
autoantibodi
play
role
progress
diseas
found
mogea
collect
diseas
process
eae
probabl
ms
regul
sever
differ
mechan
immunotherapi
perform
properli
basi
inform
tissu
transglutaminas
multifunct
enzym
involv
posttransl
modif
protein
variou
inflammationrel
process
includ
cell
adhes
migrat
suggest
play
major
role
therefor
propos
contribut
patholog
process
underli
ms
sinc
observ
immunoreact
elev
ms
lesion
question
whether
present
cn
rat
suffer
chronic
relaps
eae
creae
studi
express
creae
anim
sacrif
differ
phase
clinic
diseas
found
increas
level
mrna
protein
variou
cell
type
includ
infiltr
cell
mainli
upper
part
spinal
cord
clinic
diseas
creae
subsequ
studi
whether
contribut
clinic
diseas
creae
specif
irrevers
inhibitor
inject
ip
daili
creae
anim
first
clinic
sign
onward
anim
sacrif
pbstreat
control
reach
relaps
phase
creae
data
show
inhibit
activ
reduc
clinic
symptom
creae
dramat
effect
neuropatholog
outcom
creae
signific
effect
mrna
level
differ
gene
normal
higher
express
creae
inflammatori
mediat
gene
involv
adhes
migrat
process
immunohistochem
analysi
mhc
class
ii
marker
detect
monocyt
activ
macrophag
microglia
show
treatment
attenu
monocyt
infiltr
spinal
cord
creae
anim
wherea
microglia
remain
activ
treat
anim
data
suggest
mainli
peripher
effect
reduc
activ
infiltr
cell
therebi
attenu
cell
adhes
migrat
import
patholog
process
underli
ms
therefor
novel
therapeut
target
ms
protocol
induc
eaelik
diseas
character
massiv
infiltr
tcell
brain
spinal
cord
analys
flow
cytometri
histolog
analysi
preliminari
fac
analysi
show
cn
infiltr
tcell
symptomat
mice
nonsymptomat
mice
also
show
cell
infiltr
spinal
cord
infiltr
tcell
proport
substanti
greater
previou
studi
conventionallyimmun
mogor
mog
peptideinduc
eae
proport
tcell
cn
symptomat
mice
rang
studi
indic
tcell
play
regulatori
role
despit
display
activ
memoryeffect
phenotyp
result
studi
suggest
rout
antigen
present
may
determin
whether
activ
tcell
play
pathogen
role
present
viral
recognit
pathway
result
encephalitogen
tcell
respons
implic
understand
ms
attempt
observ
effect
block
angiogenesi
neuroinflamm
synthes
new
prodrug
thalidomid
seri
molecular
macromolecular
amphiphil
deriv
thalidomid
prepar
start
aminothalidomid
exhibit
modular
hydrophiliclipophil
balanc
biolog
activ
examin
use
myelin
oligodendrocyt
glycoprotein
peptideinduc
acut
eae
mous
mice
treat
second
day
clinic
sign
observ
total
day
two
thalidomid
deriv
molecular
weight
show
clear
efficaci
revers
clinic
sign
eae
mg
kg
equival
dose
thalidomid
studi
provid
addit
evid
vegf
angiogenesi
compon
acut
lesion
could
provid
interest
target
limit
extent
acut
ms
attack
experiment
autoimmun
encephalomyel
eae
central
nervou
system
cn
specif
diseas
primari
anim
model
multipl
sclerosi
ms
common
marmoset
callitrix
jacchu
use
studi
small
new
world
monkey
marmoset
provid
highli
use
model
studi
pathogenesi
ms
due
outbr
natur
immunolog
proxim
human
immun
nonhuman
primat
synthet
peptid
repres
amino
acid
human
myelinoligodendrocyt
mog
protein
miner
oil
incomplet
freund
adjuv
ifa
induc
fullblown
clinic
eae
anim
sensit
week
interv
develop
clinic
eae
bodi
weight
loss
magnet
reson
brain
imag
presymptomat
monkey
record
spectromet
show
larg
hyperintens
area
white
matter
immunohistolog
show
mridetect
abnorm
larg
demyelin
lesion
brain
lesion
also
present
spinal
cord
optic
nerv
posit
prolifer
tcell
respons
mog
peptid
observ
tcell
line
gener
spleen
lymph
node
express
phenotyp
nkctl
like
cell
andor
specif
cytotox
specif
tcell
line
confirm
use
peptidepuls
ebvtransform
autolog
allogen
bcell
chromium
releas
assay
target
cell
exchang
studi
show
cytolysi
peptid
specif
target
cell
independ
plead
peptid
present
invari
mhc
class
allel
caja
conclud
minim
requir
induct
eae
marmoset
primeboost
peptid
ifa
eae
caus
autoreact
cytotox
tcell
display
specif
cytolyt
activ
toward
cell
present
peptid
via
nonclass
mhc
class
caja
allel
ko
mice
recent
avail
tacon
backcross
time
onto
mice
intracross
make
homozyg
ko
immun
ko
n
mice
background
n
myelin
oligodendrocyt
glycoprotein
peptid
complet
freund
adjuv
bordetella
pertussi
toxin
ng
also
administ
ip
day
post
immun
pi
ko
mice
clinic
sign
control
mice
day
pi
display
sever
clinic
sign
pb
patholog
chang
also
significantli
wors
spinal
cord
section
stain
inflamm
p
demyelin
p
unexpectedli
extens
demyelin
section
observ
ko
mice
mice
lack
show
sever
acut
eae
propos
compens
inflammatori
mediat
exacerb
diseas
discrep
oxyrad
product
phagocyt
marmoset
rhesu
monkey
differenti
enceph
patholog
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
induc
nonhuman
primat
speci
rhesu
macaqu
common
marmoset
recombin
human
myelin
oligodendrocyt
glycoprotein
rhmog
eae
induct
rhesu
macaqu
lead
acut
ademlik
neurolog
diseas
highli
destruct
lesion
rhmog
immun
marmoset
induc
mslike
progress
neurolog
diseas
primari
demyelin
conserv
axon
sinc
axon
damag
may
caus
reactiv
oxygen
speci
ro
produc
macrophag
microglia
phagocytosi
myelin
debri
investig
profil
ro
produc
activ
phagocyt
speci
product
superoxid
anion
hydrogen
peroxid
h
analyz
pma
stimul
peripher
blood
mononuclear
cell
pbmc
granulocyt
superoxid
dismutas
inhibit
superoxid
anion
product
determin
lucigenin
luminesc
product
superoxid
anion
much
higher
rhesu
monkey
cell
cpm
marmoset
cell
cpm
product
hydrogen
peroxid
measur
horseradish
peroxidasecatalyz
oxid
amplex
red
resorufin
measur
nm
hydrogen
peroxid
product
marmoset
cell
hardli
detect
od
b
contrast
product
rhesu
monkey
cell
od
conclus
found
differ
oxid
burst
speci
sialic
acid
residu
gangliosid
express
axon
membran
myelin
promin
scaveng
hypothes
reaction
sialic
acid
h
affect
specif
bind
neuron
myelinassoci
glycoprotein
mag
contribut
disrupt
compact
myelin
enhanc
bind
autoantibodi
sinc
rhesu
monkey
cell
produc
hydrogen
peroxid
marmoset
cell
may
lead
faster
disrupt
compact
myelin
explain
acut
diseas
destruct
lesion
rhesu
monkey
eae
discuss
express
sialic
acid
mag
brain
rhesu
marmoset
eae
moreov
data
damag
dna
protein
caus
ro
discuss
costimulatori
molecul
function
interfac
antigen
present
cell
apc
immun
system
central
nervou
system
cn
also
express
reactiv
microglia
play
role
neuroinflammatori
disord
alzheim
diseas
parkinson
diseas
multipl
sclerosi
induc
variou
inflammatori
molecul
induc
nitric
oxid
synthas
ino
therefor
investig
role
semaphorin
could
modul
signal
sinc
receptor
identifi
cn
play
major
role
immun
system
prepar
primari
microglia
wildtyp
newborn
mice
background
microglia
incub
recombin
ino
express
enhanc
addit
immunohistochem
studi
reveal
express
infiltr
cell
spinal
cord
experiment
autoimmun
encephalomyel
eae
upregul
microgliamacrophag
eae
induc
adopt
transfer
wildtyp
mogreact
cell
wildtyp
mice
recipi
mice
exhibit
milder
phenotyp
wildtyp
collect
result
suggest
particip
neuroinflammatori
process
enhanc
inflammatori
process
via
interact
antigenpres
cell
apc
tcell
lead
rapid
format
immunolog
synaps
upon
recognit
appropri
antigen
swift
rise
intracellular
calcium
trigger
within
tcell
use
monitor
activ
statu
lymphocyt
approach
success
cell
cultur
vivo
calcium
imag
tcell
still
remain
major
challeng
synthet
calcium
indic
persist
intracellularli
sustain
period
overcom
problem
want
creat
transgen
tcell
stabli
express
fluoresc
calcium
sensor
longterm
track
calcium
measur
studi
retrovir
transduct
gener
tcell
transgen
express
novel
fluoresc
reson
energi
transfer
fret
base
calcium
sensor
tnxxl
sensor
featur
spectral
optim
deriv
fluoresc
protein
cfp
yfp
fret
pair
link
calciumsensit
domain
troponin
c
origin
design
calcium
imag
neuron
sensor
also
capabl
respond
modest
alter
lymphocyt
intracellular
calcium
level
transgen
tcell
use
vivo
imag
studi
experiment
autoimmun
encephalomyel
eae
plan
track
migrat
activ
tcell
upon
encount
apc
eg
pass
bloodbrain
barrier
infiltr
cn
purpos
variou
induc
well
spontan
model
eae
avail
lab
thu
provid
opportun
investig
tcell
activ
differ
diseas
condit
crucial
mediat
tissu
inflamm
eae
heterodimer
cytokin
consist
subunit
produc
antigenpres
cell
macrophag
dendrit
cell
act
primarili
cell
model
eae
shown
vital
develop
diseas
clear
eae
induct
upon
peptid
immun
trigger
mediat
respons
influenc
polar
cell
nevertheless
found
product
restrict
cell
even
greater
number
cell
due
bia
peptid
induc
eae
cell
long
neglect
experiment
model
cn
inflammatori
diseas
cell
implic
mediat
axon
damag
mice
men
nevertheless
interplay
cell
autoimmun
cn
inflamm
remain
ill
defin
mous
model
reli
express
ova
control
modifi
oligodendrocytespecif
myelin
basic
protein
mbp
promot
upon
activ
immun
mhc
class
ova
peptid
adopt
transfer
cell
mous
show
sever
eae
symptom
address
impact
cell
cross
odcova
mice
onto
background
two
subunit
preliminari
data
indic
loss
lead
chang
diseas
pattern
axi
appli
th
cell
also
encephalitogen
ctl
primari
impact
appear
cytotox
capac
ctl
rather
local
cn
tissu
respons
experi
reveal
interact
encephalitogen
cell
role
cell
eae
bacteri
cell
wall
peptidoglycan
pg
strong
proinflammatori
agent
promot
develop
cell
potenti
stimul
multipl
sclerosi
ms
lesion
activ
pg
present
innat
immun
cell
infiltr
ms
brain
tissu
staphylococcu
aureu
pg
stimul
eae
experiment
autoimmun
encephalomyel
wildtyp
mice
admix
autoantigen
incomplet
freund
adjuv
ifa
pg
stimul
cell
via
innat
immun
receptor
like
membraneassoci
tolllik
receptor
cytosol
hypothes
stimulatori
effect
aureu
pg
eae
independ
action
vivo
henc
ask
whether
aureu
pg
singl
bacteri
compon
admix
autoantigen
ifa
induc
eae
anim
genet
defici
inde
knockout
mice
still
develop
eae
induct
wellcharacter
highli
purifi
solubl
pg
aureu
knockout
similar
diseas
incid
sever
compar
wildtyp
mice
independ
activ
aureu
pg
prepar
vitro
assess
use
bonemarrow
deriv
dendrit
cell
dc
stimul
pg
wildtyp
dc
upregul
express
secret
proinflammatori
cytokin
tnfa
well
antiinflammatori
cytokin
expect
paramet
reduc
dc
knockout
mice
howev
express
tnfa
fulli
ablat
dc
lack
suggest
partial
effect
pg
ongo
importantli
aureu
pg
induc
product
essenti
sustain
polar
human
antigen
present
cell
data
provid
proof
principl
highli
purifi
solubl
aureu
pg
effect
induc
eae
absenc
engag
suggest
action
aureu
pg
reason
suffici
promot
eae
loss
noncanon
nfkb
signal
antigenpres
cell
abort
adapt
immun
hofmann
greter
melani
becher
burkhard
neuroimmunolog
univers
switzerland
inflammatori
canon
nfkb
pathway
critic
involv
virtual
aspect
inflamm
gener
hand
role
altern
noncanon
nfkb
pathway
inflamm
adapt
immun
remain
elus
altern
pathway
primarili
mediat
nfkappab
induc
kinas
nik
turn
lead
phosphoryl
cleavag
among
receptor
engag
nik
ltbr
also
requir
form
anlag
secondari
lymphoid
tissu
slt
due
point
mutat
within
nik
alymphoplasia
ali
mice
develop
slt
highli
immunodefici
howev
immunodefici
ali
mice
wide
held
stem
development
malform
overlook
mutat
nik
could
potenti
lesion
immun
verifi
notion
gener
seri
bone
marrow
chimer
mice
bmc
absenc
slt
disconnect
hematopoiet
loss
nik
function
gener
mice
lack
slt
equip
normal
system
immun
system
convers
mice
normal
slt
lack
nik
leukocyt
surprisingli
discov
nik
vital
develop
autoimmun
diseas
slt
ie
ln
spleen
etc
essenti
dispens
cell
prime
discov
nik
requir
polar
effector
cell
cell
gener
absenc
nik
howev
nik
lesion
caus
intrins
cell
defect
lead
inabl
apc
drive
cell
polar
diphtheria
toxinmedi
cell
deplet
suggest
crucial
role
nik
dendrit
cell
dc
develop
eae
data
strongli
support
find
ali
dc
show
function
deficit
matur
proinflammatori
cytokin
product
taken
togeth
loss
noncanon
nfkb
signal
dc
ultim
lead
abort
cell
prime
phosphodiesteras
pde
enzym
degrad
cyclic
nucleotid
inhibitor
pde
report
therapeut
agent
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
inhibit
antigenmedi
cell
prolifer
downregul
product
cytokin
cilostazol
known
specif
inhibitor
use
treatment
ischem
diseas
act
antiplatelet
vasodil
properti
besid
cilostazol
suppress
express
adhes
molecul
studi
investig
possibl
therapeut
effect
cilostazol
eae
eae
induc
mice
inocul
usual
protocol
mice
fed
blend
solid
diet
cilostazol
n
vehicl
control
n
cilostazol
suppress
maximum
eae
score
averag
eae
score
day
compar
control
group
recal
respons
prolifer
ifng
product
lymphocyt
cilostazolf
mice
significantli
reduc
comparison
control
mice
contrast
signific
differ
detect
level
tnfa
product
group
serum
level
significantli
lower
cilostazolf
mice
control
mice
cilostazol
may
repress
effect
eae
reduc
antigen
specif
cell
respons
decreas
express
level
adhes
molecul
although
investig
need
clarifi
detail
mechan
therapeut
effect
eae
cilostazol
hope
choic
treatment
ms
recent
emerg
critic
cytokin
cellmedi
autoimmun
diseas
produc
cell
subset
distinct
cell
induc
tnfalpha
express
inflam
tissu
tgfbeta
induc
cell
differenti
cell
vitro
shown
promot
product
cell
absenc
tcr
engag
studi
examin
infiltr
cell
cn
develop
experiment
autoimmun
encephalomyel
eae
mononuclear
cell
isol
peripher
immun
cn
tissu
day
post
immun
analyz
cytokin
express
flow
cytometri
kinet
chang
mrna
express
number
associ
cytokin
also
examin
quantit
pcr
found
signific
infiltr
cell
brain
spinal
cord
mice
immedi
prior
onset
clinic
sign
eae
approxim
total
cell
cn
mice
produc
day
induct
eae
cell
constitut
popul
express
furthermor
gamma
delta
cell
detect
cn
whilst
constitut
around
total
popul
show
produc
ifngamma
find
correl
increas
express
tgfbeta
ifngamma
tnfalpha
mrna
cerebr
cortex
cerebellum
spinal
cord
mice
day
contrast
mrna
express
well
significantli
increas
spleen
mice
day
eae
subsid
peak
diseas
addit
produc
cell
significantli
increas
spleen
day
nk
cell
cell
cn
express
signific
cours
diseas
hypothesis
cell
activ
peripheri
earli
immunis
subsequ
migrat
cn
stimul
local
product
proinflammatori
cytokin
glial
cell
found
gamma
delta
cell
infiltr
cn
develop
eae
onset
clinic
symptom
high
percentag
cell
express
may
potenti
induc
local
inflammatori
respons
eae
proteolipid
protein
plp
inocul
sjlj
mice
gener
form
experiment
autoimmun
encephalomyel
eae
exhibit
relapsingremit
cours
use
investig
mechan
diseas
relat
multipl
sclerosi
ms
hitherto
studi
concentr
sole
central
aspect
ms
patholog
howev
becom
increasingli
evid
system
event
also
contribut
ms
pathogenesi
observ
histolog
chang
liver
individu
ms
includ
recruit
neutrophil
interest
discov
whether
model
eae
also
exhibit
cellular
molecular
chang
might
contribut
system
patholog
previous
shown
neutrophil
recruit
liver
brain
injuri
associ
hepat
chemokin
product
express
classic
acut
phase
protein
app
examin
liver
anim
eae
discov
whether
also
true
immunemedi
central
nervou
system
cn
diseas
induc
eae
femal
week
old
sjlj
mice
inject
subcutan
plp
emulsifi
complet
freund
adjuv
cfa
phosphat
buffer
salin
pb
cfa
control
group
day
immun
h
later
treatment
group
receiv
intraven
inject
ng
pertussi
toxin
ml
pb
use
rtpcr
abl
establish
presenc
extend
express
app
chemokin
liver
eae
mice
prior
develop
overt
clinic
sign
show
elev
express
serum
amyloid
serum
amyloid
serum
amyloid
p
sap
ccl
cxcl
onset
clinic
symptom
day
case
persist
clinic
phase
diseas
app
return
level
day
period
remiss
furthermor
product
app
chemokin
associ
recruit
leukocyt
liver
thu
system
patholog
accompani
eae
ms
like
imping
clinic
sign
contribut
diseas
progress
identif
liver
particular
preclin
compon
ms
defin
import
time
window
chemokin
format
lesion
format
ms
relaps
may
exploit
therapeut
purpos
individu
risk
multipl
sclerosi
ms
determin
triad
gene
environ
infect
studi
show
concord
ms
higher
nonident
twin
sibl
independ
birth
suggest
influenc
simultan
utero
exposur
matern
factor
test
marmoset
monkey
whether
corticosteroid
hormon
leak
placenta
influenc
sever
cours
mslike
diseas
later
life
context
larg
multin
experi
fund
european
commiss
grant
eupeah
led
german
primat
center
pregnant
femal
marmoset
treat
dexamethason
dex
form
daili
mgkg
oral
dose
day
offspr
develop
moder
metabol
chang
reminisc
observ
children
mother
receiv
dexamethason
limit
complic
preterm
deliveri
receiv
five
femal
monkey
sibl
mother
treat
daili
dex
first
trimest
pregnanc
day
four
femal
mother
receiv
dex
late
second
trimest
day
total
day
gestat
period
four
normal
age
sexmatch
control
monkey
ad
experi
eae
induc
monkey
repeat
immun
day
interv
mix
two
mog
peptid
adjuv
monkey
develop
overt
clinic
eae
howev
eae
monkey
prenat
expos
dex
develop
rapidli
higher
lesion
load
control
monkey
remark
immunolog
effect
tcell
control
monkey
prolifer
two
immun
peptid
recombin
human
mog
protein
rhmog
tcell
dex
expos
group
prolifer
also
rhmog
suggest
epitop
diversif
beyond
mog
peptid
data
suggest
influenc
antenat
exposur
dexamethason
sever
eae
induc
adult
age
observ
chang
phosphoprotein
tumor
necrosi
factora
tnfa
transform
growth
factorb
tgfb
express
well
studi
immunosuppress
effect
simvastatin
dosag
mgkg
intraperiton
wistar
rat
experiment
autoimmun
encephalomyel
eae
guinea
pig
spinal
cord
homogen
complet
freund
adjuv
mycobacterium
bovi
bacillu
calmetteguerin
pertussi
toxin
use
immun
wistar
rat
divid
two
group
immunosuppress
effect
medicin
simvastatin
group
intraperiton
inject
simvastatin
day
pi
clinic
score
bodi
weight
record
everi
day
brain
spinal
cord
remov
day
pi
stain
immunohistochemistri
stain
differ
part
nervou
system
compar
eae
group
clinic
symptom
simvastatin
group
statist
significantli
decreas
p
b
loss
bodi
weight
incid
simvastatin
group
statist
significantli
decreas
compar
eae
group
vs
p
b
vs
p
b
respect
differ
morbid
number
infecti
foci
onset
date
simvastatin
group
eae
group
p
b
day
pi
express
tgfb
simvastatin
group
statist
significantli
increas
compar
eae
group
simvastatin
potenti
agent
inhibit
eae
effect
inhibit
mechan
simvastatin
relat
upregul
tgfb
downregul
tnfa
may
promot
transdifferenti
cell
cell
may
exert
protect
function
suppress
express
tnfa
promot
express
tgfb
rat
eae
report
paper
multipl
sclerosi
associ
cognit
deficit
disturb
memori
languag
fluenci
full
develop
dementia
deficit
start
case
earli
first
year
diseas
develop
independ
motor
deficit
anim
studi
show
cognit
deficit
autoimmun
encephalomyel
eae
model
ms
also
exist
may
depend
degener
cholinerg
pathway
studi
show
memori
deficit
exist
eae
may
also
depend
pyramid
neuron
loss
hippocampu
lewi
rat
month
old
inject
million
antimbp
cell
evok
eae
anim
suffer
tail
hind
limb
paresi
recov
complet
day
cell
infiltr
white
matter
brain
also
hippocampu
area
day
eae
induct
disappear
recoveri
period
number
pyramid
neuron
decreas
day
eae
induct
cortic
frontal
cortex
degener
visibl
time
point
microgli
astrocyt
activ
increas
day
ad
region
cell
reaction
also
increas
day
conclus
antimbp
cell
capabl
evok
inflammatori
reaction
spinal
cord
brain
lead
motor
deficit
also
may
directli
injur
hippocamp
pyramid
neuron
tischner
van
den
brandt
jen
herold
marco
reichardt
holger
institut
cellular
molecular
immunolog
goettingen
germani
institut
viroloti
immunobiolog
wuerzburg
germani
multipl
sclerosi
ms
chronic
inflammatori
diseas
central
nervou
system
presum
autoimmun
origin
acut
relaps
commonli
treat
high
dose
glucocorticoid
gc
necessit
better
understand
mechan
underli
gc
action
ms
use
differ
cellspecif
glucocorticoid
receptor
gr
knockout
mous
strain
could
show
gc
mainli
act
cell
nevertheless
differenti
effect
gc
effector
versu
bystand
cell
remain
elus
therefor
inactiv
gr
express
retrovir
express
mirna
fulli
differenti
encephalitogen
cell
tenc
gener
two
cell
line
constitut
knockdown
gr
well
one
control
cell
line
variou
apoptosi
assay
grdefici
tenc
cell
display
significantli
increas
surviv
rate
gc
treatment
indic
success
knockdown
addit
repress
effector
cytokin
ifngamma
gc
impair
cell
suggest
also
transrepress
activ
receptor
affect
collect
envisag
inactiv
gr
differenti
tenc
cell
rnai
allow
investig
influenc
gc
pathogen
effector
cell
experiment
autoimmun
encephalomyel
eae
vivo
therebi
help
elucid
mechan
underli
gc
therapi
ms
variat
sever
durat
experiment
autoimmun
encephalomyel
eae
depend
speci
method
induct
previou
studi
shown
astrocyt
express
decreas
demyelin
lesion
increas
remyelin
lesion
guinea
pig
chronic
model
purpos
studi
determin
whether
also
involv
chronic
recov
mous
eae
model
use
rna
microarray
studi
investig
modul
gap
junction
activ
potenti
therapeut
target
studi
compar
two
method
immun
myelin
oligodendrocyt
glycoprotein
mog
peptid
human
recombin
mog
protein
rmog
femal
mice
anim
use
studi
includ
mog
peptid
chronic
mice
n
chronic
control
n
rmog
n
acut
control
mog
peptid
caus
chronic
mous
model
continu
demyelin
immun
cell
infiltr
least
day
postimmun
rmog
immun
produc
less
sever
diseas
cours
mani
anim
recov
clinic
spinal
cord
remyelin
rna
level
increas
rmog
eae
model
well
oligodendrocyt
connexin
show
intercellular
commun
via
connexin
protein
astrocyt
oligodendrocyt
connexin
protein
express
cn
alter
significantli
nonconnexin
rna
transcript
potenti
therapeut
target
alter
least
relat
lymphocyt
activ
immun
regul
molecul
interest
increas
compar
healthi
control
proteoglycan
neutrophil
granul
protein
involv
cn
develop
calcium
bind
protein
found
activ
helper
cell
first
studi
compar
spontan
recov
nonrecov
chronic
mous
model
eae
model
use
characterist
rmog
recov
model
use
microarray
order
identifi
possibl
therapeut
target
mog
peptid
chronic
model
use
intervent
test
cell
commun
via
connexin
gap
junction
potenti
signific
factor
requir
recoveri
sinc
increas
express
potenti
observ
recov
mice
compar
chronic
eae
mice
healthi
control
recent
studi
suggest
cell
may
play
import
role
develop
autoimmun
diseas
includ
eae
howev
encephalitogen
cell
well
studi
use
adopt
transfer
demonstr
mbp
specif
cell
differenti
vitro
cell
receptor
transgen
cell
transfer
diseas
wherea
cell
secondari
stimul
mbpspecif
cell
mbp
three
popul
th
cell
observ
includ
produc
cell
ifng
produc
cell
cell
produc
ifng
mix
popul
cell
transfer
diseas
effici
cell
sinc
also
implic
differenti
also
investig
possibl
altern
differenti
pathway
may
result
cell
encephalitogen
found
induct
tbet
necessari
encephalitogen
regardless
differenti
pathway
togeth
find
suggest
cell
encephalitogen
induc
cell
transfer
diseas
alon
actual
biolog
function
context
inflamm
central
nervou
system
cn
remain
elus
initi
report
point
toward
major
impact
cell
polar
surviv
popul
autoaggress
cell
thought
mediat
autoimmun
effector
function
loss
result
complet
resist
tissuedirect
autoimmun
surprisingli
absenc
produc
cell
experiment
autoimmun
enceph
eae
slightli
amelior
contradict
previou
observ
howev
becom
increasingli
evid
profound
impact
accessori
cell
may
requir
gener
vivo
goal
deciph
precis
mechan
drive
autoimmun
inflamm
systemat
assess
effect
biolog
cell
well
macrophag
dendrit
cell
dc
shown
absenc
function
b
cell
vitro
differenti
bonemarrow
deriv
macrophag
stimul
produc
high
amount
proinflammatori
cytokin
alpha
tnfalpha
periton
inject
rag
anim
upregul
express
receptor
induc
product
among
other
cell
free
environ
restrict
function
impact
accessori
cell
gener
mix
bm
chimera
use
bonemarrow
rag
defici
knockout
anim
recoveri
period
eae
induc
surpris
anim
show
strong
sign
eae
could
observ
number
pattern
infiltr
cell
cn
wildtyp
anim
indic
crucial
impact
antigen
present
cell
apc
elucid
function
varieti
cell
type
gener
condit
target
allel
mice
genetarget
strategi
impact
immun
discuss
helper
cell
identifi
play
pivot
role
develop
experiment
autoimmun
encephalomyel
eae
product
inflammatori
although
alltran
retino
acid
atra
report
suppress
develop
cell
applic
atra
therapeut
treatment
limit
due
instabl
poor
bioavail
side
effect
studi
examin
whether
synthet
raragonist
superior
pharmacolog
properti
could
control
eae
attenu
inflammatori
properti
pathogen
cell
splenic
cell
stimul
condit
tgfb
presenc
atra
rarantagonist
assess
express
inflammatori
cytokin
lineagespecif
transcript
factor
suppress
effect
retinoid
assess
vitro
differenti
cell
well
mice
immun
peptid
induc
eae
treat
oral
everi
day
cnsinfiltr
cell
analyz
cytokin
product
gene
express
drain
lymph
node
cell
mog
immun
mice
without
oral
retinoid
treatment
analyz
prolifer
cytokin
product
restimul
mog
peptid
exert
potent
suppress
differenti
reciproc
induct
regulatori
cell
atra
dose
depend
manner
compound
suppress
secret
rorgt
express
alreadi
differenti
cell
well
oral
administr
amelior
sever
eae
wherea
exacerb
diseas
treatment
show
reduct
ifng
product
reduct
tnfa
product
cnsinfiltr
cell
upon
stimul
without
affect
accumul
properti
cn
intriguingli
infiltr
cell
brain
spinal
cord
character
divers
product
inflammatori
cytokin
uniqu
respons
treatment
oral
administr
mice
immun
mog
peptid
led
signific
suppress
product
drain
lymph
node
cell
upon
restimul
mog
peptid
without
affect
prolif
respons
synthet
retinoid
success
inhibit
inflammatori
cytokin
product
pathogen
cell
could
provid
novel
therapeut
approach
multipl
sclerosi
goal
studi
test
hypothesi
inhibit
glycogen
synthas
provid
protect
multipl
sclerosi
ms
inflammatori
autoimmun
diseas
affect
central
nervou
system
cn
use
mous
model
experiment
autoimmun
encephalomyel
eae
grow
evid
indic
serinethreonin
protein
kinas
major
regul
inflammatori
respons
peripheri
extent
regul
inflamm
cn
unresolv
therefor
investig
lithium
inhibitor
amelior
eae
mice
inhibitor
lithium
therapeut
eae
use
three
differ
treatment
protocol
treatment
induct
diseas
prevent
eae
treatment
initi
onset
clinic
symptom
suppress
exacerb
diseas
treatment
initi
peak
diseas
reduc
clinic
symptom
induc
partial
recoveri
amelior
eae
associ
reduc
demyelin
microglia
activ
leukocyt
infiltr
spinal
cord
convers
eae
sever
mice
express
constitut
activ
spleen
lymph
node
cell
obtain
lithiumtr
mice
prolifer
poorli
vitro
restimul
antigen
also
secret
much
lower
amount
interferongamma
compar
mononuclear
cell
obtain
untreat
mice
howev
abil
tcell
lithiumtr
mice
respond
stimul
normal
indic
lithium
intrins
affect
tcell
activ
result
suggest
lithium
therapi
suppress
gener
differenti
andor
expans
effector
cell
act
cell
innat
immun
system
major
form
clinic
ms
relapsingremit
diseas
model
femal
sjl
mice
immun
proteolipid
protein
peptid
initi
lithium
treatment
plpimmun
sjl
mice
first
clinic
episod
eae
suppress
relaps
day
howev
diseas
relaps
lithium
withdraw
remark
restor
lithium
therapi
led
partial
recoveri
result
demonstr
lithium
suppress
eae
identifi
new
target
inhibit
may
use
therapeut
intervent
ms
autoimmun
inflammatori
diseas
afflict
cn
show
stimulatori
tolerogen
function
state
intracerebr
dc
regul
system
activ
neuroantigenspecif
cell
recruit
cell
cn
onset
progress
experiment
autoimmun
encephalomyel
eae
intracerebr
microinject
stimulatori
dc
exacerb
onset
clinic
cours
eae
accompani
earli
cell
infiltr
decreas
proport
regulatori
cell
brain
contrast
intracerebr
microinject
dc
modifi
tumor
necrosi
factor
tnfalpha
induc
tolerogen
function
state
delay
prevent
eae
onset
trigger
gener
interleukin
produc
neuroantigenspecif
lymphocyt
peripheri
restrict
il
product
cn
find
suggest
dc
rate
limit
factor
neuroinflamm
impli
dc
target
therapeut
strategi
cn
diseas
clear
associ
phenotyp
autoimmun
pathogen
implic
cytokin
critic
mediat
chronic
autoimmun
diseas
experiment
autoimmun
encephalomyel
eae
studi
actual
impact
cn
inflamm
gener
transgen
mice
express
high
level
initi
crerecombin
gener
overexpress
lead
skin
inflamm
granulocytosi
cell
driven
express
impact
visibl
develop
health
mous
context
eae
demonstr
neither
celldriven
overexpress
complet
loss
signific
impact
develop
clinic
diseas
sinc
cell
also
produc
evid
act
receptor
complex
feasibl
could
compens
loss
mice
determin
actual
function
autoimmun
inflamm
cn
next
gener
mice
lack
also
produc
significantli
less
nevertheless
fulli
eae
suscept
display
unalt
emerg
expans
polar
autoreact
cell
eae
conclud
promin
express
encephalitogen
cell
margin
contribut
develop
autoimmun
cnsdiseas
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
ideal
diseas
paradigm
dissect
multipl
function
transcript
factor
nfkb
autoimmun
demyelin
neurodegener
studi
appli
condit
gene
target
mice
delet
inhibitor
nfkb
kinas
b
ikkb
catalyt
molecul
canon
nfkb
activ
select
cn
cell
lineag
studi
cellspecif
function
develop
eae
cellspecif
ikkb
delet
achiev
mate
mice
carri
loxpflank
f
ikkb
gene
exon
ikkbff
transgen
mice
express
cre
recombinas
promot
specif
endotheli
cell
mice
macrophagesmicroglia
neuron
camkiicr
ikkb
delet
endotheli
cell
endikkbko
mice
alter
clinic
cours
eae
delet
macrophagesmicroglia
mikkbko
mice
delay
onset
amelior
clinic
symptom
delet
ikkb
camkiiexpress
neuron
show
dual
opposit
effect
eae
mice
lack
neuron
ikkb
nikkbko
show
signific
delay
diseas
initi
subsequ
develop
sever
nonresolv
diseas
compar
control
mice
increas
patholog
nikkbko
spinal
cord
associ
reduc
express
neuroprotect
molecul
enhanc
express
immun
mediat
includ
cytokin
chemokin
known
import
eae
pathogenesi
result
show
neuron
ikkb
import
correct
regul
neuroprotect
mechan
cn
immun
respons
cn
autoimmun
diseas
emphas
import
neuroprotect
strategi
treatment
multipl
sclerosi
growth
factor
granulocytemacrophag
colonystimul
factor
gmcsf
well
known
cytokin
affect
differenti
dendrit
cell
dc
dc
play
crucial
role
regul
benefici
immun
respons
develop
autoimmun
diseas
multipl
sclerosi
ms
anim
model
experiment
autoimmun
encephalomyel
eae
gmcsf
preferenti
induc
expans
myeloid
dc
dc
subset
differenti
fraction
previous
found
contrast
dc
isol
eaediseas
central
nervou
system
cn
inhibit
cell
prolifer
eae
occurr
thu
aim
defin
differenti
role
gmcsf
develop
remiss
eae
gmcsf
produc
cell
inject
intracerebr
mice
immun
myelin
oligodendrocyt
glycoprotein
mog
depend
time
point
gmcsf
treatment
mice
develop
sever
eae
earli
immun
order
analyz
origin
gmcsfinduc
dc
gener
congen
bone
marrowchimer
anim
treatment
gmcsf
result
preferenti
induct
dc
contrast
cnsderiv
dc
predominantli
phenotyp
furthermor
gmcsfrecruit
stimul
cell
prolifer
wherea
dc
subset
inhibit
cell
prolifer
final
gmcsf
receptor
defici
mice
develop
eae
contain
infiltr
within
cn
diseas
develop
despit
unalt
prime
compar
wild
type
control
summari
data
demonstr
dc
recruit
diseas
sever
eae
enhanc
presenc
gmcsf
chimera
experi
suggest
effect
gmcsf
stimulatori
dc
domin
gmcsfmediat
induct
inhibitori
dc
addit
result
mice
indic
gmcsf
play
crucial
role
effector
phase
eae
experiment
autoimmun
encephalomyel
eae
lewi
rat
induc
transfer
myelin
basic
proteinreact
cell
genet
engin
express
green
fluoresc
protein
tmbpgfp
cell
diseas
free
period
day
autoreact
cell
induc
cn
inflamm
sever
paralyt
diseas
use
microscopi
visual
infiltr
process
tmbpgfp
cell
target
organ
incipi
eae
intravit
imag
spinal
cord
situ
combin
imag
spinal
cord
explant
enabl
us
track
tmbpgfp
cell
throughout
entir
cn
parenchyma
imag
complement
gene
express
profil
autoaggress
tmbpgfp
cell
isol
differ
cn
locat
cytofluorometr
cell
sort
first
tmbpgfp
cell
arriv
cn
within
h
cell
transfer
pt
cell
locat
close
contact
leptomening
blood
vessel
number
vesselassoci
tmbpgfp
cell
increas
next
h
vast
major
cell
move
continu
vessel
surfac
small
proport
cell
howev
arrest
contact
perivascular
phagocyt
day
pt
tmbpgfp
cell
start
distribut
throughout
entir
mening
area
immigr
cn
parenchyma
along
perivascular
virchowrobin
space
increas
part
cell
form
long
last
contact
perivascularmening
phagocyt
day
pt
cell
invad
parenchyma
adjac
mening
cn
vessel
within
next
h
diffus
distribut
throughout
entir
cn
tissu
within
cn
parenchyma
cell
constantli
move
wherea
stationari
microscopi
complement
studi
gene
express
profil
tmbpgfp
cell
way
cn
tissu
tmbpgfp
cell
resid
spleen
circul
blood
display
migratori
phenotyp
low
activ
marker
upregul
gene
relev
cell
migrat
importantli
upon
entri
mening
tmbpgfp
cell
strongli
activ
produc
high
amount
proinflammatori
cytokin
activ
occur
follow
entri
parenchyma
present
data
indic
autoaggress
cell
enter
target
organ
via
mening
recogn
endogen
autoantigen
present
resid
meningealperivascular
phagocyt
multipl
sclerosi
ms
immun
mediat
demyelin
diseas
central
nervou
system
cn
aim
find
mechan
toll
like
receptor
tlr
exacerb
suppress
cn
inflammatori
demyelin
effect
observ
experiment
autoimmun
encephalomyel
eae
anim
model
mstlr
exacerb
diseas
delay
onset
reduc
sever
natur
occur
regulatori
cell
treg
suppress
autoimmun
reaction
recent
found
express
tlr
process
studi
effect
treg
suppress
mous
cocultur
cell
differ
ratio
treg
without
poli
c
preliminari
studi
indic
ligand
poli
c
increas
suppress
abil
treg
mice
potenti
mechan
eae
diseas
sever
reduc
poli
c
administr
also
determin
cytokin
chemokin
induc
tlr
stimuli
murin
splenocyt
inflammatori
chemokin
unregul
tlr
hklm
lp
flagellin
follistatinlik
antiinflammatori
cytokin
unregul
stimuli
also
poli
c
cpg
also
induc
increas
product
tlr
stimuli
also
induc
increas
cell
prolifer
respons
human
monocyt
deriv
dendrit
cell
mddc
tlr
stimuli
term
matur
cytokin
chemokin
product
also
studi
unregul
tlr
stimuli
poli
c
lp
inflammatori
cytokin
tnfa
unregul
two
stimuli
also
hklm
effect
tlr
stimuli
mddc
ms
patient
progress
also
process
determin
effect
rang
tlr
stimuli
clinic
patholog
outcom
eae
tlr
stimuli
alter
regulatori
abil
treg
may
contribut
diseas
exacerb
suppress
eae
tlr
stimuli
lead
product
cytokin
chemokin
may
regul
autoimmun
diseas
potenti
aid
immunotherapi
target
tlr
cytokin
produc
rigolio
biffi
alessandro
oggioni
norberto
cavaletti
guido
degli
studi
milanobicocca
monza
itali
activ
induc
experiment
autoimmun
encephalomyel
eae
well
reproduc
model
portray
acut
phase
multipl
sclerosi
well
good
model
develop
new
promis
treatment
lymph
node
spinal
cord
sc
wide
describ
mean
molecular
biolog
immunohistochemistri
aim
studi
character
spleen
sc
lymphocyt
popul
highlight
possibl
use
marker
monitor
new
therapeut
treatment
thu
onset
day
eae
induct
peak
diseas
day
eae
induct
investig
encephalitogen
cell
preval
well
express
adhes
molecul
eae
activ
induc
subcutan
inocul
guinea
pig
myelin
basic
protein
gift
p
riccio
complet
freund
adjuv
inactiv
mycobacterium
tuberculosi
spleen
sc
dissect
healthi
control
eaeinduc
anim
cell
collect
stain
differ
combin
conjug
antibodi
acquir
use
flow
cytomet
spleen
eae
anim
report
signific
decreas
mean
absolut
cell
number
day
togeth
presenc
popul
lymphocyt
soon
day
furthermor
observ
increas
decreas
cell
compar
control
day
chang
report
day
moreov
alter
lymphocyt
percentag
well
express
cell
never
observ
spinal
cord
infiltr
lymphocyt
detect
day
therefor
result
sc
compar
obtain
spleen
day
thu
lymphocyt
percentag
higher
sc
lymphocyt
preval
decreas
also
observ
increas
cell
percentag
togeth
signific
increas
express
accentu
cell
result
confirm
eae
lewi
rat
cell
mediat
diseas
express
tcr
adhes
molecul
probabl
regul
mainli
target
organ
show
multiparametr
flow
cytometri
inform
method
describ
immun
system
cell
eae
ongo
elev
sever
member
matrix
metalloproteinas
mmp
famili
thought
promot
pathophysiolog
multipl
sclerosi
ms
anim
model
experiment
autoimmun
encephalomyel
eae
rise
particular
mmp
member
may
contrari
benefici
function
diseas
process
mrna
level
rise
significantli
spinal
cord
eaeafflict
mice
weaver
et
al
faseb
j
may
benefici
role
eae
pathogenesi
examin
role
eae
potenti
mechan
action
mice
induc
myelin
oligodendrocyt
glycoprotein
eae
mice
follow
day
determin
eae
diseas
profil
spinal
cord
isol
analyz
use
flow
cytometri
protein
array
western
blot
histolog
eae
mice
similar
day
onset
clinic
sign
wildtyp
control
subsequ
relaps
relapsingremit
eae
sever
residu
disabl
mice
remiss
also
higher
compar
wildtyp
control
worsen
relaps
remiss
mice
occur
despit
defici
antigen
recal
capac
lymph
nodederiv
cell
reduct
proport
macrophag
spinal
cord
chronic
phase
eae
significantli
larg
increas
level
chemokin
proinflammatori
antiinflammatori
cytokin
low
gcsf
level
found
spinal
cord
mice
chronic
eae
discov
well
process
multifunct
protein
osteopontin
smaller
fragment
vitro
eae
significantli
higher
sever
eae
mice
return
wildtyp
eae
score
osteopontin
doubl
mice
result
highlight
benefici
mmp
eae
cytokin
chemokin
regul
well
interact
osteopontin
therapeut
intervent
ms
aim
reduc
mmp
activ
avoid
target
cytostat
drug
edelfosin
synthet
analog
lysophosphatidylcholin
origin
regard
antitumor
agent
cancer
treatment
edelfosin
incorpor
cell
select
activ
cell
death
receptor
contrast
cytostat
drug
edelfosin
intercal
dna
vitro
treatment
cell
edelfosin
show
incorpor
effect
intracellular
concentr
highli
prolifer
cell
like
activ
immun
cell
tumor
cell
aim
studi
effect
edelfosin
immun
system
context
experiment
autoimmun
enceph
eae
order
analyz
antiinflammatori
properti
edelfosin
use
two
model
mice
immun
peptid
myelin
oligodendrocyt
glycoprotein
mog
sjl
mice
immun
peptid
proteolipid
protein
plp
effect
edelfosin
eae
diseas
cours
evalu
clinic
histolog
flow
cytometr
analysi
found
daili
treatment
mice
mgkg
edelfosin
gavag
day
immun
led
reduct
maximum
mean
eae
score
control
anim
gavag
pb
scale
control
group
anim
develop
full
blown
eae
wherea
one
mous
edelfosin
treatment
cohort
show
sever
diseas
other
demonstr
weak
sign
eae
stay
healthi
side
effect
due
drug
administr
observ
flow
cytometri
studi
day
immun
model
reveal
reduct
activ
lymphocyt
fraction
secondari
lymphoid
organ
treat
mice
compar
control
result
point
benefici
effect
edelfosin
eae
diseas
sever
suggest
interfer
immun
cell
infiltr
central
nervou
system
analysi
therapeut
valu
edelfosin
current
underway
order
examin
potenti
drug
edelfosin
treatment
multipl
sclerosi
identifi
critic
factor
inflamm
anim
model
multipl
sclerosi
ms
experiment
autoimmun
encephalomyel
eae
use
microarray
molecular
analysi
transcript
profil
central
nervou
system
cn
infiltr
heat
shock
protein
hsp
especi
among
promin
protein
group
gene
express
upregul
eae
hsp
major
inflammatoryinduc
protein
demonstr
play
protect
eg
antiapoptot
proinflammatori
eg
activ
tlr
role
recent
studi
aim
analyz
vivo
role
hsp
express
develop
autoimmun
demyelin
obtain
definit
proof
role
vivo
myelin
antigen
recognit
use
mous
defici
major
gene
encod
induc
immun
mice
myelin
oligodendrocyt
glycoprotein
mog
peptid
show
almost
complet
resist
induct
experiment
autoimmun
enceph
eae
eae
resist
correl
lost
prolif
cell
respons
well
significantli
downregul
secret
proinflammatori
cytokin
like
interferon
gamma
ifng
interleukin
cell
mice
interestingli
defici
result
cell
activ
dysfunct
demonstr
antigen
present
assay
show
reactiv
abolish
cell
mice
cocultur
wild
type
apc
defici
cell
also
fail
transfer
diseas
passiv
model
eae
mechan
cell
failur
mice
respond
tcr
depend
involv
activationinduc
apoptosi
result
provid
direct
proof
vivo
role
hsp
especi
recognit
self
myelin
antigen
mog
strengthen
hypothesi
stress
condit
lead
induct
may
enhanc
autoimmun
reaction
present
studi
aim
character
individu
function
myelin
specif
cell
eae
establish
polar
popul
deriv
mog
specif
tcr
transgen
mice
genet
background
cell
adopt
transfer
individu
combin
defici
anim
test
encephalitogen
potenti
found
subset
alon
capabl
induc
eae
notabl
howev
cotransf
cell
induc
sever
eae
earlier
onset
eae
differ
clinic
present
alon
cotransf
induc
classic
eae
around
transfer
mice
develop
atax
phenotyp
histolog
analys
indic
lesion
intens
larg
correl
astrogliosi
microglia
activ
transfer
mice
evid
spinal
cord
brain
parenchyma
especi
cerebellum
hand
transfer
mice
show
infiltr
spinal
cord
perivascular
space
brain
transfer
mice
classic
eae
present
cell
infiltr
spinal
cord
brain
parenchyma
preform
cytotox
assay
cell
astrocyt
order
elucid
detail
pathogen
mechan
two
cell
subset
cn
resid
cell
preliminari
data
show
contrast
cell
cytotox
astrocyt
cytotox
may
independ
presenc
ifng
block
mab
ad
cocultur
affect
cytotox
howev
found
correl
extent
cytotox
percentag
ifng
cell
total
popul
appli
astrocyt
cultur
conclud
helper
cell
subset
alon
potenti
induc
eae
probabl
differ
mechan
interact
potenti
autoimmun
respons
myelinspecif
cell
implic
pathogen
cell
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
recent
studi
shown
system
administr
monoclon
antibodi
significantli
reduc
incid
sever
eae
suggest
critic
role
pathogen
eae
implic
critic
factor
differenti
expans
surviv
cell
thu
specul
critic
product
autoreact
cell
subsequ
induct
eae
howev
receptor
origin
describ
memori
cell
marker
confirm
myelinspecif
cell
differenti
cell
express
similar
level
receptor
suggest
addit
differenti
may
play
role
effector
function
cell
determin
play
critic
role
differenti
effector
function
myelinspecif
cell
differenti
naiv
cell
specif
mbp
vitro
antibodi
transfer
cell
naiv
recipi
mice
although
popul
made
equival
amount
ifngamma
incid
eae
mice
receiv
cell
differenti
presenc
significantli
reduc
compar
mice
receiv
cell
differenti
data
suggest
contribut
encephalitogen
capac
cell
immunemedi
demyelin
diseas
bloodderiv
cnsderiv
apc
contribut
antigen
present
effector
phase
eae
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
mhcii
express
upregul
varieti
differ
type
antigen
present
cell
apc
cn
defin
respect
role
antigen
present
apc
eae
remain
major
challeng
address
question
gener
mice
exhibit
alter
pattern
mhcii
express
exploit
fact
class
ii
transactiv
ciita
gene
encod
master
regulatori
factor
mhcii
gene
control
three
celltyp
specif
promot
call
pi
piii
piv
recent
gener
strain
mice
lack
pi
driven
ciita
express
analysi
mhcii
express
mice
demonstr
pi
essenti
drive
ciita
mhcii
express
interferongamma
activ
macrophag
microglia
also
requir
variabl
degre
variou
dendrit
cell
dc
subset
contrast
mhcii
express
affect
margin
thymic
epitheli
cell
b
cell
pi
thu
critic
drive
ciita
mhcii
express
apc
microglia
macrophag
dc
like
implic
effector
phase
eae
therefor
studi
suscept
mice
eae
induc
activ
immun
myelin
oligodendrocyt
glycoprotein
mog
peptid
well
adopt
transfer
mogreact
encephalitogen
cell
model
mice
almost
complet
protect
activ
immun
model
mogspecif
cell
prime
essenti
normal
despit
fact
eae
ensu
taken
togeth
result
demonstr
block
eae
develop
mice
lie
level
antigen
present
effector
phase
cn
determin
whether
absenc
mhcii
express
cn
resid
microglia
bloodderiv
apc
respons
resist
mice
eae
gener
reciproc
bone
marrowchimera
wild
type
anim
interestingli
type
chimer
mice
wt
wt
develop
eae
wherea
control
chimera
remain
strongli
protect
result
show
mhciirestrict
antigen
present
bloodderiv
cnsderiv
apc
involv
effector
phase
eae
two
apc
compart
compens
absenc
experiment
autoimmun
encephalomyel
eae
anim
model
human
diseas
multipl
sclerosi
mediat
autoreact
cell
target
cn
myelin
phosphoinositid
intracellular
signal
molecul
implic
suscept
autoimmun
diseas
exist
evid
suggest
import
migrat
antigen
present
cell
apc
found
ko
mice
immun
myelin
protein
show
profound
suppress
eae
clinic
sign
mark
reduct
demyelin
inflammatori
cytokin
product
rel
wildtyp
wt
control
hypothes
primari
mechan
protect
observ
ko
mice
due
impair
myeloid
cell
migrat
site
inflamm
inher
defect
abil
apc
activ
cell
cocultur
ko
apc
compet
cell
induc
cell
prolifer
suggest
critic
process
present
antigen
develop
ko
wt
chimera
test
hypothesi
found
wt
anim
reconstitut
ko
bone
marrow
less
sever
eae
wt
chimer
control
suggest
protect
phenotyp
observ
ko
mice
mediat
immun
cell
locat
peripheri
taken
togeth
result
demonstr
key
role
activ
peripher
immun
compart
suggest
could
import
target
treatment
autoimmun
diseas
support
nih
grant
gm
ai
nation
ms
societi
grant
domin
encephalitogen
peptid
correl
abil
induc
potent
regulatori
cell
lin
miyak
sachiko
yamamura
takashi
nation
institut
neurosci
ncnp
tokyo
japan
like
human
counterpart
ms
anim
ms
model
show
great
divers
clinic
cours
famou
model
eae
suscept
believ
determin
genet
factor
slj
mice
well
known
develop
relapsingremit
eae
rreae
immun
howev
found
prime
overlap
peptid
induc
monophas
eae
meae
resist
relaps
also
reinduct
eae
peptid
unlik
rreae
alreadi
discov
resist
origin
continu
high
select
induct
regulatori
cell
coexpress
ln
cell
remiss
phase
meae
furthermor
clarifi
underli
mechan
first
compar
cell
respons
eae
prime
sever
peptid
concern
contrari
convent
understand
truncat
ntermin
residu
elong
ctermin
residu
exacerb
relaps
reinduct
eae
danger
selfpeptid
differ
less
danger
one
flank
residu
prohibit
induct
potent
treg
next
check
domin
plp
peptid
sjlj
mice
immun
spinal
cord
homogen
surprisingli
domin
among
immunodomin
epitop
sjlj
mice
ln
cell
could
react
effect
one
experi
prime
lowdos
plp
peptid
disclos
domin
encephalitogen
peptid
resist
reinduct
eae
peptid
induc
show
indic
tcrpeptid
affin
determin
abil
induc
potent
treg
final
immun
mice
peptid
emulsifi
ifa
cfa
check
whether
eae
induct
necessari
found
phenomenon
depend
peptid
independ
eae
induct
find
suggest
varieti
clinic
prognosi
ms
might
depend
differ
kinet
potenc
treg
induc
differ
regulatogen
individu
control
domin
selfpeptid
would
confirm
idea
immunolog
homunculu
explor
new
therapi
full
recoveri
resist
relaps
long
period
would
avail
pregnanc
affect
clinic
cours
autoimmun
diseas
multipl
sclerosi
ms
rheumatoid
arthriti
lupu
studi
determin
immunoregulatori
role
pregnanc
effector
phase
murin
experiment
autoimmun
encephalomyel
eae
model
studi
ms
use
adopt
transfer
system
myelin
basic
protein
mbp
peptid
activ
mbp
cell
receptor
tcr
transgen
tg
donor
cell
donor
cell
tg
tg
cell
transfer
agspecif
activ
cell
nonpregn
virgin
recipi
result
eae
howev
transfer
agspecif
activ
cell
nonpregn
recipi
result
sever
eae
mortal
result
show
transfer
activ
agspecif
cell
recipi
pregnanc
result
eae
delay
onset
reduc
clinic
sever
transfer
activ
agspecif
cell
recipi
pregnanc
result
eae
reduc
cumul
score
reduct
mortal
observ
termin
pregnanc
recipi
cell
investig
mechan
pregnanc
suppress
adopt
transfer
eae
induc
cell
explor
three
altern
delet
agspecif
pathogen
cell
anergi
agspecif
pathogen
cell
deviat
agspecif
pathogen
cell
regulatori
cell
result
show
pregnanc
suppress
agspecif
prolifer
cytokin
product
howev
number
donor
tg
cell
increas
pregnant
environ
compar
nonpregn
control
mice
result
suggest
pregnanc
provid
immunoregulatori
environ
includ
anergi
deviat
suppress
activ
encephalitogen
cell
although
sever
studi
clearli
demonstr
abil
cell
prevent
eae
mice
mani
address
phenotyp
characterist
mechan
action
perform
kinet
cytokin
analysi
cellular
composit
secondari
lymphoid
organ
central
nervou
system
cn
differ
time
point
relapsingremit
eae
induct
sjl
immun
describ
kinet
possibl
migrat
featur
differ
subpopul
cell
cours
diseas
also
surprisingli
found
approxim
cell
posit
intracellular
cytokin
stain
cytokin
posit
cell
enrich
subpopul
result
show
small
consist
percentag
tcell
doubl
posit
effector
cytokin
question
concept
marker
tout
court
associ
suppress
function
also
mice
liver
x
receptor
agonist
amelior
experiment
autoimmun
encephalomyel
suppress
product
xu
drew
paul
univers
arkansa
medic
scienc
littl
rock
unit
state
liver
x
receptor
lxr
part
nuclear
receptor
famili
believ
regul
cholesterol
lipid
homeostasi
recent
shown
liver
x
receptor
agonist
antiinflammatori
effect
activ
microglia
astrocyt
also
demonstr
decreas
clinic
sever
experiment
autoimmun
encephalomyel
eae
anim
model
multipl
sclerosi
ms
ms
tcell
initi
autoimmun
diseas
recent
data
establish
cell
driven
refer
cell
play
pivot
role
pathogenesi
eae
aim
work
determin
effect
product
express
studi
demonstr
lxr
agonist
inhibit
product
ifngamma
activ
tcell
mog
prime
mice
tcrtransgen
mice
also
inhibit
express
tcell
addit
assess
effect
mrna
protein
express
spinal
cord
eae
mice
found
significantli
suppress
molecul
data
suggest
lxr
agonist
may
mediat
autoimmun
diseas
suppress
product
prolifer
studi
show
lymphocyt
respond
better
presenc
nonpdc
compar
pdc
increas
ratio
pdct
cell
alter
cell
prolifer
contrast
nonpdc
sinc
known
amplifi
effector
immun
respons
interplay
pdc
great
interest
yet
differenti
matur
pdc
bm
cell
wt
mice
compar
furthermor
prolifer
respons
lymphocyt
use
pdc
versu
wt
mice
show
differ
specif
note
ad
antiico
cultur
reveal
inhibit
wtpdc
matur
pdc
studi
mice
lack
result
less
pdc
among
bm
cell
popul
compar
wt
anim
nevertheless
differ
stimul
autoantigen
mog
specif
lymphocyt
use
pdc
wt
anim
observ
interestingli
use
pdc
mice
mogspecif
secret
antiinflammatori
decreas
wherea
secret
tnfa
proinflammatori
increas
data
help
better
understand
matur
condit
murin
pdc
role
immunoregul
support
bmbf
gz
recombin
protein
produc
hous
cho
cell
show
homolog
human
opna
surprisingli
therapeut
daili
administr
opnlik
protein
mg
kg
sc
result
signific
decreas
clinic
score
well
reduct
durat
paralysi
acut
phase
histolog
analys
perform
either
peak
primari
attack
end
treatment
show
reduct
leukocyt
infiltr
number
macrophag
cn
addit
detect
endogen
opn
plasma
level
eae
rat
show
increas
quantiti
compar
observ
healthi
rat
mimick
alreadi
known
ms
administr
opnlik
protein
provid
stabl
circul
level
cours
diseas
reach
around
ngml
level
induc
chang
endogen
opn
level
howev
correspond
lower
level
one
use
previous
publish
studi
exacerb
activ
ropn
observ
mous
eae
find
suggest
opnlik
protein
certain
treatment
regimen
may
play
antiinflammatori
activ
modul
infiltr
leukocyt
within
cn
thu
suggest
possibl
action
bind
andor
alphavbeta
integrin
receptor
determin
role
tgfb
signal
cell
eae
pathogenesi
use
transgen
tgfb
signal
report
abl
mous
model
sbelucrt
sbelucrt
mous
upon
ligat
receptor
phosphoryl
dimer
transloc
nucleu
subsequ
activ
smad
bind
element
sbe
promot
activ
sbe
promot
drive
simultan
express
luciferas
luc
rfp
r
herp
simplex
virusthymidin
kinas
show
upon
initi
eae
progress
microglia
astrocyt
activ
product
preced
onset
clinic
diseas
astrocyt
microglia
main
produc
neuron
infiltr
cell
identifi
primari
tgfb
signal
cell
blockad
tgfb
signal
system
administr
pharmacolog
drug
reduc
eae
diseas
accumul
cell
express
cn
concurr
treatment
eae
sbelucrt
mice
ganciclovir
gcv
led
ablat
tgfb
signal
divid
cell
well
allevi
eae
diseas
upon
cellular
analysi
system
gcv
treatment
littl
effect
peripher
immun
cell
popul
composit
cnsinfiltr
cell
alter
togeth
result
suggest
pathogen
role
tgfb
signal
cell
broaden
view
potenti
pathogen
cell
eae
progress
zuiderwijksick
ella
activ
microglia
promin
multipl
sclerosi
lesion
still
unclear
whether
role
benefici
detriment
contrast
organ
termin
differenti
popul
resid
antigen
present
cell
apc
outnumb
colon
precursor
major
microglia
within
brain
remain
undifferenti
immatur
state
wherea
effect
differenti
activ
process
monocyteand
bone
marrowderiv
apc
extens
studi
much
less
known
effect
microglia
activ
recent
demonstr
differenti
also
affect
microglia
activ
differenti
primari
microglia
adult
rhesu
monkey
mcsf
gmcsf
alter
apc
capac
chang
respons
tolllik
receptor
tlr
activ
new
data
lab
show
exposur
microglia
prototyp
dc
differenti
regim
gmcsf
inde
induc
cell
surfac
molecul
express
profil
reminisc
dclike
phenotyp
howev
mark
contrast
convent
dc
gener
donor
cell
longer
produc
proinflammatori
cytokin
respons
tlrmediat
activ
irrespect
tlr
ligand
use
present
data
mechan
behind
block
tlrinduc
proinflammatori
cytokin
product
appar
paradox
cellular
phenotyp
absenc
proinflammatori
respons
activ
stimuli
uniqu
microglia
like
impact
strength
type
immun
respons
gener
microgliat
cell
encount
therefor
also
present
data
function
consequ
interact
gmcsf
microglia
cell
antiinflammatori
tolerogen
potenti
microglia
might
lead
new
therapeut
avenu
halt
ongo
immun
respons
possibl
even
reeduc
infiltr
cell
aim
present
studi
identifi
basic
mechan
infect
may
induc
neuronspecif
autoimmun
respons
gener
mice
express
ova
neuron
autoantigen
control
neuronspecif
enolas
promot
nseova
mice
intracerebr
system
infect
attenu
listeria
monocytogen
secret
ova
lmova
induc
atacticparet
neurolog
syndrom
nseova
mice
bacteri
clearanc
brain
wherea
wt
mice
remain
healthi
immun
lmova
prior
intracerebr
infect
strongli
increas
number
intracerebr
ovaspecif
cell
aggrav
neurolog
diseas
cell
deplet
adopt
transfer
experi
identifi
cell
decis
mediat
autoimmun
diseas
importantli
nseova
mice
receiv
ovaspecif
tcr
transgen
cell
develop
acceler
sever
extend
neurolog
diseas
adopt
transfer
pathogen
cell
specif
home
ovaexpress
mhc
class
neuron
correspond
clinic
symptom
neuron
anterior
horn
spinal
cord
becam
apoptot
studi
conclud
molecular
mimicri
pathogen
neuron
induc
cellmedi
neurolog
diseas
sever
influenc
frequenc
specif
cell
induct
symptomat
phase
requir
intracerebr
presenc
pathogen
express
lymphocyt
torr
souza
bruno
sampaio
andr
barro
alexandr
gollob
kenneth
dutra
walderez
romanosilva
marco
protein
involv
signal
express
found
neural
neuroendocrin
cell
involv
sever
function
exocytosi
neurotransmitt
releas
enhanc
dopamin
receptor
desensit
inhibit
current
demonstr
import
mast
cell
function
stimul
fc
epsilon
ritrigg
exocytosi
releas
arachidon
acid
metabolit
sought
investig
whether
could
express
lymphocyt
monocyt
evalu
intracellular
signal
pathway
compromis
express
pkb
mek
inhibitor
investig
particip
mekerk
intracellular
signal
pathway
express
lymphocyt
stimul
vitro
use
flow
cytometri
result
data
show
downregul
express
dosedepend
lymphocyt
presenc
mek
pkb
inhibitor
cell
stimul
activ
cell
accompani
increas
express
express
lymphocyt
depend
mekerk
commit
cell
could
good
model
studi
financi
support
cnpq
fapemig
assess
relev
neuroinflammatori
respons
behavior
neurochem
neuropatholog
cerebrospin
fluid
csf
peripher
blood
analys
perform
male
adult
mice
expos
system
administr
mptp
data
collect
correl
longitudin
earli
h
late
week
time
point
upon
mptp
administr
wide
gene
express
analysi
mrna
speci
involv
inflamm
immun
stem
selfrenew
neural
differenti
migrat
da
metabol
signal
use
lowdensitybas
array
tlda
ventral
mid
brain
vm
striata
str
describ
mptpinduc
da
neurodegener
selfrepair
like
associ
local
biphas
astrogli
respons
spatiotempor
recoveri
tyrosin
hydroxylas
th
dopamin
transport
dat
immunoreact
ir
parallel
spatiotempor
return
synaptosmi
da
uptak
capac
tempor
reconstitut
damag
da
cell
bodi
axon
termin
appear
also
parallel
switch
nigrostriat
astrogli
phenotyp
among
total
mrna
speci
analys
identifi
major
timeand
regiondepend
upregul
inflammatori
chemokin
key
transcript
involv
da
neurodevelop
especi
morphogen
winglesstyp
mmtv
integr
site
wnt
activ
astrocyt
vm
identifi
potenti
element
wnt
signal
pathway
sustain
nigrostriat
selfrepair
work
suggest
surpris
selfrepair
abil
nigrostriat
da
system
follow
mptp
neurotox
implic
mptpreactiv
situ
inflamm
key
event
molecular
cascad
link
tissu
injuri
repair
deeper
understand
manipul
neurodevelopment
cue
undergo
recapitul
upon
cn
tissu
injuri
like
import
implic
treatment
neurodeneg
diseas
includ
pd
increas
evid
suggest
spinal
microglia
could
import
player
pathogenesi
neuropath
pain
report
previous
peripher
nerv
injuri
induc
earli
transient
spinal
microgli
cell
prolifer
close
correl
spinal
microgli
activ
develop
neuropath
pain
test
hypothesi
role
new
microglia
genesi
neuropath
pain
symptom
studi
investig
effect
potent
antiprolifer
antiinflammatori
cytokin
spinal
microglia
reaction
follow
peripher
nerv
injuri
impact
nerv
injuri
inducedhypersensit
rat
partial
ligat
left
sciatic
nerv
seltzer
model
sharp
decreas
paw
withdraw
threshold
bilater
respons
mechan
von
frey
hair
stimul
withdraw
latenc
heat
insult
hargreav
significantli
lower
unilater
injur
side
correspondingli
follow
nerv
lesion
microgliosi
induc
spinal
cord
signific
increas
number
brdu
cell
intens
marker
microglia
immunoreact
ir
observ
ipsilater
side
dorsal
horn
slight
increas
contralater
side
well
intrathec
infus
rat
recombin
day
start
day
nerv
ligat
inhibit
spinal
microgliosi
ipsilater
side
dorsal
horn
reduct
brdu
cell
salin
treat
rat
treat
rat
reduct
ir
intens
vs
intrathec
treatment
reduc
partial
nerv
injuri
induc
mechan
allodynia
injur
noninjur
side
complet
abolish
thermal
hyperalgesia
ipsilater
side
togeth
result
suggest
peripher
nerv
injuri
trigger
spinal
microgli
cell
prolifer
newli
gener
spinal
microglia
involv
genesi
hypersensit
pain
behaviour
inhibit
spinal
glial
respons
central
treatment
effect
limit
spinal
microgliosi
could
reliev
partial
mechan
allodynia
howev
complet
prevent
develop
thermal
hyperalgesia
deduct
cytotox
lymphocyt
show
similar
concern
vbetajbeta
usag
length
complementar
determin
region
biochem
characterist
amino
acid
suggest
common
drive
antigen
without
share
clone
addit
cell
persist
peripheri
hint
toward
either
autoantigen
persist
viral
infect
antigen
caus
immun
reaction
taken
togeth
tcr
analysi
provid
strong
evid
antigendriven
mhc
classi
restrict
cell
mediat
attack
cn
structur
domin
pathogenesi
neural
progenitor
cell
npc
possess
abil
regener
new
neuron
could
use
potenti
therapi
neurodegen
disord
diseas
multipl
sclerosi
ms
hivassoci
dementia
approach
may
impact
activ
cell
studi
investig
effect
activ
cell
granzym
b
npc
prolifer
differenti
primari
human
fetal
npc
treat
supernat
activ
cell
gb
nm
either
maintain
medium
differenti
medium
cell
prolifer
studi
brdu
incorpor
assay
h
neuron
differenti
use
betaiiitubulin
immunostain
day
npc
lysat
use
detect
intracellular
cyclic
amp
camp
elisa
gene
express
voltag
depend
potassium
channel
realtim
pcr
npc
cultur
also
pretreat
pertussi
toxin
ptx
ngml
blocker
margatoxin
mgtx
nm
sirna
studi
mechan
supernat
activ
cell
decreas
npc
prolifer
differenti
significantli
attenu
immunodeplet
gb
p
b
recombin
gb
treatment
also
decreas
npc
prolifer
differenti
p
b
gb
also
decreas
camp
level
npc
min
treatment
dosedepend
manner
p
b
increas
gene
express
h
p
b
pretreat
ptx
revers
gbinduc
effect
camp
express
increas
npc
prolifer
p
b
specif
blocker
mgtx
sirna
pretreat
also
protect
npc
neurogenesi
gb
treatment
determin
betaiiitubulin
posit
neuron
count
p
b
sirna
also
protect
primari
human
fetal
neuron
gbcaus
neurit
damag
determin
measur
neurit
length
p
b
gb
releas
activ
cell
inhibit
npc
prolifer
differenti
underli
mechan
involv
ptxsensit
giproteincoupl
receptor
subsequ
decreas
intracellular
level
camp
activ
blockad
provid
protect
npc
neuron
could
use
potenti
therapi
cellrel
neurodegen
diseas
ms
minocyclin
report
neuroprotect
activ
variou
anim
model
neurolog
diseas
major
mechan
effect
attribut
inhibit
microglia
inflamm
much
less
describ
possibl
minocyclin
could
act
directli
neuron
independ
microglia
activ
studi
test
protect
role
minocyclin
h
toxic
enrich
human
fetal
neuron
hfn
absenc
microglia
identifi
new
target
minocyclin
use
microarray
analys
furthermor
demonstr
induc
enzym
respons
stress
heme
may
import
protect
minocyclin
vitro
vivo
hfn
treat
minocyclin
expos
h
rel
intens
neuron
marker
measur
incel
western
analysi
gene
express
profil
treat
hfn
gener
use
microarray
realtim
pcr
rtpcr
conduct
valid
microarray
result
use
hfn
contain
neuron
astrocyt
devoid
microglia
found
h
kill
neuron
document
obviou
cell
loss
decreas
intens
neuron
marker
increas
activ
incel
western
analys
minocyclin
significantli
attenu
effect
h
neuron
could
therefor
protect
minocyclin
absenc
microglia
subject
hfn
dna
microarray
use
gene
chip
across
experi
involv
differ
hfn
prepar
found
mani
gene
upregul
h
minor
reduc
express
level
neuron
protect
minocyclin
latter
target
real
time
pcr
incel
western
investig
confirm
upregul
h
reduc
minocyclin
immunohistochemistri
show
neuron
astrocyt
reactiv
enzym
follow
h
exposur
necess
minocyclin
protect
h
current
investig
use
vitro
vivo
experi
conclud
minocyclin
confer
protect
effect
hfn
h
without
need
microglia
activ
may
involv
hitherto
unknown
mechan
minocyclin
modul
level
neuron
andor
astrocyt
neuroprotect
action
estrogen
es
mptp
shown
variou
report
femal
male
mice
howev
exact
mechan
phenomenon
remain
obscur
one
potenti
mechan
es
may
exert
action
modul
inflammatori
respons
nigrostriat
system
occur
earli
consequ
injuri
system
studi
chronic
effect
mg
per
pellet
releas
administ
prior
day
experi
day
experi
mptp
treatment
male
mice
month
old
dopaminerg
neuron
degener
inflammatori
reaction
nigrostriat
pathway
mice
receiv
mgkg
mptp
intraperiton
estim
striatal
tyrosin
hydroxylas
th
glial
fibrillari
acid
protein
gfap
content
western
blot
method
cytokin
tnfa
ifng
trophic
factor
gdnf
gene
express
rtpcr
method
cell
influx
nigrostriat
pathway
immunohistochemistri
day
post
intox
mptp
treatment
reduc
striatal
th
within
day
follow
intox
show
exert
neuroprotect
effect
upon
nigrostriat
system
administ
day
prior
intox
also
observ
protect
striatum
mptp
insult
administ
day
intox
implant
pellet
intox
attenu
mptpinduc
loss
striatal
th
timepoint
also
decreas
striatal
gfap
content
administ
prior
intox
mptp
caus
rapid
increas
striatal
tnfa
ifng
gene
express
pretreat
decreas
earli
express
ifng
mrna
fail
suppress
mptpinduc
increas
striatal
tnfa
mrna
level
pretreat
also
induc
increas
striatal
gdnf
gene
express
cell
influx
injur
brain
area
contrast
decreas
cell
infiltr
administ
prior
mptp
intox
studi
suggest
neuroprotect
effect
indic
mptp
model
might
mediat
modul
molecular
cellular
factor
neuroinflammatori
reaction
character
lysolecithininduc
demyelin
focu
earli
inflammatori
respons
possibl
role
yong
v
wee
hotchkiss
brain
institut
univers
calgari
calgari
canada
demyelin
diseas
central
nervou
system
cn
multipl
sclerosi
ms
featur
oligodendrocyt
ol
myelin
loss
concord
loss
axon
neuron
thought
drive
progress
disabl
patient
sever
studi
ms
brain
specimen
shown
good
correspond
region
axon
injuri
area
contain
leukocyt
infiltr
microglia
activ
tissu
cultur
studi
product
microgliamacrophag
lymphocyt
produc
axon
dysfunct
kill
neuron
recent
appreci
aspect
neuroinflamm
benefici
highlight
experi
signific
deplet
microglia
macrophag
demyelin
model
retard
remyelin
interplay
inflammatori
cell
subset
axon
injuri
demyelin
thu
requir
closer
examin
particularli
prospect
provid
neuroprotect
prevent
demyelin
enhanc
repair
use
toxinmedi
demyelin
cn
character
earli
inflammatori
neural
respons
follow
deposit
lysolecithin
solut
dorsal
column
region
spinal
cord
mice
kill
analys
day
inject
use
varieti
marker
find
axon
injuri
accumul
nonphosphoryl
neurofila
demyelin
myelin
basic
protein
alreadi
evid
day
lysolecithin
administr
time
frame
correspond
upregul
immunoreact
marker
microglia
macrophag
activ
abl
detect
increas
ol
lesion
side
time
point
flow
cytometri
show
macrophag
infiltr
mark
day
injuri
current
experi
direct
increas
decreas
extent
period
microgliamacrophag
reactiv
address
subsequ
impact
axon
injuri
demyelin
experi
seek
clarifi
benefici
detriment
role
immun
particularli
microgliamacrophag
activ
exacerb
injuri
convers
protect
repair
axon
myelin
preserv
axon
wallerian
degener
slow
wld
mice
shown
benefici
experiment
autoimmun
encephalomyel
eae
autoimmun
model
ms
wld
mice
axon
degener
delay
due
increas
nicotinamid
adenin
dinucleotid
nad
biosynthet
enzym
nmnat
activ
downstream
effector
increas
nmnat
activ
resveratrol
natur
polyphenol
compound
red
wine
receiv
consider
attent
chemic
respons
health
benefit
red
wine
current
test
clinic
trial
potenti
therapi
cancer
resveratrol
enhanc
activ
potenti
result
axon
preserv
exhibit
antiinflammatori
antivir
activ
test
whether
resveratrol
could
therapeut
possibl
limit
axon
damag
viral
model
ms
theiler
murin
encephalomyel
viru
tmev
infect
sjlj
mice
infect
intracerebr
da
strain
tmev
group
infect
mice
fed
diet
contain
resveratrol
mgkgday
acut
stage
infect
day
chronic
stage
day
control
diet
clinic
mice
treat
resveratrol
acut
stage
show
weight
gain
control
mice
week
post
infect
p
b
anova
week
infect
central
nervou
system
cn
tissu
spleen
mononuclear
cell
mnc
harvest
convers
mice
treat
chronic
stage
tend
higher
clinic
patholog
score
control
mice
although
reach
statist
signific
signific
differ
number
cell
express
viral
antigen
cn
mnc
prolif
respons
viru
among
experiment
group
specul
signific
weight
gain
acut
stage
earli
resveratrol
treatment
group
could
due
neuroprotect
properti
resveratrol
potenti
axon
spare
activ
resveratrol
could
great
benefit
sinc
perman
clinic
disabl
ms
result
form
degener
axon
regener
cn
administr
protect
dopamin
deplet
downregul
astrogli
activ
modul
cytokin
product
nigrostriat
system
femal
mice
neurodegen
disord
immun
system
involv
patholog
process
postul
potenti
role
estrogen
es
act
neuroprotect
dopaminerg
system
may
support
epidemiolog
report
show
gender
differ
parkinson
diseas
pd
aim
present
studi
examin
chronic
effect
es
mg
per
pellet
releas
dopaminerg
system
cytokin
product
femal
mice
month
old
murin
model
pd
induc
mptp
estrogen
administ
day
prior
day
mptp
intox
mptp
mgkg
inject
anim
four
intraperiton
ip
inject
interv
anim
sacrif
spinal
cord
disloc
differ
time
interv
day
follow
mptp
intox
striatal
dopamin
da
quantifi
highperform
liquid
chromatographi
hplc
glial
fibrillari
acid
protein
gfap
express
measur
western
blot
method
tnfa
ifng
tgfb
mrna
express
examin
rtpcr
mptp
treatment
decreas
da
concentr
within
day
enhanc
gfap
express
within
day
increas
tnfa
tgfb
mrna
express
day
ifng
mrna
day
follow
mptp
inject
estradiol
exert
neuroprotect
effect
upon
dopaminerg
system
less
pronounc
mptpinduc
decreas
da
administ
day
prior
mptp
es
implant
day
mptp
estrogen
inhibit
gfap
express
day
time
point
implant
prior
intox
within
day
time
point
administ
post
mptp
inject
estradiol
decreas
tnfa
ifng
mrna
express
day
tgfb
mrna
express
day
time
point
well
tgfb
mrna
express
day
intox
find
suggest
neuroprotect
effect
es
mptp
mous
model
pd
might
mediat
modul
inflammatori
reaction
may
inhibit
activ
astrogli
cell
decreas
product
inflammatori
mediat
includ
cytokin
contribut
macrophag
spontan
recoveri
spinal
cord
injuri
sci
current
debat
macrophag
long
perceiv
inhibitori
cn
recoveri
differ
condit
cell
acquir
distinct
activ
whose
effect
tissu
vari
destruct
benefici
want
defin
specif
contribut
infiltr
monocyt
spinal
cord
recoveri
aim
use
uniqu
model
allow
us
identifi
subsequ
ablat
activ
bloodderiv
myeloid
cell
spare
resid
microglia
ablat
monocytederiv
cell
found
close
proxim
injur
site
result
impair
recoveri
motor
function
restor
monocyt
pool
restor
heal
process
immun
previous
shown
augment
recoveri
sever
spinal
cord
injuri
result
enhanc
recruit
myeloid
cell
importantli
cell
exhibit
characterist
myeloid
deriv
suppressor
cell
mdsc
restrict
local
immun
respons
via
least
part
antiinflammatori
cytokin
interleukin
argu
discrep
regard
macrophag
contribut
recoveri
due
part
heterogen
cell
need
timelyregul
respons
follow
insult
studi
identifi
essenti
novel
role
recoveri
spinal
cord
injuri
infiltr
bloodborn
monocyt
provid
resid
microglia
oral
fingolimod
suppress
establish
eae
allow
remyelin
fingolimod
novel
oral
immunomodulatori
agent
significantli
reduc
rate
inflammatori
diseas
activ
compar
placebo
patient
relaps
ms
phase
ii
clinic
trial
fingolimod
convert
vivo
activ
phosphat
sphingosin
kinas
bind
receptor
high
affin
bind
fingolimod
lymphocyt
caus
sequestr
within
peripher
lymph
node
thu
reduc
lymphocyt
infiltr
cn
consid
import
part
mechan
action
fingolimod
addit
fingolimod
readili
cross
blood
brain
barrier
cn
cell
also
express
receptor
suggest
direct
effect
within
cn
current
experi
determin
fingolimod
protect
experiment
autoimmun
encephalomyel
eae
onset
demyelin
da
rat
immun
mog
plu
cfa
fingolimod
administ
rat
daili
po
mgkg
day
begin
day
post
immun
phase
eae
start
effect
fingolimod
clinic
score
demyelin
inflamm
axon
degener
determin
histolog
mri
mtc
use
mtc
establish
demyelin
present
initi
treatment
oral
administr
fingolimod
experi
rat
wellestablish
eae
significantli
reduc
clinic
eae
sever
compar
vehicl
mtc
analysi
reveal
white
matter
loss
continu
increas
vehicl
treat
anim
stabil
treatment
fingolimod
individu
lesion
observ
normal
mtc
signal
suggest
remyelin
histopatholog
analysi
show
reduct
macrophag
cell
infiltr
spinal
cord
fingolimodtr
rat
enhanc
myelin
axon
content
studi
demonstr
fingolimod
reduc
eae
sever
even
administ
late
stage
eae
onset
demyelin
support
possibl
fingolimod
could
also
protect
effect
progress
stage
ms
slaet
helena
stefani
hendrik
jerom
carman
sofi
stinissen
pieter
hell
niel
leukemia
inhibitori
factor
lif
produc
infiltr
immun
cell
glial
cell
autoimmun
injuri
respons
central
nervou
system
cn
respons
lif
promot
surviv
glial
cell
neuron
immunomodulatori
potenti
data
underli
event
lack
goal
studi
studi
mechan
lifmedi
protect
matur
oligodendrocyt
olg
determin
effect
lif
macrophag
function
lif
mediat
effect
studi
primari
rat
oligodendrocyt
macrophag
cultur
cell
viabil
measur
annexinvpi
stain
activ
signal
pathway
analyz
western
blot
rnase
protect
assay
myelin
phagocytosi
determin
use
diilabel
myelin
flow
cytometri
show
lif
protect
olg
select
synergist
insult
proinflammatori
cytokin
ifngamma
tnfalpha
protect
oxid
stress
staurosporin
induc
apoptosi
demonstr
lif
protect
independ
suppressor
cytokin
signal
mrna
express
level
result
indic
lif
induc
shift
cellular
machineri
toward
prosurviv
execut
program
illustr
enhanc
express
isoform
antiapoptot
molecul
activ
phosphatidylinositol
kinaseakt
pathway
demonstr
lif
modul
macrophag
function
inhibit
product
oxygen
radic
tnfalpha
mediat
cn
injuri
neuroinflammatori
diseas
multipl
sclerosi
ms
show
lif
play
role
myelin
phagocytosi
stimul
myelin
uptak
macrophag
result
demonstr
lif
neuroprotect
antiinflammatori
properti
enhanc
myelin
clearanc
implic
import
factor
lesion
develop
limit
immun
mediat
demyelin
diseas
ms
harada
yawata
izumi
takeuchi
hideyuki
sonob
yoshifumi
jin
shiji
doi
yukiko
liang
jianfeng
kawanokuchi
jun
mizuno
tetsuya
suzumura
akio
nagoya
univers
nagoya
japan
shown
previous
neurotox
factor
activ
microglia
glutam
produc
glutaminas
util
extracellular
glutamin
substrat
releas
gap
junction
studi
elucid
whether
similar
mechan
oper
macrophag
infiltr
central
nervou
system
inflammatori
demyelin
diseas
examin
neurotox
induc
macrophag
comparison
microglia
experiment
allerg
encephalomyel
eae
model
multipl
sclerosi
treat
glutaminas
inhibitor
gap
junction
inhibitor
carbenoxolon
cbx
microglia
isol
primari
mix
glial
cell
cultur
prepar
neonat
mice
periton
macrophag
elicit
ml
thioglycol
inject
intraperiton
mice
collect
neuron
cultur
prepar
mice
embryon
day
microglia
macrophag
cultur
micro
gml
lp
h
grade
concentr
cbx
glutam
concentr
condit
media
determin
glutam
assay
kit
colorimetr
method
inflammatori
cytokin
chemokin
detect
rtpcr
neurotox
condit
media
microglia
macrophag
treat
cbx
determin
dye
exclus
method
propidium
iodid
eae
mice
induc
myelin
oligodendrocyt
glycoprotein
peptid
cbx
inject
intraperiton
mice
everi
day
microglia
macrophag
stimul
lp
produc
glutam
lpsstimul
macrophag
condit
media
induc
robust
neurotox
complet
inhibit
nmda
receptor
antagonist
cbx
effect
suppress
glutam
product
subsequ
neurotox
activ
microglia
macrophag
eae
sever
significantli
reduc
mgkg
cbxtreat
mice
eae
onset
delay
eae
sever
significantli
reduc
mgkg
dontreat
mice
compar
pbstreat
control
studi
demonstr
similar
machineri
oper
macrophag
well
cbx
prevent
microgliamedi
neurotox
effect
prevent
macrophagemedi
neurotox
thu
drug
may
effect
therapeut
reagent
inflammatori
demyelin
diseas
report
transgen
mice
constitut
express
cell
costimulatori
ligand
microglia
spontan
develop
cellmedi
demyelin
diseas
shown
cell
primari
effector
cellsubset
initi
patholog
process
tcr
clonotyp
map
demonstr
clonotyp
cell
expans
within
cn
understand
patholog
process
occur
anim
model
character
phenotyp
function
statu
cell
accumul
cn
vast
major
cn
cell
display
phenotyp
featur
effectormemori
cell
activ
state
howev
unlik
convent
effector
cell
express
low
level
similar
memori
cell
subset
present
increas
number
peripher
lymphoid
organ
cn
cell
exhibit
potent
cytotox
directli
ex
vivo
capabl
coproduc
high
level
ifng
tnfa
upon
restimul
vitro
activ
receptor
also
express
high
proport
cn
cell
high
level
granzym
b
detect
directli
ex
vivo
signific
number
cn
cell
also
show
surfac
mobil
without
restimul
consist
activ
engag
cytolyt
activ
vivo
data
suggest
cell
reactiv
cn
microglia
may
origin
memori
cell
subset
report
maintain
interact
commens
selfantigen
cn
cell
potent
effector
cell
well
equip
induc
tissu
injuri
variou
pathway
transplant
multipot
neural
stemprecursor
cell
npc
protect
central
nervou
system
cn
inflammatori
damag
via
number
bystand
mechan
altern
cell
replac
includ
immun
modul
show
subcutan
inject
npc
significantli
protect
mice
chronicrecurr
autoimmun
cn
inflamm
via
novel
immuneregulatori
mechan
occur
within
secondari
lymphoid
organ
inject
npc
accumul
surviv
within
drain
lymph
node
stabli
modifi
perivascular
micro
environ
within
context
npc
restrain
dendrit
cell
function
via
bone
morphogenet
protein
bmp
mechan
andin
turnprev
expans
antigenspecif
encephalitogen
cell
effect
complet
revert
antagonist
noggin
result
suggest
novel
tolerogen
mechan
exert
immun
regulatori
npc
vivo
may
exploit
modul
aberr
peripher
immun
respons
lead
chronic
tissuespecif
autoimmun
stroke
lead
caus
longterm
disabl
industri
countri
investig
molecular
cellular
mechan
regul
function
recoveri
mice
subject
transient
focal
cerebr
ischemia
eg
middl
cerebr
arteri
occlus
mcao
transplant
intraven
iv
earli
postacut
phase
name
h
mcao
syngen
neural
stemprecursor
cell
npc
transplant
npc
select
accumul
periischem
area
correspond
later
striatum
day
posttransplant
dpt
surviv
dpt
histopatholog
reveal
ivinject
npc
accumul
brain
lower
number
npc
found
peripher
organ
eg
lung
liver
spleen
kidney
great
major
transplant
npc
accumul
brain
display
undifferenti
intermediatedifferenti
featur
dpt
npc
express
marker
termin
neural
differenti
start
dpt
ivinject
npc
induc
gradualthough
slow
amelior
neurolog
deficit
clinic
improv
npctransplant
mcao
mice
compar
shamtreat
control
reach
statist
signific
day
dpt
persist
dpt
neuron
surviv
astrogli
glial
reaction
neo
angiogenesi
inflammatori
reaction
analys
perischem
area
protein
mrna
level
neuropatholog
analysi
show
iv
deliveri
npc
associ
increas
number
surviv
endogen
neuron
signific
reduct
axon
loss
well
diminish
gliotic
scar
tissu
reaction
gene
express
analysi
confirm
downregul
number
key
gene
associ
glial
prolifer
well
upregul
gene
control
neuron
surviv
preliminari
data
provid
evid
postacut
system
inject
npc
promot
signific
clinicopatholog
recoveri
mice
experiment
mcao
bystand
protect
endogen
hypoxiainjur
neuron
inhibit
astrocyt
glial
scar
format
bonnamain
michel
delphin
daguin
thinard
reynald
dugast
annesophi
brachet
philipp
anegon
ignacio
vanhov
bernard
neveu
isabel
naveilhan
philipp
porcin
neural
precursor
cell
pnpc
fetal
brain
propos
altern
use
human
fetal
neuroblast
nb
neurodegen
disord
initi
thought
use
sourc
cell
replac
therapi
abil
expand
vitro
pnpc
great
interest
also
particular
immunomodulatori
andor
immunogen
properti
inde
recent
observ
rat
transplant
pnpc
exhibit
healthi
graft
day
postgraft
wherea
pnb
graft
reject
time
point
interestingli
surviv
graft
exhibit
sign
inflamm
immunostain
activ
macrophagesmicrogli
cell
neg
addit
observ
premis
lymphocyt
infiltr
indic
absenc
cell
determin
potenti
immunomodulatori
properti
npc
rat
lymphocyt
stimul
antibodi
mix
increas
number
pnpc
thymidin
assay
clearli
show
npc
inhibit
cell
prolifer
inhibitori
effect
close
depend
cell
ratio
find
major
inhibitori
effect
ratio
pnpc
cell
decreas
prolifer
rate
observ
ratio
pnpc
cell
interestingli
decreas
number
prolifer
lymphocyt
observ
ratio
npc
cell
result
obtain
npc
deriv
fetal
rat
tissu
determin
whether
contact
cell
npc
necessari
solubl
factor
suffici
npc
plate
upper
part
transwel
wherea
cell
cultur
lower
part
thymidin
assay
perform
three
day
later
inhibitori
effect
similar
one
observ
cell
direct
contact
observ
indic
solubl
factor
releas
npc
suffici
inhibit
prolifer
activ
cell
next
step
search
solubl
factor
known
interfer
cell
prolifer
rtpcr
immunocytochemistri
analys
reveal
express
sever
immunoregulatori
molecul
virtual
npc
indic
colocalis
nestin
marker
neural
stem
cell
molecul
critic
immunoregulatori
effect
npc
current
investig
use
specif
inhibitor
recent
character
human
mesenchym
stem
cell
msc
role
hematopoiesi
immun
modul
suggest
potenti
cell
therapi
extend
beyond
tradit
accessori
function
hsc
engraft
msc
easi
obtain
abl
differenti
multipl
lineag
osteoblast
adipos
tissu
cartilag
stromal
cell
contribut
significantli
tissu
restructur
immun
function
addit
facilit
durabl
longlast
stem
cell
engraft
focu
analysi
immun
synaps
format
cytoskeleton
reorgan
investig
cellcel
contact
analys
confoc
microscopi
immun
synaps
format
presenc
msc
furthermor
studi
natur
mscdc
cellcel
contact
electron
microscopi
found
msc
impair
activ
immun
synaps
format
shown
confoc
analysi
evidenc
electron
microscopi
two
type
intim
contact
msc
dc
gap
adher
junction
experi
show
msc
contact
induc
reorgan
dc
cytoskeleton
format
actin
podosom
structur
typic
immatur
state
therefor
tolerogen
dc
result
suggest
msc
exert
tolerogen
effect
dc
mechan
mediat
solubl
factor
investig
also
mediat
cellcel
contact
contact
induc
dc
cytoskeleton
reorgan
format
actin
podosom
far
sever
hypothesi
made
mechan
underli
tolerogen
effect
due
cocultur
msc
dc
show
short
term
contact
may
induc
tolerogen
phenotyp
actin
redistribut
recent
report
mesenchym
stem
cell
msc
exert
profound
inhibitori
effect
cell
prolifer
vivo
vitro
subsequ
msc
shown
exert
similar
effect
also
b
cell
dendrit
cell
nk
cell
addit
msc
support
recruit
local
precursor
cell
provid
trophic
factor
support
surviv
repair
injur
cell
data
suggest
msc
could
use
amelior
immunomedi
diseas
although
accept
msc
play
import
role
maintain
hematopoiet
stem
cell
undifferenti
state
exact
mechan
happen
still
unknown
start
address
question
recent
character
transcript
profil
purifi
msc
compar
cell
type
show
profil
enrich
transcript
factor
compon
wnt
signal
pathway
expand
transcript
analysi
character
signatur
msc
either
alon
cocultur
cell
differ
cultur
condit
end
period
cultur
cell
gentli
remov
well
leav
adher
msc
untouch
pure
msc
expos
stimuli
provid
cell
either
prolifer
analyz
gene
express
upon
rna
extract
amplif
hybrid
onto
affymetrix
mous
genom
array
accord
manufactur
instruct
affymetrix
inc
santa
clara
ca
control
group
util
rest
msc
msc
stimul
absenc
cell
well
cell
stimul
absenc
msc
vivo
studi
iv
inject
egfp
label
msc
mice
peak
eae
induc
mog
anim
follow
day
brain
spinal
cord
remov
stain
immunofluoresc
examin
upon
identif
egfp
cell
optic
microscop
cell
interest
captur
laser
microdissect
laser
captur
microdissect
egfp
cell
pool
subject
rna
extract
amplif
hybrid
onto
affymetrix
mous
genom
array
describ
emphasi
given
express
populationdefin
transcript
factor
differenti
signal
condit
analysi
result
identif
key
molecul
potenti
therapeut
implic
dc
stimul
lp
presenc
msc
fail
upregul
mhc
class
ii
costimulatori
molecul
thu
result
impair
capac
prime
antigen
specif
cell
mmsctreat
dc
show
impair
secret
orient
cytokin
furthermor
mmsc
significantli
decreas
dc
surfac
express
key
receptor
home
lymph
node
mmsctreat
dc
downregul
intracellular
compon
antigen
process
machineri
apm
order
dissect
impact
msc
lpsmediat
activ
dc
tolllik
receptor
analyz
realtim
pcr
express
profil
tlr
gene
dc
activ
lp
observ
signific
downmodul
key
molecul
involv
tlr
signal
includ
nfkb
mapk
result
suggest
mmsc
affect
adapt
immun
direct
effect
b
cell
also
impair
capac
dc
properli
instruct
cell
although
pathogen
mechan
involv
experiment
autoimmun
encephalomyelitismultipl
sclerosi
eaem
well
understood
accumul
data
suggest
oxid
stress
play
major
role
lesion
develop
metallothionein
mt
famili
lowmolecular
weight
cysteinerich
protein
act
protect
oxid
stress
central
nervou
system
cn
two
neuroprotect
antioxid
mt
isoform
mti
mtii
brainspecif
isoform
mtiii
act
inhibitor
neuron
growth
identifi
abund
mt
isoform
induc
cn
tissu
injuri
suggest
role
mt
sever
neuropatholog
present
studi
aim
evalu
express
profil
three
brain
mt
isoform
eae
progress
follow
murin
mesenchym
stem
cell
msc
treatment
parallel
oxid
stress
condit
monitor
assess
activ
main
antioxid
enzym
express
mt
isoform
significantli
increas
eae
mice
respect
control
signific
upregul
mti
mtii
mtiii
observ
alreadi
day
onset
diseas
induct
mt
respect
healthi
mice
increas
mt
transcript
observ
day
mice
treat
msc
upregul
mt
partial
revers
day
diseas
upregul
mt
isoform
decreas
valu
lower
observ
day
eae
anim
chang
cat
sod
activ
parallel
observ
mt
express
pattern
result
demonstr
eae
progress
clearli
associ
develop
oxid
stress
condit
brain
indic
increas
express
mt
isoform
activ
cat
sod
treatment
msc
significantli
reduc
mt
upregul
increas
antioxid
enzym
activ
accompani
progress
diseas
human
mesenchym
stem
cell
msc
endow
remark
immunomodulatori
properti
result
exploit
treatment
immunemedi
diseas
multipl
sclerosi
ms
studi
address
effect
unconvent
cell
name
nkt
gammadelta
cell
like
play
role
control
pathogenesi
autoimmun
diseas
first
studi
effect
msc
vitro
expans
popul
pbmc
stimul
agalactosyl
ceramid
nkt
isopentenyl
pyrophosph
gammadeltat
cell
respect
msc
inhibit
nkt
gammadelta
cell
expans
celltocel
contact
transwel
experiment
system
without
induct
apoptosi
observ
inhibit
partial
counteract
indometacin
inhibitor
synthesi
specif
block
molecul
report
involv
modul
immun
respons
msc
ido
tgfbeta
could
detect
effect
nkt
gammadelta
cell
expans
data
indic
repres
solubl
factor
preferenti
involv
mscmediat
inhibit
gammadelta
cell
expans
also
studi
effect
msc
prolifer
cytokin
product
cytotox
activ
vitro
expand
nkt
gammadelta
cell
msc
moder
inhibit
tnfalpha
ifngamma
product
nkt
impair
prolifer
without
significantli
interf
cytotox
potenti
nkt
gammadelta
cell
contrast
msc
lyse
activ
gammadelta
cell
though
tcr
recognit
inform
relev
especi
clinic
applic
mscbase
therapi
like
treatment
autoimmun
diseas
multipl
sclerosi
hydrogen
sulfit
gener
endogen
mammalian
tissu
normal
process
sulphurcontain
amino
acid
known
action
carri
cardiovascular
nervou
immun
system
besid
endogen
sourc
known
thermal
water
rich
sulphur
precursor
molecul
tradit
use
bath
therapi
benefici
effect
human
health
still
scarc
scientif
studi
subject
focus
effect
differ
physiolog
system
separ
present
work
investig
role
sulfur
thermal
water
neuroimmun
commun
twelvemonth
old
femal
mice
use
divid
two
group
first
call
sulfur
water
group
sg
submit
daili
bath
min
sulfur
water
second
control
water
group
cg
normal
water
treatment
perform
week
day
per
week
anim
motor
condit
neuromuscular
vigour
assess
tightrop
test
anim
reach
one
side
pole
rope
anim
fall
addit
periton
leukocyt
obtain
total
glutathion
level
cell
key
antioxid
organ
natur
killer
activ
nk
lysi
tumour
cell
determin
regard
tightrop
test
mice
sg
group
show
higher
percentag
reach
one
side
pole
situat
end
rope
sg
cg
lower
percentag
fall
down
sg
cg
respect
total
glutathion
sg
show
increas
level
respect
cg
group
cell
respect
p
b
tendenc
observ
nk
activ
sinc
mice
sg
group
show
higher
percentag
lysi
sg
cg
p
b
respect
cg
group
bath
session
thermal
water
rich
sulphur
compound
modul
neuroimmun
relationship
improv
matur
mice
neuromuscular
coordin
one
relev
immun
function
nk
activ
periton
leukocyt
cell
water
also
increas
total
glutathion
level
result
show
better
preserv
homeostasi
health
treat
anim
financi
support
foundat
research
innov
medic
hydrolog
spa
bilbili
foundat
grant
reticef
previous
shown
tripletransgen
mice
alzheim
diseas
harbor
appsw
transgen
develop
plaqu
tangl
show
genderspecif
cognit
behavior
impair
also
suffer
detriment
chang
key
lymphocyt
function
name
prolifer
respons
mitogen
concanavalin
lipopolysaccharid
natur
killer
cytotox
activ
tumour
cell
chemotaxi
toward
formyl
peptid
spleen
thymu
male
show
wors
function
femal
regulatori
cytokin
tumour
necrosi
supernat
lymphocyt
cultur
also
alter
mice
environment
enrich
ee
found
effici
improv
chang
present
work
wild
type
male
femal
nonand
environment
enrich
mice
use
ee
began
adulthood
month
last
month
hous
wheel
maintain
perman
wherea
object
differ
shape
color
chang
everi
day
anim
sacrif
age
month
thymu
spleen
remov
lymphocyt
obtain
total
glutathion
content
measur
enzymat
kinet
spectrophotometr
procedur
plasma
corticosteron
determin
radioimmunoassay
result
show
gender
exert
overal
effect
plasma
corticosteron
higher
femal
male
femal
ngml
p
b
analysi
reveal
ad
increas
corticosteron
male
male
male
ngml
p
b
benefici
effect
ee
decreas
level
shown
especi
male
nonenvironment
enrich
male
environment
enrich
male
ngml
p
b
regard
glutathion
content
differ
observ
thymu
lymphocyt
wherea
gender
show
overal
effect
spleen
lymphocyt
higher
femal
male
femal
nmolmg
prot
p
b
ee
exert
gener
effect
decreas
level
glutathion
spleen
lymphocyt
none
ee
nmolmg
prot
p
b
conclus
corticosteron
seem
play
import
role
genderspecif
immun
function
behavior
chang
exert
ad
ee
gender
differ
could
contribut
differenti
develop
diseas
therapeut
effect
ee
oxid
stress
lymphocyt
old
mice
similar
wild
type
anim
age
howev
femal
show
higher
glutathion
level
spleen
lymphocyt
could
indic
level
mechan
aim
control
increas
oxid
stress
occur
age
ee
would
effici
decreas
oxid
stress
spleen
lymphocyt
old
subject
would
reflect
lower
glutathion
level
need
therefor
ee
stand
key
strategi
decreas
oxid
improv
function
immun
system
healthi
nonhealthi
elderli
subject
mec
research
group
ucmcm
reticef
complement
inhibit
abrog
nerv
sodium
channel
disrupt
rabbit
model
guillainbarr
syndromeyuki
guillainbarr
syndrom
divid
two
subtyp
acut
inflammatori
demyelin
polyneuropathi
acut
motor
axon
neuropathi
aman
autopsi
result
indic
complement
activ
follow
membran
attack
format
import
mechan
subtyp
complementmedi
disrupt
voltageg
sodium
channel
cluster
node
ranvier
play
role
pathogenesi
aman
examin
whether
nafamostat
mesil
nm
serin
proteas
inhibitor
exhibit
anticompl
activ
could
inhibit
complementmedi
nav
disrupt
rabbit
model
aman
aman
rabbit
intraven
implant
two
osmot
pump
contain
nm
dimethyl
sulfoxid
treatment
group
four
rabbit
dimethyl
sulfoxid
alon
control
group
five
rabbit
deliveri
rate
mgkgh
day
immunohistochem
analysi
perform
examin
frequenc
deposit
complement
product
disrupt
sodium
channel
cluster
node
ranvier
spinal
anterior
root
complement
deposit
sodium
channel
disrupt
significantli
less
frequent
nmtreat
rabbit
compar
control
rabbit
clinic
sign
two
rabbit
rapidli
improv
nm
treatment
although
signific
differ
total
clinic
score
nmtreat
control
group
nm
could
inhibit
complement
deposit
consequ
prevent
complementmedi
sodium
channel
disrupt
aman
model
result
provid
rational
clinic
trial
use
nm
microglia
resid
macrophag
cn
implic
mani
acut
chronic
neurolog
diseas
includ
multipl
sclerosi
trauma
stroke
mani
laboratori
studi
role
activ
microglia
cn
pathophysiolog
molecular
mechan
control
activ
process
microgli
less
understood
recent
progress
genet
identifi
new
class
rna
molecul
call
microrna
mirna
involv
gene
regul
mirna
singlestrand
rna
molecul
nucleotid
complementari
site
untransl
region
utr
mrna
anneal
mirna
mrna
either
inhibit
protein
translat
facilit
cleavag
mrna
regul
add
unexpect
layer
complex
classic
linear
concept
function
role
mirna
microgli
activ
current
unknown
use
mirna
array
qrtpcr
mirna
found
limit
number
mirna
constitut
express
high
level
like
involv
mainten
microglia
phenotyp
furthermor
identifi
sever
mirna
regul
microgli
activ
lpsifngamma
stimul
correl
mirna
regul
profil
parallel
mrna
gene
array
data
target
evalu
gain
insight
effect
specif
mirna
use
transfect
mirna
mimic
valid
predict
mirna
target
qrtpcr
western
blot
mirna
integr
part
microgli
activ
process
identif
mirna
specif
pathway
may
constitut
new
target
therapeut
intervent
cn
injuri
associ
microgli
activ
stroke
multipl
sclerosi
alzheim
diseas
studi
eleven
ms
patient
eight
healthi
control
treg
cocultur
respond
cell
ratio
presenc
absenc
blp
found
blp
revers
treg
suppress
low
tregrespond
ratio
absenc
blp
treg
patient
lower
suppress
activ
treg
healthi
control
ratio
agreement
previous
report
defect
treg
function
ms
viglietta
et
al
j
exp
med
preincub
treg
respond
cell
blp
cocultur
demonstr
predomin
effect
stimul
treg
render
less
suppress
clarifi
dose
effect
stimul
blp
human
treg
activ
treg
cocultur
respond
cell
ratio
presenc
absenc
blp
suppress
respond
cell
prolifer
treg
significantli
reduc
blp
compar
blp
concentr
lower
tregrespond
cell
ratio
contrast
lower
concentr
blp
reduc
suppress
respond
cell
prolifer
treg
studi
demonstr
previous
uncharacteris
natur
treg
respons
differ
dose
stimul
suggest
infect
may
facilit
ms
exacerb
suppress
treg
function
seventyfour
mg
patient
particip
studi
treat
either
n
cya
n
measur
blood
drug
concentr
trough
level
mgadl
score
examin
relat
blood
drug
concentr
mean
mg
patient
n
genotyp
significantli
higher
genotyp
ngml
versu
ngml
p
n
ngml
versu
ngml
p
b
improv
mean
mgadl
score
month
administr
mg
patient
either
genotyp
tend
better
genotyp
cya
concentr
comparison
genotyp
reveal
signific
differ
mg
treatment
comparison
genotyp
reveal
signific
differ
concentr
adl
improv
multipl
sclerosi
ms
consid
autoimmun
diseas
ad
suscept
condit
control
multipl
gene
environment
factor
associ
ms
autoimmun
disord
suggest
recent
protein
tyrosin
phosphatas
gene
polymorph
propos
common
suscept
factor
sever
autoimmun
diseas
associ
ms
could
nt
demonstr
identifi
coexist
system
autoimmun
featur
ms
patient
rel
investig
whether
polymorph
associ
autoimmun
featur
patient
total
patient
definit
ms
accord
mcdonald
criteria
includ
studi
patient
character
presenc
posit
famili
histori
ad
group
coexist
autoimmun
diseas
group
presenc
posit
serum
autoantibodi
group
genotyp
n
polymorph
perform
use
assay
twenti
nine
patient
report
least
one
rel
ad
ms
hashimoto
thyroid
psoriasi
ad
thirteen
patient
report
least
one
coexist
ad
sixti
nine
patient
least
one
posit
serum
autoantibodi
ad
signific
differ
allel
frequenc
among
differ
group
observ
disregard
known
familiar
aggreg
ms
result
show
increas
frequenc
ad
ms
patient
rel
compar
portugues
gener
popul
lack
associ
ad
featur
polymorph
patient
may
due
lack
statist
power
given
small
number
case
identifi
studi
provid
support
concept
ms
might
aris
background
increas
suscept
autoimmun
agreement
result
larger
canadian
studi
although
specif
autoimmun
disord
ad
associ
uniqu
clinic
serolog
featur
overlap
tendenc
toward
famili
aggreg
may
explain
presenc
common
genet
suscept
polymorph
immun
system
relat
gene
hypothes
could
influenc
suscept
diseas
cours
differ
ad
previous
show
popul
posit
ms
patient
better
clinic
outcom
also
higher
frequenc
allel
assess
preval
coexist
ad
portugues
ms
patient
famili
relat
polymorph
diseas
aggress
total
definit
ms
patient
least
year
diseas
evalu
patient
subdivid
group
patient
maintain
edss
score
year
consid
benign
ms
n
patient
edss
score
defin
nonbenign
ms
n
genotyp
polymorph
perform
use
assay
famili
eleven
benign
patient
report
least
one
first
degre
rel
ad
compar
five
nonbenign
patient
vs
p
mostli
due
ms
familiar
aggreg
coexist
ad
four
benign
four
nonbenign
patient
coexist
ad
vs
phenotyp
frequenc
higher
benign
nonbenign
patient
vs
p
variant
previous
associ
increas
suscept
autoimmun
ms
seem
associ
good
prognosi
ms
patient
togeth
observ
higher
frequenc
autoimmun
diseas
rel
patient
benign
cours
suggest
differ
pathogen
pathway
implic
subgroup
patient
altern
genet
factor
relat
autoimmun
modul
cours
diseas
murin
experiment
autoimmun
encephalomyel
eae
induc
autoimmun
demyelin
diseas
model
human
multipl
sclerosi
ms
copaxon
approv
immunomodulatori
therapi
ms
discov
studi
eae
thought
main
mode
action
copaxon
induct
shift
tcell
shown
human
ms
copaxon
therapi
induc
upregul
cytotox
suppressor
tcell
respons
suggest
cell
integr
involv
mediat
immun
effect
drug
studi
show
copaxon
induc
robust
tcell
respons
even
mice
wherea
copaxon
immun
amelior
clinic
histolog
sever
eae
wild
type
mice
protect
observ
mice
indic
cell
requir
mediat
effect
copaxon
moreov
adopt
transfer
tcell
copaxoneimmun
ovaimmun
mice
result
amelior
eae
wildtyp
mice
suggest
therapeut
potenti
copaxonespecif
tcell
cell
appear
mediat
effect
cytotoxicsuppressor
mechan
similar
find
human
ms
conclus
studi
provid
strong
evid
vivo
induct
immun
modulatori
tcell
essenti
step
mediat
therapeut
protect
autoimmun
demyelin
past
decad
sever
new
radioligand
develop
positron
emiss
tomographi
potenti
clinic
use
sinc
microglia
play
import
role
health
diseas
studi
activ
state
radioligand
may
prove
use
assess
diseas
prognosi
progress
radioligand
bind
transloc
protein
kda
tspo
formerli
known
peripher
benzodiazepin
receptor
current
scrutin
protein
express
tspo
human
brain
wellstudi
addit
cell
type
express
tspo
vivo
debat
autoradiographi
use
combin
immunohistochemistri
ihc
cellspecif
marker
autopsi
tissu
anim
model
shown
microglia
main
cell
type
upregul
tspo
astrocyt
cell
type
interest
condit
purpos
studi
detect
protein
express
tspo
normal
diseas
human
brain
via
ihc
delin
cell
express
tspo
assess
express
tspo
via
ihc
use
two
antibodi
one
polyclon
one
monoclon
develop
tspo
two
antibodi
good
agreement
show
mild
stain
normal
brain
elev
stain
patholog
condit
alzheim
diseas
multipl
sclerosi
ischem
stroke
hiv
enceph
microglia
macrophag
appear
main
cell
type
express
tspo
although
limit
astrocyt
express
also
observ
ihc
tspo
use
anim
model
inflamm
shed
light
condit
govern
upregul
futur
studi
look
region
express
tspo
may
probe
time
upregul
tspo
vitro
studi
tongu
muscl
atrophi
rel
common
muskmg
patient
howev
clear
whether
tongu
muscl
atrophi
revers
observ
retrospect
chang
tongu
atrophi
immunosuppress
treatment
mri
observ
retrospect
chang
tongu
atrophi
immunosuppress
treatment
mri
retrospect
evalu
midsagitt
mri
number
cross
section
area
tongu
mm
mm
mm
muskmg
immunemodul
treatment
result
dramat
clinic
recoveri
even
long
cours
tongu
muscl
atrophi
revers
mening
myeloid
cell
middlemen
cell
defici
depress
behavior
peripher
immun
statu
tightli
link
central
nervou
system
cn
function
origin
studi
show
cell
benefici
effect
neuron
surviv
follow
cn
injuri
recent
role
immun
system
extend
normal
brain
function
cell
implic
cognit
function
adult
neurogenesi
two
major
aspect
adult
brain
plastic
sever
combin
immun
defici
scid
mice
exhibit
reduc
neurogenesi
cognit
impair
examin
spatial
learn
memori
task
eg
morri
water
maze
moreov
deplet
immun
system
wild
type
wt
mice
follow
bone
marrow
transplant
scid
mice
also
impair
cognit
function
cell
transfus
restor
cognit
function
neurogenesi
group
thu
immun
system
affect
aspect
brain
plastic
cognit
led
us
examin
effect
immunodepriv
might
abil
brain
withstand
stress
condit
assay
scid
wt
mice
use
forc
swim
test
fst
increas
immobl
indic
depress
phenotyp
show
scid
mice
strikingli
immobil
wt
fst
assay
scid
wt
mice
open
field
assay
found
differ
baselin
activ
examin
popul
mening
cell
group
immunohistochem
observ
reveal
although
number
mening
macrophagesmonocyt
compar
group
number
mhcii
posit
cell
significantli
lower
scid
mice
mening
isol
examin
flow
cytometri
reduc
mhcii
express
substanti
moreov
found
mening
macrophag
monocyt
scid
mice
show
increas
proinflammatori
phenotyp
character
express
cytokin
tnfa
propos
lack
matur
activ
cell
lead
skew
proinflammatori
phenotyp
myeloid
cell
consequ
lead
accumul
proinflammatori
cytokin
mening
final
depress
behavior
result
may
shed
new
light
etiolog
depress
behavior
chemotherapi
patient
elderli
hivdementia
condit
tightli
associ
cell
dysfunct
found
true
abovement
condit
studi
might
lead
develop
new
therapeut
approach
depress
base
modul
adapt
immun
pathway
fractalkin
interact
involv
leukocyt
infiltr
experiment
autoimmun
encephalomyel
mice
muramoto
kuboi
yoshikazu
ogasawara
hideaki
rikitsu
etsuko
mizuno
keiko
nishimura
miyuki
imai
toshio
kan
research
institut
kobe
japan
eisai
co
ltd
tsukubashi
japan
leukocyt
migrat
central
nervou
system
involv
sever
demyelin
diseas
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
fractalkin
fkn
uniqu
chemokin
uniqu
chemokinemucin
hybrid
structur
solo
receptor
express
microglia
monocytemacrophag
dendrit
cell
cytotoxiceffector
cell
report
fractalkin
constitut
express
sever
region
cn
interact
involv
eae
clarifi
role
pathway
eae
model
effect
antifkn
monoclon
antibodi
mab
eae
model
investig
mice
antifkn
mab
administ
everi
day
day
sensit
mog
myelineoligodendrocyteglycoprotein
administr
antifkn
mab
dose
mgmice
significantli
inhibit
develop
eae
symptom
infiltr
cell
spinal
cord
analyz
fac
infiltr
cell
includ
cell
dendrit
cell
decreas
administr
antifkn
mab
mrna
level
inflammatori
immun
gene
spinal
cord
analyz
realtim
pcr
analysi
elev
mrna
leukocyt
marker
cytokin
chemokin
observ
eae
model
suppress
administr
antifkn
mab
immunohistochem
analysi
also
show
inhibitori
effect
antifkn
mab
infiltr
leukocyt
spinal
cord
activ
microglia
antifkn
mab
also
show
therapeut
effect
administ
induct
diseas
plpinduc
eae
model
result
suggest
pathway
facilit
develop
eae
leukocyt
migrat
spinal
cord
acut
chronic
phase
modul
infect
microgli
proteom
astrocyt
astrocyt
brain
homeostat
regul
modul
broad
rang
neural
function
includ
regul
extracellular
glutam
neuron
network
control
neuron
activ
neurogenesi
secretori
broad
rang
growth
factor
includ
neurotrophin
cytokin
neurolog
diseas
caus
human
immunodefici
viru
infect
astrocyt
affect
mononuclear
phagocyt
mp
perivascular
tissu
macrophag
microglia
function
secret
neurotox
factor
nonetheless
littl
known
mpastrocyt
commun
infect
examin
question
employ
proteom
approach
primari
method
profil
gel
electrophoresi
dige
technolog
protein
identif
accomplish
use
nanolcmsm
ltq
orbitrap
thermo
scientif
sequenc
tryptic
digest
peptid
primari
method
valid
western
blot
analysi
examin
differenti
regul
infect
mp
protein
cocultiv
astrocyt
confirm
western
blot
reveal
differenti
regul
redox
structur
protein
preliminari
result
demonstr
gelsolin
leukotrien
hydrolas
adenylyl
cyclaseassoci
protein
decreas
mp
astrocyt
increas
annexin
carbonyl
reductas
calreticulin
precursor
protein
observ
conclud
astrocyt
significantli
affect
mp
proteom
follow
infect
affect
diseas
onset
progress
antileukocyt
adhes
therapi
treatment
seizur
epilepsi
seizur
paroxysm
hypersynchron
discharg
central
nervou
system
cn
neuron
repeat
seizur
lead
unknown
mechan
epilepsi
chronic
neurolog
disord
affect
gener
world
popul
experiment
clinic
data
indic
repeat
seizur
activ
lead
chronic
recurr
seizur
epilepsi
mechan
respons
transit
remain
unclear
goal
studi
role
leukocyt
traffick
mechan
pathogenesi
seizur
epilepsi
epilepsi
induc
inject
mice
pilocarpin
intravit
microscopi
vivo
stain
perform
cortic
brain
vessel
postseizur
magnet
reson
imag
confoc
microscopi
immunohistochemistri
telemetri
power
spectrum
analysi
behavior
evalu
cognit
test
also
perform
mous
model
epilepsi
seizur
caus
elev
express
vascular
cell
adhes
intercellular
adhes
eand
pselectin
brain
vessel
recruit
leukocyt
brain
intravit
microscopi
reveal
enhanc
granulocyt
lymphocyt
roll
arrest
brain
vessel
seizur
leukocytevascular
interact
inhibit
blockad
leukocyt
mucin
pselectin
glycoprotein
integrin
treatment
mice
antialph
integrin
mab
dramat
reduc
acut
chronic
seizur
activ
induc
pilocarpin
genet
defici
enzym
involv
glycosyl
also
inhibit
seizur
activ
neutrophil
deplet
reduc
seizur
induct
spontan
recurr
seizur
well
bloodbrain
barrier
bbb
leakag
induc
seizur
drastic
reduc
treat
fuct
defici
anim
establish
pathogenet
link
leukocyt
adhes
bbb
damag
seizur
gener
result
suggest
leukocyt
recruit
mechan
potenti
target
prevent
treatment
epilepsi
monocyt
human
immunodefici
viru
type
infect
highli
restrict
viruscel
exposur
thought
limit
consequ
physiolog
monocyt
advent
function
proteom
tool
avail
investig
consequ
cell
function
follow
exposur
end
investig
chang
proteom
plasma
membran
pm
monocyt
monocytederiv
macrophag
mdm
day
viru
exposur
viabl
human
monocyt
pm
label
cydy
fluorophor
lyse
subject
two
dimension
differenti
ingel
electrophoresi
dige
use
compar
pm
proteom
unaffect
expos
monocyt
tandem
mass
spectrometri
lcmsm
assay
show
pm
proteom
chang
exposur
differenti
express
protein
show
higher
fold
chang
protein
redox
protein
link
pm
protect
respiratori
burst
heat
shock
protein
leukotrien
hydrolas
biliverdin
reductas
bvr
repres
upregul
pm
protein
known
protect
free
radic
confoc
imag
flow
cytometri
analys
hivexpos
control
permeabil
control
cell
show
protein
upregul
transloc
pm
virusexpos
monocyt
western
blot
flow
cytometri
assay
pm
cytozol
fraction
stain
bvr
confirm
dige
result
next
investig
whether
transloc
three
protein
plasma
membran
specif
whether
use
pm
protect
antioxid
tocopherol
acet
sanguinarin
attenu
oxid
burst
monocyt
alter
level
protein
investig
alter
metabol
redox
system
provid
insight
cellpathogen
interact
compensatori
event
engag
pathogen
kill
host
defens
modul
respiratori
burst
multipl
sclerosi
ms
inflammatori
demyelin
diseas
central
nervou
system
cn
ms
thought
tcellmedi
diseas
although
major
focu
prior
research
tcell
shown
previous
ms
patient
healthi
subject
harbor
cnsspecif
tcell
mix
function
profil
role
tcell
pathogenesi
andor
regul
ms
still
unclear
also
shown
untreat
ms
patient
show
overal
deficit
immun
suppress
abil
tcell
correct
follow
glatiram
acet
copaxon
therapi
current
studi
address
role
cnstarget
tcell
ms
patient
develop
novel
flow
cytometrybas
vitro
immun
suppress
assay
first
confirm
valid
approach
replic
suppress
regulatori
tcell
treg
healthi
subject
observ
deficit
tregmedi
suppress
untreat
ms
patient
moreov
ms
patient
also
overal
deficit
tcellmedi
suppress
copaxoneor
cultur
interestingli
tcell
ms
patient
healthi
control
subject
target
cn
autoantigen
specif
control
antigen
exhibit
regulatori
abil
suppress
prolifer
tcell
conclus
result
confirm
ms
diseas
perturb
immun
regul
also
provid
first
evid
cnsspecif
tcell
may
regulatori
role
diseas
microrna
regul
brain
bodi
antiinflammatori
signal
microrna
mir
contribut
neuron
immun
cell
fate
involv
intertissu
commun
remain
unexplor
report
role
acetylcholinesteras
ach
mrnatarget
mir
regul
braintobodi
control
inflamm
show
increas
mir
decreas
ach
human
leukocyt
expos
bacteri
endotoxin
reduc
ach
inflamm
follow
treatment
mimic
mir
impair
cholinerg
antiinflammatori
regul
leukocyt
mice
overexpress
ach
devoid
mirrespond
element
find
identifi
ach
mrnatarget
mir
function
regul
brain
bodi
signal
open
avenu
studi
neuroimmun
dialogu
posttranscript
therapeut
intervent
inflammatori
reaction
innat
antivir
immun
receptor
human
microglia
suh
zhao
mengliang
belbin
thoma
j
patient
typic
gener
myasthenia
gravi
mg
autoantibodi
acetylcholin
receptor
achr
postsynapt
membran
neuromuscular
junction
earlyonset
mg
frequent
associ
thymic
abnorm
myasthenia
often
amelior
thymectomi
character
autoreact
antibodi
produc
thymu
memori
b
lymphocyt
isol
thymu
mg
patient
immort
immort
b
cell
epstein
barr
viru
ebv
transform
provid
tool
character
autoantibodi
mg
patient
overcom
low
effici
ebvbas
immort
polyclon
b
cell
activ
cpg
ad
b
cell
iggposit
b
cell
clone
cultur
product
monoclon
antibodi
screen
clone
immunohistochemistri
muscl
tissu
show
immunoreact
striat
muscl
protein
nevertheless
antiachr
antibodi
produc
bcell
found
immort
clone
studi
specif
non
posit
striat
muscl
antibodi
perform
protein
array
techniqu
conclus
increas
immort
effici
ebv
transform
addit
polyclon
b
cell
activ
allow
us
immort
memori
b
cell
mg
patient
subsequ
produc
monoclon
antibodi
interestingli
show
thymu
contain
enrich
popul
matur
bcell
achr
specif
final
improv
method
insight
patholog
autoimmun
diseas
might
obtain
help
identifi
autoantibodi
seroposit
doubl
seroneg
mg
patient
antibodi
play
central
role
immun
form
interfac
innat
immun
system
typic
mediat
proinflammatori
activ
investig
role
novel
posttransl
modif
lead
antiinflammatori
activ
antibodi
immunoglobulin
g
isotyp
antibodi
dynam
molecul
exchang
fab
arm
swap
heavi
chain
attach
light
chain
halfmolecul
heavylight
chain
pair
anoth
molecul
result
bispecif
antibodi
antiinflammatori
properti
antibodi
test
vivo
rhesu
monkey
model
experiment
autoimmun
myasthenia
gravi
passiv
transfer
pathogen
patientderiv
antibodi
acetylcholin
receptor
achr
induc
autoimmun
myasthenia
gravi
rhesu
monkey
immunoprohylaxi
antiachr
antibodi
prevent
myasthenia
gravi
well
characterist
structur
damag
accompani
electrophysiolog
chang
neuromuscular
junction
fab
arm
exchang
shown
dampen
receptor
downmodul
may
prevent
diseas
reduc
receptor
crosslink
intern
fab
arm
exchang
suggest
import
biolog
mechan
provid
basi
antiinflammatori
activ
attribut
antibodi
studi
provid
clue
novel
approach
develop
antigenspecif
immunotherapeut
treatment
patient
suffer
mg
possibl
antibodymedi
autoimmun
disord
multipl
sclerosi
ms
immunemedi
demyelin
diseas
central
nervou
system
cn
ms
anim
model
experiment
autoimmun
encephalomyel
eae
thought
mediat
regul
tcell
sever
report
us
other
show
cell
play
import
role
mseae
immunolog
glatiram
acet
ga
copaxon
immunomodulatori
ms
therapi
believ
mediat
effect
immun
deviat
shown
ga
therapi
induc
robust
cell
respons
suppressor
cytotox
natur
may
mediat
immun
effect
hlaemedi
kill
activ
cell
show
cell
fact
essenti
mediat
effect
ga
eae
also
address
role
cnsspecif
cell
diseas
process
cell
wide
believ
pathogen
natur
show
human
ms
eae
cnstarget
cell
immun
suppressor
role
also
demonstr
untreat
ms
patient
function
defici
also
regulatori
cell
reg
interestingli
human
cell
attain
transient
state
follow
multipl
mode
stimul
importantli
state
behav
unequivoc
like
bonafid
reg
assess
vitro
suppressor
assay
thu
believ
ms
diseas
perturb
immun
regul
character
inabl
sustain
induc
reg
therefor
evalu
interplay
antigen
present
cell
cell
dissect
abil
immun
popul
modul
cell
develop
suppressor
vs
effector
cell
studi
support
grant
award
nih
nation
ms
societi
njk
harri
weaver
neurosci
scholar
nmss
concurr
symposium
neuroprotect
strategi
neuroimmunolog
diseas
chair
khouri
appel
interact
immun
system
neural
stern
cell
brigham
women
hospit
harvard
medic
school
boston
usa
multipl
sclerosi
ms
autoimmun
diseas
caus
demyelin
axon
damag
central
nervou
system
major
patient
experi
relapsingremit
symptom
follow
secondari
progress
phase
lead
perman
disabl
chronic
diseas
set
current
treatment
ms
reli
immunolog
manipul
howev
becom
clear
repair
consid
goal
treatment
experiment
autoimmun
encephalomyel
eae
anim
model
ms
provid
power
tool
investig
pathogenesi
ms
although
current
evid
show
remyelin
regener
occur
spontan
extent
nearli
suffici
enough
ms
eae
remyelin
oligodendrocyt
aris
differenti
neural
progenitor
lack
progenitor
function
propos
play
role
remyelin
failur
ms
understand
inflamm
impact
function
neural
stem
cell
nsc
acut
chronic
critic
develop
therapeut
strategi
target
endogen
exogen
nsc
cell
astrocyt
crosstalk
health
diseas
j
kipni
recent
evid
suggest
cell
influenc
neuron
plastic
support
learn
memori
exampl
celldeplet
mice
exhibit
impair
cognit
perform
could
revers
follow
inject
exogen
cell
genet
match
donor
mechan
underli
benefici
effect
cell
brain
well
understood
suggest
cognit
impair
result
malfunct
mening
immun
surveil
cell
defici
mice
myeloid
cell
occupi
subarachnoid
ventricular
space
exhibit
skew
proinflammatori
phenotyp
absenc
cell
produc
high
level
proinflammatori
cytokin
proinflammatori
cytokin
produc
mening
myeloid
cell
propos
diffus
brain
parenchyma
affect
astrogli
activ
immun
defici
mice
possess
higher
level
activ
astrocyt
along
reduc
express
synaptogen
protein
compar
wild
type
mice
moreov
immun
defici
mice
fewer
hippocamp
synaps
compar
wild
type
counterpart
show
antiinflammatori
cytokin
interleukin
il
increas
express
astrocyt
proinflammatori
cytokin
tnfalpha
inhibit
express
supposedli
respons
reduc
synaps
cognit
impair
observ
immun
defici
mice
result
shed
light
potenti
mechan
underli
cognit
dysfunct
associ
immun
declin
might
also
lead
develop
new
futur
therapi
cognit
mental
condit
target
mening
neuroinflamm
mark
gliosi
infiltr
tcell
promin
patholog
featur
human
al
well
model
neurodegen
diseas
transgen
mice
ubiquit
overexpress
mutant
cu
zn
superoxid
dismutas
chronic
neurodegen
model
inherit
amyotroph
later
sclerosi
al
exhibit
neuroinflammatori
chang
document
innat
immun
system
play
pivot
role
determin
rate
diseas
progress
mice
demonstr
microglia
either
lack
reduc
express
enhanc
motoneuron
protect
slow
diseas
progress
model
studi
carri
mice
unabl
develop
myeloid
cell
peripher
central
immun
system
modifi
provid
evid
potenti
role
adapt
immun
system
model
bred
mice
mice
unabl
develop
matur
function
tand
bcell
mice
die
earlier
mice
tcell
present
within
spinal
cord
onset
diseas
unchang
follow
irradi
transplant
wtderiv
bone
marrow
surviv
extend
mice
age
ident
mice
immunohistochem
analys
spinal
cord
section
demonstr
tcell
restor
bmt
evid
presenc
b
cell
either
mice
mice
mice
cross
mice
mice
die
earlier
mice
confirm
import
tcell
mediat
neuroprotect
mice
lack
function
tcell
tcell
also
increas
mrna
level
proinflammatori
cytokin
decreas
level
trophic
factor
glial
glutam
transport
bone
marrow
transplant
reconstitut
mice
tcell
prolong
surviv
suppress
cytotox
decreas
mrna
level
proinflammatori
cytokin
increas
mrna
express
trophic
factor
glial
glutam
transport
result
demonstr
first
time
model
chronic
neurodegener
tcell
may
provid
neuroprotect
modul
trophic
cytotox
balanc
glia
glialtcel
interact
establish
novel
target
therapeut
intervent
al
possibl
neurodegen
diseas
regener
brain
role
neural
stem
cell
neuroimmunolog
unit
institut
experiment
neurolog
insp
dibit
san
raffael
hospit
milan
itali
inflamm
degener
usual
patholog
process
occur
central
nervou
system
cn
appar
distinct
process
soon
patholog
process
becom
chronic
tendenc
becom
strictli
interrel
primari
neurodegener
trigger
secondari
inflammatori
reaction
primari
inflammatori
reaction
lead
neurodegen
phenomena
sever
molecular
cellular
event
sustain
intrins
brain
repair
mechanismsoccur
within
cn
consequ
chronic
inflammatori
andor
degen
processeshav
describ
far
divid
three
distinctalthough
strictli
interrelatedcategori
inflammationdriven
process
cn
plastic
neuro
glio
genesi
one
hand
humor
cellular
inflammatori
compon
shift
sens
function
time
tissuedamag
mode
mode
promot
tissu
repair
eg
neurotroph
support
inflammatori
cell
hand
recruit
altern
nondamag
function
neuron
pathway
cortic
map
occur
mainli
via
axon
branch
synaptogenesi
take
place
consequ
brain
damag
whether
extent
recapitul
precis
development
pathway
underli
whole
phenomenon
brain
plastic
still
matter
investig
final
endogen
neural
stemprecursor
cell
npc
selfrenew
multipot
cell
cn
capabl
drive
neurogenesi
gliogenesi
adult
lifemay
adapt
target
migrat
damag
area
promot
repair
via
sever
mechan
action
eg
neuro
gliogenesi
immunomodul
neuroprotect
still
matter
investig
whether
equal
robust
brain
repairprotect
occur
follow
recruit
within
cn
transdifferenti
stem
cell
differ
embryon
origin
eg
development
plastic
vs
cell
fusion
multipl
sclerosi
ms
common
demyelin
diseas
cn
affect
young
adultsi
autoimmun
diseas
encompass
inflammatori
myelin
axon
destruct
degen
axon
neuron
loss
featur
spontan
brain
repair
remyelin
occur
earli
ms
evolut
fail
time
recent
evid
clearli
indic
immunolog
development
cellular
event
aim
restor
tissu
integr
ms
patient
oper
earli
diseas
evolut
lose
efficaci
time
support
ensu
idea
ms
progress
view
dysfunct
intrins
brain
repair
mechan
rather
caus
uncontrol
still
undiscov
pathogen
alien
antibodi
nicotin
acetylcholin
receptor
achr
implic
myasthenia
gravi
well
autoimmun
autonom
ganglionopathi
aag
aag
present
sever
gener
sympathet
parasympathet
autonom
failur
disord
also
known
acut
pandysautonomia
idiopath
subacut
autonom
neuropathi
disabl
manifest
orthostat
hypotens
oh
gastrointestin
dysmotil
autoimmun
pathogenesi
suggest
subacut
onset
frequent
associ
anteced
viral
ill
occasion
associ
cancer
autoimmun
disord
spontan
recoveri
patient
mani
case
rapid
onset
other
chronic
progress
cours
sever
clinic
experiment
observ
indic
aag
antibodymedi
disord
aag
patient
high
level
serum
antibodi
specif
neuron
achr
autonom
ganglia
ganglion
achr
mediat
fast
synapt
transmiss
autonom
ganglia
ganglion
achr
antibodi
found
aag
patient
distinct
muscl
achr
antibodi
found
patient
mg
ganglion
achr
antibodi
level
correl
sever
autonom
deficit
patient
high
antibodi
level
combin
oh
dri
eye
dri
mouth
adi
pupil
gastroparesi
neurogen
bladder
patient
low
antibodi
level
may
mild
restrict
autonom
deficit
postur
tachycardia
syndrom
pot
remov
antibodi
use
plasmapheresi
may
result
dramat
clinic
improv
induct
ganglion
achr
antibodi
rabbit
immun
lead
experiment
aag
reproduc
mani
cardin
featur
human
diseas
passiv
transfer
ganglion
achr
antibodi
mice
caus
transient
autonom
failur
electrophysiolog
studi
ganglion
achr
antibodi
produc
reduct
ganglion
achr
current
cultur
neuroblastoma
cell
inhibit
synapt
transmiss
isol
autonom
ganglia
due
reduct
amplitud
cholinerg
excitatori
postsynapt
potenti
aag
antibodymedi
channelopathi
produc
sever
potenti
treatabl
form
autonom
failur
depart
neurolog
kinki
univers
school
medicin
osaka
japan
antigangliosid
antibodi
frequent
present
autoimmun
neuropathi
particular
present
acutephas
sera
syndrom
gb
may
directli
involv
pathogenet
mechan
bide
region
respect
target
gangliosid
local
recent
found
presenc
igg
antibodi
specif
recogn
new
conform
epitop
form
two
gangliosid
gangliosid
complex
gsc
acutephas
sera
gb
patient
igg
antibodi
andor
complex
associ
sever
gb
requir
artifici
ventil
contrast
bind
activ
antibodi
highli
specif
weaker
toward
gsc
compris
alon
undergo
conform
chang
gsc
local
larg
sensori
neuron
dorsal
root
ganglia
monospecif
igg
shown
caus
factor
sensori
atax
neuropathi
howev
gb
patient
monospecif
igg
alway
ataxia
investig
whether
reactiv
igg
gsc
differ
gb
ataxia
without
ataxia
result
reactiv
mix
significantli
reduc
atax
patient
nonatax
patient
p
b
suggest
igg
antibodi
associ
ataxia
highli
specif
thu
highli
specif
igg
may
bind
tightli
caus
ataxia
gb
patient
miller
fisher
syndrom
mf
igg
antibodi
recent
investig
show
mf
patient
antibodi
higher
titer
gsc
includ
base
result
antigsc
antibodi
assay
three
type
igg
antibodi
mf
specif
specif
complex
specif
gangliosid
along
compon
cholesterol
known
form
lipid
raft
carbohydr
portion
two
differ
gangliosid
may
form
new
conform
epitop
within
raft
gangliosid
consid
interact
import
receptor
signal
transduc
studi
need
elucid
mechan
antibodi
gangliosid
gangliosid
complex
caus
nerv
dysfunct
increas
evid
suggest
cell
play
import
role
pathogenesi
multipl
sclerosi
ms
cell
found
greater
number
cell
acut
chronic
ms
lesion
preferenti
oligoclon
expans
cell
observ
blood
csf
brain
ms
patient
furthermor
therapeut
deplet
cell
improv
diseas
ms
patient
howev
deplet
lymphocyt
reduc
new
lesion
relaps
previous
demonstr
murin
model
cell
specif
myelin
basic
protein
mbp
induc
central
nervou
system
cn
autoimmun
upon
adopt
transfer
investig
pathogenesi
mbpspecif
cellmedi
autoimmun
diseas
gener
cell
receptor
tcr
transgen
model
use
two
differ
mbpspecif
cell
clone
one
model
exhibit
strong
central
toler
model
exhibit
uniqu
form
toler
allow
mbpspecif
cell
popul
peripheri
without
induc
diseas
use
first
model
show
neg
select
mediat
thymu
crosspresent
mbp
nonbon
marrow
deriv
cell
synthesi
direct
present
mbp
bone
marrowderiv
cell
use
second
model
demonstr
uniqu
state
toler
maintain
exposur
mani
immunogen
stimuli
broken
viral
infect
data
indic
abil
viral
infect
trigger
diseas
depend
upon
express
endogen
tcr
chain
mbpspecif
tcrtransgen
cell
express
particular
endogen
tcr
alpha
chain
confer
specif
viral
epitop
cell
activ
via
virusspecif
tcr
allow
cell
respond
endogen
mbp
use
transgen
tcr
interestingli
viral
infect
mbpspecif
tcr
transgen
mice
trigger
autoimmun
diseas
data
provid
potenti
mechan
infecti
agent
may
activ
myelinspecif
cell
trigger
cn
autoimmun
dualfac
role
alpha
bcrystallin
multipl
sclerosi
han
van
noort
delta
crystallon
bv
leiden
netherland
role
cell
multipl
sclerosi
ms
remain
somewhat
confus
one
hand
infiltr
local
activ
cell
one
central
nervou
system
cn
antigen
like
crucial
lesion
format
hand
abnorm
tcell
repertoir
ms
patient
appear
exist
would
explain
autoimmun
attack
cn
seemingli
paradox
element
reconcil
assum
ms
lesion
result
autoimmun
attack
abnorm
immun
system
instead
autoimmun
provoc
driven
neurodegen
process
within
cn
data
role
alpha
bcrystallin
cryab
support
latter
model
respons
stress
variou
kind
glial
cell
includ
oligodendrocyt
produc
strongli
increas
level
cryab
whose
prime
intracellular
role
antiapoptot
even
lymphocyt
infiltr
appar
cn
ms
patient
cryab
accumul
occur
glial
cell
reflect
form
neurodegen
stress
absenc
peripher
immun
element
cryab
also
secret
chaperokin
trigger
microglia
produc
tnfalpha
rant
cryab
help
recruit
immun
surveil
point
protect
cn
neuroinflamm
cryabdefici
mice
caus
damag
normal
mice
solubl
cryab
prevent
inhibit
neuroinflamm
unfortun
howev
human
select
immun
reactiv
cryab
much
cn
antigen
ms
patient
healthi
subject
alik
mark
number
proinflammatori
memori
cell
cryab
present
circul
well
anticryab
antibodi
immunereact
state
therefor
common
human
thought
bystand
effect
prior
viral
infect
combin
data
suggest
immun
surveil
provok
stress
cn
inadvert
recruit
also
cryabreact
element
sinc
local
antigenpres
cell
cn
ms
patient
offer
high
level
cryab
could
well
trigger
inflammatori
reaction
overwhelm
origin
protect
role
cryab
creat
ms
lesion
therefor
common
among
human
caus
ms
per
se
consid
cryabreact
cell
key
element
local
fuel
inflammatori
lesion
provok
stress
cn
possibl
solut
cryab
may
use
elimin
cell
controversi
debat
continu
whether
cell
abl
promot
central
nervou
system
repair
suggest
cell
inject
vaccin
strategi
encephalitogen
antigen
contribut
protect
secondari
damag
noninflammatori
brain
spinal
cord
injuri
howev
studi
challeng
recent
find
demonstr
approach
includ
sever
detriment
effect
contradictori
data
suggest
specif
molecular
crosstalk
immun
system
nervou
system
critic
determin
ultim
outcom
cell
action
brain
investig
use
cell
marker
cytokin
treatment
spinal
cord
injuri
report
releas
cell
independ
antigen
specif
stimul
substanti
fiber
regrowth
lesion
brain
spinal
cord
vivo
il
receptor
anim
mice
select
mutat
signal
transduct
cascad
inhibitori
antibodi
deliveri
vitro
vivo
use
identifi
cytokin
molecul
respons
cell
mediat
axon
outgrowth
could
show
aktmapk
pathway
crucial
cellmedi
axon
regener
classic
pathway
play
role
effect
result
increas
local
releas
neurotrophin
cell
convey
regener
via
il
depend
modul
neurotrophin
signal
locomot
analysi
reveal
significantli
improv
neurolog
outcom
lesion
mice
treat
cell
result
featur
key
player
cell
mediat
axon
reorgan
open
door
design
novel
cn
repair
strategi
demyelin
central
nervou
system
cn
axon
caus
devast
neurolog
impair
often
follow
myelin
repair
restor
function
protect
irreplac
nerv
fibr
degener
exampl
inflammatori
demyelin
lesion
multipl
sclerosi
ms
repair
mani
patient
although
strategi
promot
myelin
repair
eagerli
sought
factor
govern
remyelin
vivo
elus
chemokin
receptor
facilit
inflammatori
demyelin
promot
myeloid
leukocyt
entri
cn
block
cell
might
suppress
inflammatori
tissu
damag
postnat
cn
organogenesi
howev
posit
oligodendrocyt
progenitor
cell
opc
spinal
cord
receiv
time
growthfactor
stimul
present
clinic
experiment
demyelin
lesion
rais
question
whether
reengag
development
properti
might
enhanc
remyelin
case
inhibit
signal
could
antagon
tissu
repair
show
action
toward
nonhematopoiet
cell
unexpectedli
delay
myelin
repair
bone
marrow
chimer
mice
wt
subject
two
distinct
model
myelin
injuri
case
myelin
repair
effici
anim
opc
demyelin
lesion
recipi
prolifer
earlier
vigor
tissu
recipi
anim
invitro
demyelin
cn
slice
cultur
also
show
faster
myelin
repair
block
neutral
antibodi
genet
delet
propos
development
cue
function
aberrantli
cn
myelin
repair
instead
result
suggest
permit
optim
spatiotempor
posit
opc
demyelin
lesion
receiv
local
prolif
differenti
signal
given
action
toward
inflammatori
myeloid
leukocyt
nonhematopoiet
cell
present
find
identifi
uniqu
drug
target
clinic
demyelin
disord
four
differ
pattern
demyelin
describ
activ
demyelin
lesion
multipl
sclerosi
ms
patient
biopsi
shortli
diseas
onset
pattern
suggest
repres
heterogen
underli
pathogenesi
aim
present
studi
determin
lesion
heterogen
also
exist
unselect
collect
autopsi
materi
patient
establish
ms
postmortem
ms
brain
tissu
avail
vu
medic
center
assess
presenc
activ
demyelin
lesion
use
magnet
reson
imag
mri
guid
sampl
immunohistochemistri
tissu
block
contain
activ
demyelin
lesionsdefin
presenc
activ
macrophag
contain
intracellular
myelin
proteinswer
evalu
presenc
complement
antibodi
deposit
oligodendrocyt
apoptosi
differenti
loss
myelin
protein
hypoxialik
damag
use
histolog
immunohistochemistri
confoc
microscopi
sixtythre
tissu
block
ms
patient
contain
activ
demyelin
lesion
block
activ
demyelin
lesion
compar
block
activ
nondemyelin
inact
lesion
deposit
antibodi
activ
complement
compon
consist
associ
activ
demyelin
antibodi
complement
coloc
myelin
protein
phagocyt
vesicl
macrophag
pattern
observ
tissu
block
contain
activ
demyelin
lesion
lesion
heterogen
patient
found
preferenti
loss
myelin
protein
extens
hypoxialik
damag
oligodendrocyt
apoptosi
absent
rare
tissu
sampl
conclud
immunopatholog
appear
activ
demyelin
lesion
establish
ms
uniform
initi
heterogen
demyelin
lesion
earliest
phase
ms
lesion
format
may
disappear
time
differ
pathway
converg
one
gener
mechan
demyelin
consist
presenc
complement
antibodi
fcgamma
receptor
phagocyt
macrophag
suggest
antibodyand
complement
mediat
myelin
phagocytosi
domin
mechan
demyelin
establish
ms
metalloproteinasedisintegrin
adam
repres
famili
membraneanchor
metalloproteinas
proteolyt
disintegrin
characterist
play
import
role
develop
neurobiolog
nervou
system
adam
implic
ectodomain
shed
surfac
protein
growth
factor
remodel
compon
extracellular
matrix
ecm
present
studi
investig
role
adam
axon
outgrowth
myelin
peripher
nervou
system
pn
rat
dorsal
root
ganglia
drg
schwann
cell
sc
studi
vitro
express
pattern
predict
activ
metalloproteinas
investig
sc
qpcr
furthermor
mrna
analysi
perform
cocultur
drg
sc
day
seed
cell
day
induct
myelin
use
qpcr
protein
express
assess
immunostain
involv
process
axon
outgrowth
myelin
studi
greater
detail
appli
hydroxamatebas
inhibitor
premyelin
stage
well
myelin
process
mean
length
axon
measur
compar
control
group
use
western
blot
protein
express
level
use
marker
myelin
synthesi
among
adam
investig
reveal
highest
level
mrna
express
sc
mrna
level
upregul
consist
p
b
drgsc
cocultur
seed
cell
neuron
well
sc
wide
express
protein
level
neuron
express
exclus
limit
axon
premyelin
stage
axon
outgrowth
take
place
inhibit
result
signific
dosedepend
decreas
mean
length
axon
p
b
lead
nearli
outgrowth
highest
dose
cultur
treat
begin
seed
significantli
express
much
less
comparison
inhibit
begin
myelin
induct
control
one
data
suggest
adam
differenti
express
drg
sc
among
adam
investig
seem
play
critic
role
axon
outgrowth
peripher
nerv
inflamm
damag
cn
increas
appreci
benefici
aspect
neuroinflamm
promot
neuroprotect
repair
particular
leukocyt
sourc
neurotroph
factor
could
use
deliv
multitud
neurotroph
factor
injur
cn
challeng
har
benefici
aspect
neuroinflamm
avoid
potenti
detriment
consequ
multipl
sclerosi
ms
medic
glatiram
acet
ga
shown
immunomodul
mechan
includ
gener
helper
cell
cell
produc
antiinflammatori
cytokin
toxic
neuron
shown
produc
bdnf
anim
model
ms
experiment
autoimmun
encephalomyel
aharoni
et
al
pna
thu
prospect
har
benefici
inflamm
repair
use
cell
generatedmodul
ga
remyelin
may
occur
spinal
cord
injuri
process
remyelin
requir
gener
oligodendrocyt
precursor
cell
opc
matur
myelin
form
oligodendrocyt
sever
growth
factor
involv
gener
opc
import
one
includ
insulinlik
growth
plateletderiv
growth
factor
pdgf
bdnf
address
whether
gareact
cell
gatreat
macrophag
produc
growth
factor
also
examin
whether
ga
treatment
mice
demyelin
injuri
spinal
cord
could
promot
gener
opc
remyelin
vivo
result
show
gareact
cell
gatreat
macrophag
elev
level
growth
factor
particularli
condit
medium
gareact
cell
promot
matur
opc
progenitor
cultur
mous
brain
moreov
demyelin
mice
inject
daili
ga
first
day
increas
number
opc
around
injuri
site
day
compar
vehicletr
anim
correspond
elev
mrna
level
growth
factor
polar
inflammatori
marker
one
antiinflammatori
final
determin
ga
increas
indic
remyelin
day
injuri
experi
highlight
feasibl
promot
spinal
cord
repair
har
benefici
inflamm
use
medic
ga
pregnanc
reduc
multipl
sclerosi
ms
diseas
activ
especi
third
trimest
mitig
often
follow
relaps
within
first
month
postpartum
biolog
mechan
underli
amelior
rebound
diseas
larg
remain
unclear
dutch
ms
pregnanc
studi
aim
identifi
biolog
paramet
ms
diseas
cours
pregnanc
first
paramet
address
focus
antigen
present
cell
apc
drive
autoreact
cell
therefor
play
major
role
ms
diseas
progress
second
paramet
address
analysi
treg
versu
helper
cell
subset
cours
pregnanc
use
affymetrix
microarray
gene
express
cell
pregnant
ms
patient
pregnant
healthi
control
compar
use
stringent
statist
analysi
five
inflamm
relat
gene
upregul
twofold
furthermor
gene
downregul
twofold
microarray
data
confirm
qpcr
analysi
multicolor
flowcytometri
analysi
perform
order
identifi
treg
cell
preliminari
result
indic
frequenc
treg
alter
pregnant
ms
patient
overal
data
show
differenti
gene
express
apc
ms
patient
pregnanc
furthermor
preliminari
data
suggest
pregnanc
influenc
number
treg
cell
ms
patient
pregnanc
dutch
ms
pregnanc
studi
contribut
understand
complex
ms
diseas
cours
pselectin
glycoprotein
alpha
fucosyltransferas
fuct
enzym
glycosyl
control
bind
capac
involv
migrat
leukocyt
site
inflamm
although
previou
studi
shown
ligand
also
protect
role
model
autoimmun
diseas
controversi
emerg
studi
perform
experiment
autoimmun
encephalomyel
eae
goal
clarifi
role
mucin
glycosylationdepend
mechan
eae
among
method
two
photon
microscopi
perform
drain
lymph
node
immun
mice
prolifer
bioplex
assay
cytokin
product
perform
adhes
interact
quantifi
inflam
brain
microcircul
use
intravit
microscopi
specif
cell
produc
mice
transfer
significantli
sever
diseas
wt
cell
cocultur
perform
treg
effector
cell
show
defici
fuctvii
lead
mark
decreas
suppress
capac
prolifer
product
proinflammatori
cytokin
effector
cell
twophoton
microscopi
experi
perform
insid
drain
lymph
node
eae
mice
show
locomot
fuctvii
defici
mogspecif
cell
significantli
decreas
arrest
coeffici
increas
compar
wt
effector
cell
suggest
lack
fuct
activ
lead
prolong
contact
dc
increas
activ
effector
cell
moreov
fuctvii
defici
treg
display
alter
behavior
increas
averag
veloc
mean
motil
coeffici
addit
dysfunct
treg
mice
present
decreas
migrat
capac
inflam
brain
compar
wt
treg
moreov
intravit
microscopi
experi
show
fuctvii
defici
treg
display
dramat
decreas
adhes
interact
inflam
brain
microcircul
final
treg
defici
fuctvii
reduc
capac
suppress
eae
compar
wt
cell
data
suggest
fucosyltransferas
activ
multipl
role
censorship
eae
treg
particip
cellcel
contact
requir
effici
suppress
lymph
node
control
treg
migrat
inflam
brain
multipl
sclerosi
ms
chronic
diseas
central
nervou
system
cn
character
inflamm
myelin
damag
axon
degener
ms
diseas
relaps
markedli
decreas
pregnanc
greatest
reduct
diseas
observ
third
trimest
studi
pregnanc
murin
model
ms
experiment
autoimmun
encephalomyel
eae
diseas
sever
significantli
reduc
pregnanc
induc
establish
eae
also
observ
postpartum
flare
diseas
score
eae
suppress
occur
gestat
period
serum
factor
implic
primari
mediat
diseas
suppress
exosom
small
lipidbound
microvesicl
found
peripher
blood
import
intercellular
commun
exosom
abl
modul
immun
respons
relay
molecular
signal
cell
origin
target
cell
bear
specif
adhes
molecul
shown
pregnancyassoci
exosom
abl
suppress
antigenspecif
cell
prolifer
also
observ
concentr
circul
serum
exosom
increas
pregnanc
exosom
hypothes
dampen
immun
respons
pregnanc
protect
semiallogen
fetu
caus
global
immunosuppress
state
thu
examin
exosom
protein
known
influenc
cell
activ
fa
ligand
heat
shock
protein
ifngamma
har
mechan
exosom
suppress
immun
consequ
eae
extraordinari
implic
therapi
develop
ms
support
nih
grant
ai
nation
ms
societi
grant
nih
grant
regulatori
cell
inhibit
experiment
autoimmun
encephalomyel
via
distinct
depend
independ
mechan
davidson
shevach
ethan
nation
institut
allergi
infecti
diseas
nih
bethesda
md
unit
state
regulatori
cell
treg
import
control
divers
array
immunolog
respons
adopt
transfer
cell
mice
result
protect
experiment
autoimmun
encephalomyel
eae
deplet
popul
result
exacerb
diseas
treg
shown
produc
cytokin
immunosuppress
potenti
may
import
abil
inhibit
diseas
vivo
adopt
transfer
treg
inhibit
eae
underlin
import
cytokin
treg
mediat
suppress
track
adopt
transfer
congen
label
treg
demonstr
presenc
lymph
node
spleen
also
cn
timepoint
onset
clinic
symptom
suggest
role
prevent
immun
respons
situ
analysi
product
intracellular
stain
indic
treg
produc
either
lymph
node
spleen
rather
express
cytokin
almost
exclus
cn
consist
result
found
antigen
specif
induc
treg
capabl
limit
prolifer
activ
effector
cell
drain
lymph
node
immun
mice
effect
requir
thu
treg
inhibit
eae
via
two
distinct
mechan
first
independ
mechan
wherebi
treg
inhibit
prime
lymph
node
second
depend
mechan
requir
product
cytokin
treg
within
cn
ration
approach
treat
autoimmun
diseas
multipl
sclerosi
ms
requir
restor
self
toler
hypothes
overrepresent
selfconstitu
thymu
requir
avoid
autoimmun
extens
ms
exploit
thymusbas
toler
mechan
purg
autoreact
tcell
reinstal
immun
toler
thu
central
aim
studi
assess
whether
intrathym
deliveri
recombin
lentivir
vector
lv
engin
overexpress
myelin
oligodendrocyt
glycoprotein
mog
key
autoantigen
ms
amelior
sign
experiment
autoimmun
encephalomyel
eae
mice
anim
model
ms
anim
intrathym
inject
concentr
lentivir
vector
engin
express
mog
lvmog
hydrogen
potassium
atpas
irrelev
autoantigen
lvhkatpas
pb
control
agedmatch
naiv
anim
also
use
anim
subsequ
immun
encaphalotogen
peptid
week
posttreat
monitor
week
thereaft
anim
human
kill
tissu
organ
analyz
neurolog
assess
indic
untreat
control
anim
inject
lvhkatpas
pb
develop
fulmin
symptom
eae
immun
contrast
anim
receiv
therapeut
lvmog
vector
manifest
significantli
reduc
symptom
histolog
analysi
brain
spinal
cord
control
anim
show
inflammatori
lesion
correl
sever
area
demyelin
axon
loss
notabl
lvmogtreat
anim
demonstr
significantli
fewer
cellular
infiltr
correspond
lower
number
demyelin
area
littl
axon
loss
function
vitro
activ
cell
respons
lvmogtreat
anim
demonstr
decreas
prolif
respons
comparison
control
final
quantif
cytokin
immunoreact
activ
spleen
cell
supernat
reveal
tcell
proinflammatori
differenti
cytokin
significantli
reduc
lvmog
treat
anim
comparison
control
collect
data
indic
intrathym
deliveri
lvmog
repres
novel
form
toler
induct
treatment
ms
approach
add
armamentarium
nontox
genebas
strategi
treatment
debilit
diseas
cell
repres
highli
proinflammatori
popul
recent
shown
play
crucial
role
autoimmun
diseas
multipl
sclerosi
break
balanc
gener
exist
effector
lymphocyt
regulatori
compart
associ
autoimmun
recent
detect
strong
immunosuppress
function
within
subpopul
treg
cell
human
furthermor
show
subset
cell
decreas
multipl
sclerosi
patient
aim
studi
character
effector
cell
subset
releas
proinflammatori
cytokin
ifngamma
well
treg
cell
healthi
individu
age
match
patient
affect
relapsingremit
form
multipl
sclerosi
perform
multicolor
cytometr
analysi
assay
vitro
order
phenotip
function
character
cell
popul
mention
surprisingli
found
within
cell
ifngamma
cell
lymphocyt
suggest
recent
activ
proinflammatori
cell
contamin
pool
treg
cell
compart
interestingli
cell
confin
neg
cell
popul
thu
confirm
express
repres
valuabl
marker
treg
cell
within
compart
monitor
frequenc
cell
treg
cell
healthi
donor
ms
patient
found
decreas
frequenc
cell
among
subset
patient
associ
increas
effector
cell
releas
proinflammatori
cytokin
result
highlight
contamin
within
regulatori
compart
recent
activ
effector
cell
lymphocyt
human
furthermor
analysi
frequenc
popul
suggest
ms
patient
equilibrium
effector
cell
regulatori
subset
shift
toward
proinflammatori
cytokin
produc
cell
implic
find
discuss
esposito
ruffini
francesca
bellon
matteo
martino
gianvito
furlan
roberto
san
raffael
scientif
institut
milano
itali
rapamycin
novel
macrolid
immunosuppress
drug
wide
use
prevent
clinic
allograft
reject
previous
report
effici
suppress
autoimmun
diseas
increas
treg
cell
number
function
effect
extens
character
vitro
vivo
effect
level
function
treg
cell
popul
still
await
elucid
treat
sjl
mice
affect
relaps
eae
induc
immun
rapamycin
use
differ
administr
rout
includ
oral
schedul
studi
effect
clinic
patholog
immunolog
paramet
found
rapamycin
treatment
independ
rout
schedul
administr
significantli
amelior
clinic
cours
eae
protect
effect
confirm
also
find
reduc
demyelin
axon
loss
therapeut
effect
rapamycin
associ
decreas
infiltr
cn
cell
especi
macrophag
increas
treg
cell
cn
peripher
lymphoid
organ
rapamycin
administr
howev
associ
decreas
prolifer
inhibit
releas
ifngamma
antigenspecif
cell
drain
lymph
node
spleen
eae
rapatr
mice
compar
control
group
preclin
result
indic
rapamycin
effici
drug
control
experiment
induc
autoimmun
respons
provid
evid
immunolog
mechan
suggest
compound
plausibl
candid
treatment
multipl
sclerosi
natalizumab
human
monoclon
antibodi
direct
reduc
relaps
rate
mri
evid
diseas
activ
patient
multipl
sclerosi
ms
block
transmigr
cell
b
cell
central
nervou
system
cn
littl
know
effect
natalizumab
activ
stage
function
circul
leukocyt
use
flow
cytometri
studi
phenotyp
peripher
blood
mononuclear
cell
pbmc
patient
relapsingremit
ms
femal
seven
male
treatment
natalizumab
tysabri
biogen
idec
inc
mg
iv
month
blood
obtain
baselin
immedi
natalizumab
infus
month
none
patient
treat
immunomodulatori
drug
least
month
inclus
studi
pbmc
stain
directli
ex
vivo
vitro
stimul
studi
cell
ifng
lp
studi
b
cell
monocyt
pretreat
measur
compar
ontreat
measur
use
mix
effect
model
observ
express
ifng
increas
cell
type
studi
cell
earli
initi
natalizumab
treatment
remain
elev
throughout
followup
p
b
addit
cell
express
higher
level
tnfa
p
b
stimul
b
cell
display
increas
express
tnfa
p
b
natalizumab
treatment
express
two
chemokin
receptor
associ
previous
activ
effectormemori
cell
also
increas
natalizumab
treatment
p
b
frequenc
cell
doubl
first
month
treatment
increas
frequenc
cell
detect
later
treatment
conclus
observ
increas
number
leukocyt
express
proinflammatori
cytokin
peripher
blood
natalizumab
treatment
presum
due
sequestr
activ
cell
peripher
circul
accumul
potenti
aggress
leukocyt
blood
may
lead
rapid
influx
inflammatori
cell
cn
discontinu
natalizumab
treatment
may
clinic
concern
differ
chaperon
usag
assembl
reveal
novel
target
intervent
cytokin
secret
neuroinflamm
member
uniqu
dimer
cytokin
famili
compos
disulphidelink
compos
disulphidelink
addit
subunit
homodimer
form
cytokin
yet
poorli
understood
chemotact
activ
human
promiscu
subunit
indic
complex
regulatori
mechan
oper
level
partner
select
assembl
matur
fold
endoplasm
reticulum
er
prior
secret
involv
differenti
induc
develop
cell
cytokin
link
stage
develop
mainten
cn
inflamm
seen
ms
eae
known
therapeut
agent
includ
mab
ustekinumab
drug
interf
transcript
subunit
via
inhibit
nfkappab
block
simultan
via
subunit
yet
drug
avail
select
interfer
either
investig
assembl
stage
cytokin
use
inlab
establish
recombin
cell
line
specif
produc
identifi
geldanamycin
solubl
version
drug
capabl
block
secret
mechan
involv
er
chaperon
rather
cytosol
homologu
nm
inhibit
secret
secret
monom
test
concentr
geldanamycin
benzoquinon
ansamycin
shown
inhibit
immunoprecipit
experi
inhibit
interact
sirna
knockdown
complet
abolish
secret
inhibitor
includ
herbimycin
radicicol
also
inhibit
geldanamycin
research
concentr
abil
target
cancer
cell
suscept
inhibit
work
show
er
chaperon
vital
fold
dispens
fold
experi
underway
lab
test
eae
model
ms
full
compar
proteom
analysi
er
foldosom
perform
natalizumab
human
integrin
monoclon
antibodi
reduc
relaps
diseas
progress
patient
multipl
sclerosi
ms
wherea
presum
mode
action
inhibit
cellmonocyt
entri
brain
littl
known
specif
effect
b
cell
increasingli
recogn
particip
ms
pathogenesi
obtain
serial
blood
sampl
patient
natalizumab
therapi
ms
month
blood
sampl
untreat
ms
patient
healthi
donor
determin
number
matur
immatur
lymphocyt
subset
flow
cytometri
sampl
analyz
marker
transcript
immatur
hematopoiet
cell
quantit
pcr
preb
lymphocyt
gene
dntt
termin
deoxynucleotidyltransferas
sampl
natalizumab
therapi
increas
matur
b
cell
lymphocytesmonocyt
blood
increas
pb
even
greater
increas
immatur
preb
cell
p
b
pattern
remain
stabl
treatment
month
transcript
lymphocyt
precursor
dntt
elev
transcript
circul
b
cell
especi
preb
cell
promin
elev
among
studi
immun
cell
subset
rais
possibl
effect
side
effect
natalizumab
partli
mediat
action
b
cell
longitudin
systemat
gene
express
studi
focus
multipl
sclerosi
ms
effect
medic
subcutan
recombin
aim
attain
human
peripher
blood
deriv
gene
transcript
differenti
regul
throughout
therapi
infer
accessori
regulatori
pathway
appli
drug
employ
affymetrix
array
transcript
speci
perform
full
genom
studi
monitor
rrm
patient
receiv
sc
period
year
peripher
blood
sampl
collect
directli
process
ficol
first
treatment
correspondingli
upcom
inject
day
week
year
transcriptom
analys
realiz
includ
data
curat
ma
absentand
changecal
respect
probeset
qualiti
geneannot
specif
sensit
selfmad
algorithm
intens
depend
fold
chang
criterion
well
avail
r
softwar
packag
pair
ttest
princip
compon
analysi
gene
regulatori
network
infer
transcript
factor
bind
site
identif
transfac
jaspar
analys
underway
consist
upregul
throughout
analyz
time
point
four
gene
name
interferoninduc
protein
nuclear
bodi
protein
alia
protein
associ
topoisomeras
ii
homolog
dna
transcript
replic
relat
antigenlik
probeset
group
function
relat
gene
chang
time
major
analyz
individu
wherea
earlier
therapi
mainli
typic
induc
gene
filter
l
set
upregul
gene
domin
year
jup
consist
upregul
year
interest
upregul
killer
cell
gene
day
downregul
integrin
gene
month
posttherapi
filter
gene
repres
promis
candid
activ
involv
regul
effect
dynam
express
chang
individu
rna
profil
reflect
intertwin
diseas
therapi
cours
complex
divers
major
ass
bcell
epitop
among
differ
mammal
affect
vaccin
design
safeti
efficaci
immunotherapi
alzheim
diseas
cribb
head
elizabeth
vasilevko
vitali
failur
first
immunotherapi
trial
alzheim
diseas
ad
patient
due
meningoenceph
patient
receiv
vaccin
provid
opportun
develop
novel
secondgener
vaccin
reduc
potenti
advers
event
translat
effect
immunotherapi
ad
like
depend
well
anim
model
predict
type
immun
respons
occur
human
notabl
evid
clinic
trial
indic
overwhelm
antibodi
respons
free
nterminu
amyloidbeta
peptid
dae
howev
previou
studi
mice
identifi
intern
sequenc
efrh
near
nterminu
major
bcell
epitop
importantli
antibodi
gener
mice
bind
amyloid
precursor
protein
app
express
surfac
cell
wherea
antibodi
gener
clinic
trial
recogn
app
thu
differ
b
cell
epitop
may
signific
consequ
efficaci
well
safeti
immunotherapi
explor
divers
immun
respons
mammal
immun
mice
rat
guinea
pig
rabbit
goat
dog
vaccin
perform
fine
epitop
map
determin
major
bcell
epitop
western
blot
analysi
determin
whether
antibodi
crossreact
amyloid
app
surprisingli
found
major
bcell
epitop
mice
rat
goat
guinea
pig
locat
intern
sequenc
serum
speci
recogn
app
western
blot
convers
antibodi
monkey
canin
rabbit
close
resembl
report
immun
respons
human
recogn
free
nterminu
depend
free
aspart
acid
posit
one
peptid
expect
serum
speci
recogn
app
western
blot
thu
care
select
anim
model
test
new
vaccin
candid
may
facilit
effect
translat
human
clinic
trial
moreov
develop
immunogen
induc
neoepitop
antibodi
recogn
free
ctermin
natur
occur
truncat
form
app
may
improv
safeti
well
efficaci
new
activ
immun
approach
neural
stemprecursor
cell
npc
capac
selfrenew
gener
function
differenti
cell
eg
neuron
astrocyt
oligodendrocyt
due
plastic
npc
could
potenti
implement
cellbas
therapi
treat
neurodegen
diseas
multipl
sclerosi
besid
benefici
role
provid
cell
replac
npc
exert
neuroprotect
inflammatori
damag
act
multipl
mechan
altern
cell
replac
transplant
npc
mice
experiment
autoimmun
encephalomyel
eae
demonstr
amelior
diseas
npc
inject
intraven
subcutan
migrat
central
nervou
system
cn
also
accumul
surviv
persist
noncn
site
undifferenti
npc
found
within
lymph
node
even
day
transplant
peripher
district
npc
seem
immunomodulatori
effect
inde
npc
inhibit
activ
dendrit
cell
dc
prevent
expans
antigenspecif
encephalitogen
cell
vitro
elucid
crosstalk
npc
cell
immun
system
perform
ex
vivo
character
eae
mous
lymphnod
dc
dc
subset
differ
bodi
district
npcinject
treat
mice
analyz
especi
activ
state
given
extens
data
insight
obtain
mous
system
aim
extend
studi
human
npc
fetal
human
brain
also
perspect
clinic
trial
immunomodulatori
properti
alreadi
demonstr
human
mesenchym
stem
cell
although
exact
mechan
remain
elus
clearli
gene
crucial
develop
hse
yet
reveal
identif
gene
involv
hse
present
import
biolog
medic
implic
provid
dissect
immun
natur
condit
ration
understand
hse
pathogenesi
hosk
lane
thoma
univers
california
irvin
irvin
unit
state
inocul
neurotrop
jhm
strain
mous
hepat
viru
jhmv
central
nervou
system
cn
mice
result
acut
encephalomyel
associ
immunemedi
demyelin
diseas
jhmv
infect
induc
transcript
chemokin
receptor
signal
ligand
acut
chronic
diseas
yet
function
signific
molecul
either
host
defens
defens
defin
therefor
goal
studi
defin
function
role
elr
chemokin
host
defens
diseas
follow
viral
infect
cn
treatment
antibodi
acut
diseas
abrog
bloodbrain
barrier
bbb
breakdown
associ
diminish
express
virusspecif
cell
infiltr
correl
elev
viral
titer
brain
increas
mortal
silenc
signal
chronic
diseas
associ
increas
mortal
independ
either
viral
recrudesc
modul
leukocyt
entri
cn
affect
sever
demyelin
howev
treatment
result
increas
number
tunelposit
oligodendrocyt
oligodendrocyt
precursor
cell
cultur
oligodendrocyt
protect
apoptosi
respons
exposur
mhv
follow
inclus
ligand
dosedepend
manner
find
reveal
previous
unrecogn
differenti
role
elr
chemokin
host
defens
increas
bbb
permeabl
acut
diseas
protect
cell
oligodendrocyt
lineag
apoptosi
chronic
neuroinflammatori
demyelin
diseas
migrat
lymphocyt
central
nervou
system
cn
viral
enceph
hinder
bloodbrain
barrier
bbb
infiltr
cell
remain
local
perivascular
space
sequestr
leukocyt
away
parenchyma
believ
protect
cn
immunopatholog
injuri
infect
cn
highli
cytopath
neurotrop
virus
west
nile
viru
wnv
howev
requir
parenchym
penetr
lymphocyt
viru
clearanc
surviv
suggest
perivascular
local
might
hinder
antivir
immun
respons
wnv
enceph
use
human
murin
brain
specimen
individu
wnv
enceph
evalu
express
receptor
bbb
test
hypothesi
inhibit
would
promot
lymphocyt
entri
cn
parenchyma
increas
viral
clearanc
antagon
significantli
improv
surviv
lethal
infect
enhanc
intraparenchym
migrat
wnvspecif
cell
within
brain
lead
reduc
viral
load
surprisingli
decreas
immunopatholog
site
benefit
enhanc
cell
infiltr
suggest
pharmacolog
target
may
therapeut
util
treatment
acut
viral
infect
cn
requir
effect
immun
respons
staphylococcu
aureusinduc
experiment
murin
brain
abscess
tolllik
receptor
tlr
play
central
role
innat
reaction
bacteri
product
transmit
specif
immun
respons
pathogen
tlr
express
numer
cell
type
includ
innat
immun
cell
astrocyt
neuron
microgli
cell
cn
lipoprotein
lipopolysaccharid
specif
recogn
respect
examin
vivo
role
staphylococcu
aureusinduc
brain
abscess
intracerebr
inocul
bacteria
perform
surviv
studi
follow
histopatholog
qualit
flowcytometr
quantit
well
molecular
qpcr
studi
relev
chemokin
cytokin
phenotyp
mice
mice
die
wt
mice
recov
clearanc
bacteria
cn
significantli
delay
mice
compar
wt
anim
recruit
granulocyt
macrophag
cn
well
microgli
activ
expans
upregul
mice
inflamm
persist
especi
cn
also
mice
wt
mice
termin
infect
effect
collect
data
show
immun
respons
experiment
aureusinduc
brain
abscess
depend
crucial
recognit
aureu
also
requir
optim
intracerebr
immun
respons
disord
although
curabl
treatment
alzheim
diseas
ad
base
grow
understand
patholog
mechan
sever
novel
therapeut
strategi
develop
wide
accept
immunotherapi
one
potenti
method
activ
passiv
immunotherapi
reduc
adlik
patholog
improv
cognit
perform
anim
model
diseas
potenti
ad
patient
hock
et
al
suggest
tissu
amyloid
plaqu
immunoreact
tapir
antibodi
correl
well
slower
cognit
declin
ad
patient
receiv
activ
immun
aduv
thu
wish
develop
monoclon
antibodi
passiv
immun
therapi
ad
use
hybridoma
techniqu
develop
tapirlik
antihuman
mous
monoclon
antibodi
character
vitro
evalu
therapeut
effect
month
old
app
transgen
mice
intraperiton
administr
antibodi
week
obtain
monoclon
antibodi
isotyp
recogn
ntermin
portion
without
bind
denatur
nativ
fragment
higher
affin
dissoci
constant
respect
stain
prefer
peripher
part
senil
plaqu
ad
brain
section
recogn
plaqu
core
less
versu
p
b
inhibit
fibril
format
well
degrad
preaggreg
peptid
thioflavin
fluoresc
spectrophotometri
assay
decreas
amyloid
burden
compar
control
group
quantit
imag
analysi
p
b
significantli
reduc
level
rather
level
brain
lysat
quantit
elisa
assay
well
oligom
tb
fraction
brain
lysat
western
blot
enter
brain
decor
plaqu
surround
microglia
week
administr
therapi
induc
lymphocyt
infiltr
obviou
increas
microhemorrhag
examin
berlin
blue
stain
tapirlik
antihuman
amyloid
monoclon
antibodi
potenti
therapeut
applic
ad
recent
genet
studi
show
independ
role
hla
classi
gene
confer
suscept
chronic
human
inflammatori
diseas
diabet
multipl
sclerosi
ms
data
provid
strong
incent
investig
contribut
mhc
classirestrict
cell
induct
develop
diseas
investig
contribut
mhc
classi
restrict
cell
mous
model
central
nervou
system
inflamm
cell
specif
target
oligodendrocyt
primari
cellular
target
ms
lesion
assess
pathogen
impact
cell
oligodendrocyt
gener
mice
refer
doubl
knock
dki
mice
wellstudi
model
antigen
influenza
hemagglutinin
ha
select
express
oligodendrocyt
introduct
haspecif
cell
tcr
transgenesi
result
sign
central
peripher
toler
cn
patholog
dki
anim
exclus
express
ha
oligodendrocyt
result
lack
tcell
silenc
reminisc
natur
myelin
selfantigen
mog
transfer
preactiv
haspecif
cell
tcr
transgen
mice
dki
recipi
led
inflammatori
lesion
optic
nerv
spinal
cord
brain
lesion
associ
tcell
infiltr
focal
loss
oligodendrocyt
demyelin
microglia
activ
reminisc
activ
ms
lesion
order
trace
haspecif
cell
vivo
label
green
floresc
protein
gfp
stain
gfp
granzym
b
reveal
haspecif
cell
contain
granzym
b
granul
detect
within
cn
lesion
dki
mice
granzym
b
cell
found
close
apposit
carbon
anhydras
ii
cyclic
nucleotid
phosphodiesteras
oligodendrocyt
also
detect
gfp
cell
polar
granzym
b
granul
face
oligodendrocyt
suggest
direct
degranul
find
provid
import
new
insight
regard
cn
tissu
damag
mediat
cell
specif
sequest
antigen
extens
understand
role
cell
human
ms
pathway
protect
cn
autoimmun
expand
myeloidderiv
suppressor
cell
cell
surfac
molecul
express
ifngproduc
cell
upon
interact
ligand
termin
immun
ligand
interact
also
play
import
role
immun
toler
mice
treat
ig
fusion
protein
mice
toler
sought
studi
precis
mechan
induc
toler
immun
system
therefor
gener
mous
strain
overexpress
either
find
strain
cell
respons
suppress
associ
increas
frequenc
cell
exhibit
morpholog
consist
myeloidderiv
suppressor
cell
mdsc
find
transgen
mice
protect
experiment
autoimmun
encephalomyel
eae
murin
model
multipl
sclerosi
ms
protect
diseas
associ
increas
frequenc
mdsc
among
central
nervou
system
cn
infiltr
cell
lastli
find
loss
revers
mdsc
expans
observ
transgen
mice
restor
normal
immun
respons
mdsc
accumul
larg
number
cancer
patient
tumorbear
mice
potent
inhibitor
antitumor
immun
accumul
mdsc
also
observ
exposur
bacteri
parasit
viral
antigen
despit
biolog
import
mdsc
regul
immun
respons
molecular
pathway
expand
regul
mdsc
unknown
known
ifng
play
import
role
mdsc
fail
accumul
ifng
mice
requir
ifng
activ
suppressor
function
made
novel
observ
pathway
play
role
expans
andor
activ
mdsc
cell
surfac
receptor
express
ifng
secret
cell
find
consist
previou
studi
implic
ifng
mdscmediat
immun
suppress
sinc
msc
shown
divert
immun
respons
autoimmun
cancer
infecti
diseas
target
pathway
may
repres
import
therapeut
target
mani
immunemedi
diseas
cnsspecif
autoreact
cell
regulatori
role
autoimmun
demyelin
york
mendoza
jason
benagh
andrew
firan
mihail
karandikar
nitin
great
deal
current
knowledg
immun
pathogenesi
multipl
sclerosi
ms
deriv
work
murin
model
experiment
autoimmun
encephalomyel
eae
vast
major
studi
ms
eae
focus
role
tcell
diseas
underli
assumpt
autoimmun
diseas
howev
sever
report
us
other
implic
import
role
tcell
diseas
studi
specif
dissect
role
autoreact
cnsspecif
tcell
eae
similar
observ
human
ms
saw
robust
induct
cnsspecif
tcell
respons
sever
establish
model
eae
howev
unlik
recent
report
cell
purifi
unabl
adopt
transfer
diseas
mice
thu
vitro
activ
tcell
tcell
capabl
adopt
transfer
eae
mice
contrast
transfer
mogstimul
tcell
result
inhibit
eae
induct
suggest
regulatori
rather
pathogen
role
cell
mogload
target
cell
specif
kill
mogimmun
mice
tcelldepend
manner
cell
well
apc
appropri
cytolyt
target
mogspecif
cell
suggest
cytotox
suppressor
mechan
cell
conclus
studi
reveal
novel
immun
regulatori
function
cnsspecif
tcell
reproduc
gener
induct
eae
neuropatholog
parkinson
diseas
pd
includ
microgli
inflammatori
respons
cell
modul
diseas
previous
show
nitrat
alphasynuclein
creat
novel
antigen
epitop
capabl
induc
innat
adapt
immun
respons
exacerb
pd
pathobiolog
demonstr
pathogen
activ
nitrat
alphasynucleinmedi
immun
attenu
regulatori
cell
treg
mice
immun
nitrat
alphasynuclein
gener
robust
cell
prolif
proinflammatori
secretori
respons
transfer
cell
mptpintox
recipi
exacerb
microglialassoci
neurodegener
show
transfer
cell
mice
inject
tolerogen
dose
vasoact
intestin
peptid
vip
mptpintox
recipi
attenu
microgli
activ
promot
neuron
surviv
cell
also
show
enhanc
regulatori
function
antiinflammatori
secretori
respons
surprisingli
found
pool
splenocyt
synucleinimmun
vipinject
donor
afford
greater
neuroprotect
upon
adopt
transfer
mptpintox
recipi
viptreat
donor
alon
due
part
greater
suppress
capabl
treg
within
popul
use
proteom
cell
biolog
assay
found
treg
capabl
modul
microgli
neurotox
activ
regul
phagocytosi
induct
redoxact
enzym
bioenerget
protein
activ
microglia
suppress
reactiv
oxygen
speci
nuclear
factor
kappa
b
activ
data
demonstr
effect
treg
nitrat
alphasynucleinmedi
immun
activ
multifacet
therapeut
benefit
primari
oligodendrocyt
death
caus
autoimmun
presenc
axon
growth
inhibitor
adult
cn
also
appear
play
promin
role
limit
axon
regener
cn
injuri
growth
inhibitor
includ
cn
myelinderiv
astrocyt
glialscar
deriv
protein
nogo
protein
signific
compon
inhibit
sinc
cn
myelin
lack
nogo
possess
reduc
axon
growth
inhibit
axon
regener
improv
recoveri
observ
certain
strain
genet
engin
mice
lack
nogo
protein
spinal
cord
injuri
sci
sinc
degre
regener
vari
age
mutat
nogo
appear
collabor
factor
appear
determin
degre
fiber
regener
sci
mice
lack
two
myelin
protein
myelin
associ
glycoprotein
mag
olgodendrocyt
myelin
glycoprotein
omgp
well
nogo
greater
recoveri
axon
damag
spinal
cord
axon
receptor
nogo
identifi
one
receptor
also
mediat
inhibit
axon
outgrowth
two
myelin
inhibitor
mag
omgp
short
peptid
function
ngr
antagonist
nogo
function
administr
peptid
promot
signific
axon
regener
rodent
sci
moreov
regener
allow
improv
walk
function
treatment
succe
even
compound
administ
system
week
injuri
block
ngr
function
extracellular
domain
receptor
deliv
mice
sci
transgen
mean
rat
sci
intrathec
degre
fiber
sprout
moder
greater
select
blockad
mice
lack
also
show
enhanc
plastic
raphespin
rubrospin
corticospin
fiber
system
spinal
cord
injuri
contrast
poor
regener
cut
corticospin
fiber
growth
contralater
spare
corticospin
fiber
robustli
increas
mice
lack
work
demonstr
nogongr
blockad
stroke
promot
axon
sprout
improv
function
neurolog
recoveri
rodent
myelin
inhibitor
limit
axon
regener
injuri
play
physiolog
role
limit
brain
experiencedepend
plastic
advanc
understand
molecular
determin
axon
growth
within
adult
cn
like
lead
therapeut
method
promot
neurolog
recoveri
acquir
injuri
brain
spinal
cord
clinic
trial
oncolyt
virus
ov
cancer
reveal
agent
well
toler
howev
clearcut
evid
efficaci
elus
fundament
issu
continu
limit
efficaci
cancer
virotherapi
respons
host
ongo
viral
infect
respons
occur
level
intracellular
tumor
defens
viral
infect
extracellular
stromal
reaction
propag
viru
importantli
activ
host
defens
consist
innat
immun
well
inflammatori
angiogen
respons
combin
host
respons
sever
limit
curtail
tumor
cell
infect
viral
replic
thu
limit
anticanc
efficaci
thu
believ
host
respons
circumv
even
temporarili
andor
partial
order
fulfil
promis
anticanc
effect
agent
immun
privileg
pauciti
dendrit
cell
dc
brain
contribut
immunolog
ignor
glioblastoma
multiform
gbm
aggress
intracrani
primari
brain
tumor
herein
uncov
activ
gbm
antigenspecif
tcell
depend
immun
respons
mediat
releas
endogen
highmobilitygroup
box
die
tumor
cell
respons
herp
simplex
type
thymidin
kinas
tk
gene
therapi
chemotherapi
radiat
therapi
tumorderiv
activ
signal
gbm
infiltr
bone
marrow
deriv
dc
induc
system
cell
depend
antigbm
immun
respons
dc
recruit
tumor
follow
intratumor
express
fmslike
tyrosin
kinas
ligand
tk
use
chimer
mice
demonstr
tumor
infiltr
dc
deriv
bone
marrow
signal
requir
infiltr
dc
tumor
subsequ
activ
dc
effici
antigen
present
elispot
antigen
specif
tcell
prolifer
assay
indic
clonal
expans
tumor
antigen
specif
tlymphocyt
induc
treatment
glioma
bear
mice
adtk
gcv
crucial
occur
mice
identifi
endogen
ligand
respons
activ
tumor
infiltr
dc
releas
tumor
cell
vitro
respons
adtk
gcv
serum
gbm
bear
adtk
treat
mice
vivo
signal
induc
media
adtk
gcv
treat
tumor
cell
could
block
either
glycyrrhizin
bind
box
domain
prevent
subsequ
signal
antibodi
data
indic
endogen
gbm
deriv
ligand
administr
either
glycyrrhizin
immunoglobulin
tumor
bear
adtk
treat
mice
abolish
gbm
regress
long
term
surviv
highlight
critic
role
play
signal
elicit
tcell
depend
tumor
regress
summari
data
provid
first
experiment
evid
role
signal
endogen
ligand
ie
regul
immun
surveil
brain
tumor
antigen
discoveri
central
role
signal
overcom
immun
ignor
brain
tumor
epilepsi
incid
affect
estim
million
american
million
individu
worldwid
seizur
occur
singli
tempor
seizur
disord
adult
children
often
associ
infect
viral
infect
mani
infectiontrigg
seizur
disord
often
refractori
mani
current
establish
antiepilept
drug
patient
epilepsi
refractori
current
antiseizur
medic
goal
defin
character
novel
viru
infectioninduc
seizur
model
mice
determin
virushost
interact
lead
seizur
epilepsi
mice
infect
da
viru
dav
strain
theiler
murin
encephalomyel
viru
mock
infect
mice
follow
seizur
weight
chang
bodi
temperatur
motor
function
right
reflex
rotorod
neurolog
chang
includ
inflamm
perivascular
cuf
pyknoticdi
neuron
addit
variou
knockout
mice
infect
determin
role
tnfalpha
ifngamma
mice
suscept
seizur
induc
dav
infect
approxim
mice
develop
acut
behavior
seizur
day
pi
follow
variabl
latent
period
half
seiz
mice
spontan
seizur
epilepsi
motor
function
coordin
impair
seiz
mice
pyramid
neuron
pyknosisdeath
inflammatori
chang
hippocampu
correl
seizur
activ
defici
mice
develop
seizur
similar
number
wildtyp
infect
mice
fewer
number
infect
defici
mice
develop
seizur
wildtyp
infect
mice
interestingli
ifngammar
defici
mice
develop
seizur
wildtyp
infect
mice
cytokin
mrna
level
monitor
array
analys
realtim
pcr
innat
immun
respons
infect
dav
result
neuron
cell
death
seizur
seizur
resolv
follow
latent
period
mice
develop
epilepsi
character
model
enabl
investig
viral
immun
contribut
central
nervou
system
develop
seizur
disord
human
immunolog
synaps
cellular
molecular
biolog
antivir
immun
respons
brain
board
governor
gene
therapeut
research
institut
cedarssinai
medic
center
dept
medicin
molecular
medic
pharmacolog
brain
research
institut
jonsson
comprehens
cancer
center
david
geffen
school
medicin
ucla
lo
angel
ca
unit
state
immunolog
synaps
iss
mediat
cell
cell
commun
immun
system
brain
mediat
commun
antivir
cell
infect
brain
cell
antitumor
cell
brain
tumor
adapt
immun
respons
clear
adenovir
infect
cell
brain
brain
tumor
cell
high
effici
order
unravel
cell
molecular
biolog
cell
mediat
clearanc
viral
infect
cell
brain
develop
novel
approach
elucid
commun
pathway
cell
infect
brain
cell
brain
tumor
glioma
cell
previous
demonstr
cellmedi
clearanc
viral
infect
cell
brain
depend
eventu
lead
death
infect
brain
cell
also
shown
iss
mediat
intercellular
commun
tcell
infect
target
antigen
present
cell
brain
demonstr
polar
cell
establish
close
synapt
contact
viral
infect
astrocyt
determin
whether
act
exclus
target
cell
contact
cell
whether
secret
nonspecif
extracellular
space
within
brain
develop
novel
method
detect
vectori
releas
level
iss
describ
construct
novel
adenovir
bicistron
vector
encod
constitut
express
gene
eg
egfp
use
marker
identifi
infect
brain
cell
second
gene
control
induc
ga
element
eg
cre
recombinas
luciferas
vector
test
vitro
vivo
induc
report
gene
express
inject
mice
antivir
cell
induc
express
indic
establish
contact
infect
cell
releas
induc
express
cre
remov
stop
codon
within
locu
allow
express
releas
immunolog
synaps
current
examin
method
allow
us
util
regul
transgen
express
mean
elucid
exist
target
vectori
releas
cell
cytokin
evalu
function
immunolog
synaps
orchestr
function
neuroimmunolog
circuit
antivir
antitumor
immun
respons
brain
vivo
support
nindsnih
viral
infect
promot
diminish
autoimmun
type
diabet
relationship
diseas
understood
found
prevent
autoimmun
diabet
acut
viral
infect
result
regul
antivir
immun
follow
challeng
prediabet
phase
lymphocyt
choriomening
viru
lcmv
program
deathligand
increas
autoreact
cell
declin
regulatori
cell
treg
enhanc
term
number
product
capac
control
even
diseas
viral
induc
upregul
delay
overt
diabet
facilit
action
viral
enhanc
treg
synergist
phenomenon
enabl
inflamm
tolllik
receptor
result
reconcil
current
discord
role
virus
provid
novel
insight
diseas
etiolog
potenti
treatment
innat
immun
evas
mechan
neurovirul
murin
coronaviru
susan
r
weiss
neurovirul
murin
coronaviru
mous
hepat
viru
mhv
possess
mechan
ensur
propag
persist
despit
exist
host
defens
strategi
type
ifn
respons
import
host
defens
vivo
demonstr
increas
suscept
mhv
ifn
receptor
knockout
mice
shown
mhv
induc
mrna
synthesi
albeit
late
time
postinfect
induc
protein
synthesi
mous
fibroblast
cultur
cell
type
prior
studi
report
produc
type
ifn
respons
mhv
plasmacytoid
dendrit
cell
howev
observ
mhv
induc
sever
type
primari
cell
cultur
deriv
murin
central
nervou
system
induc
macrophagesmicroglia
brain
well
cultur
bone
marrow
deriv
macrophag
bmm
furthermor
mhv
induct
least
bmm
depend
other
report
mhv
highli
resist
antivir
effect
ifn
fibroblast
cultur
coinfect
mhv
provid
protect
ifnsensit
sendai
viru
ifn
administ
prior
mhvsendai
coinfect
howev
pretreat
cell
mhv
provid
protect
antivir
effect
sendai
ifn
sensit
virus
includ
ndv
sindbi
vsv
use
report
link
interferonstimul
respons
element
isr
found
mhv
infect
prevent
activ
isr
sendai
infect
interestingli
mhv
prevent
transloc
nucleu
follow
treatment
suggest
mhv
abl
activ
block
later
step
bind
isr
similarli
mhv
prevent
type
interferon
independ
activ
sendai
isr
driven
report
gene
howev
inhibit
transloc
nucleu
suggest
bind
isr
may
inhibit
mhv
infect
use
quantit
realtim
pcr
shown
mhvinfect
downregul
number
wellcharacter
isg
import
recognit
viral
dsrna
antivir
defens
current
investig
signific
ifninduc
gene
defens
mhv
mechan
mhv
downregul
express
peroxisom
proliferatoractiv
receptor
ppar
belong
famili
nuclear
hormon
receptor
involv
inflamm
lipid
glucos
metabol
cell
prolifer
differenti
previou
work
laboratori
examin
efficaci
use
pparg
agonist
spinal
cord
injuri
sci
note
modest
behavior
anatom
improv
studi
examin
express
pattern
sci
ppard
preval
ppar
isotyp
central
nervou
system
involv
brain
lipid
metabol
differenti
oligodendrocyt
progenitor
cell
opc
myelin
also
appear
play
protect
role
certain
diseas
model
like
experiment
autoimmun
encephalomyel
eae
parkinson
cerebr
ischemia
studi
use
rat
spinal
contus
model
investig
whether
ppard
express
chang
spinal
cord
injuri
sci
contus
sci
perform
level
spraguedawley
rat
spinal
cord
tissu
collect
day
postinjuri
dpi
uninjur
spinal
cord
serv
control
crosssect
span
injuri
site
use
examin
number
distribut
phenotyp
cell
express
ppard
observ
injuri
ppard
cell
number
gradual
increas
throughout
first
week
dpi
express
level
significantli
elev
reach
almost
twice
uninjur
control
cell
number
remain
elev
least
dpi
ppard
local
primarili
neuron
cell
put
oligodendrocyt
progenitor
oligodendrocyt
astrocyt
rise
express
could
reflect
endogen
neuroprotect
mechan
may
influenc
cell
surviv
promot
myelin
futur
studi
examin
whether
provid
ppard
agonist
sci
benefici
test
role
endogen
ppard
signal
cn
repair
perform
sci
demyelin
injuri
ppard
knockout
mice
support
christoph
dana
reev
foundat
alzheim
research
laboratori
case
western
reserv
univers
depart
neurosci
cleveland
oh
unit
state
alzheim
diseas
ad
typifi
deposit
peptid
brain
owe
imbal
product
clearanc
peptid
apolipoprotein
e
isoform
associ
agerel
risk
alzheim
diseas
play
critic
role
homeostasi
brain
although
basi
remain
central
unansw
question
ad
pathogenesi
liver
x
receptor
lxr
ligandactiv
transcript
factor
regul
basal
induc
express
key
cholesterol
homeostat
gene
apo
importantli
lxr
also
act
potent
inhibitor
inflammatori
gene
express
report
lxr
signal
impact
develop
adrel
patholog
oral
treatment
one
year
old
mice
lxr
agonist
result
signific
reduct
amyloid
plaqu
burden
abeta
peptid
level
brain
accompani
suppress
microglialmedi
inflamm
genet
loss
either
transgen
mice
result
increas
amyloid
plaqu
load
significantli
enhanc
inflammatori
respons
find
demonstr
lxr
play
critic
role
abeta
clearanc
deposit
brain
importantli
lxr
agonist
treatment
mice
dramat
attenu
behavior
deficit
mice
lxr
activ
enhanc
clearanc
facilit
proteolyt
degrad
solubl
abeta
neprilysin
ide
apoedepend
mechan
capac
apo
promot
abeta
degrad
depend
upon
apo
isoform
lipid
statu
data
demonstr
novel
mechan
apo
facilit
clearanc
abeta
peptid
brain
suggest
lxr
agonist
may
repres
novel
therapi
ad
mechan
enhanc
express
lipid
form
apo
activ
liver
x
receptor
stimul
abeta
degrad
inde
age
mice
treat
lxr
agonist
exhibit
dramat
reduct
brain
peptid
level
plaqu
load
lxr
agonist
treatment
also
revers
contextu
memori
deficit
observ
mice
report
apo
play
previous
unappreci
role
facilit
proteolyt
clearanc
solubl
abeta
brain
abnorm
excess
inflamm
thought
contribut
progress
neurodegen
condit
although
topic
wide
studi
basic
clinic
enterpris
mechan
brain
inflamm
inde
relationship
neurodegener
inflamm
poorli
understood
microglia
princip
brainresid
immunocompet
cell
rel
potent
sourc
reactiv
oxygen
nitrogen
intermedi
thu
experi
design
better
understand
intric
relationship
intracellular
oxid
pathway
microglia
intercellular
inflammatori
signal
end
product
andor
disposit
oxygen
free
radic
microglia
manipul
determin
result
effect
oxid
inflammatori
indic
data
show
product
intracellular
oxid
microglia
macrophag
gener
crucial
subsequ
product
releas
cytokin
adopt
neurotox
phenotyp
howev
develop
signific
oxid
stress
microglia
also
associ
decreas
releas
inflammatori
mediat
abil
free
radic
control
inflammatori
signal
microgliamacrophag
may
base
oxid
alter
multicatalyt
proteasom
togeth
find
suggest
free
radic
product
brainresid
monocyt
cell
could
key
mechan
regul
brain
inflamm
respons
variou
stimuli
intervent
aim
free
radic
regul
microglia
may
provid
novel
effect
therapeut
avenu
amelior
neurotox
brain
inflamm
support
biolog
signific
posttraumat
spinal
cord
inflamm
controversi
resid
microglia
infiltr
leukocyt
eg
monocytestcel
caus
neuron
cell
death
axon
injuri
demyelin
howev
cell
promot
neuron
surviv
axon
regener
remyelin
revascular
past
year
use
numer
strategi
manipul
resid
recruit
immun
cell
effort
understand
repar
injuri
function
context
rodent
model
traumat
spinal
cord
injuri
sci
data
present
illustr
conflict
effect
activ
cn
macrophag
emphasi
newer
data
suggest
role
subset
tolllik
receptor
tlr
regul
variou
aspect
cn
repair
eg
axon
regener
remyelin
gliosi
andor
downregul
destruct
neuroinflamm
myelinreact
noncn
reactiv
lymphocyt
also
recruit
injur
spinal
cord
report
benefici
detriment
effect
data
present
illustr
pathogen
potenti
b
lymphocyt
selfreact
antibodi
model
sci
experiment
limit
clinic
implic
data
discuss
support
nih
grant
therapeut
strategi
microgliainduc
neurotox
depart
neuroimmunolog
riem
nagoya
univers
nagoya
japan
accumul
activ
microglia
reactiv
astrocyt
observ
around
degener
neuron
cytokin
activ
glial
cell
may
involv
pathophysiolog
neuron
degener
regener
studi
examin
neurotox
microgliaderiv
factor
neurotox
factor
activ
microglia
glutam
recombin
cytokin
examin
toxic
neuron
howev
tnfa
exert
neurotox
via
induc
glutam
microglia
ifng
induc
minor
neurotox
mediat
ifngr
ampa
receptor
complex
upon
stimul
tnfa
microglia
produc
glutam
glutaminas
use
extracellular
glutamin
releas
gapjunct
glutam
transport
glutaminas
gapjunct
inhibitor
suppress
glutam
releas
neurotox
microglia
examin
whether
glutaminas
inhibitor
gapjunct
inhibitor
carbenoxolon
cbx
suppress
neuron
damag
vivo
use
anim
model
cbx
significantli
suppress
delay
neuron
cell
death
hippocampu
brain
ischemia
also
increas
surviv
anim
model
amyotroph
later
sclerosi
al
blockad
uniqu
mechan
glutam
product
releas
microglia
may
use
therapeut
strategi
neuron
degener
